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Objectives: To examine the clinical effectiveness,
tolerability and cost-effectiveness of gabapentin (GBP),
lamotrigine (LTG), levetiracetam (LEV), oxcarbazepine
(OXC), tiagabine (TGB), topiramate (TPM) and
vigabatrin (VGB) for epilepsy in adults.
Data sources: Electronic databases. Internet
resources. Pharmaceutical company submissions.
Review methods: Selected studies were screened and
quality assessed. Separate analyses assessed clinical
effectiveness, serious, rare and long-term adverse
events and cost-effectiveness. An integrated economic
analysis incorporating information on costs and effects
of newer and older antiepileptic drugs (AEDs) was
performed to give direct comparisons of long-term
costs and benefits.
Results: A total of 212 studies were included in the
review. All included systematic reviews were Cochrane
reviews and of good quality. The quality of randomised
controlled trials (RCTs) was variable. Assessment was
hampered by poor reporting of methods of
randomisation, allocation concealment and blinding.
Few of the non-randomised studies were of good
quality. The main weakness of the economic
evaluations was inappropriate use of the cost-
minimisation design. The included systematic reviews
reported that newer AEDs were effective as adjunctive
therapy compared to placebo. For newer versus older
drugs, data were available for all three monotherapy
AEDs, although data for OXC and TPM were limited.
There was limited, poor-quality evidence of a significant
improvement in cognitive function with LTG and OXC
compared with older AEDs. However, there were no
consistent statistically significant differences in other
clinical outcomes, including proportion of seizure-free
patients. No studies assessed effectiveness of AEDs in
people with intellectual disabilities or in pregnant
women. There was very little evidence to assess the
effectiveness of AEDs in the elderly; no significant
differences were found between LTG and
carbamazepine monotherapy. Sixty-seven RCTs
compared adjunctive therapy with placebo, older AEDs
or other newer AEDs. For newer AEDs versus
placebo, a trend was observed in favour of newer
drugs, and there was evidence of statistically significant
differences in proportion of responders favouring
newer drugs. However, it was not possible to assess
long-term effectiveness. Most trials were conducted in
patients with partial seizures. For newer AEDs versus
older drugs, there was no evidence to assess the
effectiveness of LEV, LTG or OXC, and evidence for
other newer drugs was limited to single studies. Trials
only included patients with partial seizures and follow-
up was relatively short. There was no evidence to
assess effectiveness of adjunctive LEV, OXC or TPM
versus other newer drugs, and there were no time to
event or cognitive data. No studies assessed the
effectiveness of adjunctive AEDs in the elderly or
pregnant women. There was some evidence from one
study (GBP versus LTG) that both drugs have some
beneficial effect on behaviour in people with learning
disabilities. Eighty RCTs reported the incidence of
adverse events. There was no consistent or convincing
evidence to draw any conclusions concerning relative
safety and tolerability of newer AEDs compared with
each other, older AEDs or placebo. The integrated
economic analysis for monotherapy for newly
diagnosed patients with partial seizures showed that
older AEDs were more likely to be cost-effective,
although there was considerable uncertainty in these
results. The integrated analysis suggested that newer
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Abstract
Clinical effectiveness, tolerability and cost-effectiveness of newer
drugs for epilepsy in adults: a systematic review and economic
evaluation
J Wilby,1 A Kainth,1 N Hawkins,2 D Epstein,2 H McIntosh,1 C McDaid,1 A Mason,2
S Golder,1 S O’Meara,1 M Sculpher,2 M Drummond2 and C Forbes1
*
1 Centre for Reviews and Dissemination, University of York, UK
2 Centre for Health Economics, University of York, UK
*Corresponding author
AEDs used as adjunctive therapy for refractory patients
with partial seizures were more effective and more
costly than continuing with existing treatment alone.
Combination therapy, involving new AEDs, may be
cost-effective at a threshold willingness to pay per
quality-adjusted life year (QALY) greater than £20,000,
depending on patients’ previous treatment history.
There was, again, considerable uncertainty in these
results. There were few data available to determine
effectiveness of treatments for patients with
generalised seizures. LTG and VPA showed similar
health benefits when used as monotherapy. VPA was
less costly and was likely to be cost-effective. The
analysis indicated that TPM might be cost-effective
when used as an adjunctive therapy, with an estimated
incremental cost-effectiveness ratio of £34,500
compared with continuing current treatment alone. 
Conclusions: There was little good-quality evidence
from clinical trials to support the use of newer
monotherapy or adjunctive therapy AEDs over older
drugs, or to support the use of one newer AED in
preference to another. In general, data relating to
clinical effectiveness, safety and tolerability failed to
demonstrate consistent and statistically significant
differences between the drugs. The exception was
comparisons between newer adjunctive AEDs and
placebo, where significant differences favoured newer
AEDs. However, trials often had relatively short-term
treatment durations and often failed to limit
recruitment to either partial or generalised onset
seizures, thus limiting the applicability of the data.
Newer AEDs, used as monotherapy, may be cost-
effective for the treatment of patients who have
experienced adverse events with older AEDs, who
have failed to respond to the older drugs, or where
such drugs are contraindicated. The integrated
economic analysis also suggested that newer AEDs
used as adjunctive therapy may be cost-effective
compared with the continuing current treatment alone
given a QALY of about £20,000. There is a need for
more direct comparisons of the different AEDs within
clinical trials, considering different treatment sequences
within both monotherapy and adjunctive therapy.
Length of follow-up also needs to be considered. Trials
are needed that recruit patients with either partial or
generalised seizures; that investigate effectiveness and
cost-effectiveness in patients with generalised onset
seizures and that investigate effectiveness in specific
populations of epilepsy patients, as well as studies
evaluating cognitive outcomes to use more stringent
testing protocols and to adopt a more consistent
approach in assessing outcomes. Further research is
also required to assess the quality of life within trials of
epilepsy therapy using preference-based measures of
outcomes that generate cost-effectiveness data. Future
RCTs should use CONSORT guidelines; and
observational data to provide information on the use of
AEDs in actual practice, including details of treatment
sequences and doses. 
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Glossary
Absence seizurea Previously called ‘petit
mal’, this is a generalised seizure involving a
brief interruption of consciousness. The person
may look blank and their eyelids may flutter.
Adverse effectb Any untoward medical
occurrence that may present during treatment
with a pharmaceutical product but which does
not necessarily have a causal relationship with
the treatment.
Adverse eventb A response to a drug which is
noxious and unintended, and which occurs at
doses normally used in humans for the
prophylaxis, diagnosis or therapy of the
disease, or for the modification of physiological
function.
Ambylopiac Dimness of vision, without
detectable organic lesion of the eye.
Amnesiac Pathological impairment of
memory.
Anorexiac Lack or loss of appetite for food.
Aphasiac Defect or loss of the power of
expression by speech, writing or signs or of
comprehending spoken or written language,
due to injury or disease of the brain centres.
Astheniac Lack or loss of strength and
energy, weakness.
Ataxiac Failure of muscular coordination;
irregularity of muscular action.
Atonic seizurea Generalised seizure involving
a sudden loss of muscle tone so that the person
falls to the ground. Recovery is rapid but there
may be injuries due to the fall.
Co-morbidity In a study looking at treatment
for one disease or condition, some of the
individuals with that disease will also have
other diseases or conditions that could be
affecting their outcomes. Any other such
condition is called a ‘co-morbidity’.
Complex partial seizurea Partial seizure in
which the person’s awareness is impaired. The
person may show confused behaviour and
‘automatisms’ such as lip-smacking, chewing,
undressing, picking up objects and wandering
aimlessly. The seizure usually lasts a few
minutes and the person has no memory of
what has happened. This type of seizure often
originates in the temporal lobe of the brain, in
which case the person may be said to have
temporal lobe epilepsy. However, complex
partial seizures may also originate in other
lobes (areas) of the brain.
Confidence interval (CI) Quantifies the
uncertainty in measurement. Usually reported
as 95% CI, that is, the range of values within
which one is 95% sure that the true value for
the whole population lies.
Cost-benefit analysis (CBA) A form of
economic evaluation where both costs and
benefits are expressed in the same units,
usually monetary units, that is, all of the health
benefits (e.g. disability days avoided, life-years
gained, medical complications avoided) are
translated into monetary units. This type of
analysis is not widely used in the economic
evaluation of drugs or technologies, as it is
often difficult to determine the cost of health
benefits.
Cost-consequences analysis (CCA) A form of
cost-effectiveness analysis where costs and
effectiveness (consequences) are presented
separately and the decision-maker is left to
make their own view about the relative
importance of these factors.
continued
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Glossary and list of abbreviations
Technical terms and abbreviations are used throughout this report. The meaning is usually clear from
the context, but a glossary is provided for the non-specialist reader. In some cases, usage differs in the
literature, but the term has a constant meaning throughout this review.
Glossary and list of abbreviations
viii
Glossary continued
Cost-effectiveness acceptability curve (CEAC)
A graphical representation of the probability of
an intervention being cost-effective over a
range of monetary values for society’s
willingness to pay for an additional unit of
health gain.
Cost-effectiveness analysis (CEA) A form of
economic evaluation where costs are expressed
in monetary units and effectiveness is
expressed in some unit of effectiveness. Units
of effectiveness are usually the same as those
clinical outcomes used to measure effectiveness
in clinical trials or practice. When comparing
two interventions, the difference in cost and
effectiveness between the two interventions is
expressed as an incremental cost-effectiveness
ratio (ICER), with the difference in cost in the
numerator and the difference in effectiveness
in the denominator. A particular form of cost-
effectiveness is sometimes referred to as
cost–utility analysis, where the measure of
effectiveness is typically measured in terms of
quality-adjusted life-years (QALYs).
Cost-minimisation analysis (CMA) A special
form of cost-effectiveness analysis and the
simplest form of economic evaluation. Costs
are expressed in monetary units and the
patient outcome is assumed to be the same in
both/all of the intervention groups evaluated.
Hence, the object of this type of analysis is to
identify the least expensive alternative.
Cost–utility analysis (CUA) A special form of
cost-effectiveness analysis in which the units of
effectiveness are QALYs. Cost–utility analyses
are important in the evaluation of cancer
therapies, as such therapies are often
associated with potentially serious or
intolerable adverse events.
Crossover trial A trial in which each of the
study groups will receive each of the
treatments, but in a randomised order: that is,
they will start off in one arm of the trial, but
will deliberately ‘cross over’ to the other arm(s)
in turn.
Diplopiac The perception of two images of a
single object.
Dyspepsiac Impairment of the power or
function of digestion; usually applied to
epigastric discomfort after meals.
Emotional labilityc Emotional instability.
Equivalence margin The meaningful
difference to be ruled out when two drugs are
compared for equivalence (i.e. how much
difference is allowed between treatments for
them to be considered equivalent). This should
be specified and justified a priori because
selection of a meaningful difference may be
influenced by the trial results. 
Focal seizures See Partial seizures.
Expected value of perfect information A
measure of the cost of uncertainty associated
with a given decision problem in terms of
health forgone and resource costs. Perfect
information through further research would
remove this uncertainty and hence the cost of
uncertainty is synonymous with the value of
perfect information. Often graphically
represented over a range of monetary values
for society’s threshold willingness to pay for an
additional unit of health gain. This measure
offers an insight into whether the necessary
(but not sufficient) conditions are met for
additional research to be cost-effective.
Generalised seizuresa Generalised seizures
are those in which the abnormal electrical
activity begins in both hemispheres (sides) of
the brain at the same time.
Hazard ratio The hazard (the instantaneous
risk of patient experiencing a particular event
at a specified time point) associated with one
category of patients divided by the hazard for
another set of patients. The hazard ratio can
be estimated at an instant or averaged over an
interval.
Heterogeneous Of differing origins or
different types.
International League Against Epilepsy
(ILAE)d The ILAE is a global professional
non-profit international organisation and a
non-governmental organisation in official
relations with the WHO. The ILAE’s objectives
are: to advance and disseminate knowledge
about epilepsy (and have developed guidelines
for the classification of epilepsy and the design
of investigative trials); to promote research,
education and training; and to improve 
continued
Glossary continued
services and care for patients, especially by
prevention, diagnosis and treatment.
Incremental cost-effectiveness ratio (ICER)
An expression of the additional cost of health
gain associated with an intervention relative to
an appropriate comparator. Expressed as the
difference in mean costs (relative to the
comparator) divided by the difference in mean
effects. Sometimes expressed with confidence
intervals. 
Logistic regression See Regression analysis
Meta-analysis The statistical pooling of the
results of a collection or related individual
studies, to increase statistical power and
synthesise their findings.
Multivariate analysis Measuring the impact
of more than one variable at a time while
analysing a set of data, for example, looking at
the impact of age, gender and occupation on a
particular outcome.
Myoclonic seizurea Generalised seizure
involving brief jerks of part of or the whole
body. Recovery is rapid.
Number needed to treat A number which
gives you an estimate of how many people
need to receive a treatment before one person
would experience the beneficial outcome.
Nystagmusc Involuntary rapid movement
(horizontal, vertical, rotatory, or mixed) of the
eyeball.
Open-label trial A non-blind/non-masked
trial: one where both the clinician and patient
know what drug a participant is taking, and at
what dose.
Paresthesiac Morbid or perverted sensation;
an abnormal sensation, such as burning,
prickling, formication.
Partial seizuresa Seizure in which the
abnormal electrical activity begins in one part
of the brain. Which part of the brain is
involved will determine what actually happens
during the seizure.
Pharyngitisc Sore throat; inflammation of the
pharynx.
Postictal The period following a seizure
during which a patient may have drowsiness or
be confused.
Power Statistical power of a study: a study
needs to have a specific level of ‘power’ in
order to be able to detect reliably a difference
that a treatment might cause. To be powerful
enough, the study needs to have enough
participants, who experience enough of the
outcomes in question, to be able to come up
with statistically significant results.
Pruritusc Itching.
Q-statistic A statistical test performed when
pooling studies to assess the degree of
homogeneity between a group of studies. If 
Q > s – 1 (where s is the number of studies to
be combined) and the accompanying p-value is
less than a predefined cut-off value (e.g. 0.05),
then there is significant heterogeneity between
studies. However, this test has low statistical
power, especially where only small numbers of
studies are to be combined and often a more
stringent cut-off value is used for judging
statistical significance (i.e. p-value of ≤ 0.10 is
considered significant).
Quality-adjusted life-year (QALY) An index
of health gain where survival duration is
weighted or adjusted by the patient’s quality of
life during the survival period. QALYs have the
advantage of incorporating changes in both
quantity (mortality) and quality (morbidity) of
life.
Quality of life (QoL) A concept
incorporating all the factors that might impact
on an individual’s life, including factors such as
the absence of disease or infirmity and other
factors which might affect their physical,
mental and social well-being.
Refractory disease Disease that has failed to
respond to appropriate treatment.
Regression analysis A statistical modelling
technique. Regression analysis is used to
estimate or predict the relative influence of
more than one variable on something, for
example, the effect of age, gender and
educational level on the prevalence of a
disease. There are different types of these
models, including ‘linear’ and ‘logistic’
regression.
continued
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Glossary continued
Relative risk (RR)e The ratio of risk in the
intervention group to the risk in the control
group. The risk is the ratio of people with an
event in a group to the total in the group. A
relative risk (or risk ratio) of 1 indicates no
difference between comparison groups. For
undesirable outcomes a relative risk that is <1
indicates that the intervention was effective in
reducing the risk of that outcome. 
Rhinitisc Inflammation of the nasal mucous
membrane.
Risk ratio See Relative risk.
Secondarily generalised seizurea Seizures
where the abnormal electrical activity starts in
one part of the brain and then spreads to
involve the whole brain. The seizure begins
with a partial seizure – this is the warning, and
sometimes this phase is extremely brief – and
then becomes a generalised seizure, most
commonly tonic clonic.
Simple partial seizurea A partial seizure in
which the person remains fully conscious but
experiences unusual sensations such as strange
tastes or smells, feelings of fear or déjà vu or
involuntary twitching of limbs. A simple partial
seizure is often called an aura or warning,
because it may precede another type of seizure.
Somnolencec Drowsiness or sleepiness,
particularly in excess.
Status epilepticusa When a seizure continues
for a prolonged period (longer than
30 minutes), or when seizures occur one after
the other with no recovery between. Status
epilepticus is an emergency and requires
immediate medical attention.
Tonic seizurea Generalised seizure in which
the person’s body becomes stiff and they may
fall backwards. The seizure usually lasts less
than a minute and recovery is rapid.
Tonic–clonic seizurea Also called convulsion
or ‘grand mal’, this is a generalised seizure.
The person becomes stiff and may fall. This is
followed by rhythmical jerking of the limbs,
usually lasting a few minutes. The person may
bite their tongue and may be incontinent. They
may feel confused or sleepy afterwards, and
take a while to recover fully. 
Utility A measure of the strength of an
individual’s preference for a given health state
or outcome. Utilities assign numerical values
on a scale from 0 (death) to 1 (optimal or
‘perfect’ health), and provide a single number
that summarises health-related quality of life.
Hence utility has been described as a global
measure of health-related quality of life.
Sometimes ‘utility’ is only used to refer to
preferences (on the 0–1 scale) that are elicited
using methods which introduce risky scenarios
to the respondent (standard gamble), with the
term ‘values’ used to refer to other type of
preferences. 
Values An alternative measure of the strength
of an individual’s preference for a given health
state or outcome. In contrast to utilities, values
reflect preferences elicited in a riskless context. 
Vertigoc A sensation of rotation or movement
of one’s self or of one’s surroundings in any
plane; sometimes used erroneously to mean
any form of dizziness.
Visual field defect/visual field constriction
The visual field is the area which can be seen
by an individual when looking straight ahead
without moving the eyes. Damage to the rod
cells of the peripheral retinae narrows the field
causing peripheral loss, also called visual field
constriction. This can lead to tunnel vision,
night blindness and difficulty with changing
lighting conditions. 
Washout period (See Crossover trial). A stage
in a crossover trial after the first treatment is
withdrawn, but before the second treatment is
started. The washout period allows time for
any active effects of the first treatment to wear
off before the next phase begins.
a Definition adapted from the National Society
for Epilepsy: http://www.epilepsynse.org.uk/
pages/info/glossary/index.cfm
b World Health Organization.2
c Definition adapted from note a.
d Definition adapted from the ILAE website:
http://www.ilae-epilepsy.org/
e Definition provided by the Cochrane
Collaboration Glossary.
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List of abbreviations
ABNC Aldenkamp–Baker Neurotoxicity
Scale
ADR adverse reaction
AE adverse event
AED antiepileptic drug
AEP Adverse Events Profile
ANCOVA analysis of covariance
ANOVA analysis of variance
AZM acetazolamide
BD birth defect
BDI Beck Depression Inventory
BMI body mass index
BMJ British Medical Journal
BNF British National Formulary
BPD bipolar disorder
BVRT Benton Visual Retention Test
CBA cost–benefit analysis
CBZ carbamazepine
CCA cost–consequences analysis
CCTR Cochrane Controlled Trials
Register
CDRS Cornell Dysthymia Rating Self-
report Scale
CDSR Cochrane Database of Systematic
Reviews
CEA cost-effectiveness analysis
CEAC cost-effectiveness acceptability
curve
CHE Centre for Health Economics
CI confidence interval
CLB clobazam
CMA cost-minimisation analysis
CNS central nervous system
COSTART Coding Symbols for Thesaurus of
Adverse Reaction Terms
COWA Controlled Oral Word Association
CPI Conference Papers Index
CPS complex partial seizure
CRD Centre for Reviews and
Dissemination
CSAG Clinical Standards Advisory
Group
CSM Committee on Safety of
Medicines
CT computed tomography
CUA cost–utility analysis
CZP clonazepam
DARE Database of Abstracts of Reviews
of Effects
df degrees of freedom
DZP diazepam
EAI epilepsy activity index
ECG electrocardiography
EEG electroencephalogram
EOG electrooculogram
ERG electroretinogram
FIQ Full-scale Intelligence Quotient
FNR flunarizine
GABA -Aminobutyric acid
GBP gabapentin
GPRD General Practice Research Database
GTC generalised tonic–clonic
HEED Health Economic Evaluations
Database
HR hazard ratio
HRQoL health-related quality of life
HSTAT Health Service Technology
Assessment Text
ICER incremental cost-effectiveness
ratio
ICH International Conference on
Harmonisation
ICS International Classification of
Seizures
continued
List of abbreviations continued
ILAE International League Against
Epilepsy
IQ intelligence quotient
ISTP Index to Scientific and Technical
Proceedings
ITT intention-to-treat
LEV levetiracetam
LSI Life Satisfaction Index
LSM least-squares mean
LSSS Liverpool Seizure Severity Scale
LTG lamotrigine
MANCOVA multivariate analysis of covariance
MANOVA multivariate analysis of variance
MRI magnetic resonance imaging
MSFRR medium seizure frequency
reduction rate
NCCHTA National Coordinating Centre for
Health Technology Assessment
NGPSE National General Practice Study
of Epilepsy
NHS EED NHS Economic Evaluation
Database
NICE National Institute for Clinical
Excellence
NNT number needed to treat
NRR National Research Register
OR odds ratio
OXC oxcarbazepine
PACT prescription analysis and cost
PB phenobarbital
PCA principal component analysis
PEM prescription event monitoring
PGTC primary generalised tonic–clonic
PHT phenytoin
PMS postmarketing surveillance
POMS Profile of Moods State
POS partial onset seizure
PRM primidone
PSSRU Personal Social Services Research
Unit
QALY Quality-adjusted life-year
QOL quality of life
QOLIE Quality of Life in Epilepsy
Inventory
RCT randomised controlled trial
RR relative risk
ScHARR School of Health and Related
Research
SCI Science Citation Index
SD standard deviation
SE standard error
SEALS Side Effects and Life Satisfaction
Inventory
SEM standard error of the mean
SG standard gamble
SGTC secondarily generalised
tonic–clonic
SIGN Scottish Intercollegiate
Guidelines Network
SJS Stevens–Johnson syndrome
SMR standardised mortality rate
SPC summary of product
characteristics
SPMS simple partial motor seizure
SPS simple partial seizure
SUDEP sudden unexpected death in
epilepsy
TEN toxic epidermal necrosis
TGB tiagabine
TPM topiramate
TRIP Turning Research Into Practice
VAS visual analogue scale
VEP visual evoked potential
continued
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List of abbreviations continued
VF visual field
VFC visual field constriction 
VFD visual field defect 
VGB vigabatrin
VPA valproate
WAIS-R Wechsler Adult Intelligence 
Scale – Revised
WBC white blood cell
WMHTAC West Midlands Health
Technology Assessment
Collaboration
WMS Wechsler Memory Scale
WPSI Washington Psychosocial Seizure
Inventory
ZNS zonisamide
All abbreviations that have been used in this report are listed here unless the abbreviation is well known (e.g. NHS), or 
it has been used only once, or it is a non-standard abbreviation used only in figures/tables/appendices in which case 
the abbreviation is defined in the figure legend or at the end of the table.
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Background
Epilepsy is a complex neurological condition
responsible for considerable morbidity and
mortality. It affects over 400,000 individuals within
the UK and is responsible for over 1000 deaths
per year. Initial treatment approaches focus on
drug therapy, either monotherapy or adjunctive
therapy. In the event of drug treatment failure,
surgery might be considered but is limited to a
very specific group of patients. Drug therapy is,
therefore, the mainstay of treatment. Because
many individuals can require many years of, if not
lifelong, treatment with antiepileptic drugs
(AEDs), the clinical effectiveness, tolerability and
cost-effectiveness of drug therapy are a major
considerations. A number of drug therapies are
licensed for the treatment of epilepsy in adults,
although many are limited to specific types of
epilepsy and therapy regimens. However, at
present, there does not appear to be a uniform
approach to the selection or sequence of AED
therapy.
Aims of the review
To examine the clinical effectiveness, tolerability
and cost-effectiveness of gabapentin (GBP),
lamotrigine (LTG), levetiracetam (LEV),
oxcarbazepine (OXC), tiagabine (TGB),
topiramate (TPM) and vigabatrin (VGB) for
epilepsy in adults.
Methods
Search strategy
Over 36 electronic databases and Internet
resources were searched from inception to
May/September 2002. In addition, bibliographies
of retrieved articles were searched and
pharmaceutical company submissions examined
for further studies.
Inclusion/exclusion criteria
Studies of newer AED therapies for the treatment
of adults with newly diagnosed or refractory
epilepsy were included. Relevant comparators
included older AEDs, other newer AEDs and
placebo. Only randomised controlled trials (RCTs)
and systematic reviews were included in the review
of clinical effectiveness, and in addition non-
randomised experimental studies and
observational studies were included in the review
of serious, rare and long-term adverse events. The
assessment of cost-effectiveness included only cost-
minimisation, cost-effectiveness and cost–utility
analyses. Two reviewers independently screened all
titles and abstracts and made final decisions on
the inclusion/exclusion of studies based on full
copies of articles. Any disagreements were resolved
through discussion.
Data extraction and quality assessment
Data were extracted by one reviewer and checked
by another. Two reviewers, using specified criteria,
independently assessed the quality of all included
studies. Any disagreements were resolved through
discussion.
Analysis strategy
Separate analyses were performed to assess clinical
effectiveness, serious, rare and long-term adverse
events and cost-effectiveness. An integrated
economic analysis incorporating information on
both the costs and effects of newer and older
AEDs was performed to allow direct comparisons
of long-term costs and benefits.
Results
Included studies
A total of 8095 titles and abstracts were screened
for relevance and full copies of 1098 studies were
ordered and assessed for inclusion/exclusion. A
total of 212 studies were included in the review: 13
systematic reviews, 101 effectiveness publications
covering 88 RCTs, 88 non-randomised
experimental studies and observational publications
covering 77 studies, and 21 economic evaluations.
Quality of clinical effectiveness studies
All included systematic reviews were Cochrane
reviews and of good quality. The quality of RCTs
was variable. Assessment was hampered by poor
reporting of methods of randomisation, allocation
concealment and blinding. Few of the non-
randomised studies were of good quality.
Executive summary
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Quality of economic evaluations
The main weakness of the published economic
evaluations was inappropriate use of the cost-
minimisation design. Other issues included basing
conclusions on a small number of trials and using
inappropriate assumptions to extrapolate beyond
the length of time of the study. Only two of the 10
company submissions incorporated most of the
main features that were felt necessary to model the
treatment of epilepsy, and even these lacked a
systematic approach to obtaining and synthesising
effectiveness data.
Assessment of clinical effectiveness
The included systematic reviews reported that
newer AEDs were effective as adjunctive therapy
compared to placebo.
Monotherapy
Twenty-one RCTs (12 LTG, eight OXC and one
TPM) compared monotherapy with placebo (two
studies), older AEDs (17 studies) or other newer
AEDs (two studies). For new AEDs versus placebo,
data were only available from two trials of OXC.
Considering certain limitations of the trials, the
statistically significant differences in proportion of
seizure-free participants and time to event
outcomes in favour of OXC monotherapy versus
placebo should be interpreted with caution. There
were no data for LTG or TPM.
For newer drugs versus older drugs, data were
available for all three monotherapy AEDs,
although data for OXC and TPM were limited.
There was limited, poor-quality evidence of a
significant improvement in cognitive function with
LTG and OXC compared with older AEDs.
However, no consistent statistically significant
differences were found in other clinical outcomes,
including proportion of seizure-free patients.
Evidence for the effectiveness of newer AEDs
versus other newer AEDs was limited to one study
of LTG versus GBP. The relevance of this study to
clinical practice is unclear, given that GBP is not
licensed for monotherapy and the study included
patients with either partial or generalised seizures. 
No studies assessed effectiveness of AEDs in
people with intellectual disabilities or in pregnant
women. There was very little evidence to assess the
effectiveness of AEDs in the elderly; no significant
differences were found between LTG and
carbamazepine monotherapy.
Adjunctive therapy
Sixty-seven RCTs (10 GBP, 21 LTG, three LEV, 
two OXC, seven TGB, 14 TPM and 15 VGB)
compared adjunctive therapy with placebo (56
studies), older AEDs (seven studies) or other
newer AEDs (four studies). Three of the four
studies of newer AEDs compared to other newer
AEDs investigated two newer AEDs each, and the
other study investigated three newer AEDs. For
newer AEDs versus placebo, a trend was observed
in favour of newer drugs, and there was evidence
of statistically significant differences in proportion
of responders in favour of newer drugs. However,
as the length of follow-up was limited in many
trials, it was not possible to assess long-term
effectiveness. Most trials were conducted in
patients with partial seizures.
For newer AEDs versus older drugs, there was no
evidence to assess the effectiveness of LEV, LTG or
OXC, and evidence for other newer drugs was
limited to single studies. Trials only included
patients with partial seizures and follow-up was
relatively short. Data were available for proportion
of seizure-free patients, proportion of responders
and limited quality of life and cognitive outcomes.
The available evidence showed mainly non-
significant differences, and should be regarded
with caution because of weaknesses in the design
and quality of the studies.
There was no evidence to assess effectiveness of
adjunctive LEV, OXC or TPM versus other newer
drugs, and there were no time to event or
cognitive data. Available evidence was limited to
single studies, with the exception of two studies
that compared GBP with VGB and two studies that
compared GBP with LTG. In general, studies
enrolled patients with partial seizures and follow-
up was limited. One study showed a statistically
significant difference in proportion of responders
in favour of VGB over GBP. Another study of
patients with intellectual disabilities found
statistically significant differences in quality of life
in favour of GBP over LTG. These findings should
be interpreted with caution because of flaws in the
quality of the studies.
No studies assessed the effectiveness of adjunctive
AEDs in the elderly or pregnant women. A
number of studies included people with
intellectual disabilities, but only three provided
data exclusively from this population. There was
some evidence from one study (GBP versus LTG)
that both drugs have some beneficial effect on
behaviour in people with learning disabilities.
Adverse events
Eighty RCTs reported the incidence of adverse
events. There was no consistent or convincing
Executive summary
evidence from these studies to draw any clear
conclusions concerning relative safety and
tolerability of newer AEDs compared with each
other, older AEDs or placebo. Observational data
provided some evidence of possible serious, rare
and long-term adverse events beyond those
reported in RCTs. However, the evidence reviewed
does not provide proof of association between
drug and event. 
Assessment of cost-effectiveness
Regarding monotherapy for newly diagnosed
patients with partial seizures, the integrated
economic analysis showed similar health benefits
for the various AEDs and that newer AEDs were
more expensive than older therapies.
Consequently, the older AEDs were more likely to
be cost-effective. There was considerable
uncertainty in these results. 
The integrated analysis suggested that newer
AEDs used as adjunctive therapy for refractory
patients with partial seizures were more effective
and more costly than continuing with existing
treatment alone. Combination therapy, involving
new AEDs, may be cost-effective at a threshold
willingness to pay per quality-adjusted life year
(QALY) greater than £20,000. The exact value of
this threshold depends on patients’ previous
treatment history. There was, again, considerable
uncertainty in these results. 
There were few data available to determine
effectiveness of treatments for patients with
generalised seizures. LTG and VPA showed similar
health benefits when used as monotherapy. VPA
was less costly and was likely to be cost-effective.
The analysis indicated that TPM might be cost-
effective when used as an adjunctive therapy, with
an estimated incremental cost-effectiveness ratio of
£34,500 compared with continuing current
treatment alone. 
Conclusions
There was little good-quality evidence from
clinical trials to support the use of newer
monotherapy or adjunctive therapy AEDs over
older drugs, or to support the use of one newer
AED in preference to another. In general, data
relating to clinical effectiveness, safety and
tolerability failed to demonstrate consistent and
statistically significant differences between the
drugs. The exception was comparisons between
newer adjunctive AEDs and placebo, where
significant differences favoured newer AEDs.
However, trials often had relatively short-term
treatment durations and often failed to limit
recruitment to either partial or generalised onset
seizures, thus limiting the applicability of the data. 
Text removed due to reference to commercial-in-
confidence data.
In addition, newer AEDs, used as monotherapy,
may be cost-effective for the treatment of patients
who have experienced adverse events with older
AEDs, who have failed to respond to the older
drugs, or where such drugs are contraindicated.
The integrated economic analysis also suggested
that newer AEDs used as adjunctive therapy may
be cost-effective compared with the continuing
current treatment alone given a threshold
willingness to pay per QALY of about £20,000. 
Recommendations for research
There is a need for the following: 
 more direct comparisons of newer versus newer
and newer, versus older AEDs within clinical
trials, considering different treatment sequences
within both monotherapy and adjunctive
therapy; 
 good-quality trials with appropriate designs,
ideally adopting the International League
Against Epilepsy guidelines on the design of
trials, particularly with regard to length of
follow-up; 
 trials specifically to recruit patients with either
partial or generalised seizures; 
 more good-quality trials to investigate
effectiveness and cost-effectiveness in patients
with generalised onset seizures; 
 more good-quality trials to investigate
effectiveness in specific populations of epilepsy
patients; 
 studies evaluating cognitive outcomes to use
more stringent testing protocols and to adopt a
more consistent approach in assessing
outcomes; 
 further research to assess quality of life within
trials of epilepsy therapy, adopting any measure
shown to have validity in the assessment of
epilepsy patients, but also using preference-
based measures of outcomes that generate
appropriate utilities for cost-effectiveness
analysis; future RCTs to be adequately reported
according to CONSORT guidelines; and 
 observational data to provide information on
the use of AEDs in actual practice, including
details of treatment sequences and doses.
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Aim of the review
The aim of this review was to examine the clinical
effectiveness, tolerability and cost-effectiveness of
newer drugs for epilepsy in adults. For the
purposes of this review newer antiepileptic drugs
(AEDs) included gabapentin (GBP) (Neurontin®,
Parke-Davis), lamotrigine (LTG) (Lamictal®,
GlaxoSmithKline), levetiracetam (LEV) (Keppra®,
UCB Pharma), oxcarbazepine (OXC) (Trileptal®,
Novartis Pharmaceuticals), tiagabine (TGB)
[Gabatril®, Cephalon (UK)], topiramate (TPM)
(Topomax®, Janssen-Cilag) and vigabatrin (VGB)
(Sabril®, Hoechst Marion Roussel). A concurrent
review was performed by the West Midlands
Health Technology Assessment Collaboration
(WMHTAC), Birmingham, to examine the clinical
effectiveness, tolerability and cost-effectiveness of
newer drugs for epilepsy in children.
Background
Description of underlying health
problem
Epilepsy is a neurological disorder characterised 
by recurring seizures and is generally defined by
two or more unprovoked seizures. The seizures are
presumed to be the consequence of an abnormal
and excessive discharge of a set of neurons in the
brain. The condition comprises different seizure
types and syndromes.3,4 This has created
complexities in establishing the incidence and
prevalence5 and prognosis of epilepsy.6 A recent
analysis of the prevalence of treated epilepsy based
on a sample of 211 general practices [1.4 million
individuals from the UK General Practice Research
Database (GPRD)], estimated that the total number
of patients being treated for epilepsy in England
and Wales in 1998 was almost 400,000.3 It is
estimated that the risk of premature death among
individuals with epilepsy is 2–3 times higher than
in the general population.8 Approximately 1000
people die in the UK each year from causes
directly related to epilepsy. Around half of these
are due to sudden unexpected death in epilepsy
(SUDEP), for which an important risk factor is
seizure frequency.9 However, establishing the exact
number and nature of epilepsy-related deaths from
national data is difficult.9
In 1998, prevalences of 7.7 per 1000 men (age-
standardised prevalence 7.4) and 7.6 per 1000
women (age-standardised prevalence 7.2) were
reported. Prevalence increased over the age-span
in both sexes, although was higher in men over
55 years old than in women of the same age
group. Prevalence was <2 per 1000 in the under
5-years-old group increasing to over 4 per 1000 in
5–15 year olds. This increased to 15.1 per 1000 in
men and to 11.0 per 1000 in women aged
≥ 85 years. This confirms earlier findings that
incidence and prevalence is highest in the elderly
population.10,11 Overall, the UK GPRD figures are
higher than those in other studies but fall within
the broadly agreed estimate of 5–10 per 1000.5,12
Variability in the reported incidence and
prevalence of epilepsy has been attributed to
differences in case ascertainment, the age groups
studied and the location of studies.1
A relationship has been found between epilepsy
prevalence and social deprivation, although the
mechanism is still unclear.7,13 The National
Statistics Office report found a difference of 25%
in prevalence in areas categorised as most
deprived compared with least deprived.7 In the
least deprived category, the prevalence was 6.3 per
1000 in females and 6.0 per 1000 in males rising
to 7.9 per 1000 in females and 8.0 per 1000 in
males in the most deprived. This confirms
findings from studies conducted in the USA,
although there have been no previous similar
studies in the UK.12
Epilepsy does not have one underlying cause.
Attributable causes in adults include hippocampal
sclerosis, cortical dysgenesis, vascular insults, head
injuries and drug or alcohol abuse.12
Seizures are generally categorised into two main
types: partial and generalised onset (Table 1).
Partial onset seizures arise from a focal or local
cortical lesion and may or may not lead to a loss
of consciousness. Partial seizures may then spread
to the whole brain causing a generalised seizure
(secondary generalisation). Generalised onset
seizures involve both sides of the brain and range
from brief absence attacks to major convulsions.3
The categorisation of seizure type can be difficult
and this may be a factor in the variable estimates
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of the frequency of the different seizure types.5
Partial seizures are the most common seizure type
experienced. In the National General Practice
Study of Epilepsy, 52% of patients had partial
seizures (with or without secondary
generalisation), 39% had generalised seizures and
9% of seizures were unclassifiable.10 Even higher
frequencies of partial seizures (72%) have been
reported in other studies.14
Onset of epilepsy can occur at any age, but is most
common during childhood or older age. Not all
patients with seizures develop the chronic
condition; some children have seizures that do not
progress into adulthood and some adults may
experience remission. A prospective study found
that, after 9 years, 71% of newly diagnosed
patients had experienced a 5-year remission.
When patients with acute symptomatic seizures
and those who had experienced only one seizure
were excluded, 60% achieved a 5-year remission.6
However, despite receiving medical therapy, up to
one third of patients experience persistent seizures
or refractory epilepsy.15,16
When considering the impact of epilepsy on the
life of an individual, the social and psychological
consequences can be as important as the seizures
experienced. The Clinical Standards Advisory
Group (CSAG) has highlighted how epilepsy may
impact on many aspects of individuals’ lives such
as employment prospects, personal development,
mental health and personal relationships.12 The
relationship between the physical, psychological
and socio-economic aspects of epilepsy is likely to
be a complex one. Physical dimensions such as
seizure frequency and seizure severity and the
side-effects of AEDs are likely to have different
significance for different patient groups.17 For
example, it is suggested that seizure severity may
have a greater impact on psychosocial well-being
than seizure frequency in individuals experiencing
refractory epilepsy.17
Current service provision
There is a professional consensus that neurologists
should take the lead role in the treatment of adult
epilepsy.12 Other healthcare professionals also play
an important role. GPs are involved in the
monitoring, auditing and surveillance of epilepsy.
Other specialists involved in management include
general physicians, geriatricians and psychiatrists
involved in the care of people with learning
disabilities who have epilepsy.12 The aim of
treatment is to reduce seizure frequency and
preferably to enable individuals to be seizure free.
In a broader sense, good treatment will also
improve psychosocial outcomes.12 AEDs are the
primary route through which seizure reduction is
achieved. No drug treatment and neurosurgery
are other options. Older AEDs include
carbamazepine (CBZ), benzodiazepines,
acetazolamide (AZM), ethosuximide,
phenobarbital (PB) and other barbiturates,
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TABLE 1 Classification of epileptic seizures3,12
I. Partial seizures A. Simple (consciousness not A1. With motor manifestations
impaired) A2. With sensory manifestations
A3. With autonomic manifestations
A4. With psychic manifestations
B. Complex B1. With simple partial features (as above, A1–A4) at onset
followed by impairment of consciousness
B2. With impairment of consciousness at onset (both B1 and
B2 may be followed by automatism)
C. Secondarily generalised C1. Simple partial seizure evolving to generalised seizure
C2. Complex partial seizure evolving to generalised seizure
C3. Simple partial seizure evolving to complex partial seizure
evolving to generalised seizure
II. Generalised seizures A. Absence seizures (may be 
typical or atypical
B. Myoclonic seizures
C. Clonic seizures
D. Tonic seizures
E. Tonic–clonic seizures
F. Atonic seizures
III. Unclassified seizures
phenytoin (PHT) and valproate (VPA). Each has a
different profile of action, set of indications and
potential side-effects.18
The choice of drug depends upon the seizure type
experienced by a particular patient and likely
tolerability of potential side-effects.18 Drugs are
administered as monotherapy or as adjunctive
therapy if monotherapy is not effective. The
CSAG survey found that 70% of those with mild
epilepsy (in a community and hospital sample),
46% of those with severe epilepsy in the
community sample and 32% of those in the
hospital sample were on monotherapy.12 In a
general practice sample, 65% were receiving
monotherapy.19 Three of the most commonly used
older AEDs are CBZ, VPA and PHT.12,19 There is
evidence of a slight decrease in the use of older
AEDs between 1994 and 1998.7 In males, the
decrease was from 99.8 to 98.1% and in females
from 99.4 to 96.8%. Those over 65 years old were
most likely to be prescribed older AEDs. There
was little variation in prescribing patterns across
NHS Regional Office areas.7
Description of interventions
Since 1989, several newer AEDs have been
licensed which are promoted as being as effective
as the older drugs but with fewer side-effects.7 For
the purposes of this review the newer AEDs under
investigation are GBP, LTG, LEV, OXC, TGB,
TPM and VGB (see ‘Aim of the review’, p. 1).
Mode of action
The newer AEDs are most commonly used either
as second-line monotherapy or as adjunctive
therapy to conventional drugs. The drugs have a
range of modes of action as outlined in Table 2.
Both older and newer drugs in some cases interact
with each other and with other drugs, which is an
important consideration in adjunctive therapy. For
this reason, adjunctive therapy should preferably
be used only when monotherapy with several
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TABLE 2 Mode of action and recommended dose of newer AEDs in adults20,21
Drug Mode of action Recommended dose
GBP Structurally related to the neurotransmitter GABA. The exact mode of 0.9–1.2 g/day
action remains unclear, but appears to differ from mechanisms used by Maximum dose 2.4 g/day
other drugs
LTG Use-dependent blocker of voltage-gated sodium channels and inhibitor Monotherapy 100–200 mg/day 
of glutamate release (up to 500 mg/day)
Adjunctive therapy with VPA 
100–200 mg/day
Adjunctive therapy without VPA 
200–400 mg/day (up to 700 mg/day)
LEV Pyrrolidone derivative. Mechanism of action is unknown but appears to 3 g/day
be unrelated to existing mechanisms used by other drugs
OXC Thought to block voltage-sensitive sodium channels. In addition increases 0.6–2.4 g/day
potassium conductance and modulation of high-voltage activated calcium 
channels, which may also have a role in controlling seizures
TGB Inhibits the uptake of the neurotransmitter GABA, which results in an With enzyme-inducing drugs 
increase in GABA-mediated inhibition within the brain 30–45 mg/day
Without enzyme-inducing drugs 
15–30 mg/day
TPM Sulphamate-substituted monosaccharide. Mode of action probably 200–400 mg/day
involves the following: blockade of voltage-sensitive sodium channels; Maximum 800 mg/day
enhancement of GABA activity; antagonism of certain subtypes of 
glutamate receptor; and inhibition of some isoenzymes of carbonic 
anhydrase
VGB Selective irreversible inhibitor of GABA transaminase (enzyme 2–3 g/day
responsible for the breakdown of the neurotransmitter GABA). Maximum 3 g/day
Increases levels of GABA-mediated inhibition within the brain
GABA, -aminobutyric acid.
alternative drugs has proved ineffective. These
interactions are often complex and may enhance
the toxicity of the drugs without resulting in a
corresponding increase in antiepileptic effect. The
most common interactions are usually caused by
hepatic enzyme induction or hepatic enzyme
inhibition. These interactions are highly variable
and unpredictable. Plasma monitoring is therefore
often recommended when using adjunctive
therapy. Table 3 summarises important interactions
between AEDs. 
Current indications 
Most of the newer drugs are licensed for
adjunctive therapy only (GBP, LEV, TGB, TPM
and VGB). LTG and OXC are licensed for
monotherapy or adjunctive therapy (see Table 4).
Both LTG and TPM are licensed for the widest
range of seizure types; partial onset seizures
(POSs), primary onset and secondarily generalised
tonic–clonic (SGTCs) seizures and seizures
associated with Lennox–Gestaut syndrome (see
Table 4). All of the other newer drugs are licensed
for the treatment of partial seizures with or
without secondary generalisation (see Table 4). All
the drugs are indicated for second-line treatment,
but only LTG and OXC are licensed for first-line
therapy in newly diagnosed epilepsy. All the drugs
can be used as second-line treatment where older
AEDs have been unsuccessful in controlling
epilepsy. Owing to its associated toxicities VGB is
often considered as a drug of last resort for the
treatment of refractory partial and secondary
generalised seizures that have not responded to
other AEDs. 
Warnings or cautions
Table 5 details the current warnings or cautions
and side-effects for the newer drugs.21 The
adverse effects of AEDs as a drug group are dose-
related, mild, transient central nervous system
effects.22 For adverse effects that occur with all the
drugs, frequency and severity vary across drugs.
For example, sedation is more common with
barbiturates and benzodiazepines.22 Other adverse
effects are related to specific properties shared by
only certain drugs. For example, reduced efficacy
of oral contraceptives can occur with inducers of
enzymes that metabolise these steroids.22
In particular, caution is recommended when
treating specific populations of patients. When
treating elderly patients, caution is required with
GBP (may require reduced dose), LTG, OXC and
VGB (closely monitor neurological function).
Antiepileptic treatment during pregnancy and
breastfeeding is also problematic. During
pregnancy, total plasma concentrations of
antiepileptics (particularly PHT) may fall,
especially in the later stages of pregnancy, but free
plasma concentrations may remain the same (or
even rise). AEDs also pose a risk to the unborn
Objectives and background
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TABLE 3 Summary of interactions between AEDs20,21
Drug Interactions
CBZ Often decreases plasma concentration of clobazam, clonazepam, LTG, an active metabolite of OXC and of PHT
(but may also raise PHT concentration), TGB, TPM and VPA
GBP No reported interactions
LTG Sometimes increases plasma concentration of an active metabolite of CBZ (but evidence is conflicting)
LEV No reported interactions
OXC Sometimes decreases plasma concentration of CBZ (but may raise concentration of active metabolite of CBZ).
Sometimes increases plasma concentration of PHT. Often increases plasma concentration of PB
PHT Often decreases plasma concentration of clonazepam, CBZ, LTG, an active metabolite of OXC, and of TGB,
TPM, and VPA. Often increases plasma concentration of PB. Sometimes lowers plasma concentration of
ethosuximide and PRM (by increasing conversion to PB)
TGB No reported interactions
TPM Sometimes increases plasma concentration of PHT
VGB Often reduces plasma concentration of PHT. Sometimes decreases plasma concentration of PB, and PRM
VPA Sometimes lowers plasma concentration of active metabolite of OXC. Often increases plasma concentration of
active metabolite of CBZ and of LTG, PRM, PB and PHT (but may also lower). Sometimes increases plasma
concentration of ethosuximide and PRM (and tendency for significant increase in PB level)
CZP, clonazepan; PRM, primidone.
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TABLE 4 Licensed indications for the newer AEDs21
Licensed indication
Drug name Monotherapy Adjunctive Newly Partial Generalised 
therapy diagnosed onset onset Adult Child
GBP No Yes No Yes No Yes Yes
>6 y only
LTG Yes Yes Yes Yes Yes Yes Yes
<12 y mono 
not 
recommended
LEV No Yes No Yes No Yes No
OXC Yes Yes Yes Yes No Yes Yes
>6 y only
TGB No Yes No Yes No Yes Yes
>12 y only
TPM No Yes No Yes Yes Yes Yes
>2 y only
VGB Noa Yes No Yes No Yes Yes
a VGB is licensed for use as monotherapy in West’s syndrome.
TABLE 5 Summary of warnings, cautions and side-effects of newer AEDs
Drug Warnings or cautions21 Side-effects21
GBP Avoid sudden withdrawal (taper off over at least
1 week); history of psychotic illness, elderly (may need
to reduce dose), renal impairment, diabetes mellitus,
false-positive readings with some urinary protein tests;
pregnancy and breastfeeding
Somnolence, dizziness, ataxia, fatigue; also nystagmus,
tremor, diplopia, amblyopia; pharyngitis, dysarthria,
weight gain, dyspepsia, amnesia, nervousness, coughing,
asthenia, paraesthesia, arthralgia, purpura, leucopenia;
rhinitis, myalgia, headache, rarely pancreatitis, altered
liver function tests and Stevens–Johnson syndrome;
nausea and vomiting reported
LTG Closely monitor (including hepatic, renal and clotting
parameters) and consider withdrawal if rash, fever,
influenza-like symptoms, drowsiness or worsening of
seizure control develops; avoid abrupt withdrawal
(taper off over 2 weeks or longer) unless serious skin
reaction occurs; hepatic and renal impairment; elderly;
pregnancy and breastfeeding. The Committee on
Safety of Medicines (CSM) has advised prescribers to
be alert for symptoms and signs suggestive of bone
marrow failure such as anaemia, bruising or infection.
Aplastic anaemia, bone marrow depression and
pancytopenia have been associated rarely with LTG
Commonly rashes, fever, malaise, influenza-like
symptoms, drowsiness and rarely hepatic dysfunction,
lymphadenopathy, leucopenia and thrombocytopenia
reported in conjunction with rash; angiodema and
photosensitivity; diplopia, blurred vision, conjunctivitis,
dizziness, drowsiness, insomnia, headache, ataxia,
tiredness, gastrointestinal disturbances (including
vomiting), irritability, aggression, tremor, agitation,
confusion; headache, nausea, dizziness, diplopia and
ataxia in patients also taking CBZ usually resolve when
dose of either drug is reduced. Serious skin reactions
have occurred and have been associated with
concomitant use of VPA, initial LTG dose higher than
recommended and more rapid dose escalation than
recommended
LEV Hepatic impairment; renal impairment; pregnancy and
breastfeeding; avoid sudden withdrawal
Drowsiness, asthenia, dizziness; less commonly,
anorexia, diarrhoea, dyspepsia, nausea, amnesia, ataxia,
depression, emotional lability, aggression, insomnia,
nervousness, tremor, vertigo, headache, diplopia, rash;
also respiratory tract infection
continued
foetus, although this risk is reduced if treatment is
limited to monotherapy. The associated
teratogenicity results in an increased risk of neural
tube and other defects, particularly when using
CBZ, OXC, PHT and VPA. It is recommended
that any woman taking AEDs who may become
pregnant should be fully informed of the possible
consequences. If women wish to become pregnant
they should be referred for specialist advice and if
they become pregnant whilst undergoing
treatment with AEDs, they should be counselled
and offered antenatal screening (-fetoprotein
measurement and a second trimester ultrasound
scan) in order to assess the risk to the foetus.
Costs
Over recent years, there has been an increase in
prescriptions for newer AEDs in the treatment of
epilepsy.7 Between 1994 and 1998 there was an
increase from 6.8 to 11.9% of men being
prescribed the newer drugs and from 7.5 to 13.7%
of women. The prescribing of newer AEDs was
highest in the 5–15-year-old group for both sexes
and lowest in men aged 75–84 years and women
Objectives and background
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TABLE 5 Summary of warnings, cautions and side-effects of newer AEDs (cont’d)
Drug Warnings or cautions21 Side-effects21
OXC Hypersensitivity to CBZ; avoid abrupt withdrawal;
hepatic and renal impairment; pregnancy and
breastfeeding; elderly, hyponatraemia (monitor plasma
sodium concentration in patients at risk), heart failure
(monitor body weight), cardiac conduction disorders
Nausea, vomiting, constipation, diarrhoea, abdominal
pain, dizziness, headache, drowsiness, agitation, amnesia,
asthenia, ataxia, confusion, impaired concentration,
depression, tremor, hyponatraemia, acne, alopecia, rash,
vertigo, nystagmus, visual disorders including diplopia;
less commonly urticaria, leucopenia; rarely arrhythmias,
Stevens–Johnson syndrome, systemic lupus erytheatosus,
hepatitis, thrombocytopenia, angioedema,
hypersensitivity reactions
TGB Hepatic impairment; avoid abrupt withdrawal; may
impair performance of skilled tasks (e.g. driving)
Diarrhoea, dizziness, tiredness, nervousness, tremor,
concentration difficulties, emotional lability, speech
impairment; rarely confusion, depression, drowsiness,
psychosis; leucopenia reported
TPM Avoid abrupt withdrawal; ensure adequate hydration
(especially if predisposition to nephrolithiasis);
pregnancy; hepatic impairment; renal impairment. Has
been associated with acute myopia with secondary
angle closure glaucoma, typically within 1 month of
starting treatment. Choroidal effusions resulting in
anterior displacement of the iris and lens have also
been reported. If raised intra-ocular pressure occurs,
the advice of the Committee on Safety of Medicines is
to seek specialist opthalmological advice, reduce intra-
ocular pressure and stop TPM as soon as is feasible
Abdominal pain, nausea, anorexia, weight loss; impaired
concentration and memory, confusion, impaired speech,
emotional lability with mood disorders and depression,
altered behaviour, ataxia, abnormal gait, paraesthesia,
dizziness, drowsiness, fatigue, asthenia, visual
disturbances, diplopia, nystagmus, acute myopia with
angle closure glaucoma, taste disorder, hypersalivation,
also psychotic symptoms, aggression, cognitive
problems, leucopenia
VGB Renal impairment; elderly (closely monitor
neurological function); avoid sudden withdrawal (taper
over 2–4 weeks); history of psychosis, depression or
behavioural problems; pregnancy and breastfeeding;
absence seizures may be exacerbated. Is associated
with visual field defects with onset varying from
1 month to several years after starting. In most cases,
visual field defects have persisted despite
discontinuation. Visual testing is advised before
treatment and at 6-month intervals. Patients should be
warned to report any new visual problems that
develop and those with symptoms should be referred
for an urgent opthalmological opinion
Drowsiness (rarely causes marked sedation, stupor and
confusion with non-specific slow wave EEG), fatigue,
visual field defects, dizziness, nervousness, irritability,
behavioural effects such as excitation and agitation
especially in children; depression, abnormal thinking,
headache, nystagmus, ataxia, tremor, paraesthesia,
impaired concentration; less commonly confusion,
aggression, psychosis, mania, memory disturbance, visual
disturbance (e.g. diplopia); also weight gain, oedema,
gastrointestinal disturbances, alopecia, rash; less
commonly urticaria, occasional increase in seizure
frequency (especially if myoclonic), decrease in liver
enzymes, slight increase in haemoglobin; photophobia
and retinal disorders (e.g. peripheral retinal atrophy);
optic neuritis, optic atrophy also reported
aged ≥ 85 years. The threefold increase in the cost
of prescribing AEDs in the community has been
largely attributed to the increased prescribing of
newer AEDs, which are more expensive.7 Of the
four drugs that accounted for the highest
percentage of these costs, GBP and LTG
accounted for 44% of the total cost and 9% of the
total prescription volume, whereas CBZ and VPA
accounted for 35% of the total cost and 56% of the
total volume.7 These data are based on prescribing
analyses and cost (PACT) data, which also include
prescriptions for conditions other than epilepsy,
e.g. GBP is primarily licensed for the treatment of
neuropathic pain. 
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Assessment of clinical effectiveness
Search strategy
The sources below were searched for studies
relating to the clinical effectiveness of the newer
AEDs, GBP, LTG, LEV, OXC, TGB, TPM and
VGB. This first set of literature searches were
designed to retrieve systematic reviews and
randomised controlled trials (RCTs) only.
However, some databases cannot be reliably
restricted by study type and in these cases the
search was not limited by study design, and the
results of the searches were screened by hand. A
range of free text terms and subject headings were
used as appropriate. Further details of the search
strategies are reported in Appendix 2.
CRD internal administration databases (searched
20 March 2002)
 Database of Abstracts of Reviews of Effects (DARE)
 Health Technology Assessment Database (HTA) 
Internet resources and databases (searched 
2 April 2002)
 Controlled Clinical Trials
http://controlled-trials.com
 Health Evidence Bulletins Wales
http://www.uwcm.ac.uk/uwcm/1b/pep
 Health Services Technology Assessment Text
(HSTAT)
http://text.nlm.nih.gov/
 Index to Scientific and Technical Proceedings
(ISTP)
http://wos.mimas.ac.uk/
 National Coordinating Centre for Health
Technology Assessment (NCCHTA)
http://www.hta.nhsweb.nhs.uk
 National Guideline Clearinghouse
http://www.ahcpr.gov/clinic/assess.htm
 National Institute for Clinical Excellence
(NICE) (published appraisals)
http://www.nice.org.uk/nice-web/
 Science Citation Index (SCI) (1981 onwards)
http://wos.mimas.ac.uk/
 Scottish Intercollegiate Guidelines Network
(SIGN) Guidelines
http://www.sign.ac.uk/
 Turning Research Into Practice (TRIP) Index
http://www.ceres.uwcm.ac.uk/framset.cfm?
section=trip 
CD-ROM resources
 Cochrane Controlled Trials Register (CCTR)
(2002: Issue 1) (searched: 2 April 2002)
 Cochrane Database of Systematic Reviews
(CDSR) (2002: Issue 1) (searched: 2 April 2002)
 EMBASE (1980–February 2002) (searched: 
27 March 2002)
 MEDLINE (1966–March 2002) (searched: 
26 March 2002)
 National Research Register (NRR) (2002: 
Issue 1) (searched: 2 April 2002)
 PREMEDLINE (up to 22 March 2002)
(searched: 26 March 2002)
 PsycINFO (1967–week 3, July 2002) (searched:
3 September 2002)
Online resources (searched 8 April 2002)
 Conference Papers Index (CPI) (1973 onwards)
Paper resources
 Clinical evidence: a compendium of the best available
evidence for effective health care. Issue 6, 2001.
London: BMJ Publishing Group.
No date or language restrictions were placed on
any of the literature searches. Owing to financial
and logistical constraints, non-English publications
were not included in the review. However, not
limiting the literature searches by language
enabled an estimate of the size of the non-English
literature to be obtained. In addition, search
strategies were not limited by age although the
review only included data relating to adults. This
was due to the fact that many records do not
mention the appropriate patient group within the
title, abstract or indexing.
The bibliographies of all included studies were
reviewed in order to identify any further relevant
studies. A list of studies found from bibliographies
and industry submissions, but not meeting the
inclusion criteria for this review, are listed in
Appendix 3.
Inclusion and exclusion criteria 
Two reviewers independently screened all titles
and abstracts in order to determine relevance. Full
paper manuscripts of potentially relevant titles
and abstracts were obtained where possible and
the eligibility of the study for inclusion in the
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Chapter 2
Methods
review was assessed by two authors independently,
according to the four criteria outlined below. Any
discrepancies were resolved by consensus and, if
necessary, a third reviewer was consulted. Studies
that did not fulfil all of the criteria were excluded.
Owing to time and financial constraints, only
studies reported in English were included in the
analysis section of this review. Eligible studies in
other languages were identified but only brief
details tabulated. 
Study design
The following study designs were included in the
review: 
 Single-blinded, double-blinded or unblinded
RCTs using a parallel or crossover design,
designed to assess the equivalence, non-
inferiority or superiority of comparators
 Systematic reviews meeting the criteria for
inclusion in DARE
(http://nhscrd.york.ac.uk/darehp.htm)
Participants
Studies recruiting adults (i.e. individuals aged
18 years or over) with either newly diagnosed or
refractory epilepsy were included. Seizure types
included POS (with or without secondary
generalisation) and generalised onset seizures.
Trials enrolling only patients with single seizures,
status epilepticus, seizures following neurosurgery
or head injury and trigeminal neuralgia were
excluded. Studies that enrolled participants with
excluded indications were evaluated to determine
whether (1) the study results reported data for the
excluded indications groups of participants
separately or (2) the number of excluded
indications participants was small. In either case
the relevant data were included in this review. 
Studies with mixed age groups were identified
during the inclusion/exclusion process. The data
reported in these studies were discussed and divided
accordingly in coordination with the Birmingham
review team responsible for reviewing the evidence
for the treatment of children. The discussion
determined whether (1) the study results reported
data for the different age groups of participants
separately or (2) the numbers of younger or older
participants were small. Data were only extracted if
relevant to the age group under consideration.
Interventions
Newer AEDs (GBP, LTG, LEV, OXC, TGE, TPM
and VGB) used either as monotherapy and/or
adjunctive therapy were included. Comparators
included older AEDs, newer AEDs or placebo.
Trials in which epilepsy surgery was the
comparator were excluded. Older AEDs included
AZM, benzodiazepines, CBZ, ethosuximide, PB
and other barbiturates, PHT and VPA.
Outcomes
A wide range of outcomes were extracted from the
studies, including: 
 Time to withdrawal after randomisation.
 Time to first, second or other seizure after
randomisation (time to first seizure after
randomisation allowed the determination of the
proportion of patients at different time points
who remained seizure free).
 Time to achieving remission (e.g. at 6 months,
1 year or 2 years).
 Change in seizure severity.
 Change in seizure frequency.
 Proportion of responders (response defined as a
≥ 50% reduction in seizure frequency).
 Change in seizure-free interval.
 Change in seizure duration.
 Change in seizure pattern.
 Change in functional capacity.
 Patient-related quality of life (QoL).
 Cognitive function.
 Withdrawal from therapy due to one or more
adverse events (AEs)
 Incidence, prevalence and severity of adverse
events at different time points.
However, the analysis focused on the following
outcomes
 proportion of seizure-free participants
 proportion of participants experiencing at least
a 50% reduction in seizure frequency (i.e.
responders)
 time to exit/withdrawal
 time to first seizure
 all QoL outcomes
 all outcomes relating to cognitive function
 safety (incidence of adverse events, mortality
rate) and tolerability (incidence of withdrawals).
Appendix 4 lists the definitions for QoL outcomes
included in the review and Appendix 5 those for
cognitive outcomes.
Data extraction strategy
Data relating to study design, participants,
interventions and outcomes were extracted in a
standardised manner into an Access database by
one reviewer and independently checked for
accuracy by a second reviewer. Details of the types
of data extracted are listed in Appendix 6.
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Attempts were made where possible to contact
authors for missing data. Data from studies with
multiple publications were extracted and reported
as a single study. Where studies reported
cognitive/QoL data and seizure frequency
outcomes in separate publications, both
publications were considered.
Quality assessment strategy
Systematic reviews
To be included in the review of effectiveness, as
previously mentioned, all systematic reviews were
required to meet the criteria necessary for inclusion
in DARE. Refer to Appendix 7 for the list of criteria
used to assess the quality of systematic reviews.
These criteria assess the quality of the review and so
any reviews meeting the inclusion criteria were
judged to be of reasonable quality. Assessment of
the criteria was performed by one reviewer and
independently checked by a second reviewer.
Disagreements were resolved through consensus
and, if necessary, a third reviewer was consulted.
Randomised controlled trials
The quality of the individual RCTs was assessed
using criteria adapted from those used in the
publication Undertaking systematic reviews of research
on effectiveness: CRD’s guidance for carrying out or
commissioning reviews.23 In addition, quality issues
specifically pertaining to crossover24,25 and
equivalence trials26,27 were applied where
appropriate. Refer to Appendix 8 for the list of
criteria used to assess the quality of the individual
RCTs.
In each case, the quality of the trials was assessed
by one reviewer and independently checked by a
second reviewer. Disagreements were resolved
through consensus and, if necessary, a third
reviewer was consulted.
Handling company submissions
Data submitted by drug manufacturers by the
deadline of 6 September 2002 were included.
Submissions were checked for unpublished studies
and any additional relevant information in
relation to already published studies. Unpublished
studies were assessed according to the
inclusion/exclusion criteria above. Data extraction
and quality assessment were carried out as for
published studies. No submissions were received
from the manufacturers of GBP or VGB.
Data analysis
Systematic reviews
Data identified from systematic reviews are
summarised in table form and briefly discussed in
relation to the requirements and findings of this
current review.
Randomised controlled trials
Data from the RCTs were presented in tables and
discussed in a narrative. Effect sizes [relative risks
(RRs) or hazard ratios (HRs) with 95% confidence
intervals (CIs)] were reported where appropriate.
RRs and HRs were considered to be statistically
significant if the range of the 95% CIs did not
include 1. Data were only pooled statistically
(fixed-effects model) if studies were considered to
be clinically and statistically (Q-statistic)
homogeneous. Owing to the low power of the 
Q-statistic where numbers of studies are small (i.e.
<20), a p-value of 0.10 was used as a threshold for
statistical significance. Studies were only pooled
using the fixed-effects model if the Q-statistic was
less than the number of degrees of freedom (df)
and the associated p-value >0.10.
Assessment of serious, rare and
long-term adverse events studies
Search strategy
Literature searches were carried out to identify
serious, rare and long-term adverse events not
likely to have been found by the clinical
effectiveness RCT search strategies. The searches
aimed to find studies of adverse effects of the
seven drugs irrespective of the condition treated.
Therefore, no epilepsy terms were added. It is well
reported in the literature that conducting
electronic database searching for adverse events is
problematic.28–30 The procedure for tracing papers
of adverse events is not as well established as in
other areas of research such as RCTs and systematic
reviews. A broad experimental search strategy was
therefore adopted using textwords and thesaurus
terms for each drug limited to the appropriate
subheadings and known serious or rare adverse
effects as both textwords and thesaurus terms.
Adverse effects deemed serious fell into one or
more of the following categories: death, life
threatening, hospitalisation, disability (including
vision), congenital abnormality, cancer and
overdose.
Databases were searched from the date of
inception to the most recent date available.
Internet resources and databases (all searched
9 September 2002)
 ABPI electronic Medicines Compendium (eMC)
(Version 2)
http://emc.vhn.net/
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 Controlled Clinical Trials
http://controlled-trials.com
 Developmental and Reproductive Toxicology
(DART/ETIC)
http://toxnet.nlm.nih.gov/cgi-
bin/sis/htmlgen?DARTETIC
 Drug Checker – Interactions Search
http://www.drugs.com/data/channel/md/
drkoop.cfm?int=1://
 Drug facts and comparisons
http://www.drugfacts.com
 Emedicine
http://www.emedicine.com/
 General Practice Notebook
http://www.gpnotebook.co.uk
 Health Evidence Bulletins of Wales
http://hebw.uwcm.ac.uk/
 HSTAT
http://text.nlm.nih.gov/
 ISTP (1990 onwards)
http://wos.mimas.ac.uk/
 The Merck Manual
http://www.merck.com
 NCCHTA
http://www.hta.nhsweb.nhs.uk
 National Guideline Clearinghouse
http://www.ahcpr.gov/clinic/assess.htm
 NICE (published appraisals)
http://www.nice.org.uk/nice-web/
 SCI (1981 – onwards)
http://wos.mimas.ac.uk/
 SIGN Guidelines
http://www.sign.ac.uk/
 TOXLINE – Toxicology Bibliographic
Information (1965 – present)
http://toxnet.nlm.nih.gov/cgi-
bin/sis/htmlgen?TOXLINE
 TRIP Index
http://www.ceres.uwcm.ac.uk/framset.cfm?
section=trip
CD-ROM resources (searched 10 September
2002)
 EMBASE (1980 – week 36, 2002)
 MEDLINE (1996 – week 4, August 2002) 
Paper resources (searched: 4 September 
2002)
 ABPI medicines compendium. Epsom: Datapharm
Communications; 2002.
 AHFSFirst professional edition version 2.71.
Bethesda, MD: American Society of Health-
System Pharmacists; 2002.
 British National Formulary (BNF). London:
British Medical Association/Royal
Pharmaceutical Society of Great Britain. 
Issue 43 March 2002.
 Dukes MNG, Aronson JK, editors. Meylers’s side
effects of drugs: an encyclopedia of adverse reaction
and interactions. 14th ed. Oxford: Elsevier; 2000.
 Sweetman SC, editor. Martindale: the complete
drug reference. 33rd ed. London: Pharmaceutical
Press; 2002.
Further details of the full search strategy are
reported in Appendix 2.
Inclusion and exclusion criteria
In this review, non-randomised experimental
studies and observational studies were included to
enhance retrieval of information about serious, rare
and long-term AEs. Reporting of safety data in
RCTs is largely inadequate31–34 and most systematic
reviews of RCTs only include safety data as reported
in the primary studies. Furthermore, RCTs are
often too small and of insufficient duration to
detect rare and delayed AEs. Consequently,
evaluation of the safety of therapeutic interventions
needs to go beyond RCTs.
Two reviewers independently screened all titles
and abstracts against predefined inclusion criteria.
Differences were resolved by discussion and full
papers were obtained for all studies potentially
eligible for inclusion. Two reviewers then
independently applied the inclusion criteria to all
full papers and differences were again resolved by
discussion.
Three categories of studies were included:
 Studies that investigated the effects of newer
AEDs, including safety and/or tolerability. Study
designs eligible for inclusion were uncontrolled
trials, open-label extension phases of controlled
trials, cohort studies (controlled or uncontrolled)
and case–control studies. These studies, RCTs of
newer AEDs in diseases other than epilepsy, and
RCTs of dose or titration comparisons in
epilepsy, were included only if more than 300
participants were exposed to the newer AED or
if follow-up exceeded 6 months. These limits
were based on the duration and size of
effectiveness RCTs to identify longer and larger
studies. Combination therapies and dose
comparisons were included within the
aforementioned parameters. Case series, case
reports, cross-sectional studies, audits and
surveys were excluded.
 Studies that investigated a specific adverse
effect [such as visual field defects (VFDs)]. Study
designs eligible for inclusion were as described
above but without the restriction on study size
or duration.
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 Reports of prescription event monitoring 
(PEM) studies and prospective postmarketing
surveillance (PMS) studies. Spontaneous case
reports of suspected adverse drug reactions
such as those collated by the Medicines 
Control Agency and other bodies were not
included.
Data extraction strategy
One reviewer extracted data using a standardised
data extraction form (see Appendix 9). Adverse
effects data were extracted in detail only for
serious, rare and long-term effects and for
withdrawal or discontinuation of treatment due to
adverse effects. Published sources were used for
guidance on the nature of serious and rare AEs
associated with the newer AEDs.22,35,36 Serious
included death, life threatening, hospitalisation,
disability, congenital abnormality, cancer and
overdose. Both serious and rare included any
effect defined as such in the study reports. Long-
term was defined as longer than 6 months.
PEM and prospective PMS studies were data
extracted directly into summary tables by one
reviewer.
Quality assessment strategy
Data on methodological quality were extracted by
one reviewer using standardised data extraction
forms. Cohort and case–control studies were
assessed using criteria derived from Centre for
Reviews and Dissemination (CRD) Report 4 (see
Appendix 10).23 RCTs, non-randomised and
uncontrolled studies were assessed against the
criteria used in the review of effectiveness (see
Appendix 8). As there is no tool to assess the
internal validity of open-label extension phase or
follow-up studies, three appraisal questions taken
from the tools used to assess other study designs
were applied. These were chosen as useful
indicators of selection bias (one aspect of internal
validity), and how appropriate the dose of AED
and the length of follow-up were (aspects of
external validity). PMS and PEM studies were not
quality assessed owing to the lack of an
appropriate tool; the methods used in those
studies are summarised in the included studies
tables.
Handling company submissions
Data submitted by drug manufacturers by the
deadline of 6th September 2002 were searched 
for relevant studies according to the
aforementioned inclusion criteria. No submissions
were received from the manufacturers of GBP or
VGB. 
Data analysis
Tables describing the included studies and a
narrative synthesis were presented for each drug. 
Assessment of cost-effectiveness
Search strategy
Those databases restricted by study design in the
clinical effectiveness searches were searched again
using a search strategy designed to retrieve cost-
effectiveness studies or economic models. Two
specialist databases were also searched, the NHS
Economic Evaluation Database (NHS EED) and
the Health Economic Evaluations Database
(HEED). No economic filter was necessary for
these databases.
CRD internal administration databases (searched
20 March 2002)
 NHS EED
CD-ROM resources 
 EMBASE (1980–February 2002) (searched: 
27 March 2002)
 HEED (March 2002) (searched: 28 March 2002)
 MEDLINE (1966–March 2002) (searched: 27
March 2002)
 PREMEDLINE (up to 22 March 2002)
(searched: 27 March 2002)
Further details of the search strategies used are
reported in Appendix 2.
Inclusion and exclusion criteria
Three reviewers independently screened all of the
titles and abstracts of the retrieved references
according to following inclusion criteria. Any
disagreements were resolved by consensus.
Study design
Only full economic evaluations were included.
Types of designs included:
 Cost-effectiveness analyses (CEAs) including
cost-minimisation analyses (CMAs) and
cost–consequences analyses
 Cost–benefit analyses (CBAs)
 Cost–utility analyses (CUAs)
Participants
Studies recruiting adults (i.e. individuals aged
≥ 18 years) with either newly diagnosed or
refractory epilepsy were included. Seizure types
included both POS (with or without secondary
generalisation) and generalised onset. Trials
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enrolling only patients with single seizures, status
epilepticus, seizures following neurosurgery or
head injury and trigeminal neuralgia were
excluded. Studies that enrolled participants with
both included and excluded indications were
evaluated to determine whether (1) data for
included and excluded participants were reported
separately or (2) the number of participants with
excluded indications was small. Any relevant data
were included.
Interventions
Newer AEDs (GBP, LTG, LEV, OXC, TGB, TPM
and VGB) used either as monotherapy and/or
adjunctive therapy were included. Comparators
included older AEDs, newer AEDs or placebo.
Trials where epilepsy surgery was the comparator
were excluded. Older AEDs included AZM,
benzodiazepines, CBZ, ethosuximide, PB and
other barbiturates, PHT and VPA.
Outcomes
In order to be included in the review of cost-
effectiveness, evaluations had to report both costs
and clinical effectiveness.
Data extraction strategy
Data from each individual study were extracted into
an Access database by one reviewer and checked by
a second reviewer. Details of the categories of data
extracted are presented in Appendix 11. 
Quality assessment strategy
The quality of each published economic evaluation
was assessed independently by two reviewers using
the criteria listed in Appendix 12. Appendix 13
lists the economic model with any associated
quality issues. In both cases, disagreements were
resolved through discussion with a third reviewer 
if necessary. 
Handling company submissions
Data submitted by drug manufacturers by the
deadline of 6 September 2002 were included.
Submissions were checked for unpublished
economic evaluations and models. Such
evaluations were subjected to similar processes
(carried out by reviewers DE and NH) of study
selection, data extraction and data analysis as
reported for published evaluations.
Data analysis 
Summary tables of the data within the included
economic evaluations are presented along with a
critical appraisal of the design and findings of
each of the evaluations. In addition, an overview
and comparison of the models reported within the
company submissions is presented, in order to
assess the suitability of the evaluations for use in
an integrated economic evaluation of all the 
newer AEDs. 
Both the clinical and cost-effectiveness sections of
the report employ meta-analysis techniques to
summarise the trial evidence in order to aid
decision-making. The clinical effectiveness analysis
employed traditional meta-analytic techniques.
The pooling of data in the clinical effectiveness
section was only performed where the data were
found to be statistically homogeneous. The CEA
required a measure of the absolute response rate
for each treatment under consideration. A
systematic analysis using mixed treatment
comparisons was undertaken in order to estimate
these measures. The heterogeneity between studies
was to some extent incorporated in the measures of
uncertainty surrounding the mean response rates. 
Integrated economic evaluation
In order to determine the cost-effectiveness of the
newer AEDs, all of the relevant available
treatments must be directly compared. As
described in the section ‘Analysis’ (p. 22), none of
the published evaluations or industry submissions
represented a direct comparison of all of the
newer and older AEDs specified in the scope for
this review. Therefore, a decision analytic model
was developed which incorporated all of the
available information on the cost-effectiveness of
the various newer and older AEDs that allowed
direct comparisons to be made. The details of the
structure of this analytic model, the information
used to parameterise it and the results of the
analysis are described in the section ‘Integrated
analysis of cost-effectiveness’ (p. 105). In summary,
a CUA was performed: using quality-adjusted life-
years (QALYs) calculated using utility weights
estimated from EQ-5D responses and UK public
valuations, so that the cost-effectiveness of the
newer AEDs could be compared with the cost-
effectiveness of treatments for other conditions.
Methods
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Quantity of research available
Clinical effectiveness studies
Included studies
Figure 1 summarises the inclusion/exclusion
process. A total of 4211 titles and abstracts were
screened for relevance. Of these, 887 full paper
copies of studies were ordered. After further
examination, an additional 616 papers were
excluded. From the remaining 271 papers and
additional studies in the manufacturers’
submissions, 142 studies were finally included in
the review: 13 systematic reviews, 108 effectiveness
studies (see Appendix 14) and 21 economic
papers. The remaining 121 papers were identified
as duplicate publications and abstracts. For studies
with multiple publications only the main
publication for each study has been assessed.
Related publications are listed (see Appendix 15)
and were checked for any additional information
missing from the main publication. Where studies
had separate publications for seizure outcomes
and QoL/cognitive outcomes, both publications
were included.
Seven clinical effectiveness RCTs and one
economic evaluation that met the inclusion criteria
were not published in English. Owing to time
constraints these were not included in the main
assessment of effectiveness (see Appendix 16).
The manufacturers’ submissions revealed an
additional six relevant clinical effectiveness RCTs
and 10 economic evaluations. These were also
included in the review, bringing the total number
of studies to 142 (13 systematic reviews, 108
effectiveness RCTs and 21 economic evaluations).
Excluded studies
In total, 3324 references did not appear to be
relevant and were excluded at the first stage of
screening (title and abstract screening). After
further examination, 616 of the papers were
excluded for the following reasons: literature
reviews/background (175); systematic reviews/meta-
analyses not meeting criteria (132); not RCT
(118); not relevant intervention (9); not relevant
population (18); not relevant outcomes (4); dose
comparison studies (19); unavailable publications
[104; consisting of NRR records of registered trials
in progress (92) and unable to obtain the paper
(12)]; methodology papers (6); follow-up studies
(19); unsure (4); ongoing studies (4); and non-
English studies (4). For the 12 papers not
obtainable, these were from six journal issues, and
comprised conference abstracts (9), foreign
language papers (1) and background papers (2).
Non-English language studies are summarised in
Appendix 16 and ongoing studies are summarised
in Appendix 17.
Serious, rare and long-term adverse
events studies
Included studies
Literature searches retrieved a total of 3884 titles
and abstracts, which were screened for relevance.
A total of 227 full paper copies of potentially
relevant studies were ordered. Further
examination of these papers revealed 86
publications that met the inclusion criteria. These
publications related to 75 studies. Two additional
studies were identified from the manufacturers’
submissions, bringing the total number of studies
included in the review to 77.
Excluded studies
During the screening of title and abstracts, 3657
papers were excluded as not being relevant. After
further examination of the 227 full papers that
were ordered a further 110 studies (141
publications) were excluded for the following
reasons: non-English publication (60), incorrect
study design (13), insufficient number of
participants (3), length of follow-up too short (7),
insufficient number of participants and length of
follow-up too short (11), no relevant data (4),
duplicate publications (2), ongoing study (1), study
included in main review of clinical effectiveness
(1), pooled data (not systematic review) (2) and
review (not systematic) (6).
Cost-effectiveness studies
Included studies
All 4211 titles and abstracts were screened for
relevance as in Figure 1. Of these, 55 were 
selected as being potentially relevant. Seven
references referred to the ongoing UK SANAD
trial and authors were contacted regarding the
availability of interim results. Full paper copies of
the remaining 48 titles/abstracts were ordered.
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Titles and abstracts
identified and screened,
n = 4211
Excluded,
n = 3324
Full copies retrieved and
inspected,
n = 887
Excluded n = 616
• Literature reviews/
background, n = 175
• Systematic
reviews/meta-analyses
not meeting criteria,
n = 132
• Not RCT, n = 118
• Not relevant
intervention, n = 9
• Not relevant population,
n = 18
• Not relevant outcomes,
n = 4
• Dose comparison
studies, n = 19
• Unable to obtain paper
copies, n = 104
• Methodology papers,
n = 6
• Follow-up studies,
n = 19
• Unsure, n = 4
• Ongoing studies, n = 4
• Non-English language,
n = 4
Publications meeting
inclusion criteria,
n = 271
Studies meeting
inclusion criteria,
n = 126
Systematic reviews, n = 13
Effectiveness RCTs, n = 102
Economic evaluations, n = 11
Total number of studies
included in the review,
n = 142
Systematic reviews, n = 13
Effectiveness RCTs, n = 108
Economic evaluations, n = 21
Non-English language
studies meeting
criteria,
n = 8
Systematic reviews, n = 0
Effectiveness RCTs, n = 7
Economic evaluations, n = 1
Unpublished studies
provided by drug
manufacturers,
n = 16
Systematic reviews, n = 0
Effectiveness RCTs, n = 6
Economic evaluations, n = 10
Related publications
Abstracts or duplicates
of included studies,
n = 121
FIGURE 1 Summary of study identification, retrieval and inclusion/exclusion
After further examination, a total of 12 papers
were found to fulfil the inclusion criteria for
economic evaluations. Of these 12 papers, two
were found to address the same study. In total, 
11 economic evaluations of AEDs were included
in the review.
In addition to these published evaluations,
submissions from five of the drug manufacturers
(no submissions were received from the
manufacturers of GBP or VGB) revealed an
additional 10 previously unpublished economic
evaluations, bringing the total number of
economic evaluations included in the assessment
of cost-effectiveness to 21.
Excluded studies
Of the 4211 references retrieved through the
literature searches, 4156 were excluded at the first
stage of screening (title and abstract screening) as
they did not appear to be relevant. After further
examination of the 48 full paper copies that were
ordered, a further 36 references were excluded for
the following reasons: background papers (24), no
economics data (4), letters or comments on the
economic evaluations (4), duplicates (2), economic
evaluation of surgery (1) and non-English
publication (1).
Quality of included studies
Clinical effectiveness studies
Systematic reviews
The quality of the systematic reviews was assessed
using criteria developed by CRD for DARE (see
Appendix 7). Only reviews considered as being of
adequate quality according to these criteria were
included in the review and hence all of the reviews
were of reasonable quality. In addition, all of the
included reviews were produced by the Cochrane
Collaboration and so were subject to the
organisation’s own quality standards.
Randomised controlled trials
The quality of the effectiveness studies was
assessed as outlined in the methods section using
the criteria listed in Appendix 8. Details of the
quality of individual studies are reported in
Appendix 18 according to drug and study design
(parallel and crossover studies). In addition, a
summary table is provided in Appendix 19 listing
the main quality issues of concern for each study
and the assessment of quality according to the
three quality issues that have been shown to affect
study outcomes: use of an appropriate method of
randomisation; use of an appropriate method of
allocation concealment; and effective blinding of
outcome assessors, clinicians and participants.37
The quality assessment shows that there were a
number of problems associated with the studies.
Certain problems only related to individual
studies, but there were a number of issues that
were common across studies. It was difficult to
assess the true quality of many studies owing to
poor reporting. For example, the summary table
(see Appendix 19) shows that many details
relating to randomisation, allocation concealment
and blinding were not reported. In certain
circumstances, only abstract reports were available
and so again details relating to the quality of the
studies concerned were often lacking. However,
important issues of study quality such as those
reported above are discussed in the results section
of the report in order to put the findings of the
studies in context and highlight any potentially
biased results.
In the following section, each of the quality
criteria is discussed individually and the overall
quality of the studies is summarised briefly
according to the criterion. 
1. Were the eligibility criteria for the study
specified?
Reporting the eligibility criteria for a study is
important in determining how applicable the
findings of the study are to the general population
of individuals with epilepsy. In this review, it was
important in determining whether studies should
be included in terms of the ages of the
participants (only studies of adults were included
in this review) and in assessing the effectiveness of
the drugs in specific groups of individuals (i.e. the
elderly, those with intellectual disabilities and
pregnant women).
The majority of studies (95) were judged to have
provided adequate details of their eligibility
criteria. However, details were lacking in 16
studies and four failed to provide details.38–40 Two
of these studies were only published in abstract
form.40,41
2. Was an a priori power calculation for adequate
sample population size performed?
An a priori power calculation is important in
determining whether a study has sufficient
numbers of participants to detect significant
differences in the outcome measures under
assessment. In the case of equivalence studies this
is particularly important as a greater number of
participants are required to demonstrate
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equivalence and hence any a priori power
calculation should be adequate to test the null
hypothesis. 
Details of a priori power calculations were
presented in less than half of the studies (50). In
the remaining studies (63) details were not
presented and in two cases it was unclear whether
the power calculations were performed before or
after the study was completed.39,42
3. Was the number of participants who were
randomised stated?
This criterion is important when assessing the size
of the study and for assessing what happened to
participants through the process of the trial in
order to assess the potential for ‘attrition bias’ or
‘exclusion bias’.
The majority of the studies reported the number
of participants randomised. Only six studies failed
to do so.40,43–47 Five of these studies were reported
in abstract form only.40,44–47
4. Was the method used to assign participants to
the treatment groups really random?
Adequate randomisation is important in
preventing bias in study findings. For the purposes
of this review, computer-generated random
numbers and random number tables were
accepted as adequate. In contrast, approaches
considered inadequate included the use of
alternation, case record numbers and birth dates
or days of the week. These are classed as ‘quasi’
methods of randomisation.
Poor reporting was the main problem in assessing
this criterion. In 74 studies there was insufficient
information to assess whether the process of
randomisation was adequate. However, where
details were reported (41), the methods were
found to be adequate in all cases.
5. Was the allocation of treatment concealed? 
This criterion relates to the concealment of the
treatment allocation process so as to prevent
tampering or interference. Research has shown
that lack of adequate allocation concealment is
associated with bias and this criterion has been
found to be more important than the method of
randomisation in preventing bias.37 For this
review, methods considered to provide adequate
concealment of the treatment allocation included
centralised or pharmacy-controlled assignment or
where the following were used: serially numbered
containers, serially numbered opaque envelopes
and on-site computer-based systems where
assignment is unreadable until after allocation.
Other robust methods considered adequate to
prevent foreknowledge of the allocation sequence
to clinicians were also considered as fulfilling this
criterion. Any predictable or decipherable
sequence was considered inadequate.
In the majority of studies (78), it was unclear
whether the method used in the study was
adequate, as the method used was not reported.
However, 37 studies used methods that were
considered adequate.
6. Were the outcome assessors blinded to the
treatment allocation?
Outcome assessors may have an opinion about the
efficacy of the treatment under investigation. This
may influence the reporting of the outcome data if
the treatment allocation is not blinded, thereby
distorting study findings. In addition, if outcome
assessors are aware of which treatment patients are
receiving, this may influence their interpretation
of marginal findings or cause them to provide
differential encouragement during assessments.
Blinding of outcome assessors ensures that they
are ignorant of the allocated intervention. This
protects against performance and detection bias,
and can also contribute to adequate concealment
of allocation. 
The majority of studies (80) did not report
whether outcome assessors were blinded to
treatment allocation. Twenty studies reported
outcome assessors to be blinded and 10 reported
that they were unblinded. In four studies assessors
were blinded to some but not all of the outcomes
assessed.48–51
7. Were those individuals who administered 
the intervention blinded to the treatment
allocation?
Individuals administering the intervention may
have an opinion about the efficacy of the
treatment under investigation. Again blinding
prevents any such individuals from unduly
influencing the trial outcomes. Blinding of
individuals administering the intervention ensures
that they are ignorant of the allocated
intervention. This protects against performance
and detection bias, and can also contribute to
adequate concealment of allocation.
The majority of studies (68) did not report if those
administering the interventions were blinded to
treatment allocation. Where reported,
administrators were blinded in 31 studies and
unblinded in 16 studies.
Results
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8. Were the participants who received the
intervention blinded to the treatment allocation?
Participants’ opinions about a particular treatment
may also influence the outcome of a trial if
treatment allocation is unblinded.
Participants were blinded to treatment allocation
in the majority of studies, although in 15 studies
they were not. Three studies did not provide
sufficient detail to determine whether participants
were blind.40,52,53 However, two of these studies
were reported in abstract form only and hence
lack detail.40,52
9. Was the success of the blinding procedure
assessed?
Where blinding procedures were reported, it is
important that the success of such procedures is
assessed to determine if individuals remained
blinded throughout the study or if at any point
blinding was broken. 
This criterion was not applicable in 12 studies
where outcome assessors, those administering the
intervention and participants were unblinded.
Where applicable, the majority of the studies (100)
did not report whether the success of the blinding
procedure was assessed and only three studies
reported assessing the success of blinding.54–56
10. Were details of the baseline comparability of
the treatment groups presented?
It is important that details of the baseline
comparability of treatment groups are presented in
order to determine if the groups were similar at
the start of the study. Treatment groups should be
similar in terms of baseline characteristics such as
age and gender, and also characteristics that are
specific to the prognosis and outcome. Ideally,
treatment groups should be similar for all the
factors that determine the clinical outcomes, except
whether they received the experimental treatment.
Sixty-seven studies presented details of baseline
comparability of treatment groups and 34 studies
did not present any such details. Fourteen studies
presented some but not all specified baseline
comparability details. 
11. Were adjustments made for differences in the
baseline characteristics of the treatment groups?
If treatment groups differ in terms of baseline
characteristics, statistical analyses that permit
adjustment of the study result for baseline
differences should be used to ensure that any
observed effects in outcome are unaffected.
Ideally, both adjusted and unadjusted analyses
should be used, if baseline differences exist, and
estimates should be compared and implications
for any observed differences discussed. Where
there were no differences in baseline
characteristics, this criterion was not applicable. 
Adjustments for differences in baseline
characteristics were not applicable for the majority
of studies (66). Where applicable, seven studies
made adjustments and 42 provided insufficient
detail to determine if adjustments were made.
12. Were appropriate doses of the intervention
drugs used?
Doses of control drug should be appropriate for
clinical practice. For the purpose of this review,
appropriate dose ranges were as reported by the
BNF.21 Any doses below the lowest recommended
limit or exceeding the upper recommended limit
were considered inappropriate.
The majority of studies (94) used appropriate doses
of the intervention drug. In 14 studies, some doses
were appropriate, but others were not. In three
studies all doses were outwith the recommended
range.41,45,57 Four studies failed to report the dose
of the intervention drug.58–61 Three of these were
only published in abstract form.59–61
13. Were appropriate doses of the control drugs
used?
Doses of control drug should be appropriate for
clinical practice. For the purpose of this review,
appropriate dose ranges were as reported by the
BNF.21 Any doses below the lowest recommended
limit or exceeding the upper recommended limit
were considered inappropriate. This criterion was
considered not applicable for placebo. 
This criterion was not applicable in 71 studies.
Where applicable, all but 10 studies used
appropriate doses. In five studies, some doses were
appropriate but others were not. In one study the
dose was higher than the recommended range.45
Four studies, two of which were reported in
abstract form only,59,61 failed to report the dose of
control drug.58,59,61,62
14. Were any co-interventions identified that
could influence the outcomes for the treatment
groups?
Co-interventions may influence outcome effects
and so weaken or distort findings. This is
particularly important if two treatment groups
differ in this regard. The presence of co-
interventions is most problematic when studies are
not double-blind, or when very effective non-study
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treatments are allowed at the physician’s
discretion.63 For the purpose of this review newer
AEDs, other than those under investigation, were
considered to be co-interventions that could
influence the outcomes. 
Only 10 of the studies reported co-interventions
that may have influenced the outcomes. The
remaining studies did not report any such co-
interventions. 
15. Was patient adherence to the assigned
treatment assessed?
It is important to assess patient adherence to
treatment, as deviations from the treatment
protocol could influence outcome effects. For the
purpose of this review, one appropriate method for
assessing patient compliance was the measurement
of plasma AED levels. Residual pill counts were also
considered appropriate, although this method
would be open to abuse unless medication was
administered under supervision. Participant
response to questioning was considered inadequate. 
Over half of the studies (63) failed to report
whether compliance was assessed. The remaining
studies (52) used adequate methods of assessment. 
16. Were all patients who were originally
considered for the study accounted for at its
conclusion?
Some participants may leave before the conclusion
of a trial. Such participants may systematically
differ from those participants who complete the
study. For example, some patients may not attend
assessments if they are too ill to travel, or others
may feel well and therefore not attend. All
participants who entered the study should be
accounted for at its conclusion. There is cause for
concern if a large proportion of randomised
patients are lost to follow-up. This is particularly
pertinent if more patients are lost from one
treatment group than the other.64
The majority of studies (93) accounted for all
patients and six did not.43,65–69 Twelve studies,
including eight abstracts,40,41,44–47,59,60 provided
insufficient information. In four studies, one of
which was an abstract,61 all patients were
accounted for in some, but not all, outcome
assessments.57,61,70,71
17. Was a valid intention-to-treat analysis
included? 
In an intention-to-treat (ITT) analysis, all
participants are analysed according to their initial
treatment assignment, regardless of any treatment
change, withdrawal or non-compliance. This
preserves the values of randomisation and protects
against attrition bias. 
Thirty-two studies performed a valid ITT analysis.
Approximately half of the studies (55) failed to
report a valid ITT analysis and in 18 studies it was
unclear whether a true ITT analysis was used.
Seven studies used a valid ITT population for
some but not all outcomes and in three studies,
one of which was an abstract47 and another of
which was provided on a ‘commercial-in-
confidence’ basis,72 it was unclear from the
information provided whether the analysis was
based on ITT or per protocol data.47,72,73
18. Were at least 80% of the participants
originally included in the randomisation process
included in the follow-up assessments? (i.e. were
less than 20% of the follow-up data classified as
missing data?)
The larger the amount of missing data within a
study, the greater is the potential for bias. Patients
with missing data may have different prognoses or
experience different adverse events compared with
other participants. Alternatively, their condition
may have improved and so they have failed to
return for further assessment.63
In the majority of studies (83) this criterion was
met. In 18 studies, over 20% of data were
classified as missing. In three studies, the criterion
was partially met39,74,75 and the remaining 11
studies reported insufficient information.
19. Were appropriate methods used to account
for missing follow-up data in the intention-to-
treat analysis? (i.e. sensitivity analyses to
examine the effect of missing data and different
methods of accounting for missing data)
Where an ITT analysis is used, appropriate
methods should be used to account for missing or
incomplete data. Appropriate methods include last
observation carried forward (the last observed
value is used where data are incomplete) and ITT
repeated measures models using maximum
likelihood or generalising estimating equations.
This criterion was not applicable to studies that
failed to report an ITT analysis (55).
The majority of the studies (55) failed to report
methods used to account for missing data and
only four studies reported the use of appropriate
methods.76–80
The next four criteria relate only to crossover
studies (n = 30).
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1. Did all participants have established epilepsy
with a constant and predictable seizure
frequency and type?
Crossover studies are only appropriate in
participants with stable disease which returns to a
baseline state once treatment is complete, allowing
subsequent treatments to be assessed under
equivalent conditions.81 Therefore, this type of
study is only appropriate when patients have
established epilepsy with a constant and
predictable seizure type and frequency. 
Nearly all (25) of the crossover studies (30) met
this criterion. Four studies, two of which were
abstracts,40,82 provided insufficient
information.40,49,50,82 Only one study failed to
meet this criterion.53
2. Was the crossover design appropriate (for the
patient groups included in the study)?
As crossover studies are only suitable for patients
with established epilepsy, in most cases patients
will already be on a standard AED therapy that
can be continued during the trial. Crossover
studies are therefore most appropriate for
assessing adjunctive therapy in patients with
refractory epilepsy, but not for trials of
monotherapy in newly diagnosed patients.81
Crossover designs were appropriate in all but two
of the studies.53,69
3. Was an appropriate washout allowed between
the different treatments? (i.e. the investigators
should justify their choice of washout period.
They may monitor blood levels of the treatment
drugs or perform statistical analysis to look for
treatment period interactions)
In crossover trials, the administration of
treatment in the initial period may have an effect
that carries over into the second period. The
possibility of such a carryover effect can be
reduced with an appropriate washout period
between treatments. This period should be
sufficient to allow the intervention drug to be
eliminated from the body. 
Most studies (18) used appropriate washout
periods. In seven studies, there was no justification
for the lack of a washout period.49,50,80,83–86 Five
studies, two of which were abstracts,40,82 failed to
provide the information necessary to judge
whether this criterion was met.39,40,69,82,87
4. Was an appropriate analysis using paired 
data performed?
In crossover studies, each patient receives all of
the interventions. Within-patient variation is
usually smaller than that between different
patients, and in such cases there is considered to
be a correlation between responses to the
different treatments. Crossover trials should be
analysed using a method specific to paired data,
such as the McNemar test or a paired t-test. 
The analysis may also examine the possibility of
order, period, or period-by-treatment interaction
effects.25
The majority of the crossover studies (19)
performed an appropriate analysis using paired
data. Three studies, two of which were
abstracts,40,82 did not report sufficient detail to
determine if an appropriate analysis was
used.40,82,83 Seven studies failed to perform an
appropriate analysis,49,53,69,88–91 and in one study
some analyses were appropriate but others were
not.84
The next six criteria relate only to equivalence
studies (n = 2).
1. Was the equivalence margin specified before
the study?
Study findings may influence the selection of a
meaningful difference between two drugs. The
equivalence margin (the choice of a meaningful
difference to be ruled out) should be specified
and justified a priori.27
For the two equivalence and two non-inferiority
trials, two specified an equivalence margin before
the study,92,93 and the other two did not report
sufficient detail in order to assess this
criterion.69,94
2. Was the active control treatment previously
found to be effective?
It is a fundamental requirement that the control
regimen (including the dosing schedule) is clearly
effective. Ideally, this should be reported in a
systematic review of placebo-controlled trials, with
benefits that exceed a minimal clinically important
effect and minimum inertial heterogeneity.
Although two drugs may be shown to be
equivalent, it is not possible to determine if both
are effective or ineffective in the absence of such
detail.27
The active control treatment was previously found
to be effective in three of the equivalence/non-
inferiority trials.69,92,93 The other trial did not
report sufficient detail in order to assess this
criterion.94
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3. Were the study participants and outcome
variables similar to those in the original trials
establishing the efficacy of the active control?
Patients in equivalence trials and their risk of
adverse outcomes should be as similar as possible
to the patients and outcomes in the placebo-
controlled trials in which efficacy of the active
control was established. This similarity ensures
that the active control will have its usual effect.27
One trial met this criterion,93 and the other three
did not report sufficient detail to assess this
criterion.69,92,94
4. Was it appropriate to test a null hypothesis?
Equivalence trials are designed to rule out
meaningful differences between two treatments;
they test the null hypothesis that there is a
difference (unlike superiority trials which are
designed to disprove a null hypothesis that there
is no difference between two treatments using a
two-sided approach).27 A drug may be thought to
be non-inferior to an active control only if the
upper limit of the 95% CI for the difference in
efficacy is less than a prespecified equivalence
margin. 
In two trials it was appropriate to test a null
hypothesis,92,93 and the other two trials did not
provide sufficient information to determine if this
was appropriate.69,94
5. Were treatments applied in an optimal
fashion? 
Issues regarding the design or execution of the
intervention and follow-up that can lead to the
false-negative conclusion that the two treatments
are the same when they are not should be avoided.
Such issues include non-equipotent doses, low
compliance, incomplete follow-up, other effective
therapies to the patient (co-interventions) that
may distort the results and lack of blinding.27
This criterion was only partially met by all four
trials, as treatments were applied in an optimal
fashion with regard to certain aspects but not
others.
6. Was the analysis appropriate for an
equivalence trial?
In equivalence trials, ITT analysis may lead to the
false-positive conclusion that treatments are
equivalent when they are not. In such trials a per
protocol analysis should be used. However, this
can also have limitations, such as if withdrawal
rates between the two treatment groups differ, for
example if there are substantially more AEs in one
treatment group, the bias may go in either
direction. Characteristics for those excluded from
the ‘per protocol’ analysis must therefore be
carefully examined for any such biases.27
The analysis was appropriate in two studies,92,93
and inappropriate in one study.69 In the
remaining study it was unclear from the
information provided whether the analysis was
appropriate.94
Serious, rare and long-term adverse
events studies
Refer to Appendix 20 for the results of the quality
assessment of serious, rare and long-term AE
studies.
Cost-effectiveness studies
Refer to Appendix 21 for the results of the quality
assessment of cost-effectiveness studies.
Analysis
Assessment of clinical effectiveness
Systematic reviews
Thirteen systematic reviews were identified as
meeting the inclusion criteria; all were produced
by the Cochrane Collaboration or based on their
reviews. Nine of the reviews were published as full
systematic reviews. Protocols were only available
for the remaining four reviews (i.e. no outcome
data were available). Overall, the reviews
considered all of the drugs included in this review.
However, the effectiveness of the drugs was only
considered in relation to adjunctive therapy versus
placebo. One review considered comparisons of
the drugs against each other but this was based on
indirect comparisons as no trial data were
available. Participants of all ages were considered
in the systematic reviews, in contrast to this review,
which only considers data relating to adults. Brief
details of the reviews and their stage of
development are presented in Table 6. Further
details of the reviews are presented in Tables 7 and
8 and Appendix 22.
Results from two published reviews and five
Cochrane Collaboration systematic
reviews96–98,105,108 are shown in Table 7. These
reviews evaluated adjunctive therapy for the
outcome of 50% responders with odds ratios (ORs)
and 95% CIs in comparisons of newer drugs
versus placebo.
A brief summary of the overall findings of the
eight reviews is presented in Table 8. 
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Overall, the systematic reviews were of good
quality, but did not encompass all of the drugs,
treatment comparisons and outcome measures
required for this review. The reviews looked at
adjunctive GBP, LTG, LEV, OXC, TGB, TPM and
VGB versus placebo, and considered time to
exit/withdrawal, proportion of 50% responders
and the incidence of specified adverse events as
outcomes measures. Logistic regression analyses to
study the effect of drug dose were performed
where possible and did show evidence of a dose
response relationship for GBP and LEV. Some of
the reviews were in the process of being updated
and may therefore not have included all of the
studies identified in this review.
In conclusion, the reviews reported that the 
newer AEDs (GBP, LTG, LEV, OXC, TGB, TPM
and VGB) were effective as adjunctive treatments
in comparison with placebo based on the outcome
measures considered. The authors concluded that
the findings of the reviews could not be
extrapolated to long-term use or to 
monotherapy. The findings of this review will be
discussed in the context of these previous reviews,
where relevant in the discussion section (see
Chapter 4).
Randomised controlled trials
The following section is divided into licensed and
unlicensed drug indications. All of the drugs are
licensed for adjunctive therapy in patients with
refractory partial seizures. However, only LTG,
LEV and OXC are licensed for use in newly
diagnosed patients and only LTG and TPM are
licensed for treating generalised seizures. In
addition, OXC, LTG and TPM are the only newer
AEDs currently licensed for monotherapy. Overall,
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TABLE 6 A brief summary of systematic reviews and protocols meeting the inclusion criteria
Author, year Study details
Adab, 200295 Protocol. Review due Issue 2, 2003. Common AEDs and their use in pregnancy
Castillo, 200296 Review. RCTs of OXC vs placebo (adjunctive therapy only) in patients (adults and children).
Looks at effectiveness and AEs. Includes one study involving only children
Chaisewikul, 200297 Review. RCTs of LEV vs placebo (adjunctive therapy only) in patients (adults and children). Looks
at effectiveness and AEs
Jette, 200298 Review. RCTs of TPM vs placebo (adjunctive therapy only) in patients (adults and children).
Looks at effectiveness and AEs. Includes one study involving only children
Kälviäinen, 200299 Review withdrawn. Review is delayed owing to problems in obtaining data. RCTs of VGB vs
CBZ (monotherapy only) in patients (adults and children). Looks at effectiveness and AEs
Marson, 1997100 Review. RCTs of GBP, LTG, TGB, TPM, VGB or zonisamide vs placebo (adjunctive therapy only)
in patients (adults and children). Looks at effectiveness and AEs. Includes one study involving
only children. 
Also reported in Chadwick 1996,101 Chadwick 1997,102 Marson 1996103
Marson, 2001104 Review. RCTs of LEV, OXC (remacemide and zonisamide) vs placebo (adjunctive therapy only) in
patients (adults and children). Looks at effectiveness and AEs. Includes one study involving only
children
Marson, 2002105 Review. RCTs of GBP vs placebo (adjunctive therapy only) in patients (adults and children).
Looks at effectiveness and AEs. Includes one study involving only children
Muller, 2002106 Protocol. RCTs of OXC vs PHT (monotherapy only) in patients (adults and children). Looks at
effectiveness and AEs. 
Pereira, 2002107 Review. RCTs of TGB vs placebo (adjunctive therapy only) in patients (adults and children).
Looks at effectiveness and AEs.
Ramaratnam, 2002108 Review. RCTs of LTG vs placebo (adjunctive therapy only) in patients (adults and children).
Looks at effectiveness and AEs. Includes one study involving only children
Rashid, 2002109 Protocol. RCTs of TGB vs placebo (adjunctive therapy only) in patients (adults and children).
Looks at effectiveness and AEs. (This study was withdrawn after this work was completed.)
White, 2002110 Protocol withdrawn. RCTs of LTG vs CBZ (monotherapy only) in patients (adults and children).
Looks at effectiveness and AEs. The completion of this individual patient data review has been
delayed owing to difficulties in acquiring individual patient data for one of the four included
trials.
LTG is the only one of the newer group of AEDs
(included in this review) which is licensed for
mono-adjunctive therapy, partial and generalised
seizures and refractory and newly diagnosed
patients. In this review, a few trials included
patients with partial and patients with generalised
seizures. The proportion of patients with each
seizure type was often not reported and the
outcome data were not reported separately for the
two groups. This makes interpretation of these
trials problematic. Owing to difficulties in
differentiating between partial and generalised
seizure types clinically, especially in older trials,
studies with mixed populations are included in the
Results
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TABLE 7 Proportion of 50% responders for newer AEDs versus placebo in adjunctive therapy (systematic review data)
Proportion of 50% responders: OR (95% CI)
Drug Chadwick 1996101 Marson, 1997100 Cochrane Collaboration Reviews96–98,105,108
GBP 2.31 (95% CI: 1.54 to 3.45) 2.29 (95% CI: 1.53 to 3.43) 1.93 (95% CI: 1.37 to 2.71)
LEV 3.81 (95% CI: 2.78 to 5.22)
LTG 2.24 (95% CI: 1.42 to 3.53) 2.32 (95% CI: 1.47 to 3.68) 2.71 (95% CI: 1.87 to 3.91)
OXC 3.35 (95% CI: 2.32 to 4.83)
TGB 3.01 (95% CI: 1.99 to 4.55) 3.03 (95% CI: 2.01 to 4.58)
TPM 4.27 (95% CI: 2.84 to 6.43) 4.07 (95% CI: 2.87 to 5.78) 4.21 (95% CI: 2.79 to 5.20)
VGB 3.68 (95% CI: 2.45 to 5.51) 3.67 (95% CI: 2.44 to 5.51)
TABLE 8 Summary of the findings of included systematic reviews
Author, Year Summary of findings
Castillo, 200296 OXC has efficacy as an adjunctive treatment in patients with drug-resistant partial epilepsy, in
both adults and children. However, the trials reviewed were of relatively short duration, and
provide no evidence about the long-term effects of OXC. Results cannot be extrapolated to
monotherapy or to patients with other types of epilepsy
Chaisewikul, 200297 LEV reduces seizure frequency when used as an adjunctive treatment for patients with a drug-
resistant localisation-related (partial) epilepsy, and seems well tolerated. Minimum effective and
maximum tolerated doses have not been identified. The trials reviewed were of 16–24 weeks
duration and results cannot be used to confirm longer term effects. Our results cannot be
extrapolated to monotherapy or to patients with other seizure types or epilepsy syndromes.
Great care should also be taken with any attempt to apply these results to children
Jette, 200298 TPM has efficacy as an adjunctive treatment for drug-resistant partial epilepsy. However, the
trials reviewed were of relatively short duration and provide no evidence for long-term efficacy
of TPM. Results cannot be extrapolated to monotherapy or treating other epilepsy types
Marson, 2001104 The data suggest a useful effect for LEV, OXC and zonisamide. LEV has the more favourable
‘responder-withdrawal ratio’ followed by zonisamide and OXC
Marson, 1997100 The review shows clear evidence that each of these drugs (GBP, LTG, TGB, TPM, VGB or 
Chadwick, 1996101 zonisamide) is better than placebo at preventing seizures. When the results are compared 
Chadwick, 1997102 across drugs, the CIs overlap, and there is therefore no conclusive evidence of differences in 
Marson, 1996103 efficacy and tolerability. However, owing to the lack of actual study data these comparisons
across drugs are based on indirect comparisons and are therefore subject to potentially severe
bias
Marson, 2002105 GBP has efficacy as an adjunctive treatment in patients with drug-resistant epilepsy. However,
the trials reviewed were of relatively short duration, and provided no evidence for the long-
term efficacy of GBP. Results cannot be extrapolated to monotherapy or patients with other
epilepsy types
Pereira, 2002107 TGB reduces seizure frequency but is associated with some side-effects when used as an
adjunctive treatment for people with drug-resistant localisation-related seizures
Ramaratnam, 2002108 LTG adjunctive therapy is effective in reducing the seizure frequency in patients with drug-
resistant partial epilepsy. Further trials are needed to assess the long-term effects of LTG and to
compare it with other adjunctive drugs
licensed section of the review even where the drug
is licensed only for partial seizures. However, data
have been reported separately from those studies
that recruited only partial or only generalised
epilepsy patients. The relevance of the findings
from ‘mixed seizure type’ studies to patients with
either partial or generalised seizure types remains
unclear.
Within the unlicensed section, only very brief
details of the studies are presented in tables. The
main focus of the review is on the licensed use of
the drugs. This section is presented as a narrative
and divided up in terms of monotherapy and
adjunctive therapy, subdivided in each case into
newer drug versus placebo, newer drug versus
older drug and newer drug versus newer drug
comparisons (newer drugs being the seven drugs
under investigation).
Estimates of effect from individual trials are based
on ITT data, that is, all those participants
included in the randomisation process are
considered in the final analysis based on the
treatment groups to which they were originally
assigned. In some cases these data were not
reported in the studies or, where ITT data were
presented, a true ITT population was not
reported. In this review, missing data have been
assumed to be a negative outcome. Ideally, a
sensitivity analysis should have been performed to
consider both the worst (i.e. assuming missing
data as negative outcomes) and best (i.e. assuming
missing data as positive outcomes) scenarios, but
this was not possible owing to time constraints.
The ITT analysis used in this review therefore
presents a conservative estimate of the effects. 
Individual estimates of effect are presented as
Forest plots (unpooled) where possible. No
consideration has been given to the effect of dose,
although ideally the effects of different doses
should be explored using a logistic regression
analysis. This was not possible within the time
frame of this review.
Effect sizes for the proportion of seizure-free
participants, proportion of 50% responders and
the number of participants experiencing AEs have
been expressed as RRs with 95% CIs. In the case
of time to event outcomes such as time to first
seizure and time to exit/withdrawal, the data
require special consideration and statistical
analysis in the form of survival curves or HRs. All
of these statistical methods take into account the
fact that the outcome of interest may never be
observed over the period of follow-up (i.e.
observations may be censored) and that
throughout the follow-up period individuals will
be lost to the analysis. For the purposes of this
review, HRs with 95% CI intervals are used to
represent effect sizes and any comparisons tested
using a log-rank test (with accompanying p-values)
where appropriate. Although HRs are the
preferred way of reporting effect sizes for time to
event outcomes, these data were not always
reported. Where possible, HRs were calculated if
sufficient alternative data were available. Where
this was not possible, the data are reported as in
the trial. In some cases where data were presented
as HRs, the accompanying CIs were not reported
as 95% CIs. In order to make an equivalent
comparison between studies, these were converted
into 95% CIs using the following equations:
ln (95% lower CI) = ln (HR) – {1.96 [ln (HR) –
ln (lower 90% CI)]/1.645}
ln (95% upper CI) = ln (HR) + {1.96 [ln (HR) –
ln (lower 90% CI)]/1.645}
where HR = hazard ratio, ln = natural logarithm
and 1.645 is the Z value for 90%. The ln 95% CIs
were then converted back to 95% CIs.
Data from the studies were presented separately
for each study. In addition, where it was
considered clinically and statistically reasonable to
do so, the data were pooled. Where data were
pooled, a Q-statistic was used to test for the
presence of statistical heterogeneity and study data
were combined using a fixed-effects model.
In the absence of current methodology for the
assessment of cognitive and QoL outcomes, data
have been summarised in tables and discussed in a
narrative.
Data relating to safety (number of AEs and
number of deaths) and tolerability (number of
withdrawals) of the drugs were summarised in
tables. Owing to the vast number of different AEs
reported, it was not feasible within the confines of
this review to report data for every event.
Consequently, analysis was limited to the five most
commonly reported AEs associated with each of
the seven AEDs. The data were subdivided
according to the specific event and the drug under
investigation. In addition, RRs (95% CI) were
calculated for each individual study within the
subsections and these data were summarised in the
text. Owing to problems with the reporting of data
relating to safety and tolerability (i.e. missing data
due to not every AE being considered in every
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study and some studies only reporting data where
the incidence of AEs reached a certain threshold
value) and the presence of statistical heterogeneity
(Q-statistic and p-value), combining data from the
different studies was problematic and they were
not combined.
Throughout the review, the quality of the studies
was considered when interpreting the findings.
Specific problems with individual studies were
highlighted and the overall quality of all of the
studies was considered.
Studies are subgrouped where feasible according
to epilepsy syndrome or type of seizure where
these data are available. Different types of epilepsy
syndrome/seizure type (e.g. POSs or generalised
onset seizures) are considered separately and,
where possible subgroup analyses of the following
were performed: women of childbearing age,
adults with learning disabilities and the elderly. In
addition, throughout this chapter the findings of
the studies are reported in association with any
potential quality issues that may possibly impact
on robustness of the data.
A number of studies included in the review used
crossover, equivalence and non-inferiority designs
rather than the more common parallel superiority
designs. Where crossover designs were used, only
first-phase data have been included in Forest plots
and pooled RRs. Where Cochrane systematic
reviews reported first-phase data, these were
extracted and included in the analysis. By using
only first-phase data, readers should be aware that
the data lose statistical power to detect a
difference between treatments. Ideally, studies
should have performed a paired analysis suitable
for crossover studies, but this was often not
performed. Where this has been used, the paired
data have also been presented in the text
accompanying the Forest plots.
Where equivalence or non-inferiority designs have
been used, the International League Against
Epilepsy (ILAE) recommends that per protocol
data be used. However, these data were not always
reported and, in order to present equivalent data
in the Forest plots, ITT data from equivalence
studies have been used. Readers should be aware
that ITT data are more likely to show false
equivalence. If per protocol data were available
these have been reported in the text
accompanying the Forest plots. 
A number of trials used a conditional response
design, which is likely to affect the clinical
relevance and applicability of the data. Such trials
required that participants achieve a specified
reduction in seizure frequency whilst undergoing
AED treatment in the pretrial phase, in order to
be included in the main assessment phase of the
trial. Similarly, a small number of trials included
participants who were undergoing evaluation for
surgical treatment. Surgery is a treatment option
for some patients but it is appropriate for only a
very specific group of patients. Both of these trial
designs were highlighted where appropriate and
considered separately in the analyses. 
Data extraction tables from the included RCTs of
clinical effectiveness are presented in Appendix
23. These are organised by drug (alphabetically)
and then grouped first by licensed or non-licensed
use and then by crossover or parallel study design.
To assist the reader, boxed summary statements
have been placed at the end of each results section
and subsection.
Licensed indications
Monotherapy
Only LTG, OXC and TPM are licensed for use as
monotherapy and only data relating to these
drugs are discussed in the following section. If
applicable, the use of other drugs (GBP, LEV,
TGB, and VGB) as monotherapy is discussed and
briefly summarised in the unlicensed section of
this report.
Overall, 21 studies investigated the effects of
monotherapy: LTG (12), OXC (8) and TPM (1).
Two compared newer AEDs with placebo78,111 and
one compared one newer AED with another
AED.93 The remaining studies all compared newer
AEDs with older AEDs. All were parallel studies,
two used a non-inferiority design93,94 and the
remainder were superiority trials. Treatment
periods ranged between 1.5 and 56 weeks (mean
= 33 weeks). A number of studies were continued
for extended periods, but such ‘follow-up’ periods
usually adopted an open-label, non-randomised
design, which was not eligible for inclusion in the
main part of the review, although it was
considered in the review of rare, serious and long-
term AEs. 
Five studies included patients with refractory
epilepsy78,112–115 and two studies included patients
with refractory and patients with newly diagnosed
epilepsy.72,116 The remaining studies only included
patients with newly diagnosed epilepsy. Three
studies included only patients with POSs78,111,112
and one study included only patients with
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generalised onset seizures.62 The remaining 17
studies recruited mixed populations of patients,
some of whom had partial seizures and others who
had generalised seizures. The proportion of
participants with each seizure type was often not
reported and similarly outcome data were not
reported separately for each of the different
seizure types. The relevance of these data to
individual seizure types was unclear. Similarly,
there was no information on the use of
monotherapy in pregnant women and individuals
with intellectual disabilities and only one study
examined the effects of monotherapy in elderly
patients.117 This makes it difficult to make
statements about the use of monotherapy in these
groups of patients. In terms of the size of the
monotherapy trials, the number of participants
ranged from 37 to 877 (mean = 288). Table 9
summarises the number of studies assessing
monotherapy AEDs and the outcomes reported.
1. Newer drugs versus placebo
a. Seizure frequency
i. Seizure freedom
Both studies of newer drugs versus placebo
(monotherapy) reported the proportion of seizure-
free participants. A summary of the main
characteristics of these studies is presented in
Table 10.
No studies examined the use of LTG or TPM, and
evidence for OXC was limited to only two
relatively small trials (169 participants in total).
Both trials considered participants with partial
seizures; however, one trial looked at newly
diagnosed participants whereas the other
examined refractory patients. The two trials also
used different doses of drug (1200 and
2400 mg/day) and neither trial examined effects
over a long period of time. In particular, the trial
of refractory partial patients only considered
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TABLE 9 Number of monotherapy studies assessing each comparison and outcome
No. of studies reporting outcome measures
Comparison N Seizure free 50% Time to Time to
responders 1st seizure exit Cognitive QoL
New vs placebo 2 (OXC) 2 (OXC) 0 1 (OXC) 1(OXC) 0 0
New vs old 12 (LTG) 10 (LTG) 3 (LTG) 4 (LTG) 5 (LTG) 1 (LTG) 6 (LTG)
6 (OXC) 4 (OXC) 2 (OXC) 1 (TPM) 2 (OXC) 1 (OXC) 1 (OXC)
1 (TPM) 1 (TPM) 1 (TPM)
New vs new 1 (LTG) 1 (LTG) 0 1 (LTG) 1 (LTG) 0 0
N, total number of studies.
TABLE 10 Summary of studies (monotherapy, newer drugs vs placebo) assessing the proportion of seizure-free participants
Study characteristicsa
Drug Refractory/ Seizure type Dose Comments Study details
newly diagnosed Follow-up
N
LTG No studies
OXC Refractory Partial 2400 mg/day Specifically includes Schachter, 199978
10 days patients under 
N = 102 evaluation for surgery
Newly diagnosed Partial 1200 mg/day Sachdeo, 1998111
90 days
N = 67
TPM No studies
N, total number of randomised participants.
a Both were parallel, superiority trials unless stated otherwise.
treatment over a 10-day period and was carried
out in a specific group of patients who were
undergoing evaluation for possible surgery.
Therefore, the findings of this trial have limited
applicability to the general population of patients
with partial seizures. In view of the clinical
heterogeneity between the studies it was not
appropriate to combine the individual RRs (see
Figure 2).
The unpooled RRs show that monotherapy OXC
is favoured over placebo, but only the data from
the larger trial proved to be statistically significant.
In addition, these findings must be viewed in the
context of their short duration and relatively small
population sizes. Taking these factors into
consideration along with the relatively limited
applicability of the larger study of potential
candidates for surgery, there is very little evidence
on which to base an assessment of the effectiveness
of monotherapy OXC, LTG or TPM versus
placebo.
ii. 50% reduction in seizure frequency
No studies of newer drugs versus placebo
(monotherapy) reported the proportion of
participants who experienced at least a 50%
decrease in seizure frequency.
b. Time to first seizure
One of the two studies of newer drugs versus
placebo (monotherapy) reported time to first
seizure. A summary of the main characteristics of
this study is presented in Table 11.
The study examined the use of OXC in 67 newly
diagnosed patients with partial seizures over a
relatively short 90-day period. The study reported
the median time to first seizure for each of the
treatment arms (OXC, 11.67 days; placebo,
3.23 days; p = 0.0457), but failed to report an HR.
The reported data appear to favour OXC over
placebo, but this finding must be considered in
the context of the relatively small population size
and treatment period. 
c. Time to withdrawal/exit
One of the two studies of newer drugs versus
placebo (monotherapy) reported the time to
withdrawal/exit. A summary of the main
characteristics of this study is presented in 
Table 12.
The study examined the use of 2400 mg/day OXC
in 102 patients with refractory partial seizures over
a 10-day period, during which the patients were
evaluated as potential candidates for surgery. Such
patients represent a very specific group for whom
drug treatment has proved particularly ineffective
and problematic. The aetiology of their seizures is
also very specific and hence findings from such a
group of patients are unlikely to be applicable to
the general population of patients with epilepsy.
The log-rank test significantly favoured OXC over
Results
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2.406 (95% CI: 0.986 to 6.096)
13.000  (95% CI: 2.333 to 76.368)
RR (95% CI) (unpooled)Study details
Favours OXCFavours placebo
Sachdeo 1998
1200 mg/d (N = 67)
(90 days)
Schachter 1999
2400 mg/d (N = 102)
(10 days)
FIGURE 2 Proportion of seizure-free participants (unpooled RRs, 95% CI) for monotherapy trials of OXC vs placebo (ITT data)
placebo (p = 0.0001) and similarly the Cox’s
proportional hazards regression model also
showed significance in favour of OXC
(p = 0.0001). However, this apparent evidence in
favour of OXC should be considered with caution
in the light of the limited data, the short
treatment period and the lack of generalisability
of the results.
d. Quality of life
No studies of newer drugs versus placebo
(monotherapy) reported QoL outcomes.
e. Cognitive function
No studies of newer drugs versus placebo
(monotherapy) reported cognitive function
outcomes.
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TABLE 11 Summary of studies (monotherapy, newer drugs vs placebo) assessing time to first seizure
Study characteristicsa
Drug Refractory/ Seizure type Dose/ Comments Study details
newly diagnosed Follow-up
N
LTG No studies
OXC Newly diagnosed Partial 1200 mg/day Sachdeo, 1998111
90 days
N = 67
TPM No studies
N, total number of participants randomised.
a Parallel, superiority trial.
TABLE 12 Summary of studies (monotherapy, newer drugs vs placebo) assessing time to withdrawal/exit
Study characteristicsa
Drug Refractory/ Seizure type Dose Comments Study details
newly diagnosed Follow-up
N
LTG No studies
OXC Refractory Partial 2400 mg/day Specifically includes Schachter, 199978
10 days potential candidates
N = 102 for surgery
TPM No studies
N, total number of participants randomised.
a Parallel, superiority trial.
Summary statement for monotherapy newer
AEDs versus placebo
Data were only available for proportion of
seizure-free participants and the time to event
outcomes (first seizure and exit/withdrawal).
There were no data for LTG or TPM
monotherapy versus placebo, and only two trials
compared OXC with placebo. Both OXC trials
included only two patients with partial seizures
(refractory in one case and newly diagnosed
patients in the other). 
In conclusion, there is no evidence on which to
base an assessment of LTG and TPM. The
evidence to support OXC in favour of placebo
was also very limited. The data come from small
trials conducted over short treatment durations
and one trial relates specifically to patients
undergoing evaluation for surgery, limiting its
applicability. Considering all of these factors, the
statistically significant differences observed in the
proportion of seizure-free participants and the
time to event outcomes in favour of OXC versus
placebo should be regarded with caution.
2. Newer drugs versus older drugs
a. Seizure frequency
i. Seizure freedom
Fifteen out of 19 studies of newer drugs versus
older drugs (monotherapy) reported the
proportion of seizure-free participants. A summary
of the main characteristics of these studies is
presented in Table 13.
Overall, 10 parallel superiority trials compared
LTG with an older drug. The drug dose varied,
but in each case was within the recommended
range. The majority of the trials (seven trials) were
carried out in newly diagnosed patients with either
partial or generalised seizures. Other trials
specifically looked at newly diagnosed patients
with generalised seizures (one trial) or refractory
patients with either partial or generalised seizures
(two trials). It was unclear in the remaining trial
whether patients were refractory or newly
diagnosed. The main comparators were CBZ (six
trials) and VPA (three trials). The remaining trials
used PHT (one trial) or conventional therapy
(two trials), which involved physicians choosing the
comparator that patients received. Overall, the
studies recruited between 115 and 877
participants (mean = 347) and followed up the
effects of therapy for between 18 and 48 weeks
(mean = 30 weeks).
Overall the trials were of reasonable quality. Two
were open-label trials, one of which may possibly
have been underpowered according to the a priori
sample size calculations.118 The other showed a
baseline difference in seizure rate between the
study groups, which does not appear to have been
Results
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TABLE 13 Summary of studies (monotherapy, newer drugs vs older) assessing proportion of seizure-free participants
Study characteristicsa
Drug Refractory/ Seizure type Dose Comments Study details
newly Follow-up
diagnosed N
LTG Newly diagnosed Combination of Median 200 mg/day LTG vs VPA or CBZ GlaxoSmithKline,
partial/generalised 20 weeks (doses NS). The 2000118
N = 712 physician was allowed 
to choose after 
randomisation which 
of two conventional 
therapies (CBZ or 
VPA) was used
Newly diagnosed Combination of Median 200 mg/day LTG vs CBZ (Median Nieto Barrera,
partial/generalised 18 weeks 600 mg/day) 2001119
N = 385
Newly diagnosed Combination of 100 mg/day or Two doses of LTG Reunanen, 1996120
partial/generalised 200 mg/days compared with CBZ 
26 weeks (600 mg/day)
N = 343
Newly diagnosed Combination of 150 mg/day LTG vs CBZ Brodie, 1995121
partial/generalised 48 weeks (600 mg/day)
N = 260
Newly diagnosed Combination of 75–500 mg/day Specifically looks Brodie, 1999117
partial/generalised 24 weeks at elderly patients,
N = 150 LTG vs CBZ 
(200–2000 mg/day)
Newly diagnosed Combination of Max. 400 mg/day LTG vs PHT Steiner, 199975
partial/generalised 48 weeks (max. 600 mg/day)
N = 181
Newly diagnosed Generalised 100–500 mg/day LTG vs VPA GlaxoSmithKline, 
24 weeks (dose NS) 200162
N = 313
continued
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TABLE 13 Summary of studies (monotherapy, newer drugs vs older) assessing proportion of seizure-free participants (cont’d)
Study characteristicsa
Drug Refractory/ Seizure type Dose Comments Study details
newly Follow-up
diagnosed N
Refractory Combination of 100–500 mg/day LTG vs conventional Martinez, 2002114
partial/generalised 32 weeks therapy (CBZ, PHT 
N = 115 or VPA; doses NS). 
Physicians were 
allowed to choose 
which of the 
conventional therapies 
their patients received
Refractory Combination of 200–500 mg/day LTG vs CBZ (dose Kerr, 2001122
partial/generalised 28 weeks NS) and LTG vs VPA 
N = 877 (dose NS). Participants 
were assigned to 
either the LTG vs 
CBZ or the LTG vs 
VPA branch of the 
study according to 
their physician’s choice
Combination of Combination of 200 mg/day LTG vs VPA Biton, 2001116
newly diagnosed/ partial/generalised 32 weeks (20 mg/kg/day)
refractory N = 133
OXC Newly diagnosed Combination of Median 900 mg/day OXC vs VPA Christe, 1997123
partial/generalised 48 weeks (600–2700 mg/day)
N = 249
Newly diagnosed Combination of Dose NS OXC vs PHT Aikia, 199258
partial/generalised 12 months (dose NS)
N = 37
Newly diagnosed Combination of 600–2100 mg/day OXC vs PHT Bill, 1997124
partial/generalised 48 weeks (100–650 mg/day)
N = 287
Newly diagnosed Combination of 300–1800 mg/day OXC vs CBZ Dam, 1989125
partial/generalised 48 weeks (300–1400 mg/day)
N = 194
TPM Newly diagnosed Combination of 100 and 200 mg/day Non-inferiority trial. Privitera, 200294
partial/generalised 6 months Two doses of TPM 
N = 621 compared with VPA 
(1250 mg/day) and 
CBZ (600 mg/day). 
Physicians were allowed 
to choose whether they 
wanted participants to 
be entered into the TPM 
vs CBZ or the TPM vs 
VPA branch of the 
trial. Study includes 
children (≥ 6 years) – 
data not presented 
separately
N, total number of randomised participants; NS, not stated.
a All were parallel, superiority trials unless stated otherwise.
considered in the findings.119 One trial used a
lower than recommended dose of comparator
(CBZ 600 mg/day), which potentially favoured
LTG.120 Finally, three trials allowed physicians to
choose which comparator participants received
either before122 or after114,118 they were
randomised. 
RRs (95% CI) were calculated for each individual
study based on ITT data (see Figure 3).
Owing to the presence of clinical (different
participants, drug doses, follow-up periods and
comparators) and statistical (Q-statistic)
heterogeneity, it was inappropriate to pool the data.
Examining the unpooled data, only one study
showed a statistically significant difference that
favoured LTG over the older comparator drug
(CBZ).117 This study was specifically conducted in
elderly patients (≥ 65 years) with newly diagnosed
partial/generalised seizures, which may limit its
applicability to the general population of patients
with epilepsy. Overall, based on the available
evidence, LTG does not appear to be more or less
effective than older drugs in terms of the
proportion of seizure-free participants.
Four parallel superiority studies investigated the
effectiveness of monotherapy OXC versus an older
drug.58,123–125 All examined refractory patients
with either partial or generalised seizures for
periods of around 1 year (range 48-–52 weeks,
mean 49 weeks). OXC is licensed only for the
treatment of partial seizures and so the relevance
of the findings from these mixed groups of
patients is unclear. 
The population size varied from 37 to 287
participants (mean = 192). Two of the trials
compared OXC with PHT,58,124 one with CBZ125
and the fourth with VPA.123 All used doses of 
OXC and comparator within the recommended
ranges.
Overall, the quality of the studies was reasonable.
The main aim of one of the trials comparing OXC
with PHT was to investigate cognitive outcomes
and the study included only a small number of
participants (37).58
Owing to clinical (different participant
characteristics, drugs, drug doses and length of
follow-up) and statistical (Q-statistic) heterogeneity,
in the majority of cases it was not appropriate to
pool data. The unpooled data are shown in
Figure 4. None of the studies showed statistically
significant differences between OXC and older
drugs.
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Steiner, 1999 400 mg/d LTG vs 
PHT 48 weeks
Brodie, 1995 150 mg/d LTG vs 
CBZ 48 weeks
0.5 1 2 5
Study details RR (95% CI) (unpooled)
Favours older drug Favours LTG
0.973 (95% CI: 0.790 to 1.216)
0.954 (95% CI: 0.557 to 1.625)
Nieto-Barrera, 2001 200 mg/d LTG vs CBZ 18 weeks
Reunanen, 1996 100 mg LTG vs CBZ 26 weeks 0.938 (95% CI: 0.734 to 1.196)
Reunanen, 1996 200 mg LTG vs CBZ 26 weeks 1.103 (95% CI: 0.882 to 1.384)
Biton, 2001 200 mg/d LTG vs VPA 32 weeks
1.104 (95% CI: 0.641 to 1.903)
0.905 (95% CI: 0.609 to 1.343)
GSK, 2000 200 mg/d LTG vs. (VPA,CBZ) 20 weeks
1.018 (95% CI: 0.868 to  1.195)
Brodie, 1999 75–500 mg/d LTG vs CBZ 24 weeks 1.882 (95% CI: 1.073 to 3.491)
Kerr, 2001 1–500 mg/d LTG vs VPA 28 weeks
0.918 (95% CI: 0.778 to 1.099)
Martinez, 2002 1–500 mg/d LTG vs
(CBZ, VPA, PHT) 32 weeks
1.308 (95% CI: 0.530 to 3.196)
Kerr, 2001 2–500 mg/d LTG vs CBZ 28 weeks
GSK, 2001 2–500mg/d LTG vs VPA 24 weeks
1.095 (95% CI: 0.779 to 1.556)
1.383 (95% CI: 0.974 to 1.972)
FIGURE 3 Proportion of seizure-free participants (unpooled RRs, 95% CI) for monotherapy LTG vs older drugs (ITT data)
Data were pooled from the two trials comparing
OXC and PHT (see Table 14).58,124 The resultant
pooled RR (fixed effects) was not significant.
Overall, based on the available evidence,
monotherapy OXC does not appear to be more or
less effective than older drugs. Of particular
concern is that the studies included both patients
with partial and patients with generalised seizure
types, but OXC is licensed only for partial
seizures. Therefore, the applicability of the
findings to the licensed monotherapy treatment of
patients with partial seizures is also unclear.
Data relating to the comparison of monotherapy
TPM with older drugs were limited to one
unpublished non-inferiority study comparing TPM
with CBZ or VPA, which was submitted by the
manufacturer.94 This study involved 621 newly
diagnosed participants with either partial or
generalised seizures and followed the effects of
therapy over a period of 6 months. However, the
study suffered from a number of potential
problems with regards to its overall design and
quality, which may influence the robustness of the
data. 
First, both children and adults were included in
the study and the outcome data were not
presented separately for children and adults. As
this review is concerned only with the treatment of
adults, the data from this study may not be
generally applicable. Second, physicians were
allowed to choose which branch of the trial they
wished participants to enter (i.e. TPM versus VPA
or TPM versus CBZ). Within each of the specified
branches participants were initially randomised to
one of two doses of TPM (100 or 200 mg/day) or
the comparator drug. However, the study was only
powered with the aim of combining the two TPM
dose groups within each branch should the
200 mg/day group not appear to be more
effective. This suggests that the study was probably
not sufficiently powered to detect a difference
between the two doses. The study also pooled the
Health Technology Assessment 2005; Vol. 9: No. 15
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FIGURE 4 Proportion of seizure-fee participants (RRs, 95% CI) for monotherapy trials of OXC vs older drugs (ITT data)
0.2 0.5 1 2
Favours OXCFavours older drug
Study details RR (95% CI) (unpooled) 
0.934 (95% CI: 0.691 to 1.256)
0.775 (95% CI: 0.413 to 1.415)
1.022 (95% CI: 0.804 to 1.298)
0.995 (95% CI: 0.764 to 1.298)
Dam, 1989 300–1800 mg/d OXC vs CBZ (n = 194)
48 weeks
Aikia, 1992 dose NS OXC vs PHT (n = 37)
12 months
Bill, 1997 600–2100 mg/d OXC vs PHT (n = 287)
48 weeks
Christe, 1997 900 mg/d OXC vs VPA (n = 249)
48 weeks
TABLE 14 Proportion of seizure-free participants (pooled RRs, 95% CI) for studies of monotherapy OXC vs PHT (ITT data)
Characteristics Studies RR (95% CI)
n = 37 Aikia, 199258 0.775 (95% CI: 0.413 to 1.415)
n = 287 Bill, 1997124 1.022 (95% CI: 0.804 to 1.298)
OXC vs PHT in newly diagnosed patients Pooled (n = 2) Pooled RR = 0.987 (95% CI: 0.791 to 1.232)
with partial/generalised seizures, 
48–52 weeks follow-up
Heterogeneity, Q = 0.702 (df = 1), p = 0.402
TPM treatment groups across the branches and
compared the combined TPM group with the
older drugs, thereby breaking the randomisation
within the two branches. The authors state the
groups were homogeneous based on a chi-squared
analysis, but the findings of the study should be
interpreted with caution in view of the design
used. Finally, the dose of comparator (600 mg/day
CBZ) was below the usual recommended dose
(800–1200 mg/day), which may bias the findings in
favour of TPM.
In order to provide an equivalent comparison
between studies, unpooled RRs based on ITT data
are shown in Figure 5 for both comparisons of
TPM with older drugs (TPM versus VPA and TPM
versus CBZ). Both were not statistically significant
and should be interpreted with great caution for
the reasons stated previously. However, as this trial
uses a non-inferiority design, the ILAE
recommends that per protocol data be used. In
this case, the per protocol data were not reported
in the trial report and so this analysis could not be
performed. Using ITT data suggests false
equivalence. In summary, based on the available
evidence, monotherapy TPM does not appear to
be more or less effective than older drugs.
ii. 50% reduction in seizure frequency
Five out of the 19 studies of newer drugs versus
older drugs (monotherapy) reported the
proportion of participants who experienced at
least a 50% decrease in seizure frequency. A
summary of the main characteristics of these
studies is presented in Table 15.
Three studies compared LTG with an older
drug.114,116,122 Two studies116,122 used VPA as a
comparator, of which one122 also compared LTG
with CBZ. The third study compared LTG with
‘conventional therapy’, which included VPA, CBZ
or PHT.114 All of the studies used doses of LTG
within the recommended ranges. The studies
included mixed populations of patients with
partial or generalised seizures. Two of the studies
focused on refractory disease114,122 but it was
unclear whether the third study116 involved newly
diagnosed or refractory patients. All of the trials
followed participants for a similar period (range
28–32 weeks, mean 31 weeks). Two trials114,116
included 115–133 participants whereas the third
trial was larger (877 participants).122
Overall, the trials were of reasonable quality,
although two involved physicians choosing which
older drug therapy participants received.114,122
This may have influenced the findings of the
studies.
RRs (95% CI) were calculated for each individual
study based on ITT data (see Figure 6). None of
the studies showed statistically significant
differences between LTG and older drugs. 
Pooled RRs (95% CI) were not calculated owing to
the presence of clinical (different participant
characteristics, drug comparisons, drug doses and
length of follow-up) and statistical (Q-statistic)
heterogeneity between the three studies. Overall,
the available evidence shows no consistent
statistically significant differences between LTG
and older drugs. In addition, it is difficult to assess
the applicability of findings from the trials of
mixed seizure types to the individual seizure types.
Two studies compared monotherapy OXC with
older comparator drugs. Both used CBZ as a
Results
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0.2 0.5 1 2
Favours TPMFavours older drug
Study details RR (95% CI) (unpooled) 
1.091 (95% CI: 0.873, 1.387)
0.981 (95% CI: 0.723, 1.359)Privitera, 2002 100 or 200 mg/d TPM vs VPA (n = 223) 6 months
Privitera, 2002 100 or 200 mg/d TPM vs CBZ (n = 390) 6 months
FIGURE 5 Proportion of seizure-free participants (RRs, 95% CI) for monotherapy trials of TPM vs older drugs (ITT data)
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TABLE 15 Summary of studies (monotherapy, newer drugs vs older drugs) assessing proportion of participants experiencing at least a
50% decrease in seizure frequency
Study characteristicsa
Drug Refractory/ Seizure type Dose Comments Study details
newly Follow-up
diagnosed N
LTG Refractory Combination of 100–500 mg/day LTG vs conventional Martinez, 2002114
partial/generalised 32 weeks therapy (CBZ, PHT or 
N = 115 VPA; doses NS). 
Physicians were allowed 
to choose which of the 
conventional therapies 
their patients received
Refractory Combination of 200–500 mg/day LTG vs CBZ (dose NS) Kerr, 2001122
partial/generalised 28 weeks LTG vs VPA (dose NS). 
N = 877 Participants were 
assigned to either the 
LTG vs CBZ or the LTG 
vs VPA branch of the 
study according to their 
physician’s choice
Combination of Combination of 200 mg/day LTG vs VPA Biton, 2001116
newly diagnosed/ partial/generalised 32 weeks (20 mg/kg/day)
refractory N = 133
OXC Newly diagnosed Combination of 300–1800 mg/day OXC vs CBZ Dam, 1989125
partial/generalised 48 weeks (300–1400 mg/day)
N = 194
[Information relating to this study is designated Loiseau, 199872
commercial-in-confidence and has been removed]
TPM No studies
N, total number of participants randomised; NS, not stated.
a All were parallel, superiority trials unless stated otherwise.
0.2 0.5 1 2 5 
Study  details RR (95% CI) (unpooled) 
Favours LTGFavours older drug
1.187 (95% CI: 0.610 to 2.324)
Martinez, 2002 1–500 mg/d LTG vs (CBZ, PHT, VPA)
(N = 115)
0.986 (95% CI: 0.794 to 1.228)
0.986 (95% CI: 0.794 to 1.228)
Kerr, 2001 2–500 mg/d LTG vs VPA (N = 877)
Kerr, 2001 2–500 mg/d LTG vs CBZ (N = 877)
Biton, 2001 200 mg/d LTG vs VPA (N = 133) 1.016 (95% CI: 0.730 to 1.413)
FIGURE 6 Proportion of 50% responders (unpooled RRs, 95% CI) for monotherapy trials of LTG vs older drugs (ITT data)
comparator in patients with either partial or
generalised seizures. One study focused on 194
newly diagnosed patients and followed treatment
over a period of 48 weeks.125 Information relating
to the other study is designated commercial-in-
confidence72 (text relating to this study has been
removed).
It was not possible to combine the data from the
two trials owing to clinical (participant
characteristics) and statistical (Q-statistic)
heterogeneity between the studies. The published
trial was of reasonable quality and the unpooled
RR failed to show any statistically significant
differences between OXC and CBZ in terms of the
proportion of 50% responders (see Figure 7).125
Overall, based on the available evidence, there
were no statistically significant differences between
OXC and older drugs.125 Of particular concern is
that the study included both patients with partial
and patients with generalised seizure types, but
OXC is licensed only for the treatment of partial
seizures. Therefore, the applicability of findings to
the licensed monotherapy treatment of patients
with partial seizures is unclear.
No studies that compared monotherapy TPM with
older drugs were identified.
b. Time to first seizure
Five out of 19 studies of newer versus older drugs
(monotherapy) reported the time to first seizure. A
summary of the main characteristics of these
studies is presented in Table 16.
No studies compared monotherapy OXC with
older drugs with regard to the time to first seizure.
Three studies examined the effectiveness of
monotherapy LTG versus CBZ117,120,121 and a
fourth study compared monotherapy LTG with
PHT.75 All of the studies used a parallel superiority
design and recruited newly diagnosed patients
with either partial or generalised seizure types.
One of the studies specifically examined the effects
of monotherapy LTG in elderly patients aged
≥ 65 years.117 In general, the studies were of
reasonable size recruiting between 150 and 260
participants (mean = 205) and followed the
course of treatment for between 24 and 48 weeks
(mean = 37 weeks).
Overall, the quality of the studies was reasonable.
However, two of studies used doses of comparator
(600 mg/day CBZ) below the usual recommended
range (800–1200 mg/day), which may bias the
findings in favour of LTG.120,121
Table 17 reports the findings of the four
monotherapy LTG studies. Where HRs (95% CI)
were reported, data have been included in the
table. Study data were not combined owing to
clinical (different study designs, length of follow-
up, drug doses, comparators) and statistical
heterogeneity.
None of the studies reported statistically
significant differences between monotherapy LTG
and older drugs. Two studies reported individual
HRs for the different seizure types (partial and
Results
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0.2 0.5 1 2 5 
Study details RR (95% CI) (unpooled) 
Favours OXCFavours older drug
1.064 (95% CI: 0.879 to 1.289)
Data are commercial in confidence
Dam, 1989 300–1800 mg/d OXC vs CBZ (N = 194)
Loiseau, 1998
FIGURE 7 Proportion of 50% responders (unpooled RRs, 95% CI) for monotherapy trials of OXC vs older drugs (ITT data)
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TABLE 16 Summary of studies (monotherapy, newer drugs vs older drugs) assessing time to first seizure
Study characteristicsa
Drug Refractory/ Seizure type Dose Comments Study details
newly Follow-up
diagnosed N
LTG Newly diagnosed Combination of 75–500 mg/day Specifically looks at Brodie, 1999117
partial/generalised 24 weeks elderly patients,
N = 150 LTG vs CBZ 
(200–2000 mg/day)
Newly diagnosed Combination of Max. 400 mg/day LTG vs PHT Steiner, 199975
partial/generalised 48 weeks (max. 600 mg/day)
N = 181
Newly diagnosed Combination of 150 mg/day LTG vs CBZ Brodie, 1995121
partial/generalised 48 weeks (600 mg/day)
N = 260
Newly diagnosed Combination of 100 or 200 mg/day Two doses of LTG vs Reunanen, 1996120
partial/generalised 26 weeks CBZ (600 mg/day)
N = 228
OXC No studies
TPM Newly diagnosed Combination of 100 or 200 mg/day Non-inferiority trial. Privitera, 200294
partial/generalised 6 months Two doses of TPM 
N = 621 compared with CBZ 
(600 mg/day). Physicians 
were allowed to choose 
whether they wanted 
participants to be 
entered into the 
TPM vs CBZ or the 
TPM vs VPA branch of 
the trial
N, total number of randomised participants.
a All were parallel, superiority trials unless stated otherwise.
TABLE 17 Individual HR (95% CI) (time to first seizure) for newer vs older drugs (monotherapy)
Drug Study Comparators HR (95% CI)
LTG Brodie, 1999117 LTG vs CBZ No difference between the treatments
Steiner, 199975 LTG vs PHT All seizure types: HR 1.4 (95% CI: 0.8 to 2.3)
Partial seizures: HR 1.0 (95% CI: 0.5 to 2.2)
Primary generalised seizures: HR 1.5 (95% CI: 0.7 to 3.2).
Secondarily generalised seizures: none occurred in the LTG
group so no HR could be calculated.
Difference between LTG and PHT was not significant
Brodie, 1995121 LTG vs CBZ HR 0.8 (95% CI: 0.6 to 1.2). There was no significant
difference between the two groups in time to first seizure
either for the whole study population or for the subgroup
with partial seizures with or without secondary
generalisation or the subgroup with primary tonic–clonic
seizures
Reunanen, 1996120 Two doses of LTG 100 mg/day vs CBZ: HR = 0.8 (95% CI: 0.5 to 1.4)
LTG vs CBZ LTG 200 mg/day vs CBZ: HR = 0.9 (95% CI: 0.5 to 1.6)
TPM Privitera, 200294 TPM vs CBZ Only combined HR given for 100/200 mg/day 
TPM vs CBZ/VPA: 1.081 (95% CI: 0.847 to 1.380)
Privitera, 200294 TPM vs VPA
generalised), but again both failed to find
statistically significant differences between
monotherapy LTG and older comparators.75,121
Only one study investigated the effectiveness of
monotherapy TPM over a 6-month treatment
period.94 The study used a non-inferiority design
and recruited 621 newly diagnosed patients (both
partial and generalised seizure types). Two doses of
TPM (100 and 200 mg/day) were compared with
600 mg/day CBZ and 1250 mg/day VPA. There were
a number of issues relating to the quality of this
study, which may have affected the robustness of the
final data. These have been discussed previously
with regard to the reporting of the proportion of
seizure-free participants, and similarly great caution
is required when interpreting the findings of this
study with regard to time to first seizure.
Table 17 shows that there were no statistically
significant differences between TPM
(100/200 mg/day) and older drugs (CBZ and 
PHT combined).
Overall, the evidence relating to time to first
seizure suggested there were no significant
differences between newer and older drugs in
newly diagnosed patients. However, data for OXC
and TPM were limited and consequently it is
difficult to make overall conclusions about the
effectiveness of newer versus older drugs.
c. Time to withdrawal/exit
Eight out of 19 studies of newer versus older
drugs (monotherapy) reported the time to
withdrawal/exit. A summary of the main
characteristics of these studies is presented in
Table 18.
Five studies compared the effectiveness of
monotherapy LTG versus older drugs. Two made
comparisons with CBZ,120,121 one with PHT,75 one
with VPA112 and one with conventional
treatment.114 Three studies recruited newly
diagnosed patients with either partial or
generalised seizures75,120,121 and the remaining
two studies recruited refractory patients with
either partial112 or mixed seizures (partial or
generalised).114 The numbers of participants
recruited varied from 115 to 260 (mean = 188)
and treatment durations from 12 to 48 weeks
(mean = 33 weeks).
Overall, the studies were of reasonable quality.
However, two studies used doses of comparator
(CBZ 600 mg/day), which were lower than the
recommended range, thereby possibly favouring
LTG.120,121 One study suffered from a high
dropout rate, resulting in a large amount of
missing data that could influence the study
findings.112 In addition, one other study allowed
physicians to choose which of the comparator
drugs patients received once they had been
randomised to conventional treatment, which
could bias the study findings.114
Three of the studies reported HRs (see Table 19).
There were no statistically significant differences
in time to exit/withdrawal in the study comparing
LTG with phenytoin.75 Similarly, one study
comparing LTG with CBZ failed to find a
statistically significant difference between the two
drugs, although the 200 mg/day LTG dose did
show a non-significant difference in favour of
LTG.120 The remaining study that compared
monotherapy LTG with CBZ reported a
statistically significant difference in time to
exit/withdrawal in favour of LTG (HR 1.57, 95%
CI: 1.07 to 2.31).121 However, as has already been
discussed both studies used low doses of CBZ
which could influence the outcome in favour of
LTG.
The two remaining studies of LTG monotherapy
only reported mean/median times to
exit/withdrawal and there was insufficient data to
calculate an HR (see Table 19). These studies
reported a difference in favour of LTG, which in
the case of partial seizures in refractory patients
appeared to be statistically significant, although
the study only followed patients over a 12-week
period.112 The significance of these findings is
unclear in view of the potential quality issues
previously mentioned and the inability to calculate
and compare appropriate data (i.e. HRs). Data
were not combined owing to clinical (different
populations, length of follow-up, drug doses,
comparators) and statistical heterogeneity. Overall,
the evidence comparing monotherapy LTG with
older drugs is limited.
Two parallel superiority studies compared the
effectiveness of monotherapy OXC versus older
drugs.123,124 Both recruited large numbers (249123
and 287124) of newly diagnosed patients with
either partial or generalised seizures and used
treatment periods of 48 weeks. One study
compared OXC with VPA123 and the other with
PHT.124 Both studies were of reasonable quality,
but failed to report HRs.
Data from the two studies were not combined
owing to clinical (different comparators) and
statistical (Q-statistic) heterogeneity. The unpooled
Results
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TABLE 18 Summary of studies (monotherapy, newer drugs vs older drugs) assessing time to withdrawal/exit
Study characteristicsa
Drug Refractory/ Seizure type Dose Comments Study details
newly Follow-up
diagnosed N
LTG Newly diagnosed Combination of Max. 400 mg/day LTG vs PHT Steiner, 199975
partial/generalised 48 weeks (max. 600 mg/day)
N = 181
Newly diagnosed Combination of 150 mg/day LTG vs CBZ Brodie, 1995121
partial/generalised 48 weeks (600 mg/day)
N = 260
Newly diagnosed Combination of 100 mg/day or LTG (100 mg/day or Reunanen, 1996120
partial/generalised 200 mg/day 200 mg/day) vs CBZ 
26 weeks (600 mg/day)
N = 228
Refractory Partial 400–500 mg/day LTG vs VPA Gilliam, 1998112
12 weeks (100 mg/day)
N = 156
Refractory Combination of NS LTG vs conventional Martinez, 2002114
partial/generalised 32 weeks therapy (CBZ, PHT or 
N = 115 VPA; doses NS). 
Physicians were 
allowed to choose 
which of the 
conventional therapies 
their patients received
OXC Newly diagnosed Combination of Mean = 900 g/day OXC vs VPA Christe, 1997123
partial/generalised 48 weeks (600–2700 mg/day)
N = 249
Newly diagnosed Combination of Mean = 1028 g/day OXC vs PHT Bill, 1997124
partial/generalised 48 weeks (100–650 mg/day)
N = 287
TPM Newly diagnosed Combination of 100 mg/day or Non-inferiority trial. Privitera, 200294
partial/generalised 200 mg/day Two doses of TPM 
6 months (100 or 200 mg/day) 
N = 621 were combined and 
compared with CBZ 
(600 mg/day) or 
VPA (1250 mg/day). 
Physicians were allowed 
to choose whether 
they wanted participants 
to be entered into the 
TPM vs CBZ or the 
TPM vs VPA branches 
of the trial
N, total number of randomised participants; NS, not stated.
a All were parallel, superiority trials unless stated otherwise.
data (see Table 19) showed a statistically significant
difference between treatment groups (p = 0.02) in
favour of OXC compared with PHT.124 No
statistically significant differences were evident
between monotherapy OXC and VPA,123 although
this study did use a lower mean dose of OXC than
that of Bill and colleagues.124
Only one study compared monotherapy TPM
versus older drugs.94 This study has been discussed
previously with regard to the proportion of seizure-
free patients and the time to first seizure. The HR
reported in Table 19, suggests that although a
difference in favour of TPM versus the older drugs
(CBZ and VPA) was evident, it was not statistically
significant. However, as reported previously, this
study suffers from a number of potential problems
that may bias the findings and so the data
regarding time to exit/withdrawal should also be
regarded with great caution. This leaves no good-
quality evidence on which to base an assessment of
monotherapy TPM versus older drugs.
d. Quality of life
Nine out of 19 studies of monotherapy treatment
compared QoL outcomes between newer drugs
and older drugs. These studies are briefly
described in Table 20.
Seven studies used monotherapy LTG. One
compared LTG with CBZ,77 one with PHT,75 two
with VPA122,126 and two with conventional
therapy.114,118 Three studies used monotherapy
OXC. One compared OXC with CBZ,125 one with
PHT124 and one with VPA.123 There were no
studies of monotherapy TPM.
All of the studies used a parallel superiority
design, but a variety of measures were used to
assess quality of life (see Table 21). In total, 10
different types of QoL measures were used, all of
which were used in the LTG studies and two in the
OXC studies, with subjective global evaluations by
both the patient and the physician/investigator
being common to both drugs. The most common
measure used was subjective global evaluation by
the physician/investigator.
Details of the individual study data are reported in
Appendix 23 and details of the individual QoL
measures in Appendix 4. Table 22 summarises the
overall findings of the QoL assessments. Three of
the six LTG trials were in newly diagnosed
patients with either partial or generalised seizure
types.75,77,118 Two trials included patients with
either refractory partial or generalised
seizures.114,122 One trial included both refractory
Results
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TABLE 19 Time to exit/withdrawal (unpooled data) for monotherapy trials of newer vs older AEDs
Drug Study Comparators HR (95% CI) (or other reported data)
LTG Steiner, 199975 LTG vs PHT Unadjusted HR = 0.885, (95% CI: 0.555 to 1.410)
Adjusted (for baseline seizure counts) HR = 0.935 
(95% CI: 0.583 to 1.499)
Brodie, 1995121 LTG vs CBZ HR 1.57 (95% CI: 1.07 to 2.31)
Reunanen, 1996120 LTG vs CBZ LTG 100 mg vs CBZ: HR = 0.9 (95% CI: 0.6 to 1.3) 
LTG 200 mg vs CBZ: HR = 1.3 (95% CI: 0.8 to 1.9)
Gilliam, 1998112 LTG vs VPA LTG: Median = 168 days (p ≤ 0.001)
VPA: Median = 57 days
Martinez, 2002114 LTG vs conventional LTG (n = 57): mean time = 175 days (SD 83.1)
therapy (CBZ/PHT/VPA) Conventional therapy (PHT, VPA or CBZ) (n = 58): 
mean time = 156 days (SD 80.7)
OXC Christe, 1997123 OXC vs VPA The log-rank test showed no difference between
treatment groups (p = 0.33) (data not reported)
Bill, 1997124 OXC vs PHT The log-rank test showed a statistically significant
difference between treatment groups (p = 0.02) in favour
of OXC (data not reported)
TPM Privitera, 200294 TPM vs CBZ Only combined HR given for 100/200 mg/day TPM vs
CBZ/VPA: 1.223 (95% CI: 0.917 to 1.631)
Privitera, 200294 TPM vs VPA
SD, standard deviation.
and newly diagnosed patients who experienced
either partial or generalised seizure types.126 The
studies recruited between 122 and 877
participants (mean = 422) and followed-up the
effects of therapy for between 20 and 48 weeks
(mean = 34 weeks). Overall, the quality of the
trials was poor. Four trials may have lacked power
to detect differences between the
AEDs.114,118,122,126 Three trials allowed physicians
to choose which comparator participants received
either before122 or after114,118 they were
randomised and were also open-label trials. One
trial provided no details of patients baseline
characteristics.122 In one trial over 50% of patients
in each of the two treatment groups discontinued
by the end of the study and the dose of the
comparator drug was sometimes not within the
recommended range.75 All of these issues could
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TABLE 20 Total number of studies assessing QoL outcomes (monotherapy, newer vs older drugs)
Total no. of studies assessing 
QoL outcomes
Drug Crossover Parallel All studies Study details
LTG 0 6 6 Gillham, 2000;77 GlaxoSmithKline, 2000;118 Kerr, 2001;122
Martinez, 2002;114 Sackellares, 2000;126 Steiner, 199975
OXC 0 3 3 Bill, 1997;124 Christe, 1997;123 Dam, 1989125
TPM 0 0 0
TABLE 21 Types of QoL assessments used (monotherapy, newer vs older drugs)
QoL measure No. of studies using QoL measure
LTG OXC TPM Total
SEALS 3 0 0 3
QOLIE-89 1 0 0 1
QOLIE-31 2 0 0 2
Subjective global evaluations (patient) 1 2 0 3
Subjective global evaluations (physician/investigator) 1 3 0 4
Patient acceptability 1 0 0 1
BDI 1 0 0 1
POMS 1 0 0 1
CDRS 1 0 0 1
Liverpool AEP 1 0 0 1
Total no. of different measures used 10 2 0 –
BDI, Beck Depression Inventory; CDRS, Cornell Dysthymia Rating Self-report Scale; Liverpool AEP, Adverse Events Profile;
POMS, Profile of Moods States; QOLIE-31, Quality of Life in Epilepsy Inventory-31; QOLIE-89, Quality of Life in Epilepsy
Inventory-89; SEALS, Side Effect and Life Satisfaction Inventory.
TABLE 22 Summary of overall findings of QoL assessments (monotherapy, newer vs older drugs)
Drug Summary of findings of QoL assessments
LTG Four75,77,114,122 of the six75,77,114,118,122,126 studies examining LTG found statistically significant differences in
favour of LTG on at least one measure of QoL. However, the quality of these studies was generally poor.
Based on the available evidence, it is unclear whether LTG monotherapy is more or less effective than older
drugs in terms of QoL.
OXB Only one124 of the three123–125 studies examining OXC found statistically significant differences in favour of
OXC, using subjective measures of QoL. Based on these findings, there is no strong evidence for OXC
monotherapy affecting QoL in comparison with older drugs. 
affect study findings and must be considered when
interpreting the data.
All three studies using SEALS75,77,122 and both
studies using QOLIE-31114,122 found statistically
significant differences in QoL in favour of LTG in
comparison with older AEDs. However, in some
cases these differences were only found at one
time point and not in subsequent assessments.77
One study using one or more of the other eight
types of QoL measures reported statistically
significant differences in at least one of these
measures in favour of LTG.126 Considering these
findings in context of the quality issues discussed
above, there was no strong evidence either in
favour of or against LTG monotherapy compared
with older drugs in terms of quality of life. 
All three OXC trials included newly diagnosed
patients with either partial or generalised seizures.
However, OXC is not licensed for the treatment of
generalised seizures. Follow-up was 48 weeks125 or
56 weeks,123,124 and studies recruited between 235
and 287 participants (mean = 257). Overall, the
trials were of reasonable quality. However, two
studies used doses of OXC and comparator drugs
that were not within the recommended
range.124,125 One of these studies may have lacked
power to detect differences between AEDs and no
sample size calculations were reported.125 In
addition, over 20% of the follow-up data were
classified as missing. These issues may influence
the study findings and should be taken into
consideration when interpreting the data. 
Only one study found statistically significant
differences in favour of OXC in comparison with
an older drug. This used subjective QoL measures
(patient and physician global evaluations).124
Based on these findings, there is no strong
evidence of OXC monotherapy affecting QoL
compared with older drugs.
e. Cognitive function
Two out of 19 studies of newer versus older AEDs
assessed some aspect of cognitive functioning 
(see Table 23). One study compared monotherapy
LTG with CBZ47 and the other compared
monotherapy OXC with CBZ.58 Both were 
parallel studies of newly diagnosed patients with
partial or generalised seizures, which used similar
durations of treatment (48 weeks47 and
52 weeks58).
Nine different cognitive assessment measures were
used (see Table 24).
Results
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TABLE 23 Total number of studies assessing cognitive function
Total no. of studies assessing cognitive function
Drug Crossover Parallel All studies Study details
LTG 0 1 1 Brodie, 199947
OXC 0 1 1 Aikia, 199258
TPM 0 0 0
TABLE 24 Assessments used to measure cognitive function
No. of studies using cognitive measure
Cognitive measure LTG OXC TPM Total
Stroop test 1 1 0 2
Logical reasoning test 1 0 0 1
Verbal learning 1 0 0 1
Recognition test 1 0 0 1
Semantic processing test 1 0 0 1
List learning 0 1 0 1
Trailmaking test A 0 1 0 1
Trailmaking test B 1 1 0 2
Modified finger tapping test 0 1 0 1
Total no. of different measures used 6 5 0 –
Details of the individual study data are reported in
Appendix 23 and details of the cognitive measures
in Appendix 5. Table 25 summarises the overall
findings of the cognitive assessments.
Six cognitive tests reported a significant difference
in favour of LTG on at least one visit.47 Data
included four follow-up visits and nine different
outcome measures. However, it was unclear
whether the two treatment groups had similar
baseline levels of cognitive function. In addition,
the number of participants was lower than the
total number included in the main effectiveness
part of the trial.127 The larger sample presented a
weaker positive effect in favour of LTG. The study
did not specify whether the cognitive assessor was
blind to treatment allocation, what time of day
tests were performed or whether participants who
were postictal had their assessment rescheduled.
Given the potentially poor quality of the study, the
findings should be interpreted with caution. 
The OXC study did not report an a priori estimate
of sample size.58 Given the small sample size (37
participants), the study may be underpowered. It
was not possible to carry out a full assessment of
the quality of the trial owing to poor reporting of
randomisation, concealment and blinding. ITT
data were not reported.
The study did not state whether participants who
were postictal had their assessment rescheduled. It
also did not specify whether repeated testing was
carried out at the same time of day or whether
tests were administered in a set order.
Overall, the studies do not present strong good-
quality evidence of either a positive or negative
effect of newer drugs compared with older drugs.
Both studies included participants with partial or
generalised onset seizures, although OXC is not
licensed for generalised onset seizures. Data were
not reported separately for the different seizure
types, consequently the relevance of the findings
to clinical practice is unclear.
3. Newer drugs versus newer drugs
a. Seizure frequency
i. Seizure freedom
The one study that compared a newer AED with
another newer AED (monotherapy) reported the
proportion of seizure-free participants. A summary
of the main characteristics of this study is
presented in Table 26.
This non-inferiority study included 309 newly
diagnosed participants with either partial or
generalised seizures and compared monotherapy
LTG with monotherapy GBP.93 This was a
reasonable quality study but only followed
treatment over a 30-week period. In addition, 
Summary statement for monotherapy newer
versus older AEDs
The most commonly reported outcome
measure in studies comparing newer
monotherapy AEDs with older AEDs was the
proportion of seizure-free patients. Data were
available for all three monotherapy AEDs,
although data relating to OXC were limited.
Similarly, only one poor-quality study reported
for monotherapy TPM. 
In most cases the studies recruited a mixture of
newly diagnosed patients with partial or
generalised seizures, so the applicability of the
findings to individual seizure types was unclear.
All of the trials were of a reasonable size but
none considered treatment periods of greater
than 1 year duration. Older drugs comparators
included CBZ, VPA and PHT. 
There was limited poor-quality evidence to
suggest a significant difference in cognitive
function for LTG and OXC compared with
older AEDs. However, no consistent statistically
significant differences were found in the other
outcomes.
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TABLE 25 Summary of overall findings of cognitive assessments
Drug Summary of findings of cognitive assessments
LTG The authors concluded that a long-term differential effect on cognitive functioning was found in favour of
LTG47
OXC The one study in this category found that there were no significant differences in the effects of OXC
compared to PHT with cognitive functioning58
the dose of GBP was above that currently
recommended, but as yet GBP is only licensed 
for adjunctive and not monotherapy use, hence
this comparison is not relevant to clinical 
practice. 
One study considered this outcome and is
presented in Table 27.
Details of this study have been reported previously
with regard to the proportion of seizure-free
participants. Based on ITT data there was no
difference between monotherapy LTG and GBP
(HR = 1.061, 95% CI: 0.758 to 1.485). However,
ITT data may suggest false equivalence. As
mentioned previously, the relevance of this study
to clinical practice is unclear and similarly it 
was difficult to assess the effectiveness of newer
AEDs versus other newer AEDs given the lack 
of data.
ii. 50% reduction in seizure frequency
[Data have been designated 
commercial-in-confidence and have been
removed]
b. Time to first seizure
[Data have been designated 
commercial-in-confidence and have been
removed]
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TABLE 26 Summary of studies (monotherapy, newer drugs vs newer drugs) assessing proportion of seizure-free participants
Study characteristicsa
Drug Refractory/ Seizure type Dose Comments Study details
newly Follow-up
diagnosed N
LTG Newly diagnosed Combination of 100–300 mg/day Non-inferiority trial Brodie, 200293
partial/generalised 30 weeks LTG vs GBP
N = 309 1800–3600 mg/day
OXC No studies
TPM No studies
N, total number of participants randomised.
a Parallel, superiority trial.
TABLE 27 Summary of studies (monotherapy, newer drugs vs newer drugs) assessing time to first seizure
Study characteristicsa
Drug Refractory/ Seizure type Dose Comments Study details
newly Follow-up
diagnosed N
LTG Newly diagnosed Combination 100–300 mg/day Non-inferiority trial, Brodie, 200293
30 weeks LTG vs GBP
N = 309 1800–3600 mg/day
OXC No studies
TPM No studies
N, total number of participants randomised.
a Parallel, superiority trial.
FIGURE 8 Proportion of seizure-free participants 
(RR, 95% CI) for the monotherapy trial of LTG vs GBP 
(per protocol data)
[Data have been designated commercial-in-confidence
and have been removed]
c. Time to withdrawal/exit
The one study that compared a newer AED with
another newer AED (monotherapy) reported the
time to withdrawal/exit. A summary of the main
characteristics of this study is presented in 
Table 28.
This study has been considered with regards to
previously described outcomes comparing newer
monotherapies versus each other. 
[Data have been designated commercial-in-
confidence and have been removed]
This study had an upper 90% CI, which was less
than the predetermined upper equivalence level
(1.85). However, when the data were recalculated
to report 95% CIs, this was not the case. Although
this HR was based on evaluable patient data as
recommended by ILAE guidelines for
equivalence/non-inferiority trials, the relevance to
practice is unclear given the fact that GBP is not
licensed for monotherapy use.
[Data have been designated commercial-in-
confidence and have been removed]
Given the lack of available data comparing newer
drugs with each other, it was difficult to assess the
effectiveness of newer AEDs compared with other
newer AEDs. 
d. Quality of life
The one study that compared a newer AED with
another newer AED (monotherapy) did not report
QoL outcomes.
e. Cognitive function
The one study that compared a newer AED with
another newer AED (monotherapy) did not report
cognitive function outcomes.
4. The use of monotherapy in special populations
(elderly, intellectually disabled and pregnant
women)
There were no studies of monotherapy that
examined effectiveness in participants with
intellectual disabilities. Similarly, there were no
studies that included pregnant women; in fact,
women of childbearing age were required to use
adequate methods of contraception in order to be
included in trials. One study did, however,
examine the effectiveness of monotherapy in
elderly patients.117 This parallel superiority trial
compared LTG monotherapy with CBZ
monotherapy in newly diagnosed patients with
partial and/or generalised seizures over a period
of 24 weeks. All of the participants (150) were
aged ≥ 65 years. The study reported no statistically
significant differences between the treatment
groups with respect to time to first seizure and the
proportion of seizure-free participants
(RR = 0.905, 95% CI: 0.609 to 1.343). Although
this was a reasonable quality study with no obvious
problems in terms of its design, it followed
treatment over only a relatively short period and
the BNF advises caution when treating elderly
Summary statement for monotherapy newer
versus newer AEDs
[Data have been designated commercial-in-
confidence and have been removed]
There was insufficient evidence to assess the
effectiveness of one newer AED compared with
another.
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TABLE 28 Summary of studies (monotherapy, newer drugs vs newer drugs) assessing time to withdrawal/exit 
Study characteristicsa
Drug Refractory/ Seizure type Dose Comments Study details
newly Follow-up
diagnosed N
LTG Newly diagnosed Combination 100–300 mg/day Non-inferiority trial, Brodie, 200293
partial/generalised 30 weeks LTG vs GBP
seizures N = 309 1800–3600 mg/day
OXC No studies
TPM No studies
N, total number of participants randomised.
a Parallel, superiority trial.
patients with LTG. In view of the lack of data, it
was difficult to make any assessments regarding
the effectiveness of monotherapy LTG, or
monotherapy in general, in elderly patients.
Adjunctive therapy All seven newer AEDs are
licensed for use as adjunctive therapy in POSs.
However, only LTG and TPM are licensed for use
in generalised onset seizures. 
Overall, 68 studies investigated the effects of
adjunctive therapy: GBP (10 studies), LTG (21
studies), LEV (four studies), OXC (two studies),
TGB (seven studies), TPM (14 studies) and VGB
(15 studies). Seven compared newer AEDs with
old44,66,69,84,128–130 and four compared one newer
AED with another AED.61,131–133 The remaining
studies all compared newer AEDs with placebo.
Forty-six studies used a parallel design and 26
were crossover studies. There was one equivalence
trial.69 Treatment periods ranged between 1 week
and 78 weeks (mean = 22 weeks). A number of
studies were continued for extended periods, but
such ‘follow-up’ periods usually adopted an open-
label, non-randomised design, which was not
eligible for inclusion in the main part of the
review, although was considered in the review of
rare, serious and long-term AEs.
All of the studies included only patients with
refractory epilepsy. Three studies included only
patients with generalised onset seizures,76,79,134 and
13 studies included patients with partial or
generalised seizures.51,82–86,88,131,135–139 The
proportion of participants with each seizure type
was often not reported in studies of mixed seizure
types and similarly outcome data were not reported
separately for each of the different seizure type.
The relevance of these data to individual seizure
types was unclear. The remaining studies recruited
only patients with POSs. There was no information
on the use of monotherapy in pregnant women
and elderly patients. This makes it difficult to make
statements about the use of adjunctive therapy in
these groups of patients. However, eight studies
included patients with intellectual
disabilities.49,66,84,85,131,137,140,141 In terms of the size
of the adjunctive trials, the number of participants
ranged from 10 to 629 (mean = 133). 
Table 29 summarises the number of studies assessing
adjunctive AEDs and the outcomes reported.
1. Newer drugs versus placebo
a. Seizure frequency
i. Seizure freedom
Twenty-six out of 56 studies of newer drugs versus
placebo (adjunctive therapy) reported the
proportion of seizure-free participants. A summary
of the main characteristics of these studies is
presented in Table 30.
One crossover trial compared adjunctive GBP
(2400 mg/day) with placebo in patients with
refractory partial seizures.90 The study was of
reasonable quality but included only 27
participants and used a relatively short treatment
period of 12 weeks. First-phase data were not
reported, but the authors reported that two out of
21 participants remained seizure free during GBP
Summary statement for monotherapy studies
The most commonly reported outcome measure
was the proportion of seizure-free participants,
followed by the time to event outcomes (first
seizure and exit/withdrawal). The majority of
data related to newly diagnosed participants
and mixed populations of patients with partial
or generalised seizures. Few studies reported
data regarding the proportion of 50%
responders, cognitive and QoL outcomes. In
general, trials considered only the short-term
effects of therapy and there was little good-
quality evidence for the effectiveness of
monotherapy AEDs (LTG, OXC and TPM),
especially with regard to TPM and OXC. 
There was insufficient evidence to assess the
relative effectiveness of one newer drug as
monotherapy versus another. Compared with
older AEDs (CBZ, VPA and PHT), newer AEDs
failed to show any statistically significant
differences in outcomes, with the exception of
cognitive function, where limited poor-quality
evidence suggested a difference in favour of
LTG and OXC compared with older AEDs.
Similarly, there was little evidence to assess the
effectiveness of the newer AEDs compared with
placebo. Limited evidence to suggest a
difference in the proportion of seizure-free
participants and the time to event outcomes in
favour of OXC compared with placebo should
be regarded with caution. 
No studies assessed the effectiveness of
monotherapy AEDs in people with intellectual
disabilities or pregnant women. There was very
little evidence to assess the effectiveness of
monotherapy AEDs in the elderly. No
significant differences were found between
monotherapy LTG and monotherapy CBZ in
this population.
Results
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TABLE 29 Number of adjunctive studies assessing each comparison and outcome
No. of studies reporting outcome measures
Comparison N Seizure-free 50% Time to Time to Cognitive QoL 
responders 1st seizure exit 
New vs placebo 5 (GBP) 1 (GBP) 5 (GBP) 0 0 1 (GBP) 3 (GBP)
17 (LTG) 5 (LTG) 14 (LTG) 2 (LTG) 9 (LTG)
4 (LEV) 4 (LEV) 4 (LEV) 3 (TGB) 1 (LEV)
1 (OXC) 1 (OXC) 1 (OXC) 6 (VGB) 2 (TGB)
5 (TGB) 2 (TGB) 5 (TGB) 9 (TPM)
12 (TPM) 10 (TPM) 11 (TPM) 8 (VGB)
12 (VGB) 5 (VGB) 11 (VGB)
New vs old 2 (GBP) 1 (GBP) 1 (GBP) 0 0 1 (TGB) 1 (GBP)
1 (LTG) 1 (VGB) 1 (TGB) 1 (TPM) 1 (TGB)
1 (OXC) 1 (VGB) 2 (TPM)
1 (TGB)
2 (TPM)
1 (VGB)
New vs newa 3 (GBP) 3 (GBP) 3 (GBP) 0 0 0 2 (GBP)
3 (LTG) 3 (LTG) 3 (LTG) 2 (LTG)
1 (TGB) 1 (TGB) 1 (TGB) 1 (TGB)
2 (VGB) 2 (VGB) 2 (VGB) 1 (VGB)
N, total number of studies.
a N in newer AEDs vs other newer AEDs refers to the number of studies reporting comparisons including the drugs and
therefore does not represent the total number of studies.
TABLE 30 Summary of studies (adjunctive therapy, newer drugs vs placebo) assessing proportion of seizure-free participants
Study characteristicsa
Drug Refractory/ Seizure type Dose Comments Study details
newly Follow-up
diagnosed N
GBP Refractory Partial 2400 mg/day Crossover study Leach, 199790
12 weeks
N = 27
LTG Refractory Partial 100–250 mg/day Crossover study Binnie, 198750
7 days
N = 10
Refractory Partial Max. 500 mg/day Schachter, 199556
28 weeks
N = 334
Refractory Combination of 100 or 200 mg/day Specifically looks at Veendrick-Meekes, 
partial/generalised 16 weeks patients with intellectual 2000137
N = 68 disabilities
Refractory Combination of 500 or 300 mg/day Two doses of LTG Matsuo, 1993142
partial/generalised 24 weeks compared with 
N = 216 placebo
LEV Refractory Partial 1000 or 3000 mg/day Two doses of LEV Cereghino, 2000143
38 weeks compared with 
N = 294 placebo
continued
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TABLE 30 Summary of studies (adjunctive therapy, newer drugs vs placebo) assessing proportion of seizure-free participants (cont’d)
Study characteristicsa
Drug Refractory/ Seizure type Dose Comments Study details
newly Follow-up
diagnosed N
Refractory Partial 3000 mg/day One dose of LEV Ben-Menachem,
16 weeks compared with 2000144
N = 286 placebo
Refractory Partial 1000 or 2000 mg/day Two doses of LEV Shorvon, 2000145
16 weeks compared with 
N = 324 placebo. Reports 
first-phase data for 
crossover study; 
Boon, 200280
Refractory Combination of 2000 or 4000 mg/day Two doses of LEV Betts, 2000139
partial/generalised 24 weeks compared with 
N = 119 placebo
OXC Refractory Partial 600, 1200 or Three doses of OXC Barcs, 200070
2400 mg/day compared with 
28 weeks placebo
N = 694
TGB Refractory Partial 12–52 mg/day Crossover study. Entry Richens, 1995146
7 weeks into the trial was 
N = 46 dependent on the 
fulfilment of certain 
response criteria
Refractory Partial 16–64 mg/day Crossover study. Entry Crawford, 2001147
6 weeks into the trial was 
N = 44 dependent on the 
fulfilment of certain 
response criteria
TPM Refractory Partial 600 mg/day Tassinari, 199642
12 weeks
N = 60
Refractory Partial 400 mg/day Sharief, 1996148
11 weeks
N = 47
Refractory Partial 600 mg/day Korean Topiramate, 
18 weeks Study Group, 1999149
N = 177
Refractory Partial 200, 400 or Three doses of TPM Faught, 199667
600 mg/day compared with 
16 weeks placebo
N = 181
Refractory Partial 1000 mg/day Rosenfeld, 199641
19 weeks
N = 209
Refractory Partial 200 mg/day Guberman, 2002150
12 weeks
N = 263
continued
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treatment compared with none out of 21
participants during the placebo period.
Four superiority trials, one of which used a
crossover design,50 compared adjunctive LTG
versus placebo in patients with refractory epilepsy.
In two trials, patients had either partial or
generalised seizures137,142 and in the other two all
patients had partial seizures.50,56 The trials
followed up between 10 and 334 patients 
(mean = 130) for periods of 1–28 weeks 
(mean = 15 weeks). Drug doses varied between
trials, but in each case were within the
recommended range. One trial used two separate
doses of LTG.142
The trials were of reasonable quality. The
crossover study used a very short treatment period
of only 7 days and it was difficult to assess baseline
comparability between treatment groups.50 One
trial included only patients with intellectual
disabilities, and therefore findings may have
limited applicability.137 These issues could affect
the findings of the studies and should be
considered when interpreting the data.
Owing to the presence of clinical (different
participants, drug doses and follow-up periods)
and statistical (Q-statistic) heterogeneity, it was
inappropriate to pool data. The unpooled RRs are
presented in Figure 9.
The crossover study failed to report first-phase
data (not included in Figure 9) and did not carry
out an appropriate analysis for crossover data.
However, the study reported no difference
between LTG and placebo in the number of
patients remaining seizure free.
TABLE 30 Summary of studies (adjunctive therapy, newer drugs vs placebo) assessing proportion of seizure-free participants (cont’d)
Study characteristicsa
Drug Refractory/ Seizure type Dose Comments Study details
newly Follow-up
diagnosed N
Refractory Partial 800 mg/day Ben-Menachem, 
13 weeks 1996151
N = 56
Refractory Partial 600, 800 or Three doses of TPM Privitera, 199668
1000 mg/day compared with 
18 weeks placebo
N = 190
Refractory Generalised onset 175 or 225 or Barrett, 199776
400 mg/day
20 weeks
N = 80
Refractory Generalised onset 175–400 mg/day Biton, 199979
20 weeks
N = 80
VGB Refractory Partial 2–3 g/day Provinciali, 1996152
4 months
N = 40
Refractory Partial Max. 4 g/day Bruni, 2000153
4 weeks
N = 111
Refractory Partial 1, 3 or 6 g/day Three doses of VGB Dean, 1999154
12 weeks compared with 
N = 174 placebo 
Refractory Partial 3 g/day French, 1996155
12 weeks
N = 182
N, total number of participants randomised; NS, not stated.
a All were parallel, superiority trials unless stated otherwise.
Only one study in Figure 9 showed a statistically
significant difference, which favoured LTG
300 mg/day over placebo.142 Overall, however, the
evidence suggests a trend in favour of LTG
compared with placebo.
Four superiority trials, one of which was a
crossover trial,145 compared adjunctive LEV with
placebo in patients with refractory epilepsy. Three
studies included only patients with refractory
partial seizures.143–145 The remaining study
included both patients with refractory partial and
refractory generalised seizures.139 The trials
included between 119 and 324 patients (mean =
256) and followed patients for periods of
16–38 weeks (mean = 23.5 weeks). Drug doses
varied between trials. Three trials compared two
separate doses of LEV with placebo and one
compared only one dose of LEV with placebo.144
The trials were of reasonable quality. One study
used a dose of LEV (4000 mg/day) which is
outwith the recommended range.139 The crossover
trial did not use a washout period between
treatments.145
In view of the clinical (different participants, drug
doses and follow-up periods) and statistical 
(Q-statistic) heterogeneity between studies, it was
inappropriate to pool data. Figure 10 shows the
unpooled RRs. 
First-phase data from the crossover study80 were
reported in a separate publication145 and are
included in Figure 10. Final crossover data showed
that 10 out of 183 participants in the1000 mg/day
LEV group, compared with 10 out of 175 in the
2000 mg/day LEV group and two out of 172 in the
placebo group, remained seizure free.
In Figure 10, only two trials showed a statistically
significant difference, favouring LEV 3000 mg/day
over placebo.143,144 Overall, there was a trend in
favour of LEV compared with placebo.
Only one parallel superiority trial of 694
refractory patients with partial seizures compared
adjunctive OXC with placebo.70 The trial
compared three separate doses of OXC (600, 1200
and 2400 mg/day). All doses were within the
recommended range. The trial was of reasonable
quality, but followed treatment for only a relatively
short period (28 weeks). The RRs for each of the
OXC doses are shown in Figure 11. All of the doses
favoured OXC over placebo but the differences
were significant for only two of the doses (1200
and 2400 mg/day). Overall, there was very limited
evidence on which to base an assessment of the
effectiveness of adjunctive OXC compared with
placebo.
Two crossover studies compared TGB with placebo
in patients with refractory partial seizures.146,147
Results
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0.1 0.2 0.5 1 2 5 10 100 
Veendrick-Meekes, 2000 100/200 mg/day (N = 6)
16 weeks
Matsuo, 1993 300 mg/day (N = 144)
24 weeks
Matsuo, 1993 500 mg/day (N = 145)
24 weeks
Schachter, 1995 Max. 500 mg (N = 334)
28 weeks
Study details RRs (95% CI) (unpooled)
Favours placebo Favours LTG
3.733 (95% CI: 0.377 to 39.475)
7.19 (95% CI: 1.201 to 44.325)
5.069 (95% CI: 0.812 to 32.354)
0.671 (95% CI: 0.146 to 3.112)
FIGURE 9 Proportion of seizure-free participants (unpooled RRs, 95% CIs) for adjunctive trials of LTG vs placebo (ITT data)
Both included only small numbers of participants
(46146 and 44147) and used only short treatment
periods of 6147 and 7 weeks.146 Neither study
presented first-phase data. However, one trial
reported that one out of 42 participants with
complex partial seizures, two out 13 with simple
partial seizures and 10 out 27 with SGTC seizures
remained seizure free whilst receiving TGB (these
data include participants who were also seizure
free during the placebo period).146 The other trial
reported that three out of 36 participants with
partial seizures remained seizure free while using
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FIGURE 10 Proportion of seizure-free participants (unpooled RRs, 95% CIs) for adjunctive trials of LEV vs placebo (ITT data)
FIGURE 11 Proportion of seizure-free participants (RRs, 95% CIs) for the adjunctive trial of OXC vs placebo (ITT data)
0.2 0.5 1 2 5 10 100 1000
Study details RRs (95% CI) (unpooled)
Cereghino, 2000 1000 mg/day
(N = 193) 38 weeks
Cereghino, 2000 3000 mg/day 
(N = 196) 38 weeks
Shorvon, 2000 1000 mg/day 
(N = 218) 16 weeks
Shorvon, 2000 2000 mg/day
(N = 218) 16 weeks
Betts, 2000 2000 mg/day
(N = 81) 24 weeks
Betts, 2000 4000 mg/day
(N = 77) 4 weeks
Favours LEV
2.113 (95% CI: 0.280 to 16.004)
3.714 (95% CI: 0.589 to 24.226)
6.786, (95% CI: 0.648 to 72.188)
15.990 (95% CI: 1.642 to 159.752)
5.283 (95% CI: 0.836 to 33.841)
2.053 (95% CI: 0.279 to 15.334)
Favours placebo
Ben-Menachem,  2000
3000 mg/day (N = 286) 16 weeks 8.12 (95% CI: 1.41 to 48.06)
0.5 1 2 5 10 100 1000 
Favours placebo
Barcs, 2000 600 mg/day
(N = 342) 28 weeks
Barcs, 2000 1200 mg/day
(N = 351) 28 weeks
Barcs, 2000 2400 mg/day
(N = 347) 28 weeks
Favours OXC
Study details RRs (95% CI) (unpooled)
5.118 (95% CI: 0.804 to 32.879)
17.494 (95% CI: 3.037 to 102.478)
37.782 (95% CI: 6.710 to 216.942)
TGB compared with one out of 36 participants
using placebo.147 Both studies were of limited
applicability as only participants achieving specific
reductions in seizure frequency whilst receiving
TGB treatment were allowed to enter the trial (i.e.
both were response conditional trials). Overall,
there are limited data on which to base an
assessment of the effectiveness of TGB compared
with placebo.
Ten superiority parallel trials compared adjunctive
TPM with placebo in refractory patients. Two trials
included patients with generalised onset
seizures76,79 and the remainder included patients
with only partial seizures. Studies included
between 47 and 263 participants (mean = 134)
and used treatment period of between 11 and
20 weeks (mean = 16 weeks). The studies used
various doses of TPM, but all were within the
recommended range. Two trials compared three
separate doses of TPM, each of the three having a
different maintenance dose.67,68
Overall, the studies were of reasonable quality,
although newer AEDs were allowed as concomitant
medications in two trials, which may confound the
findings.79,150
Owing to the presence of clinical (different
participants, drug doses and follow-up periods)
and statistical (Q-statistic) heterogeneity, it was
inappropriate to pool the data in most cases.
Unpooled RRs are presented in Figure 12.
Figure 12 shows that all but three of the
comparisons with placebo favoured TPM, although
only three studies showed statistically significant
differences (TPM 40067 and 600 mg/day68,149).
Data from the two 20-week trials involving 80
patients with generalised seizures were pooled (see
Table 31).76,79 The pooled RR (fixed effects)
favoured TPM over placebo but was not
statistically significant. Data were also pooled from
the two trials of 400 mg/day TPM in patients with
partial seizures (see Table 31).67,148 The pooled RR
(fixed effects) showed a statistically significance
difference in favour of TPM. Similarly, the pooled
RR (fixed effects) from three trials that used
600 mg/day TPM in patients with partial seizures
also showed a statistically significant difference in
favour of TPM (see Table 31).42,67,149
Overall, the evidence shows that adjunctive TPM
is more effective than placebo.
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0.01 0.10.2 0.5 1 2 5 10 100 1000
Faught, 1996 #400 mg/day (N = 91) 16 weeks
Korean Topiramate Study Group, 1999 600 mg/day 
(N = 177) 18 weeks
Tassinari, 1996 600 mg/day (N = 60) 12 weeks
Privitera, 1996 600 mg/day (N = 95) 18 weeks
Privitera, 1996 800 mg/day (N = 95) 18 weeks
Ben-Menachem, 1996 800 mg/day (N = 56) 13 weeks
Privitera, 1996 1000 mg/day (N = 94) 18 weeks
Rosenfeld, 1996 1000 mg/day (N = 209) 19 weeks
Study details RRs (95% CI) (unpooled)
Favours placebo Favours TPM
Barrett, 1997
Biton, 1999 175–400 mg/day (N = 80) 20 weeks
Guberman, 2002 200 mg/day (N = 263) 12 weeks
Faught, 1996 200 mg/day (N = 90) 16 weeks
Sharief, 1996 400 mg/day (N = 47) 11 weeks
Faught, 1996 400 mg/day (N = 90) 16 weeks
5.250 (95% CI: 0.490 to 57.787)
6.615 (95% CI: 1.097 to 40.840)
1.000 (95% CI: 0.0586 to 17.063)
10.776 (95% CI: 1.102 to 109.811)
2.939 (95% CI: 0.247 to 35.417)
3.000 (95% CI: 0.7651 to 12.350)
1.000 (95% CI: 0.058 to 17.149)
5.375 (95% CI: 0.576 to 53.292)
2.661 (95% CI: 0.6780 to 10.693)
7.000 (95% CI: 0.683 to 74.087)
17.000 (95% CI: 1.804 to 16890)
5.208 (95% CI: 0.498 to 56.908)
8.809 (95% CI: 0.885 to 91.098)
1. 000 (95% CI: 0.107 to 9.387)
FIGURE 12 Proportion of seizure-free participants (unpooled RRs, 95% CIs) for adjunctive trials of TPM vs placebo (ITT data)
Four trials compared adjunctive VGB with placebo
in patients with refractory partial seizures.152–155
The studies included between 40 and 182 patients
(mean = 127) and followed treatment for between
4 weeks and 4 months (mean = 11 weeks). The
trials were of reasonable quality. However, one trial
of 40 patients was possibly underpowered and was
designed to evaluate cognitive and QoL
outcomes.152 One trial compared three different
doses of VGB with placebo but one dose exceeded
the recommended limit.154 One trial contained
patients who deviated from the prespecified
inclusion criteria.153
In view of the clinical (different drug doses and
follow-up periods) and statistical (Q-statistic)
heterogeneity between studies, it was not
appropriate to combine the individual RRs.
Figure 13 shows the unpooled RRs.
The unpooled data shown in Figure 13 shows a
trend in favour of VGB, although only one study
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TABLE 31 Proportion of seizure-free participants (pooled RRs, 95% CIs) for adjunctive trials of TPM vs placebo (ITT data)
Characteristics Studies Pooled RR (95% CI) (fixed effects)
N = 80 Barrett, 199776 1.000 (95% CI: 0.107 to 9.387)
N = 80 Biton, 199979 5.250 (95% CI: 0.490 to 57.787)
Refractory, generalised seizures, Pooled (n = 2) 2.393 (95% CI: 0.364 to 15.724)
175–400 mg/day, 20 weeks follow-up Heterogeneity: Q = 0.653 (df = 1), p = 0.419
N = 90 Faught, 199667 17.000 (95% CI: 1.804 to 168.953)
N = 47 Sharief, 1996148 5.208 (95% CI: 0.498 to 56.908)
Refractory, partial seizures, Pooled (n = 2) 11.165 (95% CI: 1.469 to 84.849)
400 mg/day Heterogeneity: Q = 0.336 (df = 1), p = 0.562
N = 91 Faught, 199667 8.809 (95% CI: 0.885 to 91.098)
N = 177 Korean Topiramate 6.615 (95% CI: 1.097 to 40.840)
Study Group, 1999149
N = 60 Tassinari,199642 1.000 (95% CI: 0.059 to 17.063)
Refractory, partial seizures, Pooled (n = 3) 6.774 (95% CI: 1.821 to 25.192)
600 mg/day Heterogeneity: Q = 1.063 (df = 3), p = 0.786
0.01 0.1  0.2 0.5  1  2  5  10  100  1000 
Dean, 1999 1 g/day (N = 90) 12 weeks
Dean, 1999 3 g/day (N = 88) 12 weeks
French, 1996 3 g/day (N = 182) 12 weeks
Provinciali, 1996 2–3 g/day (N = 40) 4 months
Bruni, 2000 Max. 4 g/day (N = 111) 4 weeks
Dean, 1999 6 g/day (N = 86) 12 weeks
1.000 (95% CI: 0.058 to 17.142)
9.409 (95% CI: 0.945 to 97.252)
5.870 (95% CI: 0.955 to 36.787)
5.000 (95% CI: 0.484 to 54.486)
2.284 (95% CI: 0.536 to 9.950)
12.048 (95% CI: 1.235 to 122.602)
Study details RRs (95% CI) (unpooled)
Favours placebo Favours VGB
FIGURE 13 Proportion of seizure-free participants (unpooled RRs, 95% CIs) for adjunctive trials of VGB vs placebo (ITT data)
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TABLE 32 Summary of studies (adjunctive therapy, newer drugs vs placebo) assessing proportion of participants experiencing at least a
50% decrease in seizure frequency
Study characteristicsa
Drug Refractory/ Seizure type Dose Comments Study details
newly Follow-up
diagnosed N
GBP Refractory Partial 2400 mg/day Crossover study Leach, 199790
12 weeks
N = 27
Refractory Partial 900 and 1200 mg/day Two doses of GBP Anhut, 1994156
12 weeks compared with placebo
N = 272
Refractory Partial 1200 mg/day UK Gabapentin Study 
14 weeks Group No. 5, 199073
N = 127
Refractory Partial 900 and 1200 mg/day Two doses of GBP Sivenius, 1991157
3 months compared with 
N = 43 placebo
Refractory Combination of 600 or 1200 or Three doses of GBP US Gabapentin Study 
partial/generalised 1800 mg/day compared with placebo Group No. 5, 1993138
12 weeks
N = 306
LTG Refractory Combination of Max. 400 mg/day Crossover study Messenheimer, 
partial/generalised 14 weeks 1994158
N = 98
Refractory Combination of 75–400 mg/day Crossover study Boas, 1996136
partial/generalised 11 months
N = 56
Refractory Combination of 75, 100 or 200 mg/day Crossover study Binnie, 1989159
partial/generalised 12 weeks
N = 34
Refractory Combination of 
partial/generalised 100–300 mg/day Crossover study Jawad, 1989160
12 weeks
N = 24
Refractory Combination of 150 or 300 mg/day Crossover study Loiseau, 199089
partial/generalised 7 weeks
N = 23
continued
showed statistically significant difference in favour
of VGB (6 g/day) compared with placebo.154 This
dose exceeded the recommended dose range. 
ii. 50% reduction in seizure frequency
Fifty out of 56 studies of newer drugs versus
placebo (adjunctive therapy) reported the
proportion of participants who experienced at
least a 50% decrease in seizure frequency. A
summary of the main characteristics of these
studies is presented in Table 32.
Five superiority trials, one of which was a crossover
trial,90 compared adjunctive GBP with placebo in
patients with refractory epilepsy.73,90,138,156,157 
Four trials included only patients with partial
seizures and the remaining trial138 included both
patients with partial and patients with generalised
seizures. The studies included between 27 and 
306 patients (mean = 155) and used treatment
period of up to 14 weeks. Various doses of GBP
were used, but all were within the recommended
range. Two trials compared two doses of GBP
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TABLE 32 Summary of studies (adjunctive therapy, newer drugs vs placebo) assessing proportion of participants experiencing at least a
50% decrease in seizure frequency (cont’d)
Study characteristicsa
Drug Refractory/ Seizure type Dose Comments Study details
newly Follow-up
diagnosed N
Refractory Combination of Max. 400 mg/day Crossover study Yaqub, 199582
partial/generalised 20 weeks
N = 43
Refractory Partial 150 or 300 mg/day Crossover study Schapel, 1993161
12 weeks
N =41
Refractory Partial Max. 300 mg/day Crossover study Schmidt, 199391
28 weeks
N = 23
Refractory Partial 200 or 400 mg/day Crossover study Smith, 199355
18 weeks
N = 81
Refractory Partial 150 or 300 mg/day Crossover study Cordova, 199540
12 weeks
N = 29
Refractory Partial 50–200 mg/day Crossover study Stolarek 1994162
36 weeks
N = 22
Refractory Generalised 75 or 150 mg/day Crossover study Beran, 1998134
24 weeks
N = 26
Refractory Combination of 100 or 200 mg/day Specifically looks at Veendrick-Meekes, 
partial/generalised 16 weeks patients with intellectual 2000137
N = 68 disabilities
Refractory Combination of 500 or 300 mg/day Two doses of LTG Matsuo, 1993142
partial/generalised 24 weeks compared with placebo
N = 216
LEV Refractory Partial 1000 or 3000 mg/day Two doses of LEV Cereghino, 2000143
38 weeks compared with placebo
N = 294
Refractory Partial 3000 mg/day One dose of LEV Ben-Menachem, 
16 weeks compared with placebo 2000144
N = 286
Refractory Partial 1000 or 2000 mg/day Two doses of LEV Shorvon, 2000145
16 weeks compared with placebo. 
N = 324 Presents first-phase 
data for crossover 
study, Boon 200280
Refractory Combination of 2000 or 4000 mg/day Two doses of LEV Betts, 2000139
partial/generalised 24 weeks compared with placebo
N = 119
OXC Refractory Partial 600, 1200 or Three doses of OXC Barcs, 200070
2400 mg/day compared with placebo
28 weeks
N = 694
continued
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TABLE 32 Summary of studies (adjunctive therapy, newer drugs vs placebo) assessing proportion of participants experiencing at least a
50% decrease in seizure frequency (cont’d)
Study characteristicsa
Drug Refractory/ Seizure type Dose Comments Study details
newly Follow-up
diagnosed N
TGB Refractory Partial 12–52 mg/day Crossover study. Entry Richens, 1995146
7 weeks into the trial was 
N = 46 dependent on the 
fulfilment of certain 
response criteria
Refractory Partial Titrated Crossover study. Entry Crawford, 2001147
6 weeks into the trial was 
N = 44 dependent on the 
fulfilment of certain 
response criteria
Refractory Partial 32 mg/day Specifically looks at Sachdeo, 1997140
16 weeks patients with 
N = 318 intellectual disabilities.
Two dose regimens of 
TGB compared with 
placebo
Refractory Partial 16, 32 or 56 mg/day Three doses of TGB Uthman, 1998163
12 weeks compared with placebo
N = 297
Refractory Partial 30 mg/day Kälviäinen, 1998164
22 weeks
N= 154
TPM Refractory Generalised 175, 225 or Barrett, 199776
400 mg/day based 
on body weight
20 weeks
N = 80
Refractory Generalised 175–400 mg/day Biton, 199979
20 weeks
N = 80
Refractory Partial 200 mg/day Guberman, 2002150
12 weeks
N = 263
Refractory Partial 1000 mg/day Rosenfeld, 199641
19 weeks
N = 209
Refractory Partial 200, 400 or Three doses of TPM Faught, 199667
600 mg/day compared with placebo
16 weeks
N = 181
Refractory Partial 600 mg/day Korean Topiramate 
18 weeks Study Group, 1999149
N = 177
Refractory Partial 600 mg/day Tassinari, 199642
12 weeks
N = 60
Refractory Partial 400 mg/day Sharief, 1996148
11 weeks
N = 47
continued
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TABLE 32 Summary of studies (adjunctive therapy, newer drugs vs placebo) assessing proportion of participants experiencing at least a
50% decrease in seizure frequency (cont’d)
Study characteristicsa
Drug Refractory/ Seizure type Dose Comments Study details
newly Follow-up
diagnosed N
Refractory Partial 800 mg/day Ben-Menachem, 
13 weeks 1996151
N = 56
Refractory Partial 300 mg/day Yen, 2000165
14 weeks
N = 46
Refractory Partial 600, 800 or Three doses of TPM Privitera, 199668
1000 mg/day compared with placebo
18 weeks
N = 190
VGB Refractory Combination of 2 or 3 g/day Specifically looks at Tassinari, 198785
partial/generalised 3 months patients with 
N = 31 intellectual disabilities.
Crossover study
Refractory Combination of 3 g/day Crossover study Loiseau, 198683
partial/generalised 10 weeks
N = 23
Refractory Combination of 2–3 g/day Crossover study Tartara, 198686
partial/generalised 7 weeks
N = 23
Refractory Combination of 2–3 g/day Crossover study McKee, 199354
partial/generalised 12 weeks
N = 24
Refractory Partial 3 g/day Includes patients with Rimmer, 198449
9 weeks intellectual disabilities.
N = 24 Crossover study
Refractory Partial 2 or 3 g/day Crossover study. Beran, 199687
8 weeks Two doses of VGB 
N = 80 compared with placebo
Refractory Partial 3 g/day French, 1996155
12 weeks
N = 182
Refractory Partial 1, 3 or 6 g/day Three doses of VGB Dean, 1999154
12 weeks compared with placebo
N = 174
Refractory Partial Max. 4 g/day Bruni, 2000153
4 weeks
N = 111
Refractory Partial 3 g/day Grunewald, 199438
18 weeks
N = 45
N, total number of participants randomised; NS, not stated.
a All were parallel, superiority trials unless stated otherwise.
(900 and 1200 mg/day) with placebo,156,157 and 
one trial compared three doses (600, 1200 and
1800 mg/day).138
One study of 43 participants failed to report a
power calculation for sample size and was likely to
have been insufficiently powered.157 Another trial
only included patients that were deemed likely to
complete the trial.138 This trial included patients
with both partial and generalised seizures,
although GBP is only licensed for the treatment of
partial seizures. One trial found statistically
significant differences between GBP and placebo
groups in some baseline characteristics, including
the duration of epilepsy.156
Owing to the presence of clinical (different
participants, drug doses and follow-up periods)
and statistical (Q-statistic) heterogeneity, it was
inappropriate to pool data. Figure 14 shows the
unpooled RRs for the four parallel trials. The
crossover study failed to report first phase data,
but reported that nine out of 21 participants
responded to treatment with adjunctive GBP.90
The unpooled data show a trend in favour of GBP
compared with placebo, but only two studies
showed statistically significant differences in favour
of GBP (900 and 1200 mg/day GBP in one
study156 and 1800 mg/day GBP138 in the other).
Overall, the evidence favours adjunctive GBP
compared with placebo in the treatment of
refractory partial seizures.
Twelve crossover trials40,55,82,89,91,134,136,158–162 and
two parallel trials137,142 compared adjunctive LTG
with placebo in patients with refractory epilepsy.
One trial included only patients with partial
seizures162 and another only patients with
generalised seizures.134 The remainder of the trials
included patients with either partial or generalised
seizures. The studies included between 22 and 216
participants (mean = 56) and used treatment
periods of between 7 and 44 weeks (mean =
20 weeks). Various doses of LTG were used, but all
were within the recommended range. One parallel
trial compared two doses of LTG with placebo.142
In two trials, an appropriate paired analysis for
crossover trials did not appear to have been
conducted.89,161 In addition, one of these trials
had skewed data owing to the inclusion of a
participant with a very large number of seizures.89
In another trial, assessment of blinding success
suggested that it may not have been effective, and
over 20% of follow-up data was classified as
missing.55 One trial was only reported as an
abstract.82 In a further trial, eligibility criteria were
altered during the study and one patient received
monotherapy LTG.136 One of the two parallel
trails included only participants with intellectual
disabilities.137
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0.1 0.2 0.5 1 2 5 10 
2.160 (95% CI: 1.096 to 4.316)Anhut, 1994 1200 mg (N = 161)
Anhut, 900 mg (N = 220) 2.935 (95% CI: 1.415 to 6.057)
2.164 (95% CI: 0.899 to 5.296)UK Gabapentin Study Group, 1200 mg (N = 127)
Study details RRs (95% CI) (unpooled)
0.750 (95% CI: 0.162 to 3.353)Sivenius, 1991 900 mg (N = 34)
2.000 (95% CI: 0.526 to 7.246)Sivenius, 1991 1200 mg (N = 27)
2.080 (95% CI: 0.871 to 4.924)US Gabapentin Study Group, 1993 600 mg (N = 151)
US Gabapentin Study Group, 1993 1200 mg (N = 199)
US Gabapentin Study Group, 1993 1800 mg (N = 152)
1.941 (95% CI: 0.894 to 4.267)
3.176 (95% CI: 1.453 to 6.964)
Favours GBPFavours placebo
FIGURE 14 Proportion of 50% responders (unpooled RRs, 95% CIs) for adjunctive trials of GBP vs placebo (ITT data)
Owing to the presence of clinical (different
participants, drug doses and follow-up periods)
and statistical (Q-statistic) heterogeneity, it was not
possible to pool all of the data. Figure 15 shows the
unpooled RRs for the first phase of nine crossover
studies and the two parallel studies. Two crossover
studies did not report first-phase data40,82 and the
third did not report first-phase data for the
placebo group.162 One of these studies reported
that 52.7% (19/36) of participants receiving LTG
responded to treatment,82 another reported that
37.5% of participants receiving LTG responded to
treatment40 and the final study reported that four
out of 22 participants responded to treatment with
LTG.162
The unpooled data showed a trend in favour of
LTG compared with placebo, but only two trials
showed significant differences in favour of LTG
(500142 and 100–300 mg/day160).
First-phase data from six of the crossover studies
were pooled (see Table 33).89,136,158–161 The pooled
RR (fixed-effects model) showed a statistically
significant difference (RR = 2.251, 95% CI: 1.146
to 4.424) in favour of LTG compared with
placebo. Overall, the evidence favours adjunctive
LTG compared with placebo.
Four superiority trials,139,143–145 including one
crossover study,145 compared adjunctive LEV with
placebo in patients with refractory seizures. Three
studies included only patients with partial
seizures143–145 and one included patients with
partial or generalised seizures.139 The trials
included between 119 and 324 patients 
(mean = 256) and followed patients for periods of
16–38 weeks (mean = 23.5 weeks). Drug doses
varied between trials. Three trials compared two
separate doses of LEV with placebo and one
compared only one dose of LEV with placebo.144
In view of the clinical (different participants, drug
doses and follow-up periods) and statistical 
(Q-statistic) heterogeneity, data were not pooled.
Unpooled RRs are shown in Figure 16139,143,145
including first-phase data from the crossover
studies145 This trial reported final crossover data
showing that 48 out of 183 (26.2%) participants
responded while receiving LEV compared with 21
out of 172 (12.2%) while receiving placebo
(p = 0.004).
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0.1 0.2 0.5 1 2 5 10 100
PARALLEL STUDIES
Veendrick-Meekes, 2000 100/200 mg/day (N = 68)
Matsuo, 1993 300 mg/day (N = 145)
Matsuo, 1993 500 mg/day (N = 144)
FIRST PHASE CROSSOVER
Binnie, 1987 100–250 mg/day (N = 34)
Smith, 1993 200/400 mg/day (N = 81)
Schmidt, 1993 Max. 300 mg/day (N = 23)
Beran, 1998 75/150 mg/day (N = 26)
Boas, 1996 74–400 mg/day (N = 56)
Binnie, 1989 75/100/200 mg/day (N = 34)
Jawad, 1989 100–300 mg/day (N = 24)
Schapel, 1993 150/300 mg/day (N = 41)
Loiseau, 1990 150/300 mg/day (N = 23)
Messenheimer, 1994 Max. 400 mg/day (N = 98)
Study details RRs (95% CI) (unpooled)
Favours placebo Favours LTG
1.545 (95% CI: 0.749 to 3.467)
1.234 (95% CI: 0.580 to 2.634)
2.129 (95% CI: 1.104 to 4.188)
2. 000 (95% CI: 0.342 to 13.062)
3.902 (95% CI: 0.6186 to 25.445)
1.091 (95% CI: 0.122 to 9.728)
1.667 (95% CI: 0.539 to 5.455)
1.733 (95% CI: 0.529 to 5.917)
1.125 (95% CI: 0.123 to 10.257)
6.000 (95% CI: 1.193 to 35.485)
5.250 (95% CI: 0.914 to 32.553)
2.545 (95% CI: 0.369 to 18.103)
1.130 (95% CI: 0.324 to 3.928)
FIGURE 15 Proportion of 50% responders (unpooled RRs, 95% CIs) for adjunctive trials of LTG vs placebo (ITT data)
The unpooled data show that all four studies
showed statistically significant differences in favour
of licensed doses of LEV compared with placebo
(1000,143,145 2000 mg/day139,145 and
3000 mg/day143,144 doses of LEV). Overall, the
evidence favours LEV as compared with placebo in
the treatment of refractory partial seizures.
Evidence for OXC was limited to one trial of 
three doses of OXC (600, 1200 and 2400 mg/day)
compared with placebo in 694 patients with
refractory partial seizures.70 The limitations of this
study have been previously discussed in the
proportion of seizure-free participants. Figure 17
shows that RRs for each of the three OXC doses
compared with placebo.
A statistically significant difference in favour of
OXC was reported for each of the three doses of
OXC (600, 1200 and 2400 mg/day). Although the
evidence was limited to one trial with 694
participants, it appears that adjunctive OXC is
favoured in comparison with placebo in patients
with refractory partial seizures. 
Three parallel trials140,163,164 and two crossover
trials146,147 compared adjunctive TGB with placebo
in patients with refractory partial seizures. The
studies included between 44 and 318 participants
(mean = 172) and used treatment period of
between 6 and 22 weeks (mean = 13 weeks).
Various doses of TGB were used, but all were
within the recommended range. One trial
Results
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Study details RRs (95% CI) (unpooled)
Favours LEVFavours placebo
Cereghino, 2000 1000 mg/day (N = 193)
Cereghino, 2000 3000 mg/day (N = 196)
Shorvon, 2000 1000 mg/day (N = 218)
Shorvon, 2000 2000 mg/day (N = 218)
Betts, 2000 4000 mg/day
(N = 77)
Betts, 2000 2000 mg/day (N = 81)
4.985 (95% CI: 2.416 to 10.582)
5.375 (95% CI: 2.623 to11.345)
2.209 (95% CI: 1.1534 to 4.282)
2.882 (95% CI: 1.552 to 5.437)
2.414 (95% CI: 1.001 to 6.077)
1.642 (95% CI: 0.618 to 4.443)
2.46 (95% CI: 1.56 to 3.96)Ben-Menachem, 2000
4000 mg/day (N = 286)
FIGURE 16 Proportion of 50% responders (unpooled RRs, 95% CIs) for adjunctive trials of LEV vs placebo (ITT data)
TABLE 33 Proportion of 50% responders (pooled RRs, 95% CIs) for adjunctive studies of LTG vs placebo (ITT data)
Characteristics Studies Pooled RR (95% CI) (fixed effects)
N = 56 Boas, 1996136 1.733 (95% CI: 0.529 to 5.917)
N = 34 Binnie, 1989159 1.125 (95% CI: 0.123 to 10.257)
N = 24 Jawad, 1989160 6.000 (95% CI: 1.193 to 35.485)
N = 41 Schapel, 1993161 5.250 (95% CI: 0.914 to 32.553)
N = 23 Loiseau, 199089 2.545 (95% CI: 0.369 to 18.103)
N = 98 Messenheimer, 1994158 1.130 (95% CI: 0.324 to 3.928)
1st-phase crossover studies, Pooled (n = 6) 2.251 (95% CI: 1.146 to 4.424)
refractory, partial/generalised Heterogeneity: Q = 3.072 (df = 5) p = 0.689
seizures, all doses 75–400 mg/day
compared three doses of TGB with placebo163 and
another trial compared two different dose
regimens (but same daily dose) of TGB with
placebo.140
In one of these trials, over 20% of participants
withdrew after the pretrial phase.146 One trial
allowed the use of VGB as a concurrent AED,164
and another trial included only patients with
intellectual disabilities.140
The unpooled RRs for the three parallel studies
are shown in Figure 18.140,163,164 Neither of the two
crossover studies reported first-phase data and so
are not shown in Figure 18.146,147 One reported
that 11 out of 42 participants with complex partial
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Barcs, 2000 600 mg/day
(N = 342)
Barcs, 2000 1200 mg/day
(N = 351)
Barcs, 2000 2400 mg/day
(N = 347)
Study details
Favours OXCFavours placebo
2.094 (95% CI: 1.3278 to 3.3299)
3.225 (95% CI: 2.124 to 4.965)
1 2 5 10
3.932 (95% CI: 2.620 to 5.995)
FIGURE 17 Proportion of 50% responders (RRs, 95% CIs) for the adjunctive trial of OXC vs placebo (ITT data)
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Study details RRs (95% CI) (unpooled)
Favours placebo Favours TGB
2.594 (95% CI: 1.390 to 4.921)Sachdeo, 1997 (8 mg q.d.) (N = 215)
Sachdeo, 1997 (16 mg b.d.)
(N = 213)
Uthman, 1998 (16 mg)
(N = 152)
Uthman, 1998  (32 mg) (N = 179)
Uthman, 1998 (56 mg) (N = 148)
Kalviainen, 1998 (30 mg)
(N = 154)
3.028 (95% CI: 1.651 to 5.663)
1.865 (95% CI: 0.560 to 6.192)
4.395 (95% CI: 1.631 to 12.122)
2.200 (95% CI: 0.841 to 5.848)
6.386 (95% CI: 2.374 to 17.527)
FIGURE 18 Proportion of 50% responders (unpooled RRs, 95% CIs) for adjunctive trials of TGB vs placebo (ITT data)
seizures, seven out of 13 with simple partial
seizures and 17 out 27 with secondary generalised
tonic–clonic (GTC) seizures responded to TGB
treatment.146 The other reported that 12 out of 36
participants responded during TGB therapy.147
However, entry into both crossover trials was
dependent on the fulfilment of response criteria
where participants were required to achieve a
certain reduction in seizure frequency.146,147 This
limits the applicability of their findings.
The unpooled data from the three parallel trials
show a trend in favour of TGB compared with
placebo, with statistically significant differences in
two of the studies.140,163 Data for doses of 30 and
32 mg/day TGB were pooled from the three
parallel trials (see Table 34). The pooled RR 
(fixed-effects model) showed a statistically
significant difference in favour of TGB 
(RR = 3.090, 95% CI: 1.925 to 4.961). Overall,
the evidence shows a statistically significant
difference in favour of adjunctive TGB
(30/32 mg/day) compared with placebo in patients
with partial seizures.
Eleven superiority parallel trials compared
adjunctive TPM with placebo in patients with
refractory epilepsy. Nine trials included only
patients with partial seizures41,42,67,68,148–151,165 and
two included only patients with generalised
seizures.76,79 Trials included between 46 and 263
participants (mean = 126) and followed treatment
over periods of between 11 and 20 weeks
(mean = 16 weeks). Different doses of TPM were
used but all were within the recommended range.
Two trials compared three different doses of TPM
with placebo.67,68 The limitations of the studies
have been discussed previously for the proportion
of seizure-free participants.
Owing to the presence of clinical (different
participants, drug doses and follow-up periods)
and statistical (Q-statistic) heterogeneity, the
pooling of data was limited. Figure 19 shows the
unpooled RRs. 
All but one of the studies76 and one TPM dose
(200 mg/day) of another trial67 showed statistically
significant differences in favour of TPM compared
with placebo.
Data were pooled from two trials following up
80 patients with generalised seizures for 20 weeks
(see Table 35). The pooled RR (fixed-effects
model) showed a statistically significance
difference in favour of TPM (RR = 2.324, 95% CI:
1.378 to 3.918). Data were pooled from the two
studies of 400 mg/day TPM in patients with partial
seizures (see Table 35).67,148 The pooled RR (fixed-
effects model) also showed a statistically significant
difference in favour of TPM (RR = 2.929, 95% CI:
1.558 to 5.509). Finally, data were pooled from the
three of 600 mg/day TPM in patients with partial
seizures (see Table 35).42,67,149 The pooled RR
(fixed-effects model) was again statistically
significant in favour of TPM compared with
placebo (RR = 3.505, 95% CI: 2.304 to 5.332).
Based on these findings, it appears that TPM (400
and 600 mg/day) adjunctive therapy is more
effective than placebo. This applies to both the
treatment of partial and generalised seizures.
Six crossover studies49,54,83,85–87 and four parallel
studies38,153–155 compared adjunctive VGB with
placebo in patients with refractory seizures. In all
but four of the trials, which involved patients with
both generalised and partial seizures,54,83,85,86 all
patients had partial seizures. The trials recruited
between 23 and 182 (mean = 72) patients and
followed them up for periods of 4–18 weeks (mean
= 10 weeks). One trial used two separate arms and
one used three separate arms of VGB, each with a
different maintenance dose.
Owing to the presence of clinical (different
participants, drug doses and follow-up periods)
and statistical (Q-statistic) heterogeneity, it was
inappropriate to pool data. Figure 20 shows the
unpooled RRs derived from the four parallel
group RCTs. The six crossover trials did not
report first-phase data and were not included in
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TABLE 34 Proportion of 50% responders (pooled RR, 95% CI) for adjunctive trials of TGB vs placebo (ITT data)
Characteristics Studies Pooled RR (95% CI) (fixed effects)
N = 213 Sachdeo, 1997140 16 mg b.d. 3.028 (95% CI: 1.651 to 5.663)
N = 179 Uthman, 1998163 4.395 (95% CI: 1.631 to 12.122)
N = 154 Kälviäinen, 1998164 2.200 (95% CI: 0.841 to 5.848)
Refractory, partial seizures, 30–32 mg/day Pooled (n = 3) 3.090 (95% CI: 1.925 to 4.961)
Heterogeneity Q = 0.873 (df = 2),
p = 0.646
Figure 20. However, they reported the number of
patients who achieved at least a 50% reduction in
seizure frequency with VGB, which ranged from 33
to 67%.49,54,83,85–87 In the trial that reported the
largest benefit, it was unclear if an appropriate
paired analysis was performed or if patients had
constant and predictable seizure frequencies.49
That study and two others83,85 did not report a
washout period but the possible effects on the
reported findings were not mentioned. Four of the
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0.5 1 2 5 10 100 1000
Faught, 1996 600 mg/day (N = 91)
Korean Topiramate Study Group, 1999 600 mg/day 
(N = 177)
Tassinari, 1996 600 mg/day (N = 60)
Privitera, 1996 600 mg/day (N = 95)
Privitera, 1996 800 mg/day (N = 95)
Ben-Menachem, 1996 800 mg/day (N = 56)      
Privitera, 1996 1000 mg/day (N = 94)
Rosenfeld, 1996 1000 mg/day (N = 209)
RRs (95% CI) (unpooled)
Favours placebo Favours TPM
Barrett, 1997
Biton, 1999 175–400 mg/day (N = 80)
Guberman, 2002 200 mg/day (N = 263)
Faught, 1996 200 mg/day (N = 90)
Yen, 2000 300 mg/day (N = 46)
Sharief, 1996 400 mg/day (N = 47)
Faught, 1996 400 mg/day (N = 90)
2.000 (95% CI: 0.997 to 4.154)
2.703 (95% CI: 1.323 to 5.779)
2.568 (95% CI: 1.318 to 5.223)
3.866 (95% CI: 2.201 to 7.007)
4.667 (95% CI: 1.658 to 14.205)
5.250 (95% CI: 2.092 to 13.905)
4.750 (95% CI: 1.872 to 12.681)
25.00 (95% CI: 2.836 to 243.464)
4.596 (95% CI: 1.801 to 12.317)
2.735 (95% CI: 1.530 to 5.295)
1.834 (95% CI: 1.249 to 2.772)
1.500 (95% CI: 0.696 to 3.289)
3.667 (95% CI: 1.308 to 11.227)
4.174 (95% CI: 1.150 to 16.337)
2.625 (95% CI: 1.349 to 5.332)
FIGURE 19 Proportion of 50% responders (unpooled RRs, 95% CIs) for adjunctive trials of TPM vs placebo (ITT data)
TABLE 35 Proportion of 50% responders (pooled RRs, 95% CIs) for adjunctive studies of TPM vs placebo (ITT data)
Characteristics Studies Pooled RR (95% CI) (fixed effects)
N = 80 Barrett, 199776 2.000 (95% CI: 0.997 to 4.154)
N = 80 Biton, 199979 2.703 (95% CI: 1.323 to 5.779)
Refractory, generalised seizures, Pooled (n = 2) 2.324 (95% CI: 1.378 to 3.918)
175–400 mg/day, 20 weeks follow-up Heterogeneity: Q = 0.318 (df = 1), p = 0.573
N = 47 Sharief, 1996148 4.174 (95% CI: 1.150 to 16.337)
N = 90 Faught, 199667 2.625 (95% CI: 1.349 to 5.332)
Refractory, partial seizures, Pooled (n = 2) 2.929 (95% CI: 1.558 to 5.509)
400 mg/day, follow-up Heterogeneity: Q = 0.326 (df = 1), p = 0.5679
N = 90 Faught, 199667 2.568 (95% CI: 1.318 to 5.223)
N = 177 Korean Topiramate 3.866 (95% CI: 2.201 to 7.007)
Study Group, 1999149
N = 60 Tassinari, 199642 4.667 (95% CI: 1.658 to 14.205)
Refractory, partial seizures, Pooled (n = 3) 3.505 (95% CI: 2.304 to 5.332)
600 mg/day, follow-up 12–18 weeks Heterogeneity: Q = 1.101 (df = 2), p = 0.577
crossover trials were conducted in patients with
partial or generalised seizures but VGB is licensed
only for the treatment of partial seizures. However,
there was no clear pattern of difference in the
percentage responders in these studies compared
with the studies that included only partial seizures.
One trial conducted in patients with intellectual
disabilities showed the lowest response rate (33%),85
but the trial that included some patients (10%)
with intellectual disabilities showed the highest
response rate.49 The findings from the crossover
trials were therefore clearly inconsistent.
The parallel trials all showed statistically significant
differences in favour of VGB as measured by the
proportion of responders (Figure 20). In two of the
trials the maintenance dose used in one of the
VGB arms exceeded the recommended limit.153,154
In one trial, some randomised patients were found
not to satisfy the prespecified inclusion criteria,153
which may impact on the ITT data included in
this review.
Overall, the evidence favoured adjunctive VGB
over placebo.
b. Time to first seizure
None of the 55 studies of newer drugs versus
placebo (adjunctive therapy) reported the time to
first seizure.
c. Time to withdrawal/exit
None of the 55 studies of newer drugs versus
placebo (adjunctive therapy) reported the time to
exit/withdrawal.
d. Quality of life
Thirty-one out of 55 studies of newer drugs versus
placebo (adjunctive therapy) reported QoL
outcomes (see Table 36). 
Three studies used GBP,90,138,156 nine
LTG,55,56,89,91,136,137,142,158,161 one levetiracetam,166
two TGB,39,167 nine TPM42,67,68,76,79,148,149,151,165
and seven VGB.38,51,87,152–154,168,169 Twenty-two
studies were parallel superiority trials and 10 were
crossover trials. No studies of adjunctive OXC
reported QoL outcomes.
A variety of measures were used to assess QoL (see
Table 37). In total 21 different types of QoL
measures were used: GBP (three measures), LTG
(10 measures), LEV (one measure), TGB (five
measures), TPM (two measures) and VGB (12
measures). The majority of measures were used
only once both between and within study drugs.
The most commonly reported measures were
subjective global evaluations by both the patient
and the physician/investigator.
Details of the individual study data are reported in
Appendix 23 and details of the individual QoL
measures in Appendix 4. Table 38 summarises the
overall findings of the QoL assessments. Three
trials of GBP, one of which was a crossover trial,90
were carried out in patients with refractory partial
Results
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1 2 5 10 100
Dean, 1999 1 g/day (N = 90)
Dean, 1999 1 g/day (N = 88) 
French, 1996 3 g/day (N = 182)
Grunewald, 1994 3 g/day (N = 45)
Bruni, 2000 Max. 4 g/day (N = 111)
Dean, 1999 6 g/day (N = 96) 
3.667 (95% CI: 1.198 to 11.695)
7.674 (95% CI: 2.728 to 23.014)
2.302 (95% CI: 1.436 to 3.770)
3.485 (95% CI: 1.223 to 10.765)
1.828 (95% CI: 1.106 to 3.117)
8.049 (95% CI: 2.867 to 24.098)
Study details RRs (95% CI) (unpooled)
Favours placebo Favours VGB
FIGURE 20 Proportion of 50% responders (unpooled RRs, 95% CIs) for adjunctive trials of VGB vs placebo (ITT data)
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TABLE 36 Total number of studies (adjunctive therapy, newer drugs vs placebo) assessing quality of life outcomes
Total no. of studies assessing 
QoL outcomes
Drug Crossover Parallel All studies Study details
GBP 1 2 3 US Gabapentin Study Group No. 5, 1993;138 Leach, 1997;90
Anhut, 1994156
LTG 6 3 9 Schachter, 1995;56 Matsuo, 1993;142 Veendrick-Meekes,
2000;137 Schmidt, 1993,91 Boas, 1996;136 Loiseau, 1990;89
Schapel, 1993;161 Smith, 1993;55 Messenheimer, 1994158
LEV 0 1 1 Cramer, 2000166
OXC 0 0 0 No studies
TGB 1 1 2 Dodrill, 1997;167 Sveinbjornsdottir, 199439
TPM 0 9 9 Barrett, 1997;76 Biton, 1999;79 Faught, 1996;67 Korean
Topiramate Study Group, 1999;149 Tassinari, 1996,42
Sharief, 1996;148 Ben-Menachem, 1996;151 Yen, 2000;165
Privitera, 199668
VGB 2 5 7 Provinciali, 1996;152 Bruni, 2000;153 Dodrill, 1995;168
Gillham, 1993;51 Beran, 1996;87 Grunewald, 1994;38 Dodrill,
1993169
TABLE 37 Types of QoL assessments used (adjunctive therapy, newer AEDs vs placebo)
QoL measure No. of studies using QoL measure
GBP LTG LEV OXC TGB TPM VGB Total
Goodrich Inventory 0 0 0 0 0 0 1 1
POMS 0 0 0 0 1 0 3 4
SEALS 1 1 0 0 0 0 0 2
Subjective global evaluations (patient) 2 1 0 0 0 9 1 13
Subjective global evaluations (physician/investigator) 2 8 0 0 0 7 2 19
Subjective global evaluations (carer) 0 1 0 0 0 0 0 1
WPSI 0 0 0 0 1 0 3 4
Zung Depression Scale 0 0 0 0 0 0 1 1
QOLIE-31 0 0 1 0 0 0 0 1
Mood Rating Scale 0 0 0 0 1 0 4 5
Mood Adjective Checklist 0 0 0 0 1 0 1 2
Staff/family assessment 0 0 0 0 1 0 0 1
General Health Questionnaire-28 0 0 0 0 0 0 1 1
Hospital Anxiety and Depression Scale 0 1 0 0 0 0 1 2
Behaviour Checklist 0 0 0 0 0 0 1 1
LSI 0 0 0 0 0 0 1 1
Nottingham Health Profile 0 1 0 0 0 0 0 1
Affect Balance Scale 0 1 0 0 0 0 0 1
Social Problems Questionnaire 0 1 0 0 0 0 0 1
Rosenberg Self-esteem Scale 0 1 0 0 0 0 0 1
Mastery Scale 0 1 0 0 0 0 0 1
Total no. of different measures used 3 10 1 0 5 2 12 –
LSI, Life Satisfaction Index; POMS, Profile of Moods State; WPSI, Washington Psychosocial Seizure Inventory; QOLIE,
Quality of Life in Epilepsy Inventory; SEALS, Side Effects and Life Satisfaction Inventory. 
seizures. The crossover trial treated 27
participants for 28 weeks and the parallel trials
treated 272156 and 306138 participants,
respectively, for 12 weeks. The trials were
generally of reasonable quality. However, the
crossover trial may possibly have been
underpowered as no a priori power calculation was
reported, the number of participants was low and
over 20% of follow-up data were classified as
missing. In addition, an appropriate analysis using
paired data was not performed. Most participant
baseline characteristics were presented only for
combined treatment arms in one parallel study,156
and in the other, one of the GBP doses used a
target maintenance dose that was below
recommendation range.138 Only one study found
statistically significant differences in favour of GBP
in comparison with placebo, using subjective QoL
measures (patient and physician global ratings).156
Based on these findings, there is no strong
evidence of any differences in QoL between
adjunctive GBP and placebo.
The LEV trial treated 385 patients with refractory
partial seizures for 38 weeks.166 This trial was not
powered to detect differences in QoL outcomes
and participants were allowed to take other
concurrent newer AEDs, which may confound the
data. There was significant improvement with both
LEV doses compared with placebo for seizure
worry and for 3000 mg/day LEV for overall QoL.
In summary, there was very little good-quality
evidence on which to base an assessment of
adjunctive LEV compared with placebo and any
significant findings should be treated with caution
in view of the potential for bias.
Both TGB trials treated patients with refractory
partial seizures for 20 weeks. The crossover trial
recruited 22 patients39 and the parallel trial
recruited 322 patients.167 The eligibility criteria
for study entry were not specified in the crossover
trial. In addition, the choice of washout period was
not justified and the possibility of carryover effects
was not investigated in the analysis of QoL. The
parallel trial failed to present details of all relevant
participant baseline characteristics, and the only
details available were for the combined treatment
groups. Neither study reported any statistically
significant differences in QoL between adjunctive
TGB and placebo. 
Seven LTG trials included patients with refractory
partial seizures,55,56,89,91,142,158,161 and two included
patients with either partial or generalised
refractory seizures.136,137 The crossover trials
included between 23 and 108 patients (mean =
56) and used treatment periods of between 28 and
46 weeks (mean = 34 weeks). The parallel trials
treated between 68 and 446 (mean = 243) patients
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TABLE 38 Summary of overall findings of QoL assessments (adjunctive therapy, newer vs placebo)
Drug Summary of findings of QoL assessments
GBP Only one156 of the three90,138,156 studies examining GBP found statistically significant differences in favour of
GBP using measures of QoL. Based on these findings, there was no strong evidence of differences in QoL in
favour of adjunctive GBP in comparison with placebo
LTG Six55,56,137,142,158,161 of the nine55,56,89,91,136,137,142,158,161 LTG studies found statistically significant differences in
favour of LTG using some measure of QoL. Most of these differences were found using a subjective measure,
which may have biased the findings, and studies were flawed with regard to other quality issues. Based on
these findings, there was a trend in favour of adjunctive TPM compared with placebo, but this was based on
potentially flawed data
LEV The trial of LEV reported some statistically significant differences in favour of LEV compared with placebo in
some subscales of QOLIE-31.166 There was very little evidence on which to base an assessment of
effectiveness of adjunctive LEV in comparison with placebo
TGB Neither TGB study reported any statistically significant differences between treatment groups. Based on these
findings, there was no evidence of differences in QoL between adjunctive TGB and placebo39,167
TPM Five out of nine42,67,68,76,79,148,149,151,165 TPM studies found statistically significant differences in favour of TPM
using at least one form of global evaluation. However, all of these evaluations were based on subjective
assessments and the studies were flawed with regard to a number of other quality issues. Based on these
findings, there was a trend in favour of adjunctive TPM as compared with placebo, but this was based on
potentially flawed data
VGB Two87,152 of the seven38,51,87,152,153,168,169 VGB trials found statistically significant differences in favour of VGB
and one found statistically significant differences in favour of placebo using at least one measure of QoL. All
studies were flawed with regard to quality issues, and based on these findings there is no strong evidence
either in favour of or against VGB adjunctive therapy compared to placebo in terms of QoL
for between 16 and 28 weeks (mean = 23 weeks).
Five trials did not present any details of a priori
power calculations and may have possibly been
underpowered.56,91,136,137,158 One parallel trial did
not present details of all relevant participant
baseline characteristics, but where available details
were only presented for combined treatment
arms.137 Two crossover trials reported that over
20% of follow-up data were missing55,136 and two
other crossover trials did not present an
appropriate analysis using paired data.89,91
Five studies reported statistically significant
differences in favour of LTG compared with
placebo using some form of subjective global
physician or investigator evaluation.56,137,142,158,161
Another study reported statistically significant
differences for happiness and mastery in favour of
LTG.55 Overall, adjunctive LTG was favoured in
comparison with placebo, but the evidence was
potentially flawed.
All trials of TPM included patients with refractory
partial seizures, with the exception of two trials
where patients had generalised seizures.76,79 Trials
included between 46 and 240 patients (median =
123) and followed treatment for between 11 and
20 weeks (median = 15 weeks). Six trials may have
been underpowered; five failed to report a priori
sample size calculations.67,68,148,151,165 In one
further trial it was unclear whether the sample size
calculation was performed a priori.42 Two of the
trials failed to present details of all relevant
baseline characteristics and the only details
presented were for combined treatment arms.42,151
In three trials, not all patients originally
randomised to the study were accounted for at its
conclusion,67,68,151 and in two trials, patients were
allowed to use newer AEDs other than TPM,
which may confound the data.76,79 In one of these
trials, a large number of the participants did not
fulfil the entry requirements for the trial.76 One
trial used doses of TPM that exceeded the
recommended limit.68
Six studies found statistically significant
differences in subjective patient global evaluations
in favour of TPM compared with
placebo67,68,76,149,151,165 and five of these studies
also reported statistically significant differences in
subjective physician global evaluations in favour of
TPM.67,68,149,151,165 Overall, adjunctive TPM was
favoured in comparison with placebo, but the
evidence was potentially flawed.
All of the VGB studies included patients with
refractory partial seizures, with the exception of
one study that included patients with refractory
generalised seizures.51 However, VGB is not
licensed for the treatment of generalised onset
seizures. The studies included between 24 and 203
patients (mean = 112) and followed treatment for
between 4 and 32 weeks (mean = 17 weeks). None
of the studies reported a priori sample size
calculation, and may potentially have been
underpowered. In two trials, some doses of VGB
exceeded the recommended limit,153,168 and in
three further studies, the number of participants
completing the study was unclear.51,152,169 In one
of these, trials over 20% of follow-up data were
classified as missing.51 One study included
patients who did not fulfil the entry criteria for the
trial153 and in another study not all relevant
details of baseline comparability between the
treatment groups were presented,169 One trial
used an open-label design thereby increasing the
risk of bias.152 In one of two crossover trials, the
duration chosen for the washout period was not
justified.87 All of these issues could affect the
findings of the studies and must be considered
when interpreting the findings. 
Two studies found statistically significant
differences in favour of VGB; one used a
measurement of global patient and investigator
evaluations,87 and the other study found
differences in depression and LSI scores.152
Another study reported statistically significant
differences in favour of placebo using POMS,
WPSI and the mood rating scale.153 Overall, there
was no good-quality evidence of consistent
statistically significant differences in QoL between
adjunctive VGB therapy and placebo.
e. Cognitive function
Twelve out of 55 studies of newer AEDs versus
placebo assessed some aspect of cognitive function
(see Table 39). The majority of studies used
VGB.38,51,152,153,168,169 One study used GBP,90 two
used LTG55,88 and three used TGB.39,43,167 No
studies of LEV, OXC or TPM were found.
A total of 51 different cognitive assessment
measures were used (see Table 40).
Details of the individual study data are reported in
Appendix 23 and details of the individual cognitive
measures in Appendix 5. Table 41 summarises the
overall findings of the cognitive assessments.
The GBP study included 27 participants in a
crossover design and found no significant
differences between adjunctive GBP and placebo.90
The authors did not report an a priori sample size
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TABLE 39 Total number of studies assessing cognitive function 
Total no. of studies assessing 
cognitive function
Drug Crossover Parallel All studies Study details
GBP 1 0 1 Leach, 199790
LTG 2 0 2 Banks, 1991;88 Smith, 199355
LEV 0 0 0 No studies
OXC 0 0 0 No studies
TGB 1 2 3 Kälviäinen, 1996;43 Dodrill, 1997;167 Sveinbjornsdottir, 199439
TPM 0 0 0 No studies
VGB 1 5 6 Dodrill, 1995;168 Provinciali, 1996;152 Bruni, 2000;153
Grunewald, 1994;38 Dodrill, 1993;169 Gillham, 199351
TABLE 40 Assessments used to measure cognitive function 
Cognitive measure No. of studies using cognitive measure
GBP LTG LEV OXC TGB TPM VGB Total
Wonderlic Personnel Test 0 0 0 0 1 0 3 4
Lafayette Grooved Pegboard Test 0 0 0 0 1 0 3 4
Stroop Test 1 2 0 0 3 0 4 10
Benton Visual Retention Test (BVRT) 0 0 0 0 1 0 3 4
Controlled Oral Word Association (COWA) 0 0 0 0 2 0 3 5
Symbol Digit Modalities 0 0 0 0 1 0 3 4
Rey Auditory–Verbal Learning Test/List Learning 0 0 0 0 3 0 4 7
(from Adult Memory and Information 
Processing Battery)
Digit Cancellation Test 0 0 0 0 1 0 2 3
Italian Matrix Test 0 0 0 0 0 0 1 1
Bell’s Test 0 0 0 0 0 0 1 1
H barrage Test 0 0 0 0 0 0 1 1
Tolouse Pieron 0 0 0 0 0 0 1 1
Trailmaking Test A 0 1 0 0 0 0 1 2
Trailmaking Test B 0 1 0 0 0 0 1 2
Digit Symbol Test 0 1 0 0 0 0 1 2
Reaction Times 0 0 0 0 0 0 1 1
Forward Digit Span 0 0 0 0 1 0 1 2
Corsi’s Blocks 0 0 0 0 1 0 1 2
Buschke–Fuld Test 0 0 0 0 0 0 1 1
Digit Span Test 0 0 0 0 0 0 1 1
Verbal Recall 0 0 0 0 0 0 1 1
Design Learning 0 0 0 0 0 0 1 1
Information Processing Tasks A and B 0 0 0 0 0 0 1 1
(from Adult Memory and Information 
Processing Battery)
Verbal Fluency 0 0 0 0 0 0 1 1
Bilateral/Bimanual Hand Movements 0 0 0 0 1 0 1 2
Tapping Rate 0 0 0 0 1 0 1 2
Decision Time 1 0 0 0 0 0 1 2
Movement Time 1 0 0 0 0 0 1 2
Threshold Detection Test 1 0 0 0 0 0 1 2
Forward Digit Span 1 0 0 0 0 0 1 2
Backward Digit Span 1 0 0 0 0 0 1 2
Forward Visual Span 1 0 0 0 0 0 0 1
Backward Visual Span 1 0 0 0 0 0 0 1
continued
calculation or whether the outcome assessors were
blinded. There were three follow-up assessments in
each treatment phase, repeated testing was carried
out at the same time of day and the authors did
report testing for an order effect.90
One of the LTG studies (n = 12) concluded that
there were indications of reduced cerebral
efficiency with LTG in patients with refractory
partial seizures,88 whereas the other study (n = 81)
showed no significant differences in
neuropsychological test scores between LTG and
placebo.55 Only one of the studies specified that
tests were administered in a set order.88 The other
study reported that neuropsychological testing was
not carried out if patients were postictal, but
testing did not appear to have been rescheduled,
and therefore those participants may have been
lost from the study.55
One of the three TGB studies found a
deterioration in cognitive function with TGB in
one out of 37 analyses. Although that was the only
study that reported an a priori power calculation
for sample size (n = 297), the one statistically
significant finding could have occurred by chance
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TABLE 40 Assessments used to measure cognitive function (cont’d)
Cognitive measure No. of studies using cognitive measure
GBP LTG LEV OXC TGB TPM VGB Total
Paired Associate Learning Test 1 0 0 0 0 0 1 2
National Adult Reading Test 0 1 0 0 0 0 0 1
Digit Span Test 0 1 0 0 0 0 0 1
Rey Complex Figure Test 0 1 0 0 0 0 0 1
Leeds Psychomotor Test 0 1 0 0 0 0 0 1
Number Cancellation Test (from the Adult 0 1 0 0 1 0 0 2
Memory and Information Processing Battery)
Logical Prose Story A 0 0 0 0 1 0 0 1
[from the Wechsler Memory Scale (WMS)]
Alternating S Task 0 0 0 0 1 0 0 1
Letter Cancellation Task 0 0 0 0 1 0 0 1
Modified Finger-tapping Test 0 0 0 0 1 0 0 1
Visual Reproduction (a subtest of the WMS) 0 0 0 0 1 0 0 1
Auditory and Visual Reaction Time 0 0 0 0 1 0 0 1
Binary Choice Reaction Time 0 0 0 0 1 0 0 1
Semantic Processing 0 0 0 0 1 0 0 1
Simple Reaction Time 0 0 0 0 1 0 0 1
Verbal Memory 0 0 0 0 1 0 0 1
Tracking Task 0 0 0 0 0 0 1 1
Rivermead Behavioural Memory Test 0 0 0 0 0 0 1 1
Total no. of different measures used 9 9 0 0 23 0 34 –
TABLE 41 Summary of overall findings of cognitive assessments
Drug Summary of findings of cognitive assessments
GBP One study showed no effect of GBP compared with placebo90
LTG One of two studies reported indications of reduced cerebral efficiency, but that it was unclear whether this was
due to LTG alone or polypharmacy effects88
TGB Overall there was no difference in cognitive function between TGB and placebo. One of three39,43,167 studies
found that one cognitive score (Form F of the Benton Visual Retention Test) out of 37 favoured placebo
compared with adjunctive TGB167
VGB Six studies provided some evidence of effect on some tests but overall this was inconsistent between trials. One
study reported an improvement in three out of 12 cognitive tests (Bells; Trailmaking Test B and the
Buschke–Fuld test).152 One study reported a poorer performance in dominant hand-tapping frequency in the
VGB group and in one design-learning task out of 16 other cognitive tests.38 One study reported a poorer
performance in the Stroop test with VGB.153 The other three studies reported no significant difference between
VGB and placebo.51,168,169
given the large number of analyses performed.167
The other two studies found no difference
between TGB and placebo, but as they recruited
small numbers of participants they may have been
underpowered to detect a difference in cognitive
function.39,43 Only one study reported that the
individuals who carried out neuropsychological
assessments were blind to treatment allocation.43
Only one study reported more than one (three)
follow-up assessments in each treatment phase.39
VGB was used in one crossover51 and five parallel
group studies.38,152,153,168,169 The crossover study
(n = 24, two patients had generalised onset
seizures) concluded that VGB did not cause
cognitive impairment. The individuals who carried
out the neuropsychological assessments were blind
to treatment allocation, there were three follow-up
assessments in each treatment phase and repeated
testing was conducted at the same time of day.51
One parallel group study (n = 40) found an
improvement with VGB in three cognitive tests.152
In two of the tests the adjunctive VGB group
scores were significantly poorer than the control
group at baseline. The individuals who carried out
the neuropsychological assessments were blind to
the treatment allocation but the patients were not
blinded. The study had two follow-up assessments,
tests were administered in a set order and testing
was not carried out if patients were postictal.
Another study (n = 45) showed a small but
statistically significant reduction in motor speed
and a modest impairment of performance on a
visual memory task with VGB.38 That study was
the only one to report a truly random assignment
method. Repeated testing was carried out at the
same time of day; however, the authors do not
appear to have taken into account the possible
impact of mood on neuropsychological
performance, and did not report the order in
which the cognitive tests were performed. One
other study (n = 111) reported a poorer
performance on the Stroop test with VGB.153 The
other two parallel group trials (n = 174 and 182)
reported no significant differences between VGB
and placebo.168,169 Two of the trials reported
administering the tests in a set order168,169 and the
other that tests were preformed according to
standardised procedures of administration (not
specified).153 Only one study reported an ITT
analysis.153 None of the VGB studies reported
whether they had used a method that was
adequate to conceal treatment allocation.
Overall, many of the cognitive function tests were
common to only a few studies, and although the
Stroop test was used in 10 studies not all of them
used the same scoring system; therefore, it was
difficult to make comparisons between studies.
The evidence for the newer drugs being superior
to placebo in terms of their impact on cognitive
functioning was neither strong nor consistent.
Also, the findings need to be considered in the
context of study quality. A complete quality
assessment of all the studies was not possible
because of poor reporting.
2. Newer drugs versus older drugs
a. Seizure frequency
i. Seizure freedom
Two out of 10 studies of newer drugs versus older
drugs (adjunctive therapy) reported the
proportion of seizure-free participants. A summary
of the main characteristics of these studies is
presented in Table 42.
No studies compared LTG, LEV, OXC, TGB or
TPM with older drugs.
One parallel superiority trial compared adjunctive
GBP with VPA in 25 patients with refractory
partial seizures.128 Treatment was followed up over
Summary statement for newer AEDs versus
placebo
A number of studies assessed the clinical
effectiveness of newer AEDs versus placebo.
The majority of studies were in patients with
refractory partial seizures and there was little
evidence concerning the use of adjunctive
therapy in patients with generalised seizures.
The most commonly reported outcome was the
proportion of 50% responders, although a
large number of the studies also reported the
proportion of seizure-free participants and
cognitive/QoL data. No studies reported time
to event outcomes (time to exit/withdrawal and
time to first seizure). 
Overall, the evidence for clinical effectiveness
suggested a trend in favour of newer adjunctive
AEDs compared with placebo. This trend was
not always statistically significant, with the
exception of the proportion of 50%
responders. Differences in QoL outcomes
suggested a similar trend in favour of
adjunctive LTG and TPM. However, many
trials only considered therapy over a period of
12–16 weeks or less, so it was not possible to
assess long-term effectiveness. Studies of
cognitive function reported limited and
inconsistent effects.
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a 12-week period. However, the study was
terminated prematurely owing to poor recruitment
and concurrent medications may have confounded
treatment effects. The RR (95% CI) reported in
Figure 21 favoured GBP over placebo, but was not
statistically significant.
Only one parallel superiority trial in 215 patients
with refractory partial seizures compared VGB
with VPA over a 12-week period.66 The trial
specifically recruited individuals with intellectual
disabilities, who were required to achieve at least a
50% decrease in seizure frequency without any
adverse events while receiving VGB during the
pretrial period. This limits the applicability of the
study findings. The RR (95% CI) reported in
Figure 22 favours VPA over VGB, but this
difference is not statistically significant. 
Overall, there was very little evidence on which to
base an assessment of the effectiveness of newer
AEDs as adjunctive therapy versus older AEDs.
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TABLE 42 Summary of studies (adjunctive therapy, newer drugs vs older drugs) assessing proportion of seizure-free participants
Study characteristicsa
Drug Refractory/ Seizure type Dose Comments Study details
newly Follow-up
diagnosed N
GBP Refractory Partial Individually titrated GBP vs VPA Maton, 1998128
12 weeks (individually titrated)
N = 25
LTG No studies
LEV No studies
OXC No studies
TGB No studies
TPM No studies
VGB Refractory Partial 4 g/day max. To enter the double- Brodie, 199966
12 weeks blind phase of the trial, 
N = 215 participants had to 
achieve at least a 50% 
decrease in seizure 
frequency without 
adverse events, during 
the pretrial period. 
Specifically looks at 
patients with intellectual 
disabilities.
VGB vs VPA
N, total number of participants randomised; NS, not stated.
a Both were parallel, superiority trials.
0.1 0.2 0.5 1 2 5 10 100
Maton, 1998 (N = 25)
GBP vs VPA
Study details
RR (95% CI)
4.5 (95% CI: 0.399 to 52.439)
Favours VPA Favours GBP
FIGURE 21 Proportion of seizure-free participants (RR, 95% CI) for the adjunctive trial of GBP vs VPA (ITT data)
ii. 50% reduction in seizure frequency
Three out of 10 studies of newer drugs versus
older drugs (adjunctive therapy) reported the
proportion of participants who experienced at
least a 50% decrease in seizure frequency. A
summary of the main characteristics of these
studies is presented in Table 43.
No studies compared LTG, LEV, OXC or TPM
with older drugs with regard to proportion of
responders.
One parallel superiority trial of 25 patients with
refractory partial seizures compared adjunctive
GBP with VPA over a 12-week period.128 The
Results
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0.5 1 2 
Brodie, 1999 (N = 215)
VGB vs VPA
0.892 (95% CI: 0.503 to 1.577)
Favours VPA Favours VGB
Study details RR (95% CI) 
FIGURE 22 Proportion of seizure-free participants (RR, 95% CI) for adjunctive trial of VGB vs VPA (ITT data)
TABLE 43 Summary of studies (adjunctive therapy, newer drugs vs older drugs) assessing proportion of participants experiencing at
least a 50% decrease in seizure frequency
Study characteristicsa
Drug Refractory/ Seizure type Dose Comments Study details
newly Follow-up
diagnosed N
GBP Refractory Partial Individually titrated GBP vs VPA Maton, 1998128
12 weeks
N = 25
LTG No studies
LEV No studies
OXC No studies
TGB Refractory Partial 80 mg/day TGB vs CBZ Sommerville, 1998129
16 weeks TGB vs PHT
N = 349
TPM No studies
VGB Refractory Partial 4 g/day max. To enter the double- Brodie, 199966
12 weeks blind phase of the trial, 
N = 215 participants had to 
achieve at least a 50% 
decrease in seizure 
frequency without 
adverse events, during 
the pretrial period. 
Specifically looks at 
patients with intellectual 
disabilities.
VGB vs VPA
N, total number of participants randomised; NS, not stated.
a All were parallel, superiority trials unless stated otherwise.
study had certain limitations, which have already
been discussed with regard to the proportion of
seizure-free participants. The RR (95% CI) shown
in Figure 23 favours VPA over GBP, but this
difference was not statistically significant.
One parallel superiority trial of 349 patients with
refractory partial seizures compared TGB with
older AEDs (CBZ and PHT) over a 16-week
period.129 This was a reasonable quality trial. The
unpooled RRs for each comparison are shown in
Figure 24. No difference was shown between TGB
and CBZ. However, the RR significantly favoured
PHT in comparison with TGB.
FIGURE 24 Proportion of 50% responders (RRs, 95% CIs) for
the adjunctive trial of TGB vs older AEDs (ITT data)
[Data have been designated commercial-in-confidence
and have been removed]
Only one parallel superiority trial of 215 patients
with refractory partial seizures compared VGB
with VPA during a 12-week period.66 This study
suffered from certain limitations, which have been
discussed with regard to the proportion of seizure-
free participants. The RR shown in Figure 25
favours VGB, but the difference is not statistically
significant.
Overall, there was very little evidence on which to
base an assessment of the effectiveness of newer
adjunctive AEDs versus older AEDs.
b. Time to first seizure
None of the 10 studies of newer drugs versus
older drugs (adjunctive therapy) reported the time
to first seizure.
c. Time to withdrawal/exit
None of the 10 studies of newer drugs versus
older drugs (adjunctive therapy) reported the time
to exit/withdrawal.
d. Quality of life
Four out of 10 of the studies of newer drugs versus
older drugs (adjunctive therapy) reported QoL
outcomes (see Table 44). 
No studies of adjunctive LTG, LEV, OXC or VGB
reported QoL outcomes. One study used GBP, one
TGB and two TPM. All studies were parallel
superiority trials. Various measures were used to
assess QoL (see Table 45). In total seven different
types of measures were used; GBP (one measure)
TGB (four measures) and TPM (three measures).
Within each drug, measures were each used in
only one study. However, the POMS was used to
assess the effects of both TGB and TPM.
Details of the individual study data are reported in
Appendix 23 and details of the individual QoL
measures in Appendix 4. Table 46 summarises the
overall findings of the QoL assessments. 
One trial of 32 patients with refractory partial
seizures compared GBP with VPA for
14–18 weeks.128 The trial recruited less than one-
quarter of the number of participants required,
and was therefore terminated prematurely.
Participants were not blind to their treatment
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0.1 0.2 0.2 1 2 5 10
Study  details RR (95% CI)
0.500 (95% CI: 0.128 to 1.676)Maton, 1998 (N = 25)
GBP vs VPA
Favours VPA Favours GBP
FIGURE 23 Proportion of 50% responders (RR, 95% CI) for the adjunctive trial of GBP vs VPA (ITT data)
Results
74
TABLE 44 Total number of studies assessing QoL outcomes (adjunctive therapy, newer vs older drugs)
Total no. of studies assessing 
QoL function
Drug Crossover Parallel All studies Study details
GBP 0 1 1 Maton, 1998128
LTG No studies
LEV No studies
OXC No studies
TGB 0 1 1 Cramer, 200165
TPM 0 2 2 Meador, 2001;44 Aldenkamp, 2000130
VGB No studies
TABLE 45 Types of QoL assessments used (adjunctive therapy, newer vs older drugs)
QoL measure No. of studies using QoL measure
GBP LTG LEV OXC TGB TPM VGB Total
Mood problems 0 0 0 0 0 1 0 1
POMS 0 0 0 0 1 1 0 2
ABNC 0 0 0 0 0 1 0 1
WPSI 0 0 0 0 1 0 0 1
Mood Rating Scale 0 0 0 0 1 0 0 1
QOLIE-89 0 0 0 0 1 0 0 1
QoL measure not stated 1 0 0 0 0 0 0 1
Total no. of different measures used 1 0 0 0 4 3 0 –
ABNC, Aldenkamp–Baker Neurotoxicity Scale.
0.5 1 2
Brodie, 1999 (N = 215)
VGB vs VPA 1.027 (95% CI: 0.794 to 1.330)
Favours VPA Favours VGB
Study details RR (95% CI)
FIGURE 25 Proportion of 50% responders (RR, 95% CI) for the adjunctive trial of VGB vs VPA (ITT data)
Health Technology Assessment 2005; Vol. 9: No. 15
75
© Queen’s Printer and Controller of HMSO 2005. All rights reserved.
allocation and some received concurrent treatment
with other newer AEDs, which may confound the
study findings. Although collected, QoL data were
not assessed.
One trial of 349 patients with refractory partial
seizures compared TGB with CBZ over a period of
24 weeks.65 Not all participants were accounted for
at the end of the study, and over 20% of the
outcome data were classified as missing. In some
cases patients received doses of TGB that
exceeded maximum recommended doses. These
issues could affect the study findings. The study
did not report any statistically significant
differences between TGB as adjunctive therapy
and older drugs in terms of QoL. 
Two trials of patients (n = 59,130 n = 7644) with
refractory partial seizures compared TPM with
VPA over a period of 24 weeks. One trial was of
reasonable quality.130 The other trial was only
reported as an abstract and so quality could not be
fully assessed. Neither of the studies reported any
statistically significant differences in QoL between
TPM and older AEDs.
e. Cognitive function
Three out of 10 studies of newer versus older
AEDs assessed some aspect of cognitive function
(see Table 47). Two studies compared TPM with
VPA adjunctive to CBZ. One study compared TGB
with PHT adjunctive to CBZ, and TGB with CBZ
adjunctive to PHT.
A total of 13 different cognitive assessment
measures were used (see Table 48). 
Details of the individual study data are reported in
Appendix 23 and details of the cognitive measures
in Appendix 5. Table 49 summarises the overall
findings of the cognitive assessments. 
One study (n = 177) compared TGB with PHT
and CBZ over a 16-week period in patients with
refractory partial seizures.57 Neither allocation
concealment nor the blinding of the outcome
assessor was reported. Eight different measures
were used to assess cognitive function at baseline
and at two follow-up visits. The study showed a
significant improvement in two tests (Digit
Cancellation Test, COWA) with TGB compared
TABLE 46 Summary of overall findings of QoL assessments (adjunctive therapy, newer vs older drugs)
Drug Summary of findings of QoL assessments
GBP The trial comparing GBP with VPA was of poor quality and did not report data.128 Therefore, there was no
evidence on which to base an assessment of the effectiveness of GBP adjunctive therapy compared with older
drugs in terms of QoL
TGB One poor-quality trial did not show any statistically significant differences between TGB and CBZ.65 Therefore,
there was very little evidence on which to base an assessment of the effectiveness of adjunctive therapy with
TGB versus older AEDs
TPM Neither of the TPM studies reported any statistically significant differences between TPM and VPA.44,130 One
study was only available as an abstract and it was not possible to assess fully the quality of the study.44 Based on
these findings, there was no evidence on which to base an assessment of adjunctive therapy with TPM versus
older AEDs
TABLE 47 Total number of studies assessing cognitive function 
Total no. of studies assessing 
cognitive function
Drug Crossover Parallel All studies Study details
GBP 0 0 0
LTG 0 0 0
LEV 0 0 0
OXC 0 0 0
TGB 0 1 1 Dodrill, 200057
TPM 0 2 2 Meador, 2001;44 Aldencamp, 2000130
VGB 0 0 0
with CBZ adjunctive to PHT. There was a trend
towards improvement in one test (Digit
Cancellation Test) with TGB compared with PHT
adjunctive to CBZ. It was not stated whether tests
were carried out in a set order, if repeated testing
was carried out at the same time of day or whether
postictal participants were assessed. 
One TPM study (n = 76) used 23
neuropsychometric tests and seven mood tests.44
Results were reported in summary and not per
test. It was unclear exactly how many statistical
analyses were performed as some of the tests may
have generated more than one score. The study
was only available as an abstract and therefore it
was not possible to assess its quality adequately.
There were two follow-up assessments over
20 weeks. At the end of the study two tests
(Symbol Digit Modalities, COWA) showed
significant negative baseline-to-titration changes
with TPM compared with VPA. It was not stated
whether tests were carried out in a set order, if
repeated testing was carried out at the same time
of day or whether postictal participants were
assessed.
The other TPM study (n = 59) reported an a priori
sample size calculation, adequate concealment of
allocation and blinding of the outcome
assessors.130 Assessments were not performed on
postictal patients or if a patient had recently taken
an antihistamine or consumed an unusual quantity
of caffeine, and repeated testing was carried out at
the same time of day. However, 20 change scores
were tested without correction for multiple testing
and the analyses were not based on ITT. One
outcome measure of memory (Rey Test Immediate
Recall) showed a statistically significant change in
mean score from baseline to end-point in favour
of VPA.
Overall, there was no strong or consistent evidence
that adjunctive TPM or TGB affect cognitive
function any more or less than the older drugs
used as comparators. All of the studies considered
only short-term effects.
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TABLE 49 Summary of overall findings of cognitive assessments
Drug Summary of findings of cognitive assessments
TGB One study that compared TGB with CBZ and PHT concluded that there was no convincing evidence for
differences between the drugs.57 There was a significant difference in favour of TGB over CBZ in two tests, and
a trend towards improvement with TGB compared with PHT in one test
TPM One study reported a small but statistically significant difference in favour of VPA over TPM in two tests, but
insufficient information was available to assess the study fully.44 The other study showed a significant difference in
favour of VPA in one test but concluded overall that the differences found between TPM and VPA were small.130
TABLE 48 Assessments used to measure cognitive function
Cognitive measure No. of studies using cognitive measure
GBP LTG LEV OXC TGB TPM VGB Total
Wonderlic Personnel Test 0 0 0 0 1 0 0 1
Lafayette Grooved Pegboard Test 0 0 0 0 1 0 0 1
Stroop Test 0 0 0 0 1 0 0 1
VSRT 0 0 0 0 1 0 0 1
COWA 0 0 0 0 1 1 0 2
Symbol Digit Modalities 0 0 0 0 1 1 0 2
Rey Auditory–Verbal Learning Test 0 0 0 0 1 1 0 2
Digit Cancellation Test 0 0 0 0 1 0 0 1
Finger-tapping Test 0 0 0 0 0 1 0 1
Simple Reaction Time 0 0 0 0 0 1 0 1
Binary Choice Reaction Test 0 0 0 0 0 1 0 1
Computerised Visual Searching Task 0 0 0 0 0 1 0 1
Recognition of Words and Figures 0 0 0 0 0 1 0 1
Total no. of different measures used 0 0 0 0 8 8 0 –
3. Newer drugs versus newer drugs
a. Seizure frequency
i. Seizure freedom
All four studies of newer drugs versus newer drugs
(adjunctive therapy) assessed the proportion of
seizure-free participants. A summary of the main
characteristics of the studies is presented in
Table 50.
No studies compared LEV, OXC or TPM with
other newer AEDs with respect to the proportion
of seizure-free participants.
Three parallel superiority trials of between 83 and
404 (mean = 196) patients with refractory seizures
compared adjunctive treatment with GBP with
other newer AEDs.61,131,132 Two studies used
treatment periods of 24 weeks131,132 and the third
followed treatment over a period of 18 months.61
Two trials included patients with partial
seizures61,132 and the third included patients with
partial or generalised seizures.131 Two trials
compared GBP with LTG61,131 and two compared
GBP with VGB.61,132
Two of the studies used an open-label design.61,131
One study was only reported as an abstract and it
was not possible to assess fully the quality of the
study.61 One study included patients with
intellectual disabilities and hence findings may
have limited applicability.131 The remaining study
was discontinued prematurely and failed to recruit
the required number of participants.132 This study
also found baseline differences between treatment
groups in the duration of epilepsy and in some
cases doses of GBP and VGB exceeded the
recommended limit.
Owing to the presence of clinical (different
participants, drug doses and follow-up periods)
and statistical (Q-statistic) heterogeneity, the
pooling of data was limited. The unpooled RRs
are shown in Figure 26.
One study comparing GBP with LTG showed no
difference61 (i.e. RR = 1) and the other favoured
LTG.131 Both of the studies comparing GBP with
VGB favoured VGB, but the differences were not
statistically significant. Data from these two studies
were pooled using a fixed-effects model (see
Table 51). The pooled RR (fixed-effects model)
slightly favoured VGB over GBP, but again the
difference was not significant.
Three parallel superiority trials examined the use
of LTG in between 48 and 404 (mean = 178)
refractory patients for periods of 20–78 weeks
(mean = 41 weeks). One trial was carried out in
patients who had either partial or generalised
seizure types131 and the other two trials were
carried out in patients with partial seizures. Two
trials compared LTG with GBP,61,131 one with
VGB61 and one with TGB.133 The studies were
limited with respect to some quality issues, one of
which was that all three studies were completely
unblinded. Other limitations have been discussed
previously in this section under the GBP studies.
These limitations could affect the findings of the
studies and should be considered when
interpreting the data.
In view of clinical (different comparators, drug
doses) and statistical (Q-statistic) heterogeneity
between the studies, data were not pooled. The
unpooled RRs are shown in Figure 27.
The study comparing LTG with TGB showed a
slight difference in favour of LTG, but this was not
statistically significant.133 One of the two studies
comparing LTG with GBP showed no difference61
and the other favoured LTG, but this difference
was not statistically significant.131 The study
comparing LTG with VGB showed a slight
difference in favour of VGB, but this was not
statistically significant.61
Overall, there was limited evidence on which to
base an assessment of newer AEDs versus other
Summary statement for newer versus 
older AEDs
There was no evidence to assess the
effectiveness of adjunctive LEV, LTG or OXC
versus older drugs. Evidence for GBP, TGB,
TPM and VGB was limited to single studies
that compared the newer drugs with CBZ,
PHT or VPA. Trials only included patients with
refractory partial seizures and treatment
periods were relatively short (3 months). Data
were only available for the proportion of
seizure-free patients, proportion of 50%
responders, and limited QoL and cognitive
outcomes. 
Overall, there was very limited evidence on
which to base an assessment of the clinical
effectiveness of adjunctive treatment with
newer AEDs versus older AEDs. Available
evidence shows mainly non-significant
differences between newer and older drugs,
and should be regarded with great caution in
view of problems with the design and quality of
the studies.
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TABLE 51 Proportion of seizure-free participants (pooled RRs, 95% CIs) for adjunctive studies of GBP vs VGB (ITT data)
Characteristics Studies Pooled RR (95% CI) (fixed effects)
N=102 Lindberger, 2000132 0.751 (95% CI: 0.412 to 1.349)
N=282 Specchio, 199961 0.911 (95% CI: 0.521 to 1.595)
Refractory, partial, GBP vs VGB Pooled (n = 2) 0.839 (95% CI: 0.555 to 1.267)
Heterogeneity: Q = 0.212 (df = 1), p = 0.645
TABLE 50 Summary of studies (adjunctive therapy, newer drugs vs newer drugs) assessing proportion of seizure-free participants
Study characteristicsa
Drug Refractory/ Seizure type Dose Comments Study details
newly Follow-up
diagnosed N
GBP Refractory Combination of 3600 mg/day Specifically looks at Crawford, 2001131
partial/generalised 24 weeks patients with intellectual 
N = 83 disabilities.
GBP vs LTG 
(400 mg/day)
Refractory Partial 1800–3600 mg/day GBP vs VGB Lindberger, 2000132
24 weeks (1000–4000 mg/day)
N = 102
Refractory Partial Dose NS GBP vs VGB (dose NS) Specchio, 199961
18 months GBP vs LTG (dose NS)
N = 404
LTG Refractory Partial 400 mg/day LTG vs TGB Chmielewska, 2001133
20 weeks (60 mg/day)
N = 48
Refractory Partial Dose NS LTG vs VGB (dose NS) Specchio, 199961
18 months LTG vs GBP (dose NS)
N = 404
Refractory Combination of 400 mg/day LTG vs GBP Crawford, 2001131
partial/generalised 24 weeks (3600 mg/day). 
N = 83 Specifically looks at 
patients with 
intellectual disabilities
LEV No studies
OXC No studies
TGB Refractory Partial 60 mg/day TGB vs LTG Chmielewska, 2001133
20 weeks (400 mg/day)
N = 48
TPM No studies
VGB Refractory Partial Dose NS VGB vs GBP (dose NS) Specchio, 199961
18 months VGB vs LGT (doses NS)
N = 404
Refractory Partial 1000–4000 mg/day VGB vs GBP Lindberger, 2000132
24 weeks (1800–3600 mg/day)
N = 102
N, total number randomised; NS, not stated.
a All were parallel, superiority trials.
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0.677 (95% CI: 0.187 to 2.403)
0.998 (95% CI: 0.557 to 1.797)
0.751 (95% CI: 0.412 to 1.349)
0.911 (95% CI: 0.521 to 1.595)
Study details
Unpooled RRs (95% CI)
FIGURE 26 Proportion of seizure-free participants (unpooled RRs, 95% CIs) for adjunctive trials of GBP vs other newer AEDs (ITT
data)
 
0.2 0.5 1 2 5 10
Study details
Unpooled RRs (95% CI)
Favours Comparator Favours LTG
Chmielewska, 2001
(N = 48) LTG vs TGB
20 weeks
Crawford, 2001 (N = 83)
LTG vs GBP  24 weeks
Specchio 1999 (N = 273)
LTG vs GBP 18 months
Specchio, 1999 (N = 253)
LTG vs VGB 18 months
1.182 (95% CI: 0.220 to 6.297)
1.477 (95% CI: 0.416 to 5.348)
1.002 (95% CI: 0.556 to 1.794)
0.913 (95% CI: 0.505 to 1.643)
FIGURE 27 Proportion of seizure-free participants (unpooled RRs, 95% CIs) for adjunctive trials of LTG vs other newer AEDs (ITT
data)
newer AEDs. There were no data comparing LEV,
OXC and TPM with other newer AEDs and data
comparing GBP with LTG, GBP with VGB and
LTG with TGB showed no consistent statistically
significant differences in the proportion of seizure-
free participants. 
ii. 50% reduction in seizure frequency
All four of the studies of newer drugs versus newer
drugs (adjunctive therapy) reported the proportion
of participants who experienced at least a 50%
decrease in seizure frequency. A summary of the
main characteristics of these studies is presented in
Table 52.
No studies compared LEV, OXC or TPM with
other newer drugs in terms of the proportion of
responders.
Three parallel superiority trials examined the 
use of GBP.61,131,132 The main characteristics of
these studies and their limitations have been
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TABLE 52 Summary of studies (adjunctive therapy, newer drugs vs newer drugs) assessing proportion of participants experiencing at
least a 50% decrease in seizure frequency
Study characteristicsa
Drug Refractory/ Seizure type Dose Comments Study details
newly Follow-up
diagnosed N
GBP Refractory Combination of 3600 mg/day Specifically looks at Crawford, 2001131
partial/generalised 24 weeks patients with 
N = 83 intellectual disabilities.
GBP vs LTG 
(400 mg/day)
Refractory Partial 1800–3600 mg/day GBP vs VGB Lindberger, 2000132
24 weeks (1000–4000 mg/day)
N = 102
Refractory Partial Dose NS GBP vs VGB (dose NS) Specchio, 199961
18 months
N = 282
LTG Refractory Partial 400 mg/day LTG vs TGB Chmielewska, 2001133
20 weeks (60 mg/day)
N = 48
Refractory Partial Dose NS LTG vs VGB (dose NS) Specchio, 199961
18 months LTG vs GBP (dose NS)
N = 404
Refractory Combination of 400 mg/day Specifically looks at Crawford, 2001131
partial/generalised 24 weeks patients with 
N = 83 intellectual disabilities.
LTG vs GBP 
(3600 mg/day)
LEV No studies
OXC No studies
TGB Refractory Partial 60 mg/day TGB vs LTG Chmielewska, 2001133
20 weeks (400 mg/day) 
N = 48
TPM No studies
VGB Refractory Partial Dose NS VGB vs GBP (dose NS) Specchio, 199961
18 months VGB vs LTG (dose NS)
N = 404
Refractory Partial 1000–4000 mg/day VGB vs GBP Lindberger, 2000132
24 weeks (180–3600 mg/day)
N = 102
N, total number of randomised participants.
a All were parallel, superiority trials.
discussed with regard to the number of seizure-free
participants.
Owing to the presence of clinical (different
participants, drug doses and follow-up periods)
and statistical (Q-statistic) heterogeneity, the
pooling of data was limited. Figure 28 shows the
unpooled RRs. 
One of the studies comparing GBP with LTG
favoured GBP131 and the other study favoured
LTG.61 However, both differences were not
statistically significant. Both of the studies
comparing GBP with VGB61,132 favoured VGB, but
only one of the differences was statistically
significant.61 Data from these two studies were
pooled (see Table 53). The pooled RR (fixed-
effects model) also showed a statistically significant
difference in favour of VGB in comparison with
GBP.
Three parallel superiority trials compared
adjunctive LTG with other newer AEDs.61,131,133
The main characteristics of these trials and their
limitations have already been discussed with regard
to the proportion of seizure-free participants. In
view of clinical and statistical (Q-statistic)
heterogeneity between the studies, data were not
pooled. The unpooled RRs are shown in Figure 29.
The study comparing LTG with TGB showed a
difference in favour of LTG, but this was not
statistically significant.133 One of the two studies
comparing LTG with GBP favoured GBP131 and
the other favoured LTG,61 but neither of these
differences was statistically significant. The study
comparing LTG with VGB showed a difference in
favour of VGB, but was not statistically
significant.61
Overall, there was limited evidence on which to
base an assessment of newer AEDs versus other
newer AEDs. There were no data comparing LEV,
OXC and TPM with other newer AEDs and data
comparing GBP with LTG, and LTG with TGB
showed no consistent statistically significant
differences in the proportion of seizure-free
participants. However, a statistically significant
difference in favour of VGB was found in trials
comparing GBP with VGB.
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FIGURE 28 Proportion of 50% responders (unpooled RRs, 95% CIs) for adjunctive studies of GBP vs other newer AEDs (ITT data)
0.5 1 2
Study details Unpooled RRs (95% CI)
Favours comparator Favours GBP
Crawford, 2001 GBP vs LTG
(N = 83)
Specchio, 1999 GBP vs LTG (N = 273)
Lindberger, 2000 GBP vs VGB
(N = 102)
Specchio, 1999 (N = 252)
GBP vs VGB
1.1282 (95% CI: 0.672 to 1.891)
0.943 (95% CI: 0.675 to 1.322)
0.861 (95% CI: 0.585 to 1.252)
0.708 (95% CI: 0.526 to 0.951)
TABLE 53 Proportion of 50% responders (pooled RR, 95% CI) for adjunctive trials of GBP vs VGB (ITT data)
Characteristics Studies Pooled RR (95% CI) (fixed effects)
N = 102 Lindberger, 2000132 0.861 (95% CI: 0.585 to 1.252)
N = 282 Specchio, 199961 0.708 (95% CI: 0.526 to 0.951)
Refractory, partial, GBP vs VGB Pooled (n = 2) 0.755 (95% CI: 0.598 to 0.954)
Heterogeneity: Q = 0.642 (df = 1), p = 0.423
b. Time to first seizure
None of the four studies of newer drugs versus
newer drugs (adjunctive therapy) reported the
time to first seizure.
c. Time to withdrawal/exit
None of the four studies of newer drugs versus
newer drugs (adjunctive therapy) reported the
time to exit/withdrawal.
d. Quality of life
Three of the four studies of newer drugs versus
newer drugs (adjunctive therapy) reported QoL
outcomes (see Table 54). 
No studies reporting QoL outcomes compared
LEV, OXC or TPM with other newer AEDs 
for adjunctive therapy. Two studies used GBP,
one comparing GBP with LTG131 and the 
other comparing GBP, VGB and LTG.132 One
study compared LTG with TGB133 All of the
studies were parallel superiority trials. Two 
studies included patients with refractory 
partial seizures132,133 and one refractory 
patients with either partial or generalised 
seizures. The studies recruited between 
48 and 109 participants (mean = 86) and 
followed treatment for between 20 and 
24 weeks.
Results
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TABLE 54 Total number of studies assessing QoL outcomes (adjunctive therapy, newer vs newer drugs)
Total no. of studies assessing 
QoL outcomes
Drug Crossover Parallel All studies Study details
GBP 0 2 2 Crawford, 2001;131 Lindberger, 2000132
LTG 0 2 2 Crawford, 2001;131 Chmielewska, 2001133
LEV No studies
OXC No studies
TGB 0 1 1 Chmielewska, 2001133
TPM No studies
VGB 0 1 1 Lindberger, 2000132
0.5 1 2 5
Study details Unpooled RRs (95% CI)
Favours comparator Favours LTG
Chmielewska, 2001 (N = 48)
LTG vs TGB
Crawford, 2001 (N = 83)
LTG vs GBP
Specchio, 1999 (N = 273)
LTG vs GBP
Specchio, 1999 (N = 253)
LTG vs VGB
1.182 (95% CI: 0.570 to 2.437)
0.886 (95% CI: 0.529 to 1.488)
1.061 (95% CI: 0.757 to 1.481)
0.752 (95% CI: 0.550 to 1.018)
FIGURE 29 Proportion of 50% responders (unpooled RRs, 95% CIs) for adjunctive trials of LTG vs other newer AEDs (ITT data)
Various measures were used to assess QoL (see
Table 55). In total six different types of QoL
measures were used; GBP (five measures), LTG
(five measures), TGB (one measure) and VGB (one
measure). Within trials of the same AED measures
were only used in one trial.
Details of the individual study data are 
reported in Appendix 23 and details of 
individual QoL measures in Appendix 4. 
Table 56 summarises the overall findings of the
QoL assessments. 
Overall, the trials were of poor quality. Two studies
recruited far fewer participants than suggested by
a priori sample size calculations,131,132 and one
study was discontinued prematurely owing to poor
recruitment.132 Two studies were open-label.131,133
and two studies used doses of newer drugs that
exceeded recommendations.131,132 One trial only
recruited patients with learning disabilities 
and so its findings may have limited applicability
to the general population of patients with
epilepsy.131 This study reported significant
differences in communication, cooperation and
restlessness in favour of GBP compared with 
LTG. None of the other studies reported
significant differences in cognitive function
between the other AEDs. 
There was no strong evidence of any consistent
significant differences between LTG, GBP, 
TGB or VGB.
e. Cognitive function
None of the four studies of newer drugs versus
newer drugs (adjunctive therapy) reported
cognitive function outcomes.
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TABLE 55 Types of QoL assessments used (adjunctive therapy, newer vs newer drugs)
QoL measure No. of studies using QoL measure
GBP LTG LEV OXC TGB TPM VGB Total
Key Carer-rated Visual Analogue Scales 1 1 0 0 0 0 0 2
Crichton Royal Behavioural Rating Scale 1 1 0 0 0 0 0 2
Whelan and Speake Rating Scale 1 1 0 0 0 0 0 2
Subjective global evaluations (physician/investigator) 1 1 0 0 0 0 0 2
QOLIE-89 1 0 0 0 0 0 1 2
Subjective global evaluation (patient) 0 1 0 0 1 0 0 2
Total no. of different measures used 5 5 0 0 1 0 1 –
TABLE 56 Summary of overall findings of QoL assessments (adjunctive therapy, newer vs newer drugs)
Drug Summary of findings of QoL assessments
GBP One study in patients with learning disability found statistically significant differences in favour of GBP over
LTG.131 The applicability of this finding to the general population of patients with epilepsy is unclear. One other
study comparing GBP with VGB found no statistically significant differences between the two drugs.132
There was very little consistent evidence of statistically significant differences between LTG and other newer
drugs
LTG One study, which included people with learning disabilities, found statistically significant differences in favour of
GBP over LTG.131 The applicability of this finding to the general population of patients with epilepsy is unclear.
The other studies found no statistically significant differences between LTG and GBP and between LTG and
TPM. There was very little consistent evidence of statistically significant differences between LTG and other
newer drugs
TGB One trial reported no statistically significant differences between TGB and LTG.133 There was very little
evidence on which to base an assessment of the effectiveness of adjunctive therapy with TGB compared with
other newer drugs
VGB One trial reported no statistically significant differences between VGB and GBP.132 There was very little evidence
on which to base an assessment of the effectiveness of adjunctive therapy with VGB compared with other newer
drugs
4. The use of adjunctive therapy in special
populations (elderly, intellectually disabled people
and pregnant women)
There were no studies of adjunctive therapy that
examined effectiveness in elderly participants.
Similarly, there were no studies that included
pregnant women; in fact, women of childbearing
age were required to use adequate methods of
contraception in order to be allowed to enter
trials. However, a number of studies (n = 8)
examined the effectiveness of adjunctive therapy
in participants with intellectual disabilities. Brief
details of these trials are presented in Table 57.
Five studies compared a new AED with placebo;
two studies compared new with old drugs; one
study compared two new drugs.
Among the placebo-controlled trials, one study
tested LTG in patients who all had an intellectual
disability.137 No details were reported about the
randomisation process or sample size
determination. No significant difference was shown
in the proportion of responders or seizure free
patients at 22 weeks or in a physician/patient global
evaluation of improvement/efficacy/tolerability.
The difference in QoL measures was significant
for physical adverse event scores but not
significant for all other measures.
The placebo-controlled study of TGB included
some patients described as mentally retarded but
did not provide separate data for that
subgroup.140 A sample size calculation was
reported and allocation was adequately concealed.
Overall, a significant difference was shown in
favour of TGB in the proportion of responders
with complex partial seizures (TGB twice daily
n = 106, p < 0.001 versus placebo; TGB four
times daily n = 103, p < 0.002 versus placebo).
The authors reported that tolerability was
satisfactory for more than 80% of patients treated
with TGB, but patients with intellectual disabilities
were not mentioned specifically.
In three placebo-controlled studies of VGB,
patients with mental disabilities comprised about
one-third of the included patients, but none of the
studies provided separate data for these patients.
Selection of participants in one trial was based on
a 50% reduction in seizure frequency in response
to treatment in an earlier phase.141 Change in
seizure frequency (total seizures) from baseline
among responders (n = 9) was significantly in
favour of VGB at 8 weeks (p = 0.002). There was
no mention of a power calculation and no details
were reported about the randomisation process.
The other two VGB studies were crossover trials.
One reported results for two subgroups of patients;
among patients with complex partial seizures only
(n = 15), the proportion of responders was
significantly greater with VGB (p < 0.02).85 The
other crossover study reported a significant
reduction in the mean weekly complex partial
seizure frequency with VGB, from baseline to
18 weeks follow-up (p < 0.001), and to a lesser
extent for tonic-clonic seizures (n = 11, p < 0.05).49
Neither of the crossover studies reported allocation
concealment or an adequate washout period; only
the participants were blinded and only one trial
appeared to have conducted an appropriate
paired analysis.85 All of the VGB studies used
doses of 2–3 g/day for between 8 and 12 weeks.
In comparisons of new versus older drugs, a
crossover study of OXC versus CBZ showed similar
seizure frequencies with both drugs.84 Different
reports of this study were inconsistent in the
assertion that all the patients had mental disabilities
and the dose of OXC exceeded the recommended
level. Although the administrators of treatment and
the patients were blinded, other quality parameters
were not well met. Randomisation was not clearly
Results
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Summary statement for adjunctive newer
versus newer AEDs
There is no evidence on which to base an
assessment of the clinical effectiveness of
adjunctive LEV, OXC or TPM versus other
newer drugs. In addition, there are no data for
any of the newer drugs regarding time to event
outcomes (time to exit/withdrawal and time to
first seizure) or cognitive outcomes. Evidence
from comparisons of the other newer drugs
with each other (GBP, LTG, TGB and VGB) is
limited to single studies, with the exception of
two studies that compared GBP with VGB and
two studies that compared GBP with LTG. In
general, the studies only examined refractory
patients with partial seizures and only followed
patients for a limited period (20–24 weeks).
None of the studies showed a statistically
significant difference between the newer drugs,
with the exception of the comparisons of VGB
with GBP, where one study showed a significant
difference in the proportion of 50% responders
in favour of VGB. One study of patients with
intellectual disabilities found statistically
significant differences in QoL in favour of GBP
over LTG. These findings should be treated
with caution in view of problems with the
quality of the studies.
described, and neither a power calculation nor a
washout period was reported. The results were not
presented or analysed as matched paired data, and
potential treatment or period effects and
treatment–period interaction were not considered. 
The other study compared VGB with VPA and
CBZ.66 An adequate sample size calculation was
reported; however, it was not clear whether the 215
patients analysed as ITT were in fact the number
randomised. The number of patients included who
had mental disabilities was not explicitly stated and
no separate analyses were conducted for that
subgroup. Allocation concealment was not reported
and only participants were blinded. Overall, the
study showed no statistically significant differences
in seizure reduction (change in seizure frequency,
proportion of responders, proportion of seizure-
free patients). 
One study compared two new drugs, GBP with
LTG, in 109 patients with intellectual disabilities
and partial or generalised seizures.131 The
authors’ initial power calculation had to be
adjusted owing to the lower numbers actually
recruited. The proportion of seizure-free patients
was 3/39 (7.7%) with GBP and 5/44 (11.4%) with
LTG. No difference was shown in the proportion
of responders or in the mean response ratio in the
proportion of seizure-free participants. In an
analysis of change in functional capacity, some
parameters measured on one scale showed a
statistically significant difference in favour of GBP
(cooperation, communication and restlessness,
p < 0.05); three other scales showed no difference
between the drugs. Within-group analysis of
changes from baseline with GBP showed a
significant improvement in several parameters
measured on four scales, including seizure severity,
sleeping pattern, attention, general health,
cooperation, restlessness and level of challenging
behaviour. Within-group analysis of changes from
baseline with LTG showed a significant
improvement in several parameters measured on
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TABLE 57 Details of adjunctive studies examining effectiveness in individuals with intellectual disabilities
Drug Study details Study details
GBP Parallel superiority trial of adjunctive GBP vs LTG in patients with Crawford, 2001131
refractory partial and/or generalised seizures. All participants (n = 109) 
were reported as having intellectual disabilities as defined by DSM IV criteria
LTG Parallel superiority trial of adjunctive LTG vs placebo in patients with Veendrick-Meekes, 2000137
refractory partial and/or generalised seizures. All participants (n = 68) had 
intellectual disability (DSM IV criteria) rated mild to profound
LEV No studies
OXC Crossover superiority trial of adjunctive OXC vs CBZ in patients with Houtkooper, 198784
refractory partial and/or generalised seizures. All participants (n = 48) had 
mental disabilities
TGB Parallel superiority trial of adjunctive TGB vs placebo in patients with Sachdeo, 1997140
refractory partial seizures. Approximately 80% of patients (n = 318) had 
abnormal neurological histories. The most common reported conditions 
were chronic headaches, mental retardation, memory impairment 
and dizziness. No further information about the exact number of 
participants involved
TPM No studies
VGB Parallel superiority trial of adjunctive VGB vs placebo in patients with Reynolds, 1991141
refractory partial seizures. 10/33 participants had neurological mental 
handicap, but results were not presented separately for this population
Crossover superiority trial of adjunctive VGB vs placebo in patients with Tassinari, 198785
refractory partial and/or generalised seizures. 10/31 participants had 
mental disability, but results were not presented separately for this population
Parallel superiority trial of adjunctive VGB vs VPA in patients with Brodie, 199966
refractory partial seizures. Reported participants with mental disabilities 
were included but did not state how many. To enter the double-blind 
phase of the trial participants had to achieve at least a 50% decrease in 
seizure frequency without adverse events during the pretrial period
Crossover superiority trial of adjunctive VGB vs placebo in patients with Rimmer, 198449
refractory partial seizures. 8/24 had mental disability
three out of four scales, seizure severity, level of
challenging behaviour and general health; the
Crichton Royal Behavioural Rating Scale showed
no significant improvement. The authors
concluded that both drugs provided effective
treatment with positive benefits on behaviour in
learning disabled patients. Potential quality flaws
in the study include no description of allocation
concealment, no blinding and no mention of ITT
analysis. The maximum dose of gabapentin used
exceeded the recommended limit.
Assessment of adverse events and tolerability from RCTs
Eighty-one RCTs recorded the incidence of AEs:
17 monotherapy studies and 64 adjunctive therapy
studies. Sixteen monotherapy studies and 42
adjunctive therapy studies reported withdrawals
due to limiting AEs. The extent and quality of AE
data was variable and, in the majority of studies,
secondary to the main aim of the study (which was
to assess the clinical efficacy of the drug). Even
where authors stated that the assessment of safety
was a main aim of the study, this was often not
reflected in the reporting of outcome data.
AE data were reported in various ways. Definitions
and descriptions of AE differed, which made it
difficult to assess the seriousness of an event, as
they were rarely graded in any way. In a minority
of studies the number of events rather than the
number of participants who experienced each
event was reported. In some instances it was
unclear whether the events recorded were
classified as drug related or whether all events
were reported. Similarly, in many instances only
events recorded in 5 or 10% of participants were
reported. In some cases it was unclear whether
predetermined thresholds were used. 
Only LTG, OXC and TPM are licensed for use
and considered in the assessment of monotherapy
AEDs. Table 58 shows the number of RCTs for
each drug that reported data on the incidence of
AEs (17 studies) and the number of withdrawals
due to adverse events (16 studies).
Table 59 shows the number of adjunctive therapy
RCTs for each drug that reported data on the
incidence of AEs (63 studies) and the number of
withdrawals due to AEs (41 studies). 
Table 60 shows the number of trials of each drug
that reported any withdrawals due to AEs, serious
AEs and the five most common specific AEs
reported for each drug.
Summary statement for adjunctive studies
The most commonly reported outcome
measure was proportion of 50% responders,
with a large number of studies also reporting
the proportion of seizure-free patients and
QoL outcomes. No studies reported time to
event data (time to exit/withdrawal and time to
first seizure). In general, trials only considered
the short-term effects of therapy in patients
with refractory partial seizures. There were
very few data regarding the treatment of
refractory generalised seizures.
Overall, there was very little good-quality
evidence from trials of adjunctive AEDs on
which to base an assessment of newer drugs
versus older drugs and newer drugs versus
other newer drugs. However, newer AEDs were
significantly more effective than placebo with
regard to the proportion of 50% responders. 
No studies assessed the effectiveness of
adjunctive AEDs in the elderly or pregnant
women. A number of studies included people
with intellectual disabilities, but only three
provided data exclusively from this population.
There was some evidence from one study (GBP
versus LTG) that both drugs have some
beneficial effect on behaviour in people with
learning disabilities.
Results
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TABLE 58 Number of RCTs of monotherapy that reported the incidence of AEs and withdrawals 
Drug No. of studies reporting AEs No. of studies reporting withdrawals due to AEs
GBP 0 0
LTG 12 12
LEV 0 0
OXC 5 4
TGB 0 0
TPM 0 0
VGB 0 0
Total 17 16
Appendix 24 shows tables of unpooled RRs with
95% CIs derived from the number of comparisons
for each drug within the included studies (some
studies included more than one comparison). These
are restricted to the five most common events
reported for each drug, and also for withdrawals
due to limiting AEs. The results presented are
based on data reported in the trials, which in all
cases except one87 were based on ITT populations. 
Considering any AE, five out of 12 comparisons
showed a statistically significant lower incidence
with placebo versus GBP. The remaining
comparisons were not statistically significant. Two
out of seven comparisons were significantly in
favour of placebo over OXC. One of three
comparisons was significantly in favour of placebo
compared with TPM. Two of six comparisons were
significantly in favour of placebo over VGB. In
comparisons of LTG versus VPA, PHT or
conventional therapy four out of six showed a
statistically significant result in favour of LTG.
Results were inconsistent in comparisons between
LTG and other newer AEDs (GBP, VGB); some
trials favoured LTG whereas others favoured the
comparator. 
For serious AEs, as defined in the studies, one of
seven comparisons was significantly in favour of LEV
compared with placebo and the others showed no
difference. One of six comparisons showed a
significantly lower incidence of serious AEs with
placebo than with VGB (6 g/day). Other comparisons
showed no statistically significant differences.
In terms of the specific AEs listed in Table 60, two
out of 17 comparisons showed a significantly lower
incidence of asthenia (weakness) with LTG than
VPA and PHT (one comparison each). All other
comparisons showed no statistically significant
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TABLE 59 Number of RCTs of adjunctive therapy that reported the incidence of AEs and withdrawals due to AEs
Drug No. of studies reporting AEs No. of studies reporting withdrawals due to AEs
GBP 9 3
LTG 18 13
LEV 4 4
OXC 1 1
TGB 7 6
TPM 11 11
VGB 14 4
Total 64 42
TABLE 60 Number of trials found for selected AEs and withdrawals
GBP LTG LEV OXC TGB TPM VGB
(n = 10) (n = 34) (n = 4) (n = 10) (n = 7) (n = 13) (n = 16)
Any AE (total) 7 14 4 5 7 3 6
Serious AEs 2 16 4 1 6 3 4
Specific events
Asthenia 0 15 4 1 5 1 0
Ataxia 3 12 0 1 2 3 1
Dizziness 3 22 2 6 5 8 7
Drowsiness 1 3 0 1 0 0 10
Fatigue 3 3 0 3 1 8 7
Headache 2 23 3 5 6 10 8
Nausea 0 16 1 5 4 3 1
Nausea and/or vomiting 1 0 0 0 0 2 0
Vomiting 0 6 0 3 2 0 0
Paresthesia 0 1 0 1 1 4 0
Rash 0 11 0 1 0 1 0
Somnolence 4 21 4 5 5 10 0
Tremor (slight) 2 7 0 2 2 0 3
Weight decrease 0 1 0 0 0 5 0
Weight increase 0 3 0 0 0 0 5
Withdrawals
Limiting AEs 3 25 3 5 6 11 4
differences. For ataxia, between half and two-
thirds of comparisons of GBP, LTG, OXC or TPM
with placebo statistically showed significantly more
events with the AED. One comparison showed
significantly more events with GBP than with LTG.
The remaining comparisons were not statistically
significant. For dizziness, statistically significant
differences in favour of placebo were shown in
50% or less of comparisons with GBP, LEV or
OXC, in 30% or less of comparisons with TGB or
TPM and in less than 20% of comparisons with
LTG. No VGB comparisons showed a statistically
significant difference. For slight tremor, two of
three comparisons with VPA significantly favoured
LTG, and the only comparison of LTG versus CBZ
favoured CBZ. Between 20 and 40% of
comparisons showed significantly more events with
OXC, TGB or VGB than placebo. 
For somnolence, ≤ 50% of comparisons between
GBP, OXC or TPM and placebo showed a
statistically significant difference, each in favour of
placebo. Less than 50% of comparisons between
LTG and placebo were significant, in favour of
placebo. However, half of the 24 comparisons of
LTG versus conventional treatment including
CBZ, VPA and PHT showed a significant
difference in favour of LTG. Few comparisons
showed statistically significant differences in
drowsiness between AEDs and placebo. One of two
GBP comparisons significantly favoured placebo,
as did three of 13 VGB comparisons. Analysis of
fatigue showed one of six GBP comparisons and
two out of 10 VGB comparisons to favour placebo
significantly. In addition, two of five OXC
comparisons and four of 12 TPM comparisons
were also significantly in favour of placebo. 
Among reports of nausea as an event in itself,
among 18 comparisons of LTG three showed a
significant difference in favour of placebo. One
comparison significantly favoured LTG over VPA.
Where the event reported was vomiting, two of
seven LTG comparisons significantly favoured
placebo, as did three of five OXC comparisons.
One comparison was statistically significant in
favour of TGB over CBZ. Where the event was
reported as nausea and/or vomiting, the data
showed no statistically significant differences for
any of the newer AEDs. 
Few studies reported change in weight. One of five
comparisons of TPM versus placebo reported a
decrease in weight in significantly more TPM
patients. Two of six comparisons of VGB versus
placebo reported increase in weight in significantly
more VGB patients. Other findings for weight
increase include two of three comparisons that
showed a statistically significant result in favour of
LTG over VPA or GBP. 
Headache was significantly more common with
LTG in only three of 26 comparisons. 
For paresthesia, half of the comparisons of TPM
with placebo significantly favoured placebo. For
rash, the findings from 12 comparisons involving
LTG were inconsistent, some in favour of LTG and
others favouring the comparator. 
Withdrawals due to limiting AEs were not reported
in most of the clinical effectiveness studies. GBP
provided the highest number of comparisons (3/5),
showing a significant difference in favour of
placebo, followed by TPM (5/15). Less than 30% of
comparisons of LTG, LEV, OXC and TGB showed
significant differences, in each case in favour of
placebo. Where different AEDs were compared,
two of 28 LTG comparisons were statistically
significant and favoured LTG over CBZ or VPA.
One comparison significantly favoured VPA over
LTG. One comparison significantly favoured OXC
over PHT. 
Assessment of serious, rare and 
long-term adverse events
Serious, rare and long-term adverse events
The included studies are summarised in
Appendix 25 (Tables 99–109). No studies of LEV
met the inclusion criteria.
The data presented purposely focus on AEs that
could be regarded as serious, rare or long-term.
Where the investigators commented on the
relationship between an AE and a specific AED,
this has been noted. Otherwise, all events reported
here must be interpreted as observations rather
than evidence of a causal association with a
particular drug or combination of drugs. It should
also be noted that since these data were not
derived from direct comparisons, they cannot be
used to compare directly one drug with another.
Summary of assessment of adverse events and
tolerability from RCTs
There appears to be no consistent or
convincing evidence from these RCTs to draw
any clear conclusions concerning the relative
safety and tolerability of newer AEDs
compared with each other or with older AEDs,
or even placebo. It was inappropriate to pool
these data because retrieval of all relevant data
was hampered by the quality of reporting. 
Results
88
Owing to time constraints, the search for studies
did not include all relevant databases and
inclusion was restricted to the English language.
Consequently, it is unlikely that all relevant studies
have been included. Covert duplicate publication
and publication of cumulative data without
reference to previous analyses were encountered.
Obvious duplicate data were considered as one
study. Where overlap was suspected, this has been
noted in the tables and text.
None of the included studies were conducted
exclusively in elderly populations, but the age
range in the majority of studies did extend to
patients in their 70s. Six primary studies (one
LTG, one TPM, three VGB, one various AEDs)
included patients with some description of mental
disability. The only data explicitly concerning
pregnant women comes from one PEM and one
PMS study. Only seven of the included primary
research studies listed pregnancy or the risk of
pregnancy as exclusion criteria; the others did not
mention this population at all.
Quality of the included studies
When the question of interest concerns AEs rather
than efficacy, the conventional hierarchy of
evidence is not necessarily the best guide. The
strongest evidence cannot automatically be
assumed to come from RCTs. Other study designs
may be more appropriate to the question although
they are open to various sources of bias. Threats to
internal validity must be minimised in the design
and conduct of a study to ensure that the findings
are reliable. Quality assessment of the additional
primary studies reviewed for serious, rare and
long-term AEs is summarised in Appendix 20.
The quality assessment tools are given in
Appendix 10.
Although formal critical appraisal tools were used
where possible, the poor description of study
design in many reports made assessment of
internal validity problematic. This was particularly
true of cohort-type studies, most of which were
basically observations on groups of patients rather
than studies based on a sound design.
The tables of included studies provide comments
on the exclusion criteria where these were
reported; exclusion criteria were not mentioned at
all in 40% of the reports. A comment is also given
on how and when AEs were recorded in each
study; only half the studies provided this
information, an additional 37% reported when or
how and 13% gave no information. Even studies
that claimed safety, tolerance or toxicity as their
primary objective failed to report either exclusion
criteria or how and when the outcomes were
measured. 
Gabapentin
Two reports of PEM in the UK were
identified170,171 (Appendix 25, Tables 99 and 108).
These studies were conducted by the Drug Safety
Research Unit, whose methods are reported
elsewhere.172 PEM of 3100 patients (85.4% with
epilepsy) found no previously unrecognised AEs.
Two cases of hyponatraemia were possibly related
to GBP, 17 patients took overdoses and three cases
of hair loss were reported after ≥ 6 months of
treatment. Mortality was comparable to that in
published studies of severe epilepsy.170 The focus
of the other PEM study was congenital
abnormality. No congenital anomalies were
observed among 11 births exposed to GBP in the
first trimester.171
One RCT of rapid versus slow initiation,173
eight uncontrolled trials (four in epilepsy
(n = 2986)174–177 and four in bipolar disorder
(BPD) (n = 60),178,181,451 four open-label extension
studies in epilepsy182–185 and one uncontrolled
cohort study of patients with spinal cord injury186
were identified. These studies are summarised in
Appendix 25, Table 100. Another uncontrolled
cohort study of several AEDs included some
patients on GBP and is summarised in Appendix
25, Table 109.187
In the RCT, reporting of serious AEs and
withdrawals lacked clarity; the randomisation
method was unclear and blinding of outcome
assessment was not stated. Two patients out of 781
were hospitalised. One was a 13-year-old girl
randomised to rapid initiation (900 mg/day from
day one) who developed generalised oedema on
day six. The other was an 85-year-old man; the
nature and timing of the serious AE that he
experienced are not clear.173
The largest of the uncontrolled trials in epilepsy
reported that convulsion was the most common
serious AE (20/2216).174 In an assessment of
tolerability, in which patients served as their own
control, serious AEs were reported by 2/278
patients on <1800 mg/day and by 4/278 patients
on >1800 mg/day. The maximum dose used
exceeded 2400 mg/day. The AEs included
infection, overdose, sudden death, grand mal
convulsion and hostility, but details of which
patients experienced these events and when were
lacking. A study in which the maximum reported
dose was 2400 mg/day reported serious AEs in
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eight out of 110 patients, possibly related to GBP
in two patients who experienced headache and
accommodation difficulty. One patient was
withdrawn owing to an overdose.175 New-onset
myoclonic jerking (2/50) was reported at doses
>3600 mg/day in one study.176 In the fourth
uncontrolled trial in epilepsy (n = 610), the dose
of GBP was within the recommended range and
the nature of AEs was similar to those reported in
RCTs.177 The uncontrolled trials in patients with
BPD did report the time at which AE-related
withdrawals occurred, although the nature of the
events was similar to those commonly reported in
controlled trials. Reasons for discontinuation after
longer periods of treatment included exacerbation
of migraine at 10 months and excessive activation
or sedation at up to 11 months.
The four open-label extension studies followed
patients who had achieved a successful response to
GBP adjunctive or monotherapy in previous
studies of 2–3 months’ duration. In the
monotherapy study 23 patients were followed for
up to 106 weeks. Myoclonic jerks was reported as a
rare adverse event (1/23) in this study in which the
mean maximum dose was 3900 mg/day.182 The
largest of the adjunctive studies (n = 240) followed
up patients, originally treated in an RCT, for up to
784 days.185 The dose of GBP exceeded the
recommended maximum. Of 10 withdrawals due
to adverse events three were occurrences of brain
tumours, two of which were recurrences. The next
largest study (n = 203) used recommended doses
and followed patients for a mean of 385 days. It
reported one case of non-Hodgkin’s lymphoma
and a case of pneumonia and increased platelets
in a patient with pleural disorder.183 The dose
used in the smallest study (n = 25) was unclear,
patients were followed for a median of 54 months
and AEs were similar to those commonly
reported.184
The uncontrolled cohort study in patients with
spinal cord injury (n = 27) reported that six
patients discontinued owing to AEs including
muscle twitching and oedema. Ten patients who
were evaluable continued to gain analgesic benefit
from GBP throughout the 3-year study period on
doses ranging from 500 to 3600 mg/day.186 The
uncontrolled cohort study that included epilepsy
patients treated with GBP (n = 158), and also
patients treated with other AEDs, reported that
10% continued to take GBP for 3 years.
Unspecified AEs led to withdrawal of 37%.187
Neither report stated how exposure was
ascertained or determined whether AEs were 
dose related.
Lamotrigine
Two reports of PEM conducted by the Drug Safety
Research Unit in the UK were identified.171,188
These reports are summarised in Appendix 25,
Tables 101 and 108. PEM of 11,316 epilepsy
patients identified seven cases of Stevens–Johnson
syndrome (SJS) in adults, four on concomitant
VPA.188 Other rare serious events possibly
associated with LTG are summarised in Table 101.
The focus of the other PEM study was congenital
abnormality. Among 39 births exposed to LTG in
the first trimester, four babies had a congenital
anomaly; concomitant drug exposure is
summarised in Table 108.171
Three reports of PMS data were identified, two
from the UK189,190 and one from the USA.191 These
reports are summarised in Appendix 25, Table 101.
A UK study of 1050 epilepsy patients showed that
LTG was strongly associated with rash compared
with GBP or VGB (p < 0.001). The LTG dose
ranged from 12.5 to 900 mg/day. Four patients
experienced serious and unexpected adverse
reactions to LTG between 7 days and 1 month of
treatment. The events were life-threatening hepatic
failure, renal failure, disseminated intravascular
coagulation and acute exacerbation of ulcerative
colitis. Other AEs associated with LTG (p < 0.05)
that were not already recognised or listed on the
manufacturers’ data sheets included pruritus,
nightmares and hallucinations. The incidence of
hospitalisation due to adverse drug reactions was
significantly higher in the first 4 months of
treatment than in the following 4 months. The
study was funded by GlaxoSmithKline.189 The USA
study determined the rate of rash among patients
treated with LTG adjunctive to VPA as 13%
(14/108). Half of the patients who discontinued
treatment because of AEs did so as a result of rash.
Rash appeared between 1 day and 10 weeks of
treatment. Other serious AEs reported were
hallucinations (two patients), hepatic enzyme
elevation and low white cell count (one patient
each).191 The second UK study focused on the risk
of birth defects in pregnancies exposed to LTG in
the first trimester. Using data from a prospective
registry maintained by GlaxoSmithKline, no birth
defect was found in association with monotherapy
(0/40). The risk of birth defect with polytherapy
was reported as 6.5% (95% CI: 3 to 13), but the
denominator used was the number of first trimester
exposures to either polytherapy or monotherapy.190
Using only the polytherapy-exposed denominator
gives a risk of 9.6% (8/83).
One multicentre case–control study,192 five
uncontrolled trials193–197 and four uncontrolled
cohort studies198–201 met the inclusion criteria.
These studies are summarised in Appendix 25,
Table 102. Two other uncontrolled cohort studies
that included some patients treated with LTG are
summarised in Table 109.187,202
The case–control study was of good quality
considering its design; only the selection of
controls was unclear. The study examined 136
cases of SJS, 216 cases of toxic epidermal necrosis
(TEN) and 1579 controls. The majority were
adults. Dissimilarities in age and gender
proportion were evident between cases and
controls overall. Of 73 cases who reported use of
AEDs, three reported intake of LTG (for
≤ 8 weeks) and comedication (CBZ, VPA).
Confounding factors were considered to be
present in one of the three cases. Univariate
analysis identified short-term LTG as a risk factor
for SJS/TEN, RR 25 (95% CI: 5.6 to infinity). The
small numbers precluded further analysis.192
Overall, the uncontrolled trials included 200
patients with epilepsy and 75 with bipolar disorder
(BPD), and the majority were adults. One trial
with 10 epilepsy patients reported one withdrawal
due to SJS after 2 weeks of treatment and one
additional withdrawal due to macrocytic anaemia
after 23 months of treatment.195 Another trial 
(n = 75) reported a serious rash in two BPD
patients and one patient on LTG monotherapy
needed hospitalisation and steroid treatment.194
Other hospitalisations (n = 8) in the same study
were due to mania-related AEs at 14–190 days on
treatment. Other reasons for withdrawal from
uncontrolled trials were similar to those commonly
reported in RCTs (including rash, insomnia,
headache, diplopia, nystagmus and behavioural
disturbance).
One large (n = 4700) uncontrolled cohort study
examined the rate of SUDEP in a well-defined
cohort of adults and children.199 The estimated
rate of SUDEP (definite, probable and possible)
was 3.5/1000 patient-years of exposure to LTG.
Two adult cases of possible SUDEP were not
included in the rate calculation because LTG was
discontinued before their deaths. The study
reported that there is no conclusive evidence that
LTG alters the risk of SUDEP in patients with
epilepsy as the rate observed was comparable to
the expected rate among young adults with severe
epilepsy.
One of the other three uncontrolled cohort studies
of LTG (n = 125) was conducted in adults with
intellectual and/or neurological deficits.198 Five of
11 withdrawals were due to negative psychotropic
effects and three to exanthema. Another study of
adults and children (n = 200) reported rash in six
patients, profound agitation in one and LTG
intoxication in 17. Which events contributed to
the 13 withdrawals were unclear.200 A smaller
study (n = 17) of adults reported five out of nine
withdrawals due to rash.201 One uncontrolled
cohort study of mixed AEDs reported on 78
patients treated with LTG, although it was unclear
if this was the number originally included in the
study. Eight LTG patients changed treatment
owing to AEs, although when the events occurred
was not reported. Rash was the most common
reason for withdrawal of LTG (3/8). The dose
taken by patients who experienced intolerable AEs
ranged from 150 to 375 mg/day.202 The other
study of mixed AEDs focused on retention rates;
for LTG this was 29% of 424 patients at 3 years,
but ascertainment of exposure to the drug was not
described.187 There may be an overlap of patients
between the latter study and the PMS study by
Wong and colleagues.189
Oxcarbazepine
Of two open-label extension studies that met the
inclusion criteria (Appendix 25, Table 103), one
included epilepsy patients who had participated in
a placebo-controlled RCT of monotherapy. Data
were only available from a poster presentation.203
The dose of OXC used in the extension phase was
not stated, and the use of concomitant AEDs was at
the discretion of the investigators. Fifty-six of the
97 patients remained on OXC throughout the 52-
week extension phase; 12 withdrawals were due to
AEs but their nature and timing were not stated.
The other study followed patients from a previous
RCT, although how many eligible patients chose to
continue was not clear. Nine patients experienced
severe AEs that were probably or definitely related
to OXC. With monotherapy the events included
diarrhoea, dizziness, nausea and rash. With
polytherapy they were vomiting, abnormal dreams,
flatulence, headache and insomnia. The dose
range used reached 3000 mg/day.204 Neither of
these study reports gave a clear description of dose
or duration of treatment for all participants, and
only one gave an adequate description of who was
included.
A controlled cohort study of the effects of various
AEDs in pregnancy included three babies born to
mothers exposed to OXC polytherapy in the first
trimester (Appendix 25, Table 109). One baby
(exposed to OXC 3000 mg/day, VPA 1800 mg/day,
clobazam (CLB) 22 mg/day) was born with spina
bifida cystica and clubfoot.205
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Tiagabine
One RCT of different dosing schedules,206 one
uncontrolled trial,207 one controlled cohort
study208 and one open-label extension study209
met the inclusion criteria. These studies are
summarised in Appendix 25, Table 104.
In the RCT (n = 347), doses of TGB up to
70 mg/day were given to patients with partial
epilepsy. Serious adverse events thought to be due
to TGB led to withdrawal of the drug from seven
patients. The events included one case of central
nervous system (CNS) neoplasia. Two patients
experienced abnormal vision after 12–24 weeks of
treatment.206 The trial was not blinded and the
method of randomisation was not reported.
AEs reported in the uncontrolled trial (n = 23)
were similar to those commonly reported in
RCTs.207 The duration of treatment was reported
to be at least 1 year.
The cohort study tested visual function in 15
adults with epilepsy who had achieved
monotherapy with TGB (mean treatment duration
38 months).208 None of the TGB patients showed
loss of concentric visual field although 7/14 had
colour vision defects compared with the healthy
controls who had no visual abnormalities.
Although the study methodology was flawed in
several aspects, the small sample size in itself
might not be representative of the larger TGB-
exposed population of epilepsy patients. 
The open-label extension study reported no signs
of concentric VFDs among 34 patients who
entered the open-label period on TGB
monotherapy, but it is unclear when these tests
were performed and on which patients. Eighteen
patients completed 96 weeks of follow-up on
monotherapy; it was not clear why the other 16
stopped treatment.209
Topiramate
One open-label extension of a double-blind
placebo-controlled RCT210 and six reports of
uncontrolled trials211–216 met the inclusion criteria.
These studies are summarised in Appendix 25,
Table 105. One uncontrolled cohort study that
included some patients treated with TPM is
summarised in Appendix 25, Table 109.187
The open-label extension study reported
continuation of adjunctive TPM up to 2.5 years in
107 out of 131 adults and children with epilepsy.
Although follow-up went as far as 909 days, the
low end of the range was only 14 days, and the
only dose reported was that recorded at the last
study visit. Commonly reported AEs were similar
to those reported in RCTs.210,217
The majority of the 1217 patients included in the
six uncontrolled trials were adults. One
uncontrolled trial (n = 277) reported two cases of
SUDEP over a treatment period of up to 2.2 years
and renal stones in two other patients.213 The dose
of TPM used went as high as 1600 mg/day. The
other studies reported around 20% withdrawal due
to AEs, the events being similar to those
commonly reported. The smallest trial (n = 15)
reported withdrawal of one patient as a result of
metabolic acidosis. The latter possibly overlaps
with multicentre data reported in another study
that reported metabolic acidosis (but not as a
cause of withdrawal) in six of 67 patients.215 The
time at which withdrawals occurred as a result of
AEs was reported in only one of the uncontrolled
trials, this being between 1 and 8 months of
adjunctive therapy at recommended doses.212 One
of the uncontrolled trials was conducted in
patients with mental retardation; one of the 19
patients was withdrawn because of unsteadiness,
disorientation and pneumonia.211
An uncontrolled cohort study of various AEDs
focused on retention rates; for TPM this was 30%
of 393 patients at 3 years, but ascertainment of
exposure to the drug was not described.
Unspecified adverse events led to withdrawal of
TPM from 40% of patients.187
Some PMS data on adverse pregnancy outcomes,
based upon the Johnson & Johnson
Pharmaceutical Research and Development drug
safety database, were reported in the
Janssen–Cilag submission prepared for NICE.218
Of 34 prospectively recorded pregnancies exposed
to TPM that provided outcome information on
live births, there were two definite and one
possible congenital anomalies. In all three cases
TPM had been used as adjunctive therapy. No
congenital abnormalities were noted among 11
pregnancies exposed to monotherapy. 
Vigabatrin
Two reports of PEM by the Drug Safety Research
Unit in the UK were identified; one focused on the
incidence of VFDs,219 and the other on congenital
abnormality.171 These reports are summarised in
Appendix 25, Tables 106 and 108, respectively.
PEM of 10,178 patients detected four cases with
objective evidence of bilateral persistent VFDs
during the 6-month observation period (incidence
0.4/1000 patients). Long-term follow-up of patients
who continued VGB treatment beyond 6 months
and who had been referred for eye tests or for
whom changes in vision (including VFDs) had been
reported identified 77 cases out of 4762 survivors
who were being followed up by ophthalmologists.
Interim data reported are 12 cases of VFD
confirmed by formal perimetry tests, 10/12
probably or possibly related to VGB use (incidence
2.0/1000 patients). The study was not designed to
determine the incidence of asymptomatic VFD.220
The other PEM study identified a congenital
anomaly in two full-term babies out of 47 births
exposed to VGB in the first trimester; concomitant
drug exposure is summarised in Table 108.171
One non-randomised placebo-controlled study in
which patients acted as their own control,221 seven
controlled cohort studies,222–228 four uncontrolled
cohort studies,229–232 six uncontrolled trials,233–238
five open-label extension studies239–243 and six
follow-up studies of patients who completed
previous studies, one of which was an RCT,244–249
met the inclusion criteria. These studies are
summarised in Appendix 25, Table 107.
A small (n = 19) study of patients treated with
VGB for up to 15 months following placebo
reported AEs similar to those commonly reported
in RCTs.221
The duration of VGB treatment in the seven
controlled cohort studies was as long as 11 years,
although all but one study (n = 60) included no
more than 25 participants. All of these studies
looked at effects of VGB on vision and all showed
a much higher incidence of VFDs with VGB
compared with controls. The effects were most
often asymptomatic. Six of the studies gave an
adequate description of how the VGB cohort was
selected and used similar but VGB-unexposed
epilepsy patients as controls.222,223,225–228 One
study failed to describe patient selection and used
healthy volunteers as controls.224 None of the
studies gave a clear description of how exposure to
VGB was ascertained in either the experimental or
control groups.
The four uncontrolled cohort studies also all
looked at effects of VGB on vision.229–232 The
duration of VGB treatment in these studies was as
long as 12 years. All the studies found VFDs in
60% or more of the patients examined; one study
assessed 155 patients and the other three studies
less than 30 patients. Two studies demonstrated a
dose–response relationship, but none of the
studies gave a clear description of how exposure to
VGB was ascertained. Among both the controlled
and uncontrolled cohort studies, correlation
between visual defects and the duration or dose of
VGB was inconsistent between studies. Other
outcomes reported in these studies are
summarised in Appendix 25, Table 107.
AEs commonly reported in the uncontrolled trials
(n = 734), including those associated with
withdrawal of VGB, were similar to those
commonly reported in RCTs. Where reported
these tended to occur in the first few weeks or
months of treatment. One withdrawal due to
profound oedema was reported in one study but
the time at which this occurred was not
reported.236 There is possibly overlap of patients
between two of the reports.237,238 A study
conducted in a group of patients who had
behavioural problems or mental retardation
reported withdrawal of one patient after
9.5 months of treatment due to
depression/aggression, one patient after
12 months due to irritability/aggression and one
patient after 24 months due to irritability. All of
these patients were in tertiary care.235 Three of the
six uncontrolled trials did not provide an adequate
description of the eligibility criteria, none clearly
stayed within the recommended dose of VGB or
mentioned compliance and four failed to account
for all participants.
The largest of the follow-up studies (n = 254), and
also the earliest published, reported that 10.5% of
reports of AEs attributed to VGB were severe (the
total number of events was not reported). Seven
patients had VGB withdrawn because of AEs,
including a severe psychotic reaction and severe
schizophrenic symptoms; when these occurred was
not stated. The VGB dose went as high as
9 g/day.249 An open-label extension study of adults
with intractable epilepsy (n = 97) who received up
to 4 g/day VGB reported 12 withdrawals due to
neurological/psychiatric AEs, one patient was
hospitalised with delirium and another with
suicidal ideation probably related to VGB, both
after 2–6 weeks of treatment; one patient was
hospitalised with psychosis definitely related to
VGB after 11 weeks.239 Another follow-up study
reported withdrawal of one patient after 7 months
of treatment due to depression and two patients
because of psychotic reactions at 12 and
22 months. The maximum VGB dose was
4 g/day.247 Psychosis was the reason for withdrawal
in a follow-up study of patients described as
mentally retarded, which also reported that
psychiatric AEs often appeared during the second
year of treatment (up to 3 g/day VGB).248
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Psychosis was the reason for withdrawal of one
patient after 1 year in an open-label extension
study in which two more patients experienced
dose-related psychotic symptoms. The dose range
reached 5 g/day.243 In the same study, visual
disturbance later diagnosed as optic neuritis
caused two patients to be withdrawn; these and
one other withdrawal for depression had occurred
by the 2-year follow-up point. Commonly 
reported AEs were similar to those reported in
short-term RCTs, although one open-label
extension study did report that such events
continued to emerge during the long-term phase
of 12–18 months among patients treated with up
to 3 g/day VGB.242 In that study, two patients were
withdrawn because of depression during the first
8 weeks. Ten of the 33 patients originally recruited
had a neurological or mental handicap but these
co-morbidities were not mentioned further in the
report.242
Three of the follow-up studies concentrated on
AEs on the eyes, all three gave an adequate
description of who was studied and follow-up
exceeded 24 months.244–246 One study examined
patients (n = 32) who were still using VGB
following an RCT of VGB versus CBZ, and
compared them with CBZ patients and healthy
controls. The study found that 13/32 VGB patients
had concentrically restricted visual fields
(compared with none of the CBZ patients or
healthy controls), but no statistically significant
correlation was found between the extent of 
visual field and the duration, dose or cumulative
amount of VGB (the actual doses were not stated).
Only one VGB patient complained of visual
problems.246 In one study, 15 patients who
completed serial testing every 3 months for 1 year,
while continuing to take VGB, showed no
worsening of visual field constriction (VFC), visual
acuity or colour vision (six had constricted visual
fields on initial testing). The dose of VGB used
was as high as 6 g/day.245 The third study
compared 29 patients who had received VGB (up
to 4 g/day) to 31 patients who received another
AED. Development of clinically relevant VFC was
significantly more common in VGB patients.
Among the patients with VFC who received
adjunctive VGB (n = 23), the median duration of
treatment was significantly longer than those who
received VGB but did not have VFC (41 versus
20 months, p = 0.04). No significant difference
was shown in the maximum dose of VGB received
by these two groups. VFC was also shown not to be
related to type and severity of epilepsy, type and
number of concomitant AEDs or length of 
follow-up.244
Summary of serious, rare and long-term
adverse events
Oedema and myoclonic jerking might be a
consequence of higher than recommended
doses of GBP. Hyponatraemia might be a rare
event, and hair loss could be a long-term effect
of GBP treatment, although not listed by the
manufacturer. Cancers and infections observed
in a few patients were not positively linked to
GBP.
Rash associated with LTG is listed in the
manufacturer’s information and was reported in
the RCTs and additional studies. The latter
provided additional reports of very serious skin
reactions. The additional studies also suggest
that life-threatening systemic reactions
including hepatic and renal failure and
intravascular coagulation are possibly rare
events associated with LTG. Lowering of white
blood cell counts and hallucinations were
observed in the additional studies. Reactions
such as mania and agitation could be a
particular risk for predisposed people. 
The few data available for OXC indicate that
serious AEs do occur with OXC but are similar
in type to those commonly reported in RCTs.
Although diarrhoea was not reported in the
RCTs, the manufacturer does list it and one
severe case led to withdrawal of the drug in one
of the additional studies.
Possible TGB-related serious AEs appear to be
mostly neurological, as is evident from the
RCTs, additional studies and the manufacturer’s
information. One report of a CNS neoplasia,
not positively linked to the TGB, came from the
additional studies. Effects on vision might be a
rare AE.
The additional studies suggest that metabolic
acidosis (the causes of which include renal
failure) and renal stones could be rare events
associated with TPM; these are not listed in the
manufacturers’ information.
The manufacturer’s information on VGB
includes a caution about VFDs. A number of the
additional studies specifically investigated the
effect of VGB on vision and consequently
provided more evidence for this than the RCTs.
Many of the additional studies provided
evidence of asymptomatic VFDs in patients
treated with VGB at both recommended and
higher doses. Follow-up studies suggest that the
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extent of VFDs could depend on the duration
of treatment. There is evidence from the RCTs
and the additional studies of psychological AEs
with VGB noted in the manufacturer’s data.
The additional studies suggest that these effects
occur in patients with and without underlying
mental disabilities, and that their emergence
can be long term. Based on the additional
studies data, aggression (not specifically
reported in the RCTs) could be significant for
patients with underlying behavioural problems.
Summary of data regarding pregnancy
Regarding pregnancy, the PEM and PMS data
included in this review provide indicators of
events but are not sufficient to assess or
compare risks associated with specific AEDs. A
full assessment of AEs in pregnancy should
include a comprehensive overview of
prospective surveillance data, such as that
maintained by the Medicines and Healthcare
Products Regulatory Agency (MHRA) and
similar agencies, and data registered in
specialist collaborative databases. In addition, a
comprehensive systematic review of research
evidence specific to pregnancy is needed. Both
of these were beyond the scope of this review. 
Unlicensed indications
Eleven studies were identified which reported
unlicensed usage of four of the drugs (GBP, LEV,
TGB, and VGB). Brief details of these studies and
the reason for the unlicensed use of the drug are
shown in Table 61.
Results of assessment of 
cost-effectiveness
Results of assessment of published 
cost-effectiveness evidence
The economic evaluations addressed monotherapy
(four studies) and adjunctive therapy (seven
studies). Results are reported separately for these
two types of antiepileptic therapy. Full details of
these studies are presented in Appendix 26.
Monotherapy studies
A summary description of the four studies of
monotherapy can be found in Table 62. All the
studies compared newer and older AEDs.252–255
Design
All the studies of monotherapy were designed as
CMAs. In a CMA, the economic evaluation is
based on a comparison of costs and not effects;
consequently, no cost-effectiveness ratio is
calculated. The justification for undertaking a
CMA is that there is no clinical evidence for a
significant difference in the relative effectiveness
of the interventions under comparison.
Treatment of effectiveness
All four studies based their assumptions of
therapeutic equivalence on findings of
effectiveness reported in the published literature.
Shakespeare and Simeon255 based their
assumption on findings from a single trial. The
remaining three monotherapy studies took
estimates of effectiveness from several trials.
Bryant and Stein cited three RCTs as evidence that
outcomes with LTG are similar to those with the
older AEDs.252 Heaney and colleagues reviewed
the evidence from eight RCTs in their UK
study.253 The same authors, in collaboration with
others, assessed five RCTs for a European study
that was published in 2000.254
Treatment of costs
The economic studies drew on several sources for
cost estimates. All used expert opinion to inform
resource use estimates and all but one252 also drew
on clinical trial data, where available. In every
study, unit costs were derived from the literature.
All four studies confined their analysis to direct
healthcare costs: although the existence of indirect
costs (lost productivity) and non-medical costs
borne by patients was acknowledged, these
categories of cost were not included in the
analyses. All four monotherapy studies included
the cost of AEDs, GP visits, neurologist
consultations, laboratory safety monitoring and
plasma tests. Shakespeare and Simeon focused
their cost analysis on the treatment of AEs, arguing
that the principal difference between the newer
and older AEDs lay in their side-effect profile.255
Comparing CBZ with LTG, these authors based
the incidence of AEs and withdrawal on clinical
trial data and modelled the corresponding
treatment pathways according to expert opinion.
In addition to costing neurologist consultations,
Shakespeare and Simeon also estimated the cost of
consultations with dermatologists and psychiatrists;
the costs of switching drugs and of additional drug
therapy were also evaluated. Only one other
monotherapy study estimated the cost of AEs,253
but this study included only the cost of GP visits
and plasma monitoring. Two studies included the
cost of emergency room visits.253,254
Combining costs and effectiveness
Since the studies were all CMAs, costs were not
combined with any unit of effectiveness. However,
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TABLE 61 Summary details of studies of unlicensed indications
Drug Author/year/country/ID Study design Unlicensed use Outcomes measured
GBP Chadwick, 1996,74 Study
Group 945-077
Multinational
Parallel trial of GBP
vs placebo
Used in seizures of
generalised onset
Change in seizure frequency;
proportion of responders (at least
50% or other specified criteria);
response ratio; AEs
Chadwick, 1998,250
Multinational
Parallel trial of GBP
vs CBZ
Used as monotherapy
in newly diagnosed
patients
Proportion of patients completing
treatment; exit/withdrawal rate;
time to exit/withdrawal; AEs
Lopes-Lima, 1999,46 Spain
and Portugal
Parallel trial of GBP
(3 different doses) vs
VPA
Used as monotherapy Time to exit/withdrawal; AEs
Brodie, 2002,93
Multinational
Parallel trial of GBP
vs LTG
Used as monotherapy
in newly diagnosed
patients
Time to exit/withdrawal;
proportion of participants
completing the trial; time to first
seizure; proportion of seizure-free
patients; AEs
LEV Ben-Menachem, 2000,144
Europe
Parallel trial of LEV
vs placebo
Used as monotherapy Proportion of patients completing
study, remaining seizure-free, and
responding; change in seizure
frequency; AEs
TGB Schachter, 1999,251
UK
Parallel trial of TGB
vs placebo
Used as monotherapy Change in seizure frequency; AEs
Aikia, 1999,52 Finland Parallel trial of TGB
vs CBZ
Used as monotherapy
in newly diagnosed
patients
Proportion of responders (at least
50% or other specified criteria);
AEs
VGB Tanganelli, 1996,53
Italy
Crossover trial of
VGB vs CBZ. Only
participants with
persisting seizures or
intolerable AEs were
crossed over to the
alternative treatment
Used as monotherapy
in newly diagnosed
patients
Proportion of seizure-free
patients; AEs
Kälviäinen, 1995,71
Riekkinen, 1997,59 Finland
Parallel trial of VGB
vs CBZ
Used as monotherapy
in newly diagnosed
patients
Proportion of responders (at least
50% or other specified criteria);
proportion of seizure-free
patients; cognitive function;
change in functional capacity; AEs
Chadwick, 1999,92 UK Parallel trial of VGB
vs CBZ
Used as monotherapy
in newly diagnosed
patients
Time to exit/withdrawal;
proportion of seizure-free
patients; time to achieve 6 months
of remission (seizure freedom);
time to first seizure; AEs
Czapinski, 1997,45
Argentina
Parallel trial of VGB
vs LTG
Used as monotherapy Proportion of responders (at least
50% or other specified criteria);
AEs
Bryant and Stein reported their findings as a cost
per patient seizure free after 24 weeks of
maintenance therapy,252 although there was no
between group difference in this measure. The
remaining three studies reported per patient costs. 
Study population
As can be seen in Table 62, there was some
variation in the study population within these four
monotherapy studies. Bryant and Stein assessed
adult patients with epilepsy,252 but the remaining
studies included only newly diagnosed patients
with either partial or generalised onset epilepsy.
Two studies included adolescents253–255 and one
focused on patients with tonic–clonic seizures.255
AEDs compared in the monotherapy studies
The AEDs included in the studies are presented in
Table 63. All four studies compared LTG with CBZ,
three studies compared these drugs with PHT and
two studies also considered VPA. No study was
found that examined the economic impact of the
following older AEDs: AZM, ethosuximide or any
barbiturates or benzodiazepines. With regard to
the newer drugs, we found no evaluation of GBP,
LEV, OXC, TGB, TPM or VGB as monotherapy;
of these, only OXC is currently licensed for use as
monotherapy in the UK.
Adjunctive studies
A summary description of the seven studies of
adjunctive therapy can be found in Table 64. 
Two of the seven economic evaluations involved 
a comparison of newer AEDs only,256,257 three
trials included older drugs only as a baseline for
the evaluation of adjunctive therapy with newer
drugs258–260 and the remaining two studies
compared newer and older AEDs.261,262
Design
Designs for the economic studies of adjunctive
treatment included CMA,256 CEA,257,258,260,262 and
CUA.261 Reinharz and colleagues examined the
costs and consequences of introducing VGB as an
adjunctive therapy, relative to current practice.259
Although benefits were not evaluated, this study
cannot be classified as a CMA because the authors
neither assert nor assume that the two treatment
strategies are therapeutically equivalent.
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TABLE 62 Summary description of monotherapy studies (n = 4)
Study Status and source Study design Comparators
Bryant, 1998252 Review/synthesis of
previous studies
CEA; adult patients with epilepsy;
proportion of patients seizure free
after 24 weeks of maintenance
therapy
CBZ monotherapy, 600 mg/day; 
LTG monotherapy, 100 mg/day; 
LTG monotherapy, 200 mg/day; 
PHT monotherapy, 300 mg/day
Heaney, 1998253 Review/synthesis of
previous studies
CMA; patients aged over 12 years,
with newly diagnosed epilepsy
(partial and generalised onsets);
health outcomes were not included
in the economic evaluation
CBZ monotherapy, 600 mg/day;
LTG monotherapy, 150 mg/day;
PHT monotherapy, 300 mg/day;
VPA monotherapy, 1000 mg/day
Heaney, 2000254 Review/synthesis of
previous studies
CMA; adults with newly diagnosed
epilepsy (partial and generalised
onsets); health outcomes were not
included in the economic evaluation
CBZ monotherapy, 600 mg/day;
LTG monotherapy, 150 mg/day;
PHT monotherapy, 300 mg/day;
VPA monotherapy, 1000 mg/day
Shakespeare, 1998255 Single study CMA; patients aged ≥ 13 years with
newly diagnosed tonic–clonic
seizures (partial and generalised
onsets); health outcomes were not
included in the economic evaluation
CBZ monotherapy, 600 mg/day;
LTG monotherapy, 150 mg/day
TABLE 63 Monotherapy studies by AED (n = 4)
AED CBZ LTG PHT VPA
CBZ NA 4 3 2
LTG 4 NA 3 2
PHT 3 3 NA 2
VPA 2 2 2 NA
No. of studies 4 4 3 2
No. of comparisons 9 9 8 6
NA, not applicable.
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TABLE 64 Summary of economic evaluations of adjunctive therapy included in the review (n = 7)
Study Status and source Study design Comparators
Hughes, 1996256 Review/synthesis of
previous studies
CMA; patients aged >12 years with
intractable partial epilepsy; health
outcomes were not included in the
economic evaluation
GBP adjunctive, 1200 mg/day; 
LTG adjunctive, 200 mg/day; 
VGB adjunctive, 2000 mg/day
Markowitz, 1998258 Review/synthesis of
previous studies
CEA; patients with refractory
epilepsy (uncontrolled by any single
older AED or by any combination
of the older AEDs); seizure-free
days gained
LTG adjunctive, 400 mg/day; 
No adjunctive therapy
(monotherapy with older AEDs)
Messori, 1998261 Single study CUA; patients aged 18–65 years
with refractory partial seizures;
short-term clinical outcomes were
assumed to remain stable over
subsequent years. These outcomes
were converted into QALYS: trial
data were extrapolated to produce
survival curves, which were
adjusted using utility data taken
from a separate prospective study
LTG adjunctive, 500 mg/day; 
no adjunctive therapy
(monotherapy with older AEDs)
O’Neill, 1995262 Review/synthesis of
previous studies and
expert opinion
CEA; patients with intractable
epilepsy (patient age range not
reported); treatment success was
defined as the achievement of both
the following conditions: (1) long-
term seizure control (at 12 months
follow-up); (2) duration of seizure
control of at least 9 months of the
12-month period
COZ adjunctive, 20 mg/day; 
LTG adjunctive, 150 mg, b.d.; 
VGB adjunctive, 2000 mg/day
Reinharz, 1995259 Single study Cost and consequences of
introducing VGB as an adjunctive
therapy
VGB adjunctive (2000, 3000 or
4000 mg/day); no adjunctive
therapy (monotherapy)
Schachter, 1999260 Single study CEA; patients with at least 4
complex partial seizures per month,
refractory to monotherapy with
older AEDs; a reduction in complex
partial seizure rate of at least 50%
PHT + CB, adjunctive, doses not
stated; PHT + TGB adjunctive,
doses not stated; CBZ + PHT
adjunctive, doses not stated;
CBZ + TGB adjunctive, doses not
stated
Selai, 1999257 Single study CEA; adult patients with refractory
epilepsy (partial) (uncontrolled by
monotherapy with older AEDs);
patients were deemed to be
‘satisfied’ if they met all 4 of the
following conditions: (1) still on
drug at 6 months follow-up; 
(2) experiencing no side-effects; 
(3) had no AEDs; (4) had a >50%
reduction in seizure frequency;
QoL was assessed, but findings not
reported
LTG adjunctive, dose not stated;
TPM adjunctive, dose not stated
Treatment of effectiveness
Three of the economic evaluations of adjunctive
therapy based their measure of effectiveness on a
review or synthesis of previously published
studies258–260 and one of these was also informed
by expert opinion.262 A single trial was the basis
for effectiveness data in three of the economic
evaluations257,260,261 and, in two of these, the
economic data were collected prospectively
alongside the trial.257,260 Schachter and colleagues
reported as their outcome measure a reduction in
seizure rate of at least 50%;260 Selai and
colleagues257 also used this measure, but also used
a more stringent measure of ‘patient satisfaction’,
incorporating treatment retention at 6 months, a
reduction in seizure rate of >50% and no
experience of side-effects or of AEs. The CUA
study reported QALYs, based on clinical trial data,
utility data from the authors’ own prospective
study and assumptions regarding the duration of
treatment effects, extrapolated from short-term
trial data.261 The remaining CEAs used seizure-
free days gained258 and ‘treatment success’,262
defined as long-term seizure control (i.e. control at
12 months follow-up after initiation of therapy)
with a duration of at least 9 months.
Treatment of costs
As in the monotherapy studies, the economic
studies of adjunctive therapy drew on several
sources for cost estimates. Four evaluations used
expert opinion to inform resource use, three used
data from a single study and two drew on evidence
from a review or synthesis of previous studies.
Reinharz and colleagues used data from three
Canadian databanks to inform their estimates of
resource use.259 All seven studies confined their
analysis to direct healthcare costs.
In some studies, it was unclear which costs had
been included in the analysis. For example,
although Selai and colleagues estimated the cost
of treating AEs, the types of healthcare resources
used (e.g. GP visit, neurologist consultation) were
not specified.257 All studies included the cost of
the AEDs. Three analyses included the cost of
surgery (and of evaluation for surgery).258,259,261 In
the absence of direct clinical trial data on surgery
rates associated with LTG, Markowitz and
colleagues justified their assumption that LTG was
associated with a reduction in surgery rates with
reference to the published literature.258 The
authors cited particular studies that found LTG
reduced seizure severity, particularly for certain
types of epilepsy, although the comparator used in
these studies was not reported. Messori and
colleagues261 also evaluated costs associated with
surgery, using rates based on a cost of illness study.
Reinharz and colleagues259 also included the cost
of surgery in their analysis, but explored the
impact of changes in the duration (and hence the
cost) of surgery, rather than changes in surgery
rates associated with adjunctive treatment. All
three economic evaluation assessed the cost
effectiveness of adjunctive therapy with a newer
drug, relative to current practice (i.e.
monotherapy with an older drug). No study
assessed the impact on surgery rates of adjunctive
therapy with an older drug. 
Combining of costs and effectiveness
All but two256,259 of the studies combined costs and
effects in their analysis.
Study population
All but one study,259 which considered adult
patients with any type of epilepsy, focused on
refractory patients. However, the definition of
‘refractory’ varied between authors: in some
studies it included patients who had not
responded to monotherapy with the older
drugs,257,260 whereas another study defined
‘refractory’ patients as those who were
unresponsive to both monotherapy and adjunctive
therapy with the older drugs.258 It is also possible
that some studies included patients unresponsive
to monotherapy with any (older or newer) drug,
although this was not explicitly stated. One study
included adolescent patients,256 three studies
included only adults257,259,261 and in the others the
patient age range was not specified.
AEDs compared in the adjunctive studies
The AEDs included in the studies are presented in
Table 65. The AED that was most frequently
compared in the economic studies was LTG: this
drug was reported in five studies and was the
subject of seven comparisons. In two studies, there
was no active comparator for adjunctive LTG;
instead, LTG was compared against ‘no adjunctive
therapy’ (or ‘monotherapy with older
drugs’),258,261 and two other studies compared
LTG against VGB.256,262 Hughes and Cockerell
also compared LTG with GBP256 and Selai and
colleagues compared LTG with TPM.257 Of the
seven comparisons with LTG, just one study
employed an older drug (CLB).262 For patients
taking PHT as the base drug, Schachter and
colleagues260 compared adjunctive CBZ with
adjunctive TGB; for another group of patients
taking CBZ as the base drug, the same study
compared adjunctive PHT with adjunctive TGB.
No other comparison of older and newer
adjunctive therapy was found.
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Findings of the published evaluations
Monotherapy
Appendix 26 summarises the results of the
published economic evaluations. Bryant and
Stein252 reported the costs of drug therapy and
medical management per patient per day to be
£552 for LTG 100 mg/day, £805 for LTG
200 mg/day and £242 for CBZ 600 mg/day.
Heaney and colleagues253 report the costs in the
first 2 years of initiating therapy, based on the
trials and from an ITT perspective, to vary
between £795 and £829 for CBZ, £736 and £768
for PHT, £868 and £884 for VPA and £1525 and
£2076 for LTG. Heaney and colleagues254 estimate
that treating a patient with LTG as first-line
therapy is between two and four times as
expensive as treatment with CBZ, PHT or VPA,
which share similar costs, over the first year. These
results are consistent in all countries considered
despite variations in the medical management of
epilepsy. Shakespeare and Simeon255 estimated the
cost of 1-year of treatment on CBZ followed by
VPA second line for the proportion of patients
intolerant to CBZ as £179. They estimate the cost
of LTG followed by CBZ second line as £522.
Therefore, all four studies found that treatment
with a newer AED was more costly than with older
AEDs, and assumed equivalent effectiveness.
Adjunctive therapy
O’Neill and colleagues262 estimated drug costs
over the first year at a dose recommended by a
clinical expert, including titration costs. These
were £94 for CLB, £650 for VGB and £648 for
LTG. The proportion of successfully treated
patients was 56.6% on CLB, and 59.3% on VBG
and LTG. The authors conclude that the results
strongly favour the less costly AED, although they
do not use a conventional CEA to make this
inference. Schachter and colleagues260 estimated
adjunctive TGB added to existing treatment of
phenytoin to cost US$719 over 16 weeks including
the cost of managing AEs. This compared with
US$784 for adjunctive CBZ. CBZ was clinically
more efficacious (50% reduction in seizure
freedom) but more detailed results are not
provided. Within the baseline CBZ arm, add-on
PHT cost US$810 compared with US$958 for
add-on TGB. Add-on phenytoin and add-on
tiagabine had similar efficacy. Compared with
current medication only, Messori and colleagues261
found adjunctive LTG cost an additional
US$1,612,370 for a cohort of 100 patients over
the patients’ lifetimes, gained an additional 39
QALYs, and calculated an incremental cost-
effectiveness ratio (ICER) of US$41,343 per QALY.
Costs and benefits were discounted at 6%.
Markowitz and colleagues258 found that LTG
therapy cost an additional US$728 compared with
the patients’ current monotherapy only,
discounted at 3% over 10 years. LTG therapy
gained 106 additional seizure-free days
(undiscounted) and an ICER of US$6.90 per
seizure-free day gained. Hughes and Cockerell256
found that GBP saved £18.52 per patient in the
first year compared with LTG and £47.18
compared with VGB, and assumed equivalent
effectiveness. Selai and colleagues257 found that
15% (7/47) of patients receiving TPM and 11%
(3/26) of patients receiving LTG were satisfied with
their treatment. The cost per patient was £472 for
TPM and £587 for LTG if the costs of telemetry
were excluded from the analysis.
Results of critical review of company submissions
Types of submissions
Table 66 summarises the types of submission
received.
Results
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TABLE 65 Adjunctive studies by antiepileptic drug (n = 7)
AED CBZ CLB GBP LTG PHT TGB TPM VGB No adjunctive 
therapy
CBZ NA 0 0 0 0 1 0 0 0
CLB 0 NA 0 1 0 0 0 1 0
GBP 0 0 NA 1 0 0 0 1 0
LTG 0 1 1 NA 0 0 1 2 2
PHT 0 0 0 0 NA 1 0 0 0
TGB 1 0 0 0 1 NA 0 0 0
TPM 0 0 0 1 0 0 NA 0 0
VGB 0 1 1 2 0 0 0 NA 1
No. adjunctive therapy 0 0 0 2 0 0 0 1 NA
No. of studies 1 1 1 5 1 1 1 3 3
No. of comparisons 1 2 2 7 1 1 1 5 3
NA, not applicable.
Types of analysis and measures of outcome
The evaluations provided a diverse range of
health outcome measures and types of analysis
(Table 67). The CMAs assume equivalence of
effectiveness between the drugs. The evidence to
support this assertion was generally limited, being
based on a small number of studies, of
heterogeneous design and without appropriate
statistical analysis. There were three CEAs. Each
chose a different measure of health outcome as
their primary measure of benefit, which restricts
comparability between the models. Four
evaluations used QALYs as a measure of health
benefit. However, comparability is again limited
since none of the four evaluations considered the
same study question, that is, the same type of
therapy and comparator. QoL in the treatment of
epilepsy cannot be adequately measured by
considering AEs or seizure freedom alone. A
composite measure is therefore needed. QALYs
have the further advantage that they allow
comparisons of health outcomes with other
treatments and disease groups.
Treatment pathways
The models differed in their approach to possible
treatments if the first study drug failed (Table 68).
Four evaluations did not allow for the possibility
that the patient would withdraw from the
drug.263–265 This approach limits the applicability
of the model to the clinical decision problem,
since withdrawal is the main mechanism by which
the patient will register dissatisfaction with the
performance of the therapy with respect to seizure
control or side-effects. Only one company
submitted evaluations that allowed for more than
one change of therapy over the lifetime of the
model and allowed for a choice of second-line
treatment.218 Since there are a large number of
permutations of possible treatment pathways in
the treatment of the disease, it is important that
the model is flexible, including consideration of
the ‘monotherapy only’ alternative in the model
for adjunctive treatment. None of the adjunctive
therapy submissions allowed comparison of newer
AEDs with all relevant alternatives, that is, other
newer AEDs, older AEDs or monotherapy only.
Sources of effectiveness data
No evaluations stated that they used a systematic
search strategy to look for effectiveness data
concerning either the therapy of interest or the
comparators. Table 69 shows the number of RCTs
used in each model as a source of effectiveness
data and how the results of these RCTs were
synthesised. These results show that in general
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TABLE 66 Types of study
Company Drug Treatment and comparator
Monotherapy Adjunctive therapy
Newer–older Newer–newer Newer–placebo Newer–older Newer–newer
Novartis263 OXC Yes Yes Yes
GSK264 LTG Yes Yes
Janssen218 TPM Yes Yes
Cephalon265 TGB Yes Yes
UCB266 LEV Yes
TABLE 67 Types of analysis submitted and measures of outcome used in the models
Therapy Comparator Type of study Primary measure of outcome
OXC mono263 Older AED CEA AE avoided
LTG mono264 Older AED CUA QALY
OXC mono263 Newer AED CMA –
TPM mono218 Newer AED CUA QALY
TGB adj265 Older AED CCA 50% reduction in seizure and incidence of AEs
TGB adj265 Newer AED CEA 50% reduction in seizure
TPM adj218 Newer AED CUA QALY
OXC adj263 Newer AED CMA –
LEV adj266 Placebo CEA Seizure freedom
LTG adj264 Placebo CUA QALY
CCA, cost–consequences analysis.
the number of sources of evidence used by the
companies was limited. In cases where a
published systematic review was used, very few
further studies were identified by the companies.
There is, therefore, a risk that the estimates of
effectiveness used in the models are incomplete.
Synthesis of trial results
Very few RCTs have compared one newer AED
directly against another. If indirect comparisons
are made using a common comparator there is a
potential for bias. Differences in outcome between
trials may be caused by different study designs and
implementation rather than differences between
the therapies. One study found trials that
compared the study drug with different older AED
comparators.264 The authors avoided making
indirect comparisons by presenting the
incremental costs and QALYs for each trial
separately. The analysis then calculated a ‘mean’
of the ICERs as a ‘composite measure of cost
effectiveness’. However, this approach is not the
preferred method of handling the second-order
uncertainty surrounding the estimates of the
interventions’ expected health effects and costs.267
Extrapolation beyond trial period
One company submitted evaluations that only
modelled the treatment decision for the 
12–16-week time horizon of the clinical trials.265
Six models extrapolated with varying degrees of
sophistication beyond the trial periods for up to
1 year264,266,268 and one company submitted
models that extrapolated 15 years beyond the
trial.218 The models with a time horizon of 
>1 year discounted costs and benefits. Table 70
shows the methods of extrapolation used by each
evaluation. These methods were: 
1. Assume that outcomes at the end of the trial
period continued to the end of the modelling
time horizon.
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TABLE 68 Maximum possible number of changes of treatment considered by the models
Therapy Monotherapies Adjunctive therapies
One change Two changes No changes One change Two changes
OXC mono263 Yes
LTG mono264 Yes
OXC mono263 Yes
TPM mono218 Yes
TGB adj265 Yes
TGB adj265 Yes
TPM adj218 Yes
OXC adj263 Yes
LEV adj266 [Data have been designated commercial-in-
confidence and have been removed]
LTG adj264 Yes
TABLE 69 Sources extent of and sources of short-term effectiveness data
Model Therapy No. of trials Method of synthesis of trials
Novartis263 Mono 1 None needed: based on one trial
GSK264 Mono 5 None: separate model presented for each trial
Novartis263 Mono 2 None: CMA
Janssen218 Mono 2 None needed: one trial per treatment
Cephalon265 Adj 1 None needed: based on one trial
Cephalon265 Adj 30a Meta-analysis from systematic review
Janssen218 Adj 4 Weighted averages
Novartis263 Adj 12b Meta-analysis from systematic review
UCB266 Adj 3 [Data have been designated commercial-in-
confidence and have been removed]
GSK264 Adj 10c Weighted averages
a Results of published systematic review.
b One RCT and one published systematic review.
c One published systematic review plus an additional trial identified by the company.
2. Assume that a fixed percentage of patients who
were successful at the end of the trial fail by the
end of the year.
3. Patients who were successful at the end of the
trial fail over the subsequent follow-up period
according to a constant hazard rate using a
Markov chain model.
No submissions considered that the transition
probabilities might change over time.
Resource use
Table 71 shows the types of costs included in each
study. There is considerable variation in the types
of costs included and the methods used to obtain
estimates of these costs. [Text deleted owing to
references to commercial-in-confidence data.]
Two evaluations used published data on the costs
incurred following seizures.218 The remaining
evaluations used ‘expert opinion’ or the authors’
assumptions.
Sensitivity analysis
The scope of sensitivity analyses varied widely
between submissions. One company submitted
(two) models with no sensitivity analysis.265 Most
companies provided one-way analyses based on
varying key parameters, with the upper and lower
limits set by their 95% CIs. Typical parameters
varied were the probability of success (seizure
reduction or seizure freedom), the probability of
withdrawal from the therapy and the utility
weights. One company submitted two models that
undertook probabilistic sensitivity analysis and
presented results on the cost-effectiveness plane
and as cost-effectiveness acceptability curves
(CEACs).218 This was repeated for a large number
of different combinations of first-line drugs,
second-line drugs and comparators. However, the
company opted to use selected pairwise
comparisons of certain treatment pathways, rather
than comparing all the treatment options head-to-
head on a single CEAC plot, which is appropriate
when there are multiple interventions under
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TABLE 70 Methods of extrapolation used by evaluation
Model Time horizon Method 1 Method 2 Method 3
Novartis mono263 1 year Yes
GSK mono264 1 year Yes
Novartis mono263 1 year Yes
Janssen mono218 15 years Yes
Cephalon adj265 16 weeks Yes
Cephalon adj265 12 weeks Yes
Janssen adj218 15 years Yes
Novartis adj263 1 year Yes
UCB adj266 1 year [Data have been designated commercial-in-
confidence and have been removed]
GSK adj264 1 year Yes
TABLE 71 Types of costs included in each study
Model Drug costs Routine carea Adverse eventsb Other side-effects Seizures
Novartis263 Yes Yes Yes
GSK264 Yes Yes
Novartis263 Yes Yes
Janssen218 Yes Yes Yes Yes
Cephalon265 Yes Yes Yes ?c ?c
Cephalon265 Yes
Janssen218 Yes Yes Yes Yes
Novartis263 Yes
UCB266 Yes Yes Yes Yes Yes
GSK264 Yes
a Routine care: costs of GP and outpatient attendances for routine care.
b Adverse events: costs of AEs leading to withdrawal.
c This study was reported only as a poster abstract and few details of the analysis were available.
consideration. Probabilistic sensitivity analysis is
preferred to univariate sensitivity analysis alone
because there is a great deal of uncertainty in the
measurement of the model parameters, and
changing the values of one of these parameters
will affect the sensitivity other parameters have on
the decision.269
Results of the analyses
Tables 72 and 73 summarise the results of the
submissions, as described by the authors, for
partial seizure types. Each manufacturer claims
that its product is either cheaper than its rivals or
superior and the additional cost represents good
value. As anticipated by the protocol, no
manufacturers address the same study question
with the same measure of economic benefit, so it is
not appropriate to summarise these results on a
cost-effectiveness plane.
Assessment of suitability of company
submissions to provide an integrated economic
evaluation of AED therapies
All of the submissions claimed that the
intervention in question was cost-effective. Because
of the range of outcome measures, interventions
and comparators evaluated, it is not possible to
compare the results directly with one another. A
summary of the industry evidence of cost-
effectiveness can be found in Appendix 26. This
section summarises the suitability of the company
submissions to provide an integrated economic
evaluation. A suitable model should include a
number of important features of the treatment of
epilepsy. There are a wide range of available
therapies, and all alternatives should be compared
head-to-head. Three analyses allowed a
comparison of the intervention in question with
several other AEDs.218,265 Four of the analyses
incorporated QoL in the measure of health
benefit.218,264 Five of the analyses allowed the
substitution of second- or third-line therapies
should the intervention in question fail.218,263,264
Two used a meta-analysis to synthesise
evidence.263,265 Two used a time horizon of
>1 year.218 Three used a broad NHS perspective
for use of resources218,266 and two used
probabilistic sensitivity analysis to handle second-
order uncertainty in the estimates of parameter
values.218 The main weakness of even the more
sophisticated evaluations was a lack of a systematic
approach to obtaining and synthesising
effectiveness data and not comparing all the
relevant alternative therapies with one another.
This indicates the need for an integrated
economic analysis that incorporates all the
available information on the costs and effects
associated with new and old AEDs and which
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TABLE 72 Results of the submissions – monotherapy
Company Therapy Comparator Result
Novartis263 OXC 1st line and CBZ 1st line and
LTG 2nd line LTG 2nd line ICER £1600 per AE avoided 
Novartis263 OXC LTG OXC cheaper than LTG
GSK264 LTG VPA or CBZ ‘Mean’ of ICER’s £13,000 per QALY
Janssen218 TPM 1st line and CBZ 1st line and ICER £38,000 per QALY. Dominates 
CBZ 2nd line TPM 2nd line LTG 1st line
TABLE 73 Results of submissions – adjunctive therapy
Company Therapy Comparator Result
Novartis263 OXC LTG OXC cheaper than LTG
GSK264 LTG Placebo ICER £16,000 per QALY
Janssen218 LEV 1st line and TPM 1st line and ICER £32,000 per QALY. Dominates 
TPM 2nd line LEV 2nd line LEV + LTG
Cephalon265 TGB Older AEDs TGB lower cost
Cephalon265 TGB Other newer AEDs Similar costs and efficacy
UCB266 LEV Placebo ICER £5000 per seizure-free patient per year
allows direct comparisons to be made on
estimated long-term costs and benefits.
Integrated analysis of 
cost-effectiveness
The integrated analysis was intended to address
the following questions:
1. What is the incremental cost-effectiveness of
the treatment of newly diagnosed patients with
individual drugs used as monotherapy?
2. What is the incremental cost-effectiveness of
the treatment of refractory patients with
individual drugs used as monotherapy?
3. What is the incremental cost-effectiveness of
individual drugs used as adjunctive therapy for
refractory patients?
Methods
Overview of the model
In order to determine the cost-effectiveness of the
newer AEDs, all of the relevant available
treatments must be directly compared. In
addition, an estimate must be made of the long-
term costs and benefits of treatment. As described
in the section ‘Results of assessment of cost-
effectiveness’ (p. 95), the various published
evaluations and industry submissions used a
variety of analytic methods, comparators and
outcomes. Therefore, a decision-analytic model
was developed which incorporated the available
information on the costs and effects associated
with the various newer and older AEDs and which
allowed direct comparisons to be made based on
estimated long-term costs and benefits.
To allow the cost-effectiveness of the various AEDs
under consideration to be compared with
therapies for other conditions, a CUA was
undertaken. QALYs were calculated using utility
weights estimated from EQ-5D responses and UK
public valuations. An NHS costing perspective was
adopted and all costs are expressed in 2001–02
UK sterling. The following cost items were
included in the model: healthcare costs associated
with starting a newer therapy; additional
healthcare costs required for the treatment for a
seizure-free epileptic patient (compared with a
non-epileptic patient); additional healthcare costs
required for the treatment for an epileptic patient
who is not seizure free (compared with a non-
epileptic patient); and the cost of AEDs. Although
in principle there could be costs associated with
the treatments of AEs, we considered these to be
small given the nature of these events. The more
important impact of AEs is the time to withdrawal
from therapy.
To enable direct comparisons of treatments to be
made based on the individual clinical trial results,
a meta-analysis of the response and withdrawal
rates from randomised trials was performed. This
used a hierarchical Bayesian model incorporating
random study effects and fixed treatment effects.
To provide a policy-relevant estimate of
incremental cost-effectiveness estimates, the long-
term costs and outcomes of treatment have to be
considered, including estimates of the future cost
and outcomes associated with those patients who
do not respond to the treatment under
consideration. Therefore, the analysis reported
here considered a time horizon of 15 years. The
randomised trial evidence available provided
comparative data on the rates of response and
failure over a short period of time, typically up to
6 months. Observational and open-label clinical
trial data were available for a limited range of
drugs for periods of several years. It was clear
from these data that the rate of withdrawal varied
with time, with patients becoming less likely to
withdraw from a drug as time progressed. The
short-term comparative trial data and the long-
term observational data were combined in a semi-
Markov process model which allowed for this time
dependence in withdrawal. In addition, the model
incorporated estimates of mortality rates for
seizure-free and non-seizure-free patients.
Second-order uncertainty in model parameters
was incorporated by running a Monte Carlo
simulation where values for the model parameters
were sampled from defined distributions.
The structure of this analytic model, the
information used to parameterise it and the results
of the analysis are described in detail below. 
Treatment pathways
The following potential treatment sequence was
considered in the decision-analytic model:
treatment of newly diagnosed patients with a
single AED (referred to later as ‘mono1’); followed
by treatment of those patients who remain
refractory with an alternative single AED (referred
to later as ‘mono2’); followed by treatment of
those patients who still remain refractory with a
combination of AEDs (referred to later as ‘comb’).
Those patients who are still refractory at the end
of this treatment sequence were assumed to be
maintained on monotherapy using older AEDs
(referred to later as ‘maint’), although in practice
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further therapy or surgery would be considered
for these patients. This treatment sequence was
felt to represent the most common sequence
currently used.270 However, there were insufficient
data available regarding the efficacy of AED
therapy conditional on specific prior treatments to
allow a more detailed consideration of alternative
general sequences such as the use of combination
therapy following initial monotherapy or the
sequential use of various combination therapies. 
Model structure
The expected costs and effects for each treatment
sequence were estimated using a probabilistic
semi-Markov process model which is illustrated in
Figure 30.
The states considered in the model were:
1. Newly diagnosed patient starts monotherapy
(one cycle only).
2. Newly diagnosed patient continues
monotherapy
3. Refractory patient starts monotherapy (one
cycle only).
4. Refractory patient continues monotherapy.
5. Patient starts combination therapy (one cycle
only).
6. Patient continues combination therapy.
7. Patient on ‘maintenance’ therapy.
8. Death.
In this model, the probabilities of patients being
in defined states are estimated at discrete time
intervals (cycles) over a simulated treatment
lifetime. The probability of a patient making a
given transition during a model cycle is
dependent on the time spent in the current state;
hence this is a semi-Markov process model
according to the classification used by Billingham
and colleagues.271 Thirty cycles, each of 6 months,
were modelled, giving a time horizon for the
analysis of 15 years. The probability of a patient
remaining on treatment after the first cycle on
each drug in the treatment sequence was
estimated from clinical trial data specific to the
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1. Start monotherapy – 
newly diagnosed patients
3. Start monotherapy
refractory patients
5. Start combination 
therapy
7. Maintenance 
therapy
2. Continue monotherapy – 
newly diagnosed patients
4. Continue monotherapy – refractory patient s
(mono2)
6. Start combination 
therapy
8. Death
Respond to therapy
in 1st cycle
Fail therapy in
Subsequent cycles
Respond to therapy
in subsequent cycles
Fail therapy in 1st cycle 
Fail therapy in 1st cycle 
Fail therapy in 1st cycle 
Respond to therapy
in 1st cycle
Respond to therapy
in 1st cycle
Fail therapy in
subsequent cycles
Fail therapy in
subsequent cycles
Respond to therapy
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FIGURE 30 Semi-Markov process model of AED treatment
drug under consideration. The probability of a
patient remaining on treatment for subsequent
cycles on each drug in the treatment sequence was
based on observational data, which was not
specific to the drug under consideration.
Model parameters
Transition probabilities between states
Patients can move through states 1–7 in sequence
(depending on the initial state). Patients spend
only one cycle in states 1, 3 and 5. Patients may
move from any state to state 8 (death). 
The parameters determining transition
probabilities which were included in the model are
shown in Table 74.
The transition probabilities for the ‘monotherapy
for newly diagnosed patients’ states which are
estimated as functions of the parameters described
above are shown in Table 75. Transition
probabilities for ‘monotherapy for refractory
patients’ and ‘combination’ therapy states were
estimated in a similar fashion.
Estimation of response to treatment during the
first cycle
The probabilities of treatment success and failure
during the first cycle of treatment for each of the
three elements of the treatment sequence were
estimated from clinical trial data. Only patients
who achieved a response to therapy during the
clinical trial continue the therapy after the first
cycle of treatment. For ‘monotherapy for newly
diagnosed patients’ a ‘response’ was defined as a
patient achieving seizure freedom and remaining
on the study drug until the end of the trial. For
‘monotherapy for refractory patients’ and
‘combination therapy’ a ‘response’ was defined as
a patient achieving a 50% reduction in seizure
frequency compared with a baseline period and
remaining on the study drug. These outcomes
reflected those most commonly measured in the
clinical trials. The response rates were not corrected
for differences in trial duration as a satisfactory
model of the relationship between trial duration
and response rates could not be determined.
The absolute probability of response was
determined from a meta-analysis of clinical trial
ITT data.
The meta-analysis of partial seizure-type data
consisted of a hierarchical Bayesian model
incorporating random study effects and fixed
treatment effect, and was conducted using
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TABLE 74 Parameters used to determine transition probabilities
Model parameter Parameter name Source Distribution for 
probabilistic analysis
Probability of a response to ‘monotherapy for PMono1 response(1) Meta-analysis of 1
a
newly diagnosed patients’ during the 1st cycle clinical trial data
Probability of treatment failure for ‘monotherapy PMono1 failure(t) NGPSE
270 2b
for newly diagnosed patients’ during the tth cycle
Probability of a response to ‘monotherapy for PMono2 response(1) Meta-analysis of 1
refractory patients’ during the 1st cycle clinical trial data
Probability of treatment failure for ‘monotherapy PMono2 failure(t) NGPSE
270 2
for refractory patients’ during the tth cycle
Probability of a response to ‘monotherapy for PComb response(1) Meta-analysis of 1
refractory diagnosed patients’ during the 1st cycle clinical trial data
Probability of failure for ‘combination therapy’ PComb failure(t) Tiagabine Study No. 2
during the tth cycle M91-604/M91-
604C272
Probability of death during the tth cycle if PMort.SF(t) NGPSE,
43 UK 3c
patient is seizure free Mortality Statistics273
Probability of death during the tth cycle if PMort.NSF(t) NGPSE,
43 UK 3
patient is not seizure free Mortality Statistics273
NGPSE, National General Practice Study of Epilepsy
a 1, Samples from the posterior distribution from the Bayesian meta-analysis of trial data.
b 2 ~Beta (,) where  = number of discontinuations at time t and  = number at risk – .
c 3, Constant.
Winbugs version1.3.274 This assumed that the
individual treatments had a specific fixed effect on
the log OR (treatment) compared with placebo, the
intercept term () corresponded to the rate in the
placebo arms on the log-odds scale and was
allowed to vary randomly between trials: 
P(event) = logit–1(j + treatmentA TA j +
treatmentB TBj …)
 ~ N(R,R
2)
where TAj, TBj, … ∈ [0,1] are indicator variables
for the treatments A, B, … for the jth data point.
Because very few clinical trials were available for
generalised seizure types, the meta-analysis for
generalised seizure data used a fixed study effects
model (that is, a common  is assumed for all
studies).
A meta-analysis was conducted for the outcomes of
response for each of the three indications
considered in the model: monotherapy for newly
diagnosed patients, monotherapy for refractory
patients and combination therapy. The uncertainty
in these probabilities of response and withdrawal
were incorporated into the model using sampled
values from the Markov chain Monte Carlo
simulation of the posterior distribution. A ‘burn-
in’ period of 10,000 samples was used to allow the
estimates to converge and the subsequent 10,000
samples were incorporated into the decision-
analytic model. Plots of the simulated values were
monitored to gauge convergence.
Clinical trials, identified during the systematic
review, which met the following criteria were
included in the meta-analyses:
 The dose of AED employed was within the
range specified in the BNF.
 The drug was licensed as used in the trial.
 The study was a parallel group design.
 The trial outcomes required for the meta-
analysis were reported.
One trial117 was excluded as it was limited to
elderly patients and was felt to be confounding.
The trial data for patients diagnosed as 
suffering from partial seizures are shown in 
Tables 76–78. The differential diagnosis of partial
and generalised epilepsy may be difficult and
some of these trials did include some patients 
with generalised seizures. The results of the 
meta-analyses for these trials are shown in 
Table 79.
Results are shown for the outcomes of both 
response and withdrawal, although only response
was used as a parameter in the decision-analytic
model.
The combined results from the various meta-
analyses are given in Table 79.
A separate analysis was also conducted including
the limited trial data for patients diagnosed with
generalised seizures. The trial data are given in
Tables 80 and 81 and the results of the meta-
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TABLE 75 Transition probabilities
Current Newer Transition description Transition probability
state state
1 2 ‘Monotherapy for newly diagnosed PMono1 response(1) × (1 – PMort.SF)
patients’ is successful during the 
first cycle
1 3 ‘Monotherapy for newly diagnosed [1 – PMono1 response(1)] × (1 – PMort.NSF)
patients’ is unsuccessful
1 8 Patient dies while on monotherapy 
during the first cycle PMort.SF + [1 – PMono1 response(1)] × (PMort.NSF – PMort.SF)
2 2 ‘Monotherapy for newly diagnosed (1 – PMono1 failure(t)) × (1 – PMort.SF)
patients’ is successful during the 
subsequent cycle t
2 3 ‘Monotherapy for newly diagnosed PMono1 failure(t) × (1 – PMort.NSF)
patients’ fails during the subsequent 
cycle t
2 8 Patient dies while on first PMort.SF +PMono1 failure(t) × (PMort.NSF – PMort.SF)
monotherapy during the 
subsequent cycle t
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TABLE 76 Clinical trial data for monotherapy for newly diagnosed patients experiencing partial seizures
Study Newer AED Week Newer AED CBZ VPA PHT
N NW (%) NR (%) N NW (%) NR (%) N NW (%) NR (%) N NW (%) NR (%)
Brodie, 1995121 LTG 48 131 46 (35) 34 (26) 129 63 (49) 37 (29)
Nieto Barrera, 2001119 LTG 24 259 58 (22) 126 (49) 126 35 (28) 63 (50)
Biton, 2001116 LTG 32 65 19 (29) 19 (29) 68 30 (44) 18 (26)
Reunanen, 1996120 LTG 24 226 79 (35) 126 (56) 117 41 (35) 64 (55)
Steiner, 199975 LTG 48 86 45 (52) 19 (24) 95 50 (53) 22 (24)
Aikia, 199258 OXC 52 19 5 (26) 9 (47) 18 3 (17) 11 (61)
Bill, 1997124 OXC 48 143 56 (39) 70 (49) 144 61 (42) 69 (48)
Christe, 1997123 OXC 48 128 52 (41) 60 (47) 121 41 (33) 57 (47)
Privitera, 200294 TPM 26 264 134 (51) 128 (48)a 126 63 (50) 56 (44)a
Privitera, 200294 TPM 26 145 83 (57) 62 (43)a 78 48 (63) 34 (44)a
NR, number responding, defined as seizure freedom; NW, number withdrawn for any reason.
a Seizure freedom during the last 6 months of the double-blind phase.
TABLE 77 Clinical trial data for monotherapy for refractory patients experiencing partial seizures
LTG CBZ VPA
No. of No. of No. of No. of No. of No. of 
patients patients patients patients patients patients 
Study Week N withdrawinga respondingb N withdrawinga respondingb N withdrawinga respondingb
Gilliam, 1998112 12 76 48 (63%) 80 67 (84%)
Kerr, 2001122 28 181 85 (47%) 93 (51%) 123 58 (47%) 67 (55%)
Kerr, 2001122 28 316 191 (60%) 114 (36%) 257 180 (70%) 94(37%)
a Withdrawn for any reason.
b Defined as >50% reduction in seizure frequency compared with baseline or seizure freedom.
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110
TABLE 79 Results of meta-analysis for AEDs used in the treatment of partial seizures
Proportion withdrawn Proportion responding
Indication Drug Mean 95% CI Mean 95% CI
Monotherapy for newly diagnosed LTG 0.35 0.26 0.44 0.40 0.30 0.50
patients (mono1) OXC 0.43 0.32 0.54 0.43 0.31 0.55
CBZ 0.41 0.32 0.51 0.41 0.31 0.51
VPA 0.43 0.33 0.54 0.42 0.31 0.53
PHT 0.41 0.30 0.53 0.42 0.30 0.55
TPM 0.43 0.31 0.54 0.44 0.32 0.56
Monotherapy for refractory patients LTG 0.58 0.40 0.75 0.44 0.23 0.67
(mono2) CBZ 0.57 0.37 0.76 0.47 0.24 0.71
VPA 0.71 0.53 0.84 0.44 0.23 0.68
Combination therapy (comb) Placebo 0.11 0.08 0.15 0.12 0.09 0.16
GBP 0.21 0.12 0.34 0.23 0.13 0.35
LEV 0.14 0.09 0.21 0.32 0.23 0.43
LTG 0.12 0.07 0.18 0.23 0.13 0.34
OXC 0.28 0.18 0.39 0.39 0.27 0.52
TGB 0.20 0.14 0.29 0.27 0.18 0.37
TPM 0.23 0.13 0.36 0.33 0.23 0.43
TABLE 78 Clinical trial data for combination therapy for partial seizures 
Active treatment arm Placebo
No. of No. of No. of No. of 
Active patients patients patients patients 
treatment Study Week N withdrawinga respondingb N withdrawinga respondingb
GBP UK Gabapentin 14 61 16 (26%) 12 (20%) 66 9 (14%) 6 (10%)
Study Group, 199073
GBP US Gabapentin 12 101 10 (10%) 18 (18%) 98 3 (3%) 8 (8%)
Study Group No. 5,
1993138
LEV Shorvon, 2000145 12 212 31 (15%) 53 (25%) 112 15 (13%) 11 (10%)
LEV Cereghino, 2000143 14 199 20 (10%) 70 (35%) 95 6 (6%) 10 (11%)
LEV Betts, 2000139c 24 42 14 (33%) 13 (31%) 39 10 (26%) 5 (13%)
LTG Matsuo, 1993142 12 143 19 (13%) 33 (23%) 73 6 (8%) 12 (16%)
LTG Schachter, 199556 28 332 51 (15%) 112 19 (17%)
LTG Veendrick-Meekes, 16 44 4 (9%) 17 (39%) 24 3 (13%) 6 (25%)
2000137
OXC Barcs, 200070 24 521 241 (46%) 205 (39%) 173 41 (24%) 22 (13%)
TGB Sachdeo, 1997140 12 211 37 (18%) 54 (26%) 107 10 (9%) 9 (8%)
TGB Uthman, 1998163c 16 149 24 (16%) 22 (15%) 91 13 (14%) 4 (4%)
TGB Kälviäinen, 1998164 22 77 21 (27%) 11 (14%) 77 8 (10%) 5 (6%)
TPM Guberman, 2002150 4 171 23 (13%) 87 (51%) 92 3 (3%) 29 (31%)
TPM Yen, 2000165 8 23 3 (13%) 11 (48%) 23 2 (7%) 3 (13%)
TPM Sharief, 1996148 11 23 6 (26%) 8 (35%) 24 2 (7%) 2 (9%)
TPM Faught, 199667 16 136 54 (37%) 45 8 (18%)
a Withdrawn for any reason.
b Defined as a >50% reduction in seizure frequency compared with baseline.
c Excludes results for unlicensed doses.
analyses in Table 82. The trials included in the
meta-analysis and an evaluation of their quality
are presented in Appendix 13.
The combined results for patients experiencing
generalised seizures are shown in Table 82.
Estimation of response to treatment during 
the subsequent cycles 
The probabilities of treatment failure subsequent
to the first cycle for monotherapy for ‘newly
diagnosed’ and ‘refractory’ patients were estimated
from the NGPSE data270 (Table 83). 
The probabilities of treatment failure during
subsequent cycles for combination therapy were
determined from the results of the TGB open-
label follow-up study (Study No. M91-604/M91-
604C)272 (Table 84). The uncertainty in the
probabilities of treatment failure were
incorporated using a beta distribution
parameterised using the observed data.
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TABLE 80 Clinical trial data for monotherapy for newly diagnosed patients experiencing generalised seizures
LTG VPA
No. of No. of No. of No. of 
patients patients patients patients 
Study Week N withdrawinga respondingb N withdrawinga respondingb
GlaxoSmithKline, 200162 24 211 49 (23%) 131 (62%) 102 21 (21%) 69 (67%)
a Withdrawn for any reason.
b Defined as seizure freedom.
TABLE 81 Clinical trial data for combination therapy for patients experiencing generalised seizures
TPM Placebo
No. of No. of No. of No. of 
patients patients patients patients 
Study Week N withdrawinga respondingb N withdrawinga respondingb
Barrett, 199776 12 40 9 (23%) 16 (41%) 40 11 (28%) 8 (20%)
Biton, 199979 12 39 5 (13%) 18 (46%) 41 3 (7%) 7 (17%)
a Withdrawn for any reason.
b Defined as >50% reduction in seizure frequency compared with baseline.
TABLE 82 Results of meta-analysis for AEDs used in the treatment of generalised seizures
Proportion withdrawing Proportion responding
Therapy Drug Mean 95% CI Mean 95% CI
Monotherapy LTG 0.23 0.18 to 0.29 0.62 0.55 to 0.68
VAP 0.21 0.14 to 0.29 0.68 0.58 to 0.76
Combination Placebo 0.17 0.06 to 0.37 0.19 0.07 to 0.39
TPM 0.18 0.06 to 0.38 0.43 0.22 to 0.67
TABLE 83 NGPSE long-term follow-up data for monotherapy270a
Duration of therapy (months) 0–12 12–24 24–48 48–72 72–96
No. of patients at risk at start of period 564 508 474 440 412
No. of discontinuations of first treatment 56 34 34 28 11
a These results were interpolated from the published graph.
TABLE 84 Study No. M91-604/M91-604C long-term follow-up
data for adjunctive therapy272
[Data have been designated commercial-in-confidence
and have been removed]
Estimation of costs associated with states
Unit cost estimates were obtained from the BNF,
March 2002, Personal Social Services Research
Unit (PSSRU), 2002,275 and NHS Reference Costs,
2001–02.276 The uncertainty in the doses of drug
treatment was incorporated using a gamma
distribution with parameters based on the
minimum and maximum doses recommended in
the BNF, March 2002. The other costs were
treated as constants. Table 85 shows the parameters
used to determine the costs incurred in each state
in the model. Further details of how these values
were derived are included in Appendix 27. Costs
in the model were discounted at an annual rate of
6% (Department of Health276)
The costs incurred in each state, described as
functions of the parameters listed in Table 85 are
shown in Table 86.
The costs of the individual AEDs used in the
model are shown in Table 87.
Estimates of QALYs
The QALYs gained for patients in each state were
calculated based on estimates of the QoL weights
(utilities) associated with being seizure free, having
a 50% or greater reduction in seizure frequency or
not responding to therapy (being uncontrolled).
Uncertainty in these estimates was incorporated
using a gamma distribution parameterised as a
function of the mean and standard deviation of
these estimates. Table 88 shows the parameters used
to estimate the expected utilities for the specific
states. The utility weights were derived from Selai
and colleagues.467 These results were based on a
non-randomised audit of 125 patients starting a
new adjunctive AED, who completed the EQ-5D
questionnaire after 6 months. Further details are
included in Appendix 27.
The utility associated with each state, as functions
of the parameters described in Table 88, are shown
in Table 89.
The mortality rate for patients who are seizure
free is estimated to be 28 deaths per 1000 patients
per year. The mortality rate for patients who
experience seizures is estimated to be 40 deaths
per 1000 patients per year.273,277 Further details
are included in Appendix 27. 
Potential comparisons
The various AEDs that might be used at the
various stages in the treatment sequence for
generalised and partial epilepsy are illustrated in
Table 90. This table is based on the indications as
listed in the BNF, March 2002. VGB is not
included in these tables as its toxicity excludes 
it from routine use.278 According to the BNF, 
CBZ is the treatment of choice for partial seizures
and VPA is the drug of choice for generalised
seizures.
This corresponds to the recommendations made
in the NHS North West Clinical Neuroscience
Partnership’s Clinical Framework for the Management
of Adults with Epilepsy,279 which recommended:
1. For generalised seizures:
(a) For newly diagnosed patients: VPA or LTG
(for child-bearing females) as monotherapy.
(b) In addition for intractable patients: LTG,
VPA, TPM, CLB, PB as adjunctive therapy.
2. For partial seizures:
(a) For newly diagnosed patients: CBZ or LTG
as monotherapy.
(b) In addition for intractable patients: OXC as
monotherapy, TPM, VPA, GBP, LEV, CLB,
TGB as adjunctive therapy. 
The specific drugs included within the analysis
were determined by the availability of clinical trial
data regarding the efficacy of specific drugs at the
various stages in the treatment sequence. In
addition, PHT was excluded from the final
analysis owing to its narrow therapeutic window
and VGB was excluded owing to its toxicity.278
Incremental cost-effectiveness analysis
Standard decision rules were followed for the
deterministic cost-effectiveness analysis.280 ICERs
were calculated based on mean costs and effects as
estimated by the Monte Carlo simulation
described above. Strategies which were either
subject to dominance (i.e. those that were more
costly and less effective than alternate strategies)
or were subject to extended dominance (i.e. where
a linear combination of other strategies could
produce greater benefit at lower cost) were
eliminated. ICERs were then calculated by
comparing each treatment strategy with the next
most costly and most effective option. The effect
of uncertainty on the results of the analysis were
illustrated in two ways. First, 95% confidence
ellipses were constructed for the differences in
costs and effects for the various treatments based
on the results of the Monte Carlo simulation
performed, and assuming a joint normal bivariate
Results
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TABLE 86 Calculation of costs for each state in the model
State Cost
1. Newly diagnosed patient starts monotherapy Cdrug + Cswitch + [1 – P(therapy fails)] × CHC|seizure-free + 
P (therapy fails) × CHC|not seizure-free
2. Newly diagnosed patient continues monotherapy Cdrug + CHC|seizure-free
3. Refractory patient starts monotherapy Cdrug + Cswitch + CHC|not seizure-free
4. Refractory patient continues monotherapy Cdrug + CHC|not seizure-free
5. Patients starts combination therapy Cdrug + Cconc + Cswitch + CHC|not seizure-free
6. Patients continues combination therapy Cdrug + Cconc + CHC|not seizure-free
7. Patient on ‘maintenance’ therapy CHC|not seizure-free + Cmain
8. Death Cost = 0
TABLE 87 Costs of individual AEDs
Recommended Recommended Implied Implied
minimum dose maximum dose Cost/mg minimum cost maximum cost
AED (mg/day) (mg/day) (£) per year (£) per year (£)
LTG 100 200 0.0121 442 884
OXC 600 2400 0.0013 285 1140
CBZ 800 1200 0.0003 88 131
VAP 1000 2000 0.0003 110 219
PHT 200 500 0.0013 95 237
LEV 1000 3000 0.0016 584 1753
TGP 15 30 0.0907 497 994
GBP 900 1200 0.0016 526 701
TPM as monotherapy 100 500 0.0108 789 1578
TPM as adjunctive therapy 200 400 0.0108 395 1973
TABLE 85 Parameters used to determine cost
Parameter description Parameter name Valuea Distributionb
Cost of starting a newer AED Cswitch £149 (1 outpatient attendance 1
b
at £128, 1 GP visit at £21)
Additional healthcare costs (excluding CHC|seizure-free £98 (includes estimates of inpatient, 2
c
AEDs) for a seizure-free patient outpatient, A&E and GP visits, see 
Appendix 26 for details of items 
included)
Additional healthcare costs (excluding CHC|not seizure-free £469 (as above) 2
AEDs) for a patient who is not seizure free
Cost of specific AED treatment Cdrug See Table 95 for cost estimates 2
for individual drugs
Cost of concomitant drug used during Cconc £153 (mean cost of older AED) 2
combination therapy
Cost of AED treatment during Cmain £153 in base case 2
maintenance therapy
a See Appendix 26 for full details.
b 1, Gamma (shape, scale), where shape = mean2/SD2, scale = mean/SD2, mean = (max. cost + min. cost)/2, SD = (max.
cost – min. cost)/(1.96 × 2).
c 2, Constant
distribution. In order to remove the additional
‘noise’ associated with the covariation in costs 
and outcomes between the therapies, the ellipses
show the costs and effects relative to LTG. 
Second, uncertainty is illustrated by CEACs.281,282
These indicated the probability of each treatment
having the greatest net benefit for a range of
maximum values that the NHS might be willing to
pay for an additional QALY in this patient
population.
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TABLE 88 Parameters used to estimate utilities based on data from Selai and colleagues467
Parameter description Parameter name Value: mean (SE) Distribution
Utility for a seizure-free patient Useizure-free 0.94 (0.024) 1
a
Utility for a patient who has a 50% reduction in seizure frequency U≥ 50% reduction 0.90 (0.020) 1
Utility for a patient who does not respond to therapy Uno response 0.84 (0.029) 1
Utility associated with dead state Udeath 0 2
b
SE, standard error.
a 1, ~1 – Gamma (shape, scale), where shape = (1 – mean)2/SD2, scale = (1 – mean)/SD2.
b 2, Constant.
TABLE 89 Calculation of utilities
State Utility
1. Newly diagnosed patient starts monotherapy [1 – P(fail monotherapy)] × Useizure-free + P(fail monotherapy) ×
Uno response
2. Newly diagnosed patient continues monotherapy Useizure-free
3. Refractory patient starts monotherapy [1 – P(fail monotherapy)] × U≥ 50% reduction + 
P(fail monotherapy) × Uno response
4. Refractory patient continues monotherapy U≥ 50% reduction
5. Patient starts combination therapy [1 – P(fail combination therapy)] × U≥ 50% reduction + 
P(fail combination therapy) × Uno response
6. Patient continues combination therapy U≥ 50% reduction
7. Patient on ‘maintenance’ therapy Uno response
8. Death Utility = 0
TABLE 90 AEDs indicated for the three stages of the treatment sequence
Drug type AEDs Monotherapy – Monotherapy – Combination 
newly diagnosed refractory therapy
patients patients
For generalised seizures Potential older AEDs CBZ CBZ
VPA VPA
PHT PHT
Potential newer AEDs LTG LTG LTG
TPM
For partial seizures Potential older AEDs CBZ CBZ
VPA VPA
PHT PHT
Potential newer AEDs LTG LTG LTG
OXC OXC GBP
LEV
OXC
TGB
TPM
Implementation of the model
The semi-Markov process model used required
transition probabilities to be a function of both the
initial state and the time spent in the initial state.
This was incorporated in the model by defining a
three-dimensional transition matrix with
dimensions corresponding to current state, time
spent in current state and potential future state.
The progress of a cohort through the model 
was tracked using a three-dimensional matrix 
with dimensions corresponding to current state,
total time since model started and time in 
current state. 
The model was implemented using R, a statistical
programming language which has the ability to
manipulate n-dimensional matrices. In addition,
the model code can be presented as a script, a full
listing of which is given in Appendix 28. It was felt
that an implementation of the model in Excel
would have been extremely difficult and hard to
audit.
Results of integrated economic model
Results for partial seizure-type patients
Monotherapy for newly diagnosed patients
In order to model the costs and effects of
monotherapy for newly diagnosed patients, the
analysis needs to include potential second-line
(monotherapy for refractory patients) and third-
line (combination) therapies should the first-line
therapy (monotherapy for newly diagnosed
patients) fail. Patients who fail first-line therapy
were assumed to receive a common set of drugs
for second and third lines. CBZ and GBP were
chosen as second-line and third-line therapies,
respectively, because based on the assumptions
made about dosing, these therapies have the least
expected acquisition cost among the available
alternatives. Other second- and third-line
therapies were considered in sensitivity analyses.
All costs are expressed in UK sterling at 
2001–02 prices.
Deterministic results The results of the deterministic
CEA, based on mean costs and QALYs, of
‘monotherapy for newly diagnosed patients’ are
shown in Table 91. The lowest expected QALY gain
is achieved by CBZ (9.392 years) and the highest
expected QALY gain is achieved by TPM
(9.430 years), but the difference between these
expected values is only 0.038 years, or 14 days,
reflecting the similarity in efficacy between drugs
in the meta-analysis. The differences in costs
between therapies are more substantial. The
therapy with the lowest expected cost is CBZ,
mainly owing to its low acquisition cost. Based on
an analysis of expected costs and benefits, LTG
and OXC are dominated or extended dominated
by CBZ, VPA and TPM therapies. TPM is cost-
effective if the threshold willingness to pay for an
additional QALY is in excess of £126,000. 
Allowing for uncertainty The 95% CIs for costs and
effects are shown in Table 91. The 95% confidence
ellipses for differences in cost and effects for the
various treatments are shown in Figure 31. The
ellipses show there is considerable overlap in the
estimated mean cost and effects for the various
treatments based on the available data. Figure 32
shows the CEACs for monotherapies for newly
diagnosed patients. At a threshold willingness to
pay for an additional QALY of £30,000, the older
AEDs have a probability of 36–41% and the newer
AEDs 2–16% of being the most cost-effective
option.
Monotherapy for refractory patients
Only two trials were identified that considered the
effectiveness of monotherapy for refractory
patients (see Table 92).112,122 For this reason, the
AEDs considered in this analysis are limited to
CBZ, VPA and LTG.
Deterministic results Mean costs and QALYs and the
deterministic CEA are shown in Table 92. CBZ and
VPA therapies are both significantly less costly
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TABLE 91 CEA of ‘monotherapy for newly diagnosed patients’a
Therapy Cost: mean (95% CI) (£) QALY: mean (95% CI) ICER (£)
CBZ 4428 (4071 to 4782) 9.392 (9.000 to 9.737) NA
VPA 4572 (4180 to 4949) 9.404 (9.002 to 9.751) 11,731
LTG 6133 (5500 to 6892) 9.382 (8.983 to 9.723) Dom
OXC 6294 (5133 to 7902) 9.415 (9.010 to 9.766) Ex Dom
TPM 7838 (5733 to 10,895) 9.430 (9.024 to 9.780) 126,519
Dom, dominated; Ex Dom, extendedly dominated.
a Excluding PHT (narrow therapeutic window).
than LTG, owing to lower costs of the AEDs. CBZ
therapy delivers slightly higher QALY gains on
average and, therefore, dominates VPA and LTG. 
Allowing for uncertainty The 95% confidence
ellipses for incremental costs and benefits, relative
to LTG, are shown in Figure 33. The CEACs in
Figure 34 show that CBZ is the preferred second-
line monotherapy compared with LTG in more
than 75% of simulations with a threshold
willingness to pay of £30,000. However, if a
patient has previously failed to respond to CBZ, or
CBZ were contraindicated for any reason, LTG
may well be cost-effective as a monotherapy for
refractory patients. Comparative data were not
available to estimate the cost-effectiveness in this
situation.
Combination (adjunctive) therapy for refractory
patients
Deterministic results Table 93 shows the results of the
deterministic CEAs for combination therapies for
refractory patients. Monotherapy (placebo) has the
lowest mean cost overall and GBP the lowest mean
cost among the newer AEDs. All AEDs offer
slightly higher mean QALY gains than
monotherapy. Based on estimated means,
treatment of all (or a proportion) of the patient
population with OXC dominates (or extendedly
dominates) other therapies. The ICER is £17,095
per QALY gained compared with monotherapy.
Allowing for uncertainty Figure 35 shows expected
values and 95% confidence ellipses for the
incremental costs and benefits of the treatments
compared with no concomitant drug therapy
(placebo). This shows the uncertainty in the cost-
effectiveness estimates. This is also demonstrated
in the CEAC (Figure 36), which shows that OXC is
the most cost-effective therapy in 65% of
simulations when the willingness to pay for an
additional QALY is £30,000. However, this does
mean that 35% of simulations showed that one of
the other treatments was more cost-effective.
Excluding oxcarbazepine and lamotrigine Table 94
represents the situation where LTG and OXC have
already been tried as monotherapy and probably
would not additionally be considered for as an
adjunctive therapy. In these circumstances, other
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FIGURE 31 Expected values and 95% confidence ellipses for incremental costs and benefits of first monotherapy AEDs compared
with LTG
therapies are more cost-effective. TGB has an
ICER of £25,473 compared with placebo and TPM
has an ICER of £47,528 compared with TGB.
Other therapies are extendedly dominated. 
Figure 37 shows the CEACs for these options. There
is greater uncertainty about the treatment decision
compared with the situation where OXC was an
option for combination therapy. At low values of
willingness to pay for an additional QALY, placebo
is most likely to be cost effective (i.e. patients
would be continued on their monotherapy alone).
When the willingness to pay is £30,000, the
probability that placebo is cost-effective is 31%
and the probability any given adjunctive AED is
cost-effective is between 15 and 22%.
Sensitivity analyses
Discount rate The probabilistic nature of the
analyses above deals with parameter uncertainty,
that is, the results reflect the imprecision in
parameter estimates. There is uncertainty in other
variables the importance of which is assessed using
standard sensitivity analysis. Univariate sensitivity
analyses were carried out by changing the discount
rate for benefits from 1.5% to 0% and 6%. Table 95
shows the sensitivity of the ICER of monotherapy
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FIGURE 32 CEACs of monotherapy AEDs for newly diagnosed patients
TABLE 92 CEA of ‘monotherapy for refractory patients’
Therapy Cost: mean (95% CI) (£) QALY: mean (95% CI) ICER (£)
CBZ 5599 (5407 to 5833) 8.865 (8.393 to 9.265) –
VPA 5728 (5526 to 5966) 8.856 (8.380 to 9.261) Dom
LTG 6749 (6245 to 7410) 8.856 (8.380 to 9.261) Dom
Dom, dominated.
for newly diagnosed patients and the ICER of
combination therapy for refractory patients to
changes in the discount rate. The decision about
whether the therapies are cost-effective is robust to
changes in the discount rate.
Choice of monotherapy for refractory patients and
combination therapies The sensitivity analysis also
considered how different choices of second- or
third-line therapy would affect the cost-
effectiveness of the monotherapies. The base case
used monotherapy CBZ as second-line and
adjunctive GBP as third-line therapies. Results are
presented for the alternative scenarios of VPA as
second-line, LMT as third-line or no adjunctive
therapy (placebo) as third-line therapy. Using VPA
as second line increases the expected costs by
about £85–107 per patient over the lifetime of the
model and reduces the QALYs gained by 0.006 for
each therapy compared with the base case
(Table 96). Using LMT as third-line therapy
increases costs by about £68–89 and increases
QALYs by about 0.005. Using placebo as third line
reduces costs by about £334–372 and reduces
QALYs by 0.013. In each scenario, the ranking of
first monotherapies seen in Table 96 does not
change. Therefore, the choice of VPA as first
monotherapy is robust to subsequent decisions
about second- and third-line therapies in this
model.
Treatment costs for patients who fail combination therapy
Lhatoo and colleagues270 estimate that 30% of
patients who start third-line therapy will fail on
this treatment. The base case assumes that these
patients receive a treatment whose cost is
equivalent to monotherapy with an older AED.
Sensitivity analysis tested the robustness of the
results to this assumption by maintaining patients
who failed combination therapy with a new
adjunctive therapy costing £1753 per year, but
maintaining patients who failed third-line
monotherapy (placebo) with a subsequent
monotherapy. This alternative assumption does
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FIGURE 33 Expected values and 95% confidence ellipses for incremental costs and benefits of second-line monotherapy AEDs
compared with LTG
not change the ranking of the results for
combination therapy compared with the base case.
Costs for all adjunctive therapies increase by
£10,800 over the time horizon of the model,
whereas costs for monotherapy only remained
unchanged. The ICER for adjunctive OXC
compared with monotherapy increased from
£17,095 to £158,432.
Annual cost of healthcare for patients who are not
seizure free The base case assumes healthcare costs
of £469 per year for patients who are not seizure
free. This may be a conservative estimate. Janssen-
Cilag218 estimated mean annual healthcare costs of
up to £1533 for these patients. The costs of
monotherapy increased by between £5500 and
£5800 for all therapies, but the ranking of
monotherapy AEDs for cost-effectiveness
remained unchanged compared with the base
case.
Results for generalised seizure-type patients
Results are presented for monotherapy for newly
diagnosed patients and for combination therapy.
There were no clinical trial data available for
monotherapy for ‘refractory’ patients. Only trials
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FIGURE 34 CEACs of monotherapy AEDs for refractory patients
TABLE 93 Cost-effectiveness of combination therapies for refractory patients
Therapy Cost mean (95% CI) (£) QALY: mean (95% CI) ICER (£)
PLA 5064 (5064 to 5064) 8.716 (8.111 to 9.229) –
GBP 5861 (5637 to 6156) 8.747 (8.176 to 9.238) Ex Dom
LTG 5926 (5601 to 6358) 8.746 (8.172 to 9.234) Ex Dom
TGB 6133 (5748 to 6624) 8.758 (8.195 to 9.240) Ex Dom
OXC 6400 (5699 to 7423) 8.794 (8.266 to 9.247) 17,095
LEV 6984 (6094 to 8173) 8.775 (8.232 to 9.243) Dom
TPM 7026 (6324 to 7902) 8.777 (8.236 to 9.243) Dom
Dom, dominated; EX Dom, extendedly dominated.
that exclusively considered patients experiencing
generalised seizures were included in the analysis.
Monotherapy for newly diagnosed generalised
seizure patients
Table 97 shows the CEA of LTG versus VPA,
assuming that TPM was used as the adjunctive
therapy for patients who failed monotherapy. Based
on the mean estimates of cost and effects, VPA is
cheaper and no less effective and, therefore,
dominates LTG therapy. The ranking of the
monotherapies was not changed when it was
assumed that combination therapy was not used for
treatment failures. Figure 38 shows the 95%
confidence ellipse for the incremental cost and effect
of VPA compared with LTG. The CEACs for the two
therapies (Figure 39) show that VPA is preferred to
LTG in at least 94% of simulations if the willingness
to pay for an additional QALY is less than £50,000.
Combination therapy for refractory generalised
seizure patients
Table 98 shows the CEA of combination therapy
for refractory patients. Based on the estimated
means, TPM is significantly more costly than
placebo but is more effective. The ICER of TPM
compared with placebo is £34,417. Figure 40 shows
the 95% confidence ellipse of incremental costs
and effects of TPM compared with placebo.
Figure 41 shows the CEACs for combination
therapy. If the willingness to pay for additional
QALYs is about £30,000, then there is a 41%
probability that TPM is cost-effective, showing that
the decision is highly uncertain.
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patients compared with no concomitant therapy (placebo)
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FIGURE 36 CEACs for adjunctive therapy AEDs
TABLE 94 Cost-effectiveness of combination therapies for refractory patients (assuming OXC and LTG are excluded because they have
been previously used as monotherapies)
Therapy Cost: mean (95% CI) (£) QALY: mean (95% CI) ICER (£)
PLA 5064 (5064 to 5064) 8.716 (8.111 to 9.229) –
GBP 5861 (5637 to 6156) 8.747 (8.176 to 9.238) Ex Dom
TGB 6133 (5748 to 6624) 8.758 (8.195 to 9.240) 25,473
LEV 6984 (6094 to 8173) 8.775 (8.232 to 9.243) Ex Dom
TPM 7026 (6324 to 7902) 8.777 (8.236 to 9.243) 47,528
Ex Dom, extendedly dominated.
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FIGURE 37 CEACs for adjunctive therapy AEDs assuming LTG and OXC are excluded because they have been previously used as
monotherapies
TABLE 95 Sensitivity of ICERs of ‘first monotherapy’ and ‘combination therapy’ to changes in discount rate for QALYs
First monotherapy Combination
Discount rate (%) ICER of TPM vs VPA (£) ICER of OXC vs placebo (£)
0 113,907 15,963
Base case (1.5) 126,519 17,095
6 170,114 20,750
TABLE 96 Changes to cost-effectiveness (ICER) of monotherapy for newly diagnosed patients compared with base case assuming
alternative second- and third-line therapies
Drug Base case (£) Monotherapy VPA Monotherapy Adjunctive LMT 
2nd line (£) 3rd line (£) 3rd line (£)
CBZ – – – –
VPA 11,731 11,483 11,838 11,967
LMT Dom Dom Dom Dom
OXC Ex Dom Ex dom Ex dom Ex dom
TPM 126,519 126,383 123,435 126,142
Dom, dominated; Ex Dom, extendedly dominated.
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TABLE 97 CEA of monotherapy in newly diagnosed patients with generalised seizure type
Therapy Cost: mean (95% CI) (£) QALY: mean (95% CI) ICER (£)
VPA 4288 (3817 to 4808) 9.814 (9.357 to 10.178) –
LTG 6675 (5729 to 7754) 9.748 (9.307 to 10.101) Dom
Dom, dominated.
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FIGURE 38 Expected values and 95% confidence ellipse for incremental costs and effects of VPA relative to LTG for monotherapy in
newly diagnosed patients with generalised seizures
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FIGURE 39 CEACs of monotherapy for generalised seizure patients
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TABLE 98 CEA of combination therapy in refractory generalised seizure type patients
Therapy Cost: mean (95% CI) (£) QALY: mean (95% CI) ICER (£)
PLA 5064 (5064 to 5064) 8.737 (8.164 to 9.231) –
TPM 7471 (6388 to 8877) 8.807 (8.286 to 9.246) 34417
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FIGURE 40 Expected values and 95% confidence ellipse of incremental costs and effects of TPM combination therapy compared with
placebo in refractory generalised seizure-type patients
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FIGURE 41 CEACs of combination therapy in generalised seizure-type patients
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Summary of results of integrated economic
evaluation
Partial seizure type
For the treatment of newly diagnosed patients
with monotherapy, the analysis showed similar
health benefits for the various AEDs and that the
newer AEDs were more expensive than the older
therapies. CBZ or VPA was cost-effective up to a
threshold willingness to pay per QALY of
£127,000, above which TPM was the most likely,
although only by a small margin, therapy to be
cost-effective. There was considerable uncertainty
in these results. 
There were few data available about the use of
AEDs as monotherapy for refractory patients.
The analysis showed that the various AEDs had
similar effectiveness and that the newer AEDs
were more expensive than the older AEDs. The
analysis suggested that, compared with VPA and
LTG, CBZ, when indicated, was the treatment
most likely to be cost-effective for refractory
patients.
The analysis indicated that the newer AEDs used
as adjunct therapy for refractory patients were
more effective and more costly than continuing
with the patients’ existing treatment alone.
Combination therapy may be cost-effective at a
threshold willingness to pay per QALY greater
than £20,000 provided that patients revert to
monotherapy should adjunctive therapy prove
ineffective. The exact value of this threshold
depends on the patients’ previous treatment
history. There was considerable uncertainty 
about this conclusion. 
Univariate sensitivity analysis showed that the
results were robust to different assumptions
about discount rates, different second- and 
third-line therapies should monotherapy fail 
and the cost of maintenance therapy for highly
refractory patients.
Generalised seizure type
There were few data available to determine the
effectiveness of treatments for patients
experiencing generalised seizures. LTG and 
VPA showed similar health benefits when used 
as monotherapy. VPA is less costly and found
likely to be cost-effective compared with LTG.
TPM used as an adjunct therapy for refractory
patients was found to be more effective and 
more costly than continuing with current
treatment alone. TPM may be cost-effective as
adjunct therapy if the threshold willingness to
pay is greater than £35,000, but there was
considerable uncertainty in these results.
The aim of this review was to assess the clinicaleffectiveness, tolerability and cost-
effectiveness of newer drugs for epilepsy in adults.
Epilepsy is a complex disease that is responsible
for considerable morbidity and mortality, affecting
over 400,000 individuals and causing over 1000
deaths per year within the UK.7 Implications of
the disease and the subsequent impact of
treatment often have serious consequences for the
individuals affected and their families.12
Initial treatment approaches focus on drug
therapy, either monotherapy or adjunctive. In the
event of drug treatment failure, surgery might be
considered but is limited to a very specific group
of patients. Drug therapy is, therefore, the
mainstay of treatment. Because many individuals
can require many years’, if not lifelong, treatment
with AEDs, the clinical effectiveness, tolerability
and cost-effectiveness of drug therapy are major
considerations. 
A number of drug therapies are licensed for the
treatment of epilepsy in adults, although many 
are limited to specific types of epilepsy and
therapy regimens.4,5 Treatment with a number of
older AEDs, including CBZ, PHT and VPA, has
been available for a number of years. In recent
years, newer AEDs have emerged. This review
focused on seven of the newer drugs with the aim
of determining their clinical effectiveness,
tolerability and cost-effectiveness compared with
conventional older drug therapies and to each
other.
Clinical effectiveness and
tolerability
The evidence
Monotherapy
Monotherapy is currently recommended for the
initial treatment of patients with newly diagnosed
epilepsy. Only after subsequent monotherapies
have failed are adjunctive therapies considered, as
this increases the chance of drug interactions and
toxicities. Of the newer AEDs, only LTG and OXC
are currently licensed for monotherapy in newly
diagnosed patients. TPM should become licensed
for monotherapy in newly diagnosed patients in
spring 2003 and hence has also been considered
in this review. LTG is licensed for the treatment of
both POSs and generalised onset seizures; OXC is
only licensed for POSs. 
One important clinical question for the treatment
of newly diagnosed patients is whether LTG, OXC
and TPM are more effective than older AEDs.
This review found insufficient evidence from
good-quality clinical trials to answer this question.
Evidence to support the use of OXC over older
AEDs such as VPA, CBZ and PHT was limited 
and few significant findings from good-quality
trials were reported with regard to any of the
outcome measures considered in this review.
Similarly, there was insufficient evidence from
good-quality trials to assess clinical effectiveness
and tolerability of newer AEDs compared with
older AEDs: only one poor-quality RCT compared
TPM monotherapy with older AEDs. A greater
number of studies focused on the use of LTG in
monotherapy, but only one considered the
treatment of generalised onset seizures. The
greater number of LTG trials probably reflects the
fact that this drug has been available for a longer
period of time. However, this review found few
consistent statistically significant differences
between LTG and the older AEDs, with the
exception of a small number of differences in
QoL. It remains unclear whether LTG is more or
less effective, especially in the treatment of
generalised onset seizures. 
As to whether one newer drug is more effective
than another for treating newly diagnosed
patients, only one study investigated this question
by comparing LTG monotherapy with GBP
monotherapy. Given that GBP is not licensed for
use in monotherapy, the clinical applicability of
this study is limited. Otherwise, evidence to
support the use of one monotherapy AED over
another is lacking.
A trend was observed in favour of OXC
monotherapy compared with placebo for the
proportion of seizure-free patients and the time to
event outcomes. However, the significance of this
finding to clinical practice is unclear as no
treatment is an unlikely option for the majority of
adult patients.
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Adjunctive therapy
Patients who fail successive monotherapy
treatments are classified as refractory and the
options for AED therapy switch to adjunctive
therapy. All seven of the newer AEDs under
investigation in this review are licensed for
adjunctive therapy in POSs. Over half of the trials
of adjunctive therapy specifically considered the
treatment of POSs. Only LTG and TPM are
licensed for generalised onset seizures. However,
only one trial of adjunctive LTG specifically
considered the treatment of generalised onset
seizures. No trials of adjunctive TGB specifically
recruited patients with generalised onset seizures.
The remaining trials considered mixed
populations of seizure types.
This review found insufficient evidence from
good-quality clinical trials to support the use of
any of the newer AEDs versus older AEDs.
Evidence was limited both by the amount of data
and by the lack of any consistent statistically
significant differences between newer and older
AEDs in most of the outcome measures considered
in this review. There was limited evidence to
suggest that both LTG and GBP may have some
beneficial effect on behaviour in people with
learning disabilities. Very few trials compared
newer AEDs with other newer AEDs and so there
was insufficient evidence to determine whether
one newer drug is more effective than another. A
trend was evident in favour of newer drugs
compared with placebo. 
Strength of the evidence
Extensive literature searches were used to identify
both published and unpublished data for inclusion
in the clinical effectiveness and tolerability sections
of this review. Owing to the difficulties in
identifying data concerning serious, rare and long-
term AEs, some data may have been omitted.
Similarly, owing to time limitations data from non-
English language publications could not be
included in any part of this review. 
The strength of the clinical evidence relating to
newer AEDs is reflected not only in the quantity
and findings of studies but also in the
methodological quality of the studies. Reporting of
methods of randomisation, allocation concealment
and blinding was often inadequate; therefore, it is
not possible to be sure that adequate measures
were taken to minimise bias. A feature noted in
some trials was that the investigators decided
which baseline treatment each participant would
take before randomisation to the experimental
treatment or control. This practice may be open to
manipulation, however well intended. In addition,
a small number of studies compared newer AEDs
with lower than recommended doses of older
comparator AEDs. This may bias the data in
favour of the newer AED.
The majority of trials included in the review 
were parallel superiority trials. Crossover designs
were also used but appropriately confined to
adjunctive therapy in refractory patients, although
some studies failed to incorporate an adequate
washout period. Data from crossover studies were
largely not reported in such a way that data from
both the first and second phases could be used.
This resulted in a loss both of statistical power 
and of the advantage of within-patient
comparisons.
Few of the included studies recruited sufficient
numbers of participants to fulfil ILAE
recommendations (at least 100–150 participants).
Numbers of participants in the included studies
ranged from 10 to 877; only one-third of the trials
included at least 150 patients. A sample size
calculation sufficient to demonstrate a defined
treatment effect was not always reported. Similarly,
the duration of most trials also failed to meet
ILAE recommendations (6 months to 1 year); only
10 studies reported a follow-up of at least 1 year.
Some of the included trials continued into a
single-treatment open-label extension phase;
however, these data were beyond the scope of this
review but some may have been included in the
review of AEs.
Often study results were based on per protocol
populations or were reported as ITT data when
they were not based on true ITT populations.
Data based on ITT populations presents a more
conservative picture of the treatment effect, except
in equivalence trials where they may suggest false
equivalence. In order to allow all of the studies,
regardless of the type of data they presented, to be
considered in an equivalent manner, all data
considered in this review were based on true ITT
populations (i.e. all randomised participants
analysed according to the treatment group to
which they were originally allocated). This
necessitated the recalculation of data in many
cases. Recalculation was based on the assumption
that missing patients were non-responders. Ideally,
the impact of this assumption would be explored
further in a sensitivity analysis using both worse-
case (i.e. all missing patients considered as non-
responders) and best-case (i.e. all missing patients
considered as responders) scenarios. However, this
was not possible in the time frame available.
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Cognitive function and QoL were considered in
both monotherapy and adjunctive therapy trials.
However, both of these outcomes used a number
of different assessment measures and scales, some
of which were more rigorous than others. Some
measures used to assess QoL were based on
subjective evaluations, e.g. physician, investigator
and patient global evaluations, and are therefore
open to biases associated with subjective reporting.
There are currently no guidelines as to which
measures are the most appropriate in trials of
epilepsy treatments.
Additional issues associated with the strength of
evidence relating to cognitive effects were
differences in dealing with practice effects (i.e.
where there is improvement in performance due
to increased familiarity with a test); a standard
order of test administration (i.e. fatigue may 
affect performance in later tests); failure to 
report postictal status during assessments (i.e.
postictal effects may confound test results) and
failure to report impact of mood on cognitive
performance (i.e. depression and anxiety can 
have a detrimental effect on cognitive
performance); problems in interpreting multiple
statistical comparisons when using a large 
number of cognitive measures. All of these 
issues may bias the results from cognitive
assessments.
Applicability
The included trials varied in the characteristics of
the participants, the interventions and the
outcome measures reported.
Population
ILAE guidelines recommend that trials recruit
sufficient numbers of participants with clinically
relevant characteristics.283 Monotherapy is
recommended for the initial treatment of patients
with newly diagnosed epilepsy and adjunctive
therapy for refractory epilepsy.279 In this respect,
the majority of trials included in this review were
conducted with appropriate patient populations.
All of the newer AEDs are licensed for the
treatment of POSs. However, only LTG and TPM
are licensed for the treatment of generalised
seizures. Many of the trials did not solely recruit
participants with seizure types appropriate to
current licensed practice. In many cases trials of
drugs licensed only for the treatment of POSs,
recruited mixed populations of POSs and
generalised onset seizures types. Outcome data
were often not reported according to seizure type
and so the clinical relevance of these trials is
unclear.
A feature of any review of summary data is the
limited capacity to explore the effects of individual
patient characteristics on outcomes. Epilepsy is
not a uniform condition and clinical trials recruit
heterogeneous populations. Meta-analysis of
individual patient data would better inform
treatment of individual patients. However,
collection and analysis of individual patient data
require collaboration and commitment from those
who conduct clinical trials. 
A number of trials included in this review used a
conditional response design, which is likely to
affect the clinical relevance and applicability of the
data. Such trials require that participants achieve a
specified reduction in seizure frequency while
undergoing AED treatment in the pretrial phase,
in order to be included in the main assessment
phase of the trial. Therefore, the trial only assesses
patients who have a good chance of responding
well to treatment. This is unlikely to apply to
populations in clinical practice. Similarly, a small
number of trials in this review included
participants who were undergoing evaluation for
surgical treatment. Surgery is a treatment option
for some patients where AED treatment has
proved particularly unsuccessful and problematic;
however it is only appropriate for a very specific
group of patients. Therefore, the applicability of
data from such populations is limited.
This review focused on the treatment of adults (i.e.
≥ 18 years old). However, younger patients were
often also included in some trials and it was not
always possible to separate data according to age.
Where data were available, this review also
considered the treatment of certain subgroups of
patients including the elderly, people with
intellectual disabilities and pregnant women. The
treatment of epilepsy in these groups of
individuals is often problematic and in some cases
the use of many AEDs is cautioned owing to
potentially toxic effects. Only one study of LTG
monotherapy considered elderly patients,
although additional studies that addressed AEs
did include these patient subgroups. Patients with
intellectual disabilities were only considered in
trials of adjunctive therapies and the majority did
not report data separately for these patients. All of
the identified RCTs excluded pregnant and
breastfeeding women and women at risk of
pregnancy. Overall, this review cannot comment
on treatment within these specific groups of
patients with epilepsy. 
Treatment
Various clinical practice guidelines recommend
treatment pathways for monotherapy and
adjunctive therapy of epilepsy including which
AEDs should be used. However, this review did 
not find convincing evidence to inform decisions
as to which is the most appropriate AED to use.
With regard to clinical practice, it is important
that trials use doses of drugs that are clinically
appropriate and within licensed ranges. In this
review, studies of LTG and TGB sometimes used
doses that exceeded those recommended in the
UK. Use of lower than recommended doses was
unusual. In addition, many trials involved a
titration period during the whole of which time
patients may not have been receiving an 
effective dose of the drug. This makes
interpretation of the data difficult, but does 
reflect clinical practice. Ideally, the impact of
different doses of drugs would have been explored
further in a logistic regression analysis. However,
this was not possible within the time frame of this
review.
Treatment effect 
The aim of most monotherapy AED regimens is
freedom from seizures. ILAE guidelines for
monotherapy trials recommend time to trial
exit/withdrawal because of inadequate drug
efficacy and/or poor tolerability as the most useful
measure of effectiveness to inform clinical
practice.284 However, the most commonly reported
outcome measure reported in the studies included
in this review was the proportion of seizure-free
participants. Less than half of the monotherapy
trials provided data for time to exit/withdrawal.
Time to first seizure was more commonly
reported; however, the ILAE argue that the time
to achieve 6 months, 1 year or 2 years of remission
has greater clinical significance (unless the
population has infrequent seizures, as in newly
diagnosed epilepsy). None of the trials reported
these outcomes. 
In adjunctive therapy, time to exit/withdrawal for
the study is also the most satisfactory measure of
effectiveness. However, change in seizure
frequency (percentage responders) may also be a
useful measure for refractory patients. The
majority of the included trials did provide data for
this outcome.
Outcomes such as the proportion of participants
seizure free were recorded at different time points
in different studies. It is possible that investigators
could have selected the time point that best
illustrated the effectiveness of the favoured
treatment. Where possible, the actual time points
used in each study were stated, and pooling of
data collected at widely varying follow-up points
was avoided.
Benefit versus harm
This review has shown no evidence of significant
benefit in epilepsy outcomes with LTG, OXC and
TPM monotherapy compared with older AEDs
and with other newer AEDs. Only one newer 
drug (OXC) showed any evidence of improved
effect over placebo. There was limited evidence
that LTG and OXC improved some aspects of
QoL and cognitive function compared with older
drugs.
This review showed evidence of some benefit in
epilepsy outcomes with LEV, OXC, TGB, TPM or
VGB added to existing therapy versus placebo, but
studies of QoL and cognitive function did not
reflect similar benefits. There was no evidence that
any newer drug in adjunctive therapy conferred
more benefit in any outcome than the other newer
drugs or older drugs. 
Less can be concluded about the risks of harm
because evidence from RCTs was lacking and
observational studies rarely included comparisons
between drugs. Observations of serious AEs were
not generally convincing of causality, with the
exception of some effects of which both
manufacturers and clinicians are already aware.
Comparison with previous reviews
All of the previous systematic reviews considered
in this current review were Cochrane reviews. The
evidence available from the Cochrane reviews was
limited to comparisons of adjunctive treatment
with placebo in refractory patients with POSs.
Similar outcomes were reported in the Cochrane
systematic reviews, but they did not address
serious, rare and long-term AEs. However, in the
majority of cases previous reviews did consider the
effects of dose (logistic regression analysis) and
included sensitivity analyses to test best- and
worst-case scenarios with respect to missing data,
which was not done in this review. In the majority
of cases, worst and best-case scenarios showed
similar effects, although discrepancies were
observed with GBP. Planned regression analyses
were often not performed owing to lack of data,
but where available dose effects were reported for
GBP and LEV. 
Overall, the previous Cochrane reviews reported
similar findings to this review, that is, that newer
adjunctive AEDs appeared to be more effective
than placebo, but evidence regarding long-term
efficacy was limited.
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Cost-effectiveness
The evidence 
Published monotherapy studies
Despite the differences in methodology between
the four studies, the findings were remarkably
similar: even if the most optimistic treatment
scenario for the newer drugs is compared against
the worst-case treatment scenario for the older
drugs, monotherapy with the older drugs is
considerably less costly.
All four studies concluded that the newer drugs
should not be used as first-line therapy for the
treatment of newly diagnosed patients. However,
one study indicated that LTG might be a good
option for patients whose epilepsy is poorly
controlled or who are unable to tolerate the older
drugs. 
All of the published studies considering
monotherapy used a CMA design. The a priori
assumption that therapies are equally effective is
not appropriate since the effect of the drugs on
QoL requires consideration of the interaction
between seizure control and AEs This is taken into
account in the integrated analysis presented above.
Published adjunctive therapy studies
Just two studies compared older and newer
adjunctive drugs head to head.260,262 Both studies
were CEAs, comparing both costs and outcomes.
O’Neill and colleagues262 found a clear cost-
effectiveness advantage for the older drug (CLB)
against the newer drugs (LTG and VGB).
Schachter and colleagues260 found that adjunctive
TGB was less expensive (including the cost of
managing AEs) but less effective than CBZ;
compared with adjunctive PHT, TGB was more
expensive and of similar clinical effectiveness. This
study was reported only as a poster abstract and
few details of the analysis were available.
Therefore, it is not possible to perform a
satisfactory assessment of its quality.
Three published evaluations compared newer
adjunctive drugs with patients’ current medication
only. One of these considered VGB versus no
adjunctive therapy. The paper was published before
the serious side-effects associated with VGB were
known. In the UK, the use of VGB is currently
restricted to patients in whom all other
combinations of AEDs are inadequate or not
tolerated. Messori and colleagues261 concluded that
LTG was cost-effective if the threshold willingness
to pay was greater than US$41,000 per QALY.
Markowitz and colleagues258 estimated that the
ICER of adjunctive LTG was US$7 per seizure-free
day gained compared with continuing
monotherapy. The main weakness of both of these
evaluations was that they were based on the results
of one or two randomised trials and extrapolated
forward over the patients’ lifetime using the
assumption that outcomes at the end of the trial
are maintained over the time horizon of the model.
Two published studies compared newer adjunctive
AEDs with other newer AEDs. Hughes and
Cockerell256 presented a CMA that was not
appropriate. Selai and colleagues257 estimated that
15% of patients using TPM and 11% of patients
using LTG were ‘satisfied’ with their treatment
after 6 months, and that the cost per patient of
TPM was £472 and LTG £587. The study was
based on a small sample size and patients were not
randomised to treatment.
None of the published economic evaluations
satisfied all of the criteria for a robust economic
evaluation of AEDs, one that considers all the
treatment alternatives, takes a sufficient time
horizon and uses a systematic method to collect
evidence.
Company submissions
All of the submissions claimed that their therapy
was cost-effective. The submissions used different
comparators and a diverse range of health
outcome measures; therefore, it was not possible to
compare the results directly with one another. The
main features felt to be essential to model the
treatment decision were to provide a comparison
between all of the relevant treatments, to
incorporate QoL in the measure of health
benefits, to allow for the possibility that the first-
or even second-line therapy might fail, to use a
systematic method to identify and synthesise
evidence, to use an adequate time horizon, to take
a broad NHS perspective and to use probabilistic
sensitivity analysis to handle second-order
uncertainty surrounding model parameters. Only
two analyses achieved most of these criteria. The
main weaknesses of even these more sophisticated
evaluations was a lack of a systematic approach to
obtaining and synthesising effectiveness data, and
none of the models provided a comparison
between all of the relevant drugs. This indicated
the need for a model based on a comprehensive
review of the evidence that allowed comparisons to
be made between alternative therapies.
Integrated economic model
The various published evaluations and industry
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submissions used a variety of analytic methods,
comparators and outcomes. A majority of the
evaluations were based on CMAs which assumed
equality of benefits and did not fully consider
uncertainty in outcomes, or were CEAs that used 
a variety of outcome measures and therefore 
could not be compared. A small number of 
CUAs were conducted; these considered only a
limited number of alternative treatments and trial
results and did not fully consider uncertainty,
especially in the extrapolation of the results of
short-term trial data to longer periods of
treatment. 
Given the limitations in submitted and previously
published economic evaluations, an integrated
CEA was conducted. This analysis incorporated
available information on the costs and effects
associated with the various newer and older
epileptic drugs and allowed direct comparisons to
be made despite the limited number and scope of
‘head-to-head’ trials. To allow the cost-
effectiveness of the various AEDs under
consideration to be compared with therapies for
other conditions, a CUA was undertaken.
The integrated CEA extrapolated from the
individual short-term clinical trials to allow direct
comparisons to be made between the various
treatments based on predicted long-term benefits
and costs. In order to allow these comparisons,
data from a variety of sources were combined in
the analysis and a number of assumptions were
required. These are summarised below and should
be borne in mind when considering the results of
the analysis.
The first assumption relates to outcomes. AEDs
may alter the intensity, frequency and pattern of
occurrence of epileptic seizures. The impact of
drug treatment on the QoL experienced by a
patient will be a complex function of these various
effects. The integrated economic analysis was
limited to those reported clinical trial outcomes,
seizure freedom and 50% reduction in seizure
frequency that were common to all drugs and
which could be interpreted in light of the available
quality of life evidence. The estimates of the
impact of seizure control on utility were based on
a single small study.467 An estimate of uncertainty
was made based on the observed study data, but
this does not account for potential variability
between studies. As these utility estimates were
common to all treatments being considered, the
effect of this uncertainty on the estimates of
differences in cost-effectiveness between
treatments is likely to be limited.
A second assumption is that, in the absence of
specific comparative long-term clinical trial data,
we estimated the short-term effectiveness based on
specific clinical trial data and the longer term
effectiveness based on generic open-label study
data. Although an estimate of uncertainty based
on the observed trial data was incorporated in the
analysis, no account was made of uncertainty
arising from potential variability between studies
and drugs. The generalisability of the clinical trial
data should also be considered when reviewing the
results of the analysis
A third assumption is that, in the absence of direct
‘head to head’ comparisons between all the drugs
included in the analysis, estimates of relative
short-term effectiveness were based on data
resulting from indirect comparisons which were
incorporated into a statistical model. When
making direct comparisons based on such indirect
comparisons, it is not possible to exclude the
effects of systematic differences between studies on
the estimates of effectiveness. Although an
estimate of uncertainty based on the observed
differences between trials was incorporated in the
analysis, uncertainty due to potential unobserved
differences was not. To an extent, the effects of
unobserved heterogeneity cannot be excluded
from standard meta-analysis, and this form of
evidence synthesis was felt to produce the best
estimates of relative efficacy, which were required
for the incremental CEA, based on the available
clinical trial data.
A fourth assumption is that, owing to a lack of
detailed observational and experimental data, our
analysis included the use of a limited range of
healthcare resource items, and the unit costs were
assumed to be common to all drugs investigated.
Most of the serious AEs are known to be rare so
this should not affect the validity of any
conclusions drawn. VGB and PHT were excluded
from the analysis as it was felt that the side-effect
profile of VGB and the narrow therapeutic index
of PHT would not be adequately accounted for in
the analysis.
A fifth assumption is that, given the lack of data
regarding the mean dose of the AEDs used in
normal practice, the uncertainty in dose was
modelled based on plausible assumptions. A
gamma distribution based on the maximum and
minimum recommended dose in the BNF was
used to reflect uncertainty. As, in general, the
various treatments were found to have similar
efficacy, the CEA will be sensitive to the
assumptions drawn regarding drug price. 
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Finally, in the absence of sufficient specific data,
the safety of the various drugs during pregnancy
was not considered in our analysis. 
Although it is important for these assumptions to
be explicit and to be considered in interpreting
results, the objective of the integrated analysis was
to provide the most reasonable synthesis of
available evidence and to quantify the uncertainty
associated with existing evidence. The analysis of
the treatment of patients experiencing partial
seizures indicated that the various drugs used in
monotherapy for newly diagnosed patients
produced similar health benefits and that the
newer AEDs were more expensive. Consequently,
older AEDs were found most likely to be cost-
effective. It is important to bear in mind that there
is a great deal of uncertainty in this conclusion
owing to the imprecision in the estimate of
benefits. As the threshold willingness to pay
increases above £30,000, it is not possible to
determine which is the most cost-effective AED
with any great degree of certainty. It is also
possible that, even at low values of the willingness
to pay per QALY, the newer AEDs may be cost-
effective as monotherapy for the treatment of
patients who have failed to respond to older
AEDs. There were insufficient clinical trial data
regarding the treatment of refractory patients to
evaluate this. 
The very limited trial data regarding monotherapy
for refractory patients with partial seizures
indicated that LTG, VPA and CBZ had similar
effectiveness and that LTG was more expensive.
The CEA indicated that CBZ was the most cost-
effective treatment. However, LTG or VPA
monotherapy may be cost-effective for patients
who have failed to respond to CBZ. There were
insufficient data on the use of other alternative
newer or older AEDs for patients who are
refractory to specific drugs to allow this to be
investigated further.
The analysis of combination therapy for refractory
patients with partial seizures indicated that the
newer treatments were more effective and more
costly than continuing with the patients’ existing
therapy alone. At low values of the threshold
willingness to pay, combination therapy with
newer AEDs was found not to be cost-effective.
Combination therapy may be cost-effective,
however, given a threshold willingness to pay for a
QALY of £20,000 or more, provided that patients
are discontinued from adjunctive drugs should
they prove to be unsuccessful. The precise value
depends on which treatment options would be
appropriate for an individual patient based on
their previous treatment history. Sensitivity
analysis showed it is not cost-effective to retain
patients on an adjunctive therapy if seizure control
proves to be inadequate. The analysis indicates
that there was a great deal of uncertainty in this
conclusion owing to the lack of precision in the
estimate of treatment benefits. Although OXC had
the greatest probability of being cost-effective
compared with other adjunctive AEDs, the
estimate for its effectiveness was based only on a
single clinical trial.
The analysis of the treatment of patients
experiencing generalised seizures indicated that
LTG and VPA had similar efficacy and that
treatment with VPA was less costly. The
incremental analysis suggested that treatment
with VPA was cost-effective compared with
treatment with LTG. LTG monotherapy may be
cost-effective, however, if VPA is contraindicated,
or if patients have failed to respond to previous
VPA treatment. There were insufficient data
available to consider other alternative newer or
older AEDs. The analysis indicated that TPM
might be cost-effective when used as an adjunctive
therapy, with an estimated ICER of £34,500
compared with continuing current treatment
alone. The analysis did, however, indicate that
there was a great deal of uncertainty in this
estimate.
The integrated economic analysis presented may
form the basis of further evaluations as more
clinical trial evidence becomes available. In
addition, value of information methods based on
this model may provide a useful framework for
setting priorities for future research in this area
and for appropriately designing trials. 
Relevance to the NHS
At present there are a number of guidelines and
recommendations for the treatment of epilepsy in
adults.279,283,285–287 NICE has recently issued
guidelines about the diagnosis and management
of epilepsy in adults. These recommend that
monotherapy with an older AED should be the
therapy of first choice and if seizures continue
adjunctive therapy should be considered. Newer
AEDs are recommended for those who have not
responded to older drugs or where older AEDs are
not suitable due to AEs, contraindications,
interactions with other medications or where
women are of childbearing age. The guidelines do
not make recommendations about the selection or
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sequence of AED therapy with regard to specific
drugs within the classes of older and newer AEDs. 
This review found no clear evidence from clinical
trials to support the use of newer AEDs over older
AEDs in first-line monotherapy or in adjunctive
therapy. Similarly, there was little evidence to
support the use of one newer AED over another. 
Monotherapy using the newer AEDs is more
expensive than monotherapy using the older
AEDs, and the treatment of refractory patients
with the new AEDs as adjunct therapy appeared is
more expensive than treatment with the patients’
existing treatment alone. However, owing to the
uncertainty in the estimates of clinical benefit,
there is considerable uncertainty over whether any
given therapy can be considered more cost-
effective than another. Based on the economic
evaluation, it may be reasonable to suggest the use
of the older AEDs in preference to the newer
AEDs unless there are clinical indications to the
contrary. The newer AEDs may have a role where
treatment with the older AEDs is contraindicated
or where patients do not respond to the older
AEDs.
Further research is ongoing to help clarify the
clinical and cost-effectiveness of the newer AEDs.
This may offer clearer evidence for the design of
treatment pathways in clinical practice.
Implications for further research 
 More direct comparisons of newer versus newer
and of newer versus older AEDs within clinical
trials, taking into account different treatment
sequences within both monotherapy and
adjunctive therapy. An example of such a trial
may be the SANAD trial, which is under way.
 Future trials of AEDs should be of good quality
and appropriate design. In particular, adequate
consideration needs to be given to the type of
study design used, the interventions compared,
the types of outcome measures used and the
size and duration. Ideally, trials should adopt
the ILAE guidelines on the design of trials.
 Trials should specifically recruit patients with
either partial or generalised seizures. Only a
limited number of the newer AEDs are licensed
for the treatment of generalised onset seizures
and the applicability of data relating to mixed
groups of patients is unclear. 
 More good-quality trials are required to
investigate the effectiveness and cost-
effectiveness of monotherapy and adjunctive
therapy in patients with generalised onset
seizures. Very few trials considered this group of
patients and the relevance of data relating to
mixed groups of patients with different seizure
types are unclear, especially where outcome data
are not presented separately for the two groups.
 More good-quality trials are required to
investigate the effectiveness of monotherapy
and adjunctive therapy in specific populations
of epilepsy patients. Caution is advised when
using some of the newer AEDs in certain
populations of patients, such as the elderly and
pregnant/breastfeeding women. There was very
little evidence to support the assessment of
effectiveness and tolerability of the newer AEDs
in these populations.
 Studies using cognitive outcome measures
should use more stringent testing protocols,
which consider practice effects, and the possible
effects of emotional state on cognitive
functioning. There is also a need for studies to
adopt a more consistent approach to assessment
of cognitive outcomes and the choice of
measure should be based on evidence to
support the validity of the measurement tool in
epilepsy patients.
 Further research into the assessment of patient
QoL within trials of epilepsy therapy is
required. Future trials should aim to adopt any
measure shown to have validity in the
assessment of epilepsy patients, but there is also
a need to use preference-based measures of
outcome, which generate appropriate utilities
for CEA.
 Future RCTs should be adequately reported
according to CONSORT guidelines.
 Value of information analysis should be
undertaken, perhaps as an extension to the
integrated modelling work presented here, to
help prioritise newer trials in this area and to
aid their optimal design.
 Observational data are required to provide
information on the use of AEDs in actual
practice, including details of treatment
sequences and doses.
Updating the review
This review identified several ongoing studies,
including the SANAD trial,288 which address some
but not all of the areas suggested by the
recommendations for further research. In order to
incorporate these data, any future update of this
review should not be considered prior to 2006.
There was little good-quality evidence fromclinical trials to support the use of newer
monotherapy or adjunctive AEDs over older drugs
or to support the use of one newer AED in
preference to another. In general, the available
data relating to clinical effectiveness, safety and
tolerability failed to demonstrate consistent and
statistically significant differences between the
drugs. The exception was comparisons between
newer adjunctive AEDs and placebo, where
significant differences favoured the newer AEDs.
However, trials often had only relatively short-
term treatment durations and often failed to 
limit recruitment to either partial or generalised
onset seizures, thus limiting the applicability of
the data. 
The lack of difference in clinical effectiveness was
also reflected in the integrated economic model,
which allowed for direct comparisons between all
of the newer AEDs and permitted extrapolation of
clinical outcomes to long-term health benefits and
costs. The estimated benefits of treatment were
similar, but differences were evident in the
estimated costs of treatment. The older
monotherapies appeared to be cost-effective when
compared with newer AEDs for the treatment of
newly diagnosed patients experiencing either
partial or generalised seizures. 
There was, however, a great deal of uncertainty in
this conclusion. In addition, the newer AEDs, used
as monotherapy, may be cost-effective for the
treatment of patients who have experienced AEs
with older AEDs, who have failed to respond to
the older drugs or where such drugs are
contraindicated. For patients experiencing partial
seizures, the integrated economic model also
suggested that newer adjunctive AEDs might be
cost-effective compared with current treatment
alone for a given threshold willingness to pay of
about £20,000 per QALY. The precise value
depends on the particular treatments that are
indicated for a patient. For patients experiencing
generalised seizures, the analysis indicated that
TPM might be cost-effective when used as an
adjunctive therapy, with an estimated ICER of
£34,500 compared with continuing current
treatment alone. Again, there was considerable
uncertainty in this conclusion.
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